Safety evaluation of certain food additives by Gürtler, Rainer et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Sep 11, 2019
Safety evaluation of certain food additives
Gürtler, Rainer; Andersen, Jens Hinge; Barrows, Julia; Benford, Diane; Dessipri, Eugenia
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Gürtler, R., Andersen, J. H., Barrows, J., Benford, D., & Dessipri, E. (2019). Safety evaluation of certain food
additives. Geneva: World Health Organization. WHO FOOD ADDITIVES SERIES, No. 75
WHO FOOD ADDITIVES SERIES: 75
Prepared by the eighty-fourth meeting of the 
Joint FAO/WHO Expert Committee 
on Food Additives (JECFA)
Safety evaluation 
of certain 
food additives 

WHO FOOD ADDITIVES SERIES: 75
Prepared by the eighty-fourth meeting of the
Joint FAO/WHO Expert Committee 
on Food Additives (JECFA)
Safety evaluation 
of certain 
food additives 
World Health Organization, Geneva, 2019
Safety evaluation of certain food additives: prepared by the Eighty-fourth meeting of the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA).
(WHO Food Additives Series, No. 75)
ISBN 978-92-4-166075-4
ISBN (PDF) 978-92-4-069864-2
ISSN 0300-0923
© World Health Organization and Food and Agriculture Organization of the United Nations, 2019
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 
IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo/).   
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, 
provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion 
that the World Health Organization (WHO) or the Food and Agriculture Organization of the United Nations (FAO) 
endorse any specific organization, products or services. The use of the WHO or FAO logo is not permitted. If you adapt 
the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a 
translation of this work, you should add the following disclaimer along with the suggested citation: “This translation 
was not created by the World Health Organization (WHO) or the Food and Agriculture Organization of the United 
Nations (FAO). WHO and FAO are not responsible for the content or accuracy of this translation. The original English 
edition shall be the binding and authentic edition”. 
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation 
rules of the World Intellectual Property Organization http://www.wipo.int/amc/en/mediation/rules.
Suggested citation. Evaluation of certain food additives: prepared by the Eighty-fourth meeting of the Joint FAO/
WHO Expert Committee on Food Additives (JECFA). Geneva: World Health Organization and Food and Agriculture 
Organization of the United Nations; 2019 (WHO Food Additives Series, No. 75). Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for 
commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. 
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, 
figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain 
permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned 
component in the work rests solely with the user.
WHO Photographs. WHO photographs are copyrighted and are not to be reproduced in any medium without 
obtaining prior written permission. Requests for permission to reproduce WHO photographs should be addressed to: 
http://www.who.int/about/licensing/copyright_form/en/
The designations employed and the presentation of the material in this publication do not imply the expression 
of any opinion whatsoever on the part of WHO or FAO concerning the legal or development status of any country, 
territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on 
maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products, whether or not these have been patented, 
does not imply that they are endorsed or recommended by WHO or FAO in preference to others of a similar nature 
that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial 
capital letters.
All reasonable precautions have been taken by WHO and FAO to verify the information contained in this publication. 
However, the published material is being distributed without warranty of any kind, either expressed or implied.  The 
responsibility for the interpretation and use of the material lies with the reader.  In no event shall WHO and FAO be 
liable for damages arising from its use.  
Design: Rania Spatha (www.raniaspatha.com)
Printed in Malta
iii
Contents
Preface vii
specific food additives 1
Brilliant Blue FCF 3
β-Carotene-rich extract from Dunaliella salina 45
Fast Green FCF 69
Gum ghatti (addendum) 97
Jagua (Genipin–Glycine) Blue 123
Metatartaric acid 145
Tamarind seed polysaccharide  165
Yeast extracts containing mannoproteins 193
Annex 1 
Reports and other documents resulting from previous meetings of the Joint FAO/WHO 
Expert Committee on Food Additives 221
Annex 2 
Abbreviations used in the monographs 233
Annex 3 
Participants in the eighty-fourth meeting of the Joint FAO/WHO Expert Committee on
Food Additives 235
Annex 4 
Toxicological and dietary exposure information and information on specifications 239

vPrefACe
The monographs contained in this volume were prepared at the eighty-fourth meeting 
of the Joint Food and Agriculture Organization of the United Nations (FAO)/World Health 
Organization (WHO) Expert Committee on Food Additives (JECFA), which met at FAO 
headquarters in Rome, Italy, on 6–15 June 2017. These monographs summarize the data on 
selected food additives reviewed by the Committee. 
 The eighty-fourth report of JECFA has been published by WHO as WHO Technical 
Report No. 1007. Reports and other documents resulting from previous meetings of JECFA 
are listed in Annex 1. The participants in the meeting are listed in Annex 3 of the present 
publication. A summary of the conclusions of the Committee with respect to the food 
additives discussed at the meeting is given in Annex 4.
 JECFA serves as a scientific advisory body to FAO, WHO, their Member States and the 
Codex Alimentarius Commission, primarily through the Codex Committee on Food Additives, 
the Codex Committee on Contaminants in Food and the Codex Committee on Residues of 
Veterinary Drugs in Foods, regarding the safety of food additives, residues of veterinary drugs, 
naturally occurring toxicants and contaminants in food. Committees accomplish this task by 
preparing reports of their meetings and publishing specifications or residue monographs 
and dietary exposure and toxicological monographs, such as those contained in this volume, 
on substances that they have considered.
 The monographs contained in this volume are based on working papers that were 
prepared by WHO and FAO experts. A special acknowledgement is given at the beginning of 
each monograph to those who prepared these working papers. The monographs were edited 
by J. Odrowaz, Toronto, Canada.
 These monographs were prepared based on the evaluation of the original studies 
and the dossier provided by the sponsor(s) of the compound, of the relevant published 
scientific literature and of the data submitted by Codex members. When found consistent 
with the data of the original study, the monographs may contain parts of the text and 
tables of the dossier submitted by the sponsor(s), but not the sponsor(s)’ conclusions. These 
monographs and their conclusions are based on an independent review of the available data 
and do not constitute an endorsement of the sponsor(s)’ position.
 The designations employed and the presentation of the material in this publication 
do not imply the expression of any opinion whatsoever on the part of the organizations 
participating in WHO concerning the legal status of any country, territory, city or area or 
its authorities, or concerning the delimitation of its frontiers or boundaries. The mention 
of specific companies or of certain manufacturers’ products does not imply that they are 
endorsed or recommended by the organizations in preference to others of a similar nature 
that are not mentioned.
 Any comments or new information on the biological or toxicological properties of 
or dietary exposure to the compounds evaluated in this publication should be addressed to: 
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WHO Joint Secretary of the Joint FAO/WHO Expert Committee on Food Additives, Department 
of Food Safety and Zoonoses, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, 
Switzerland (jecfa@who.int).
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1. explanation
Brilliant Blue FCF (Chemical Abstracts Service [CAS] No. 3844-45-9; 
International Numbering System for Food Additives [INS] No. 133) is a 
dye with a triphenylmethane base structure permitted as a food colour in 
the European Union, Japan, the United States of America (USA) and other 
regions. It is used for colouring breakfast cereals, cakes and cupcakes, 
candies, chewing gum, dairy products, decorations for baking, flavoured 
water and frozen treats.
The Committee previously evaluated the use of Brilliant Blue FCF 
as a food colour at the thirteenth meeting in 1969 (Annex 1, reference 
19). The specifications for Brilliant Blue FCF were prepared at the twenty-
eighth Joint FAO/WHO Expert Committee on Food Additives (JECFA) 
meeting in 1984 and revised for metal specifications at the fifty-ninth 
meeting in 2002 (Annex 1, references 66 and 160). An acceptable daily 
intake (ADI) of 0–12.5 mg/kg body weight (bw) was established by the 
Committee in 1969 (Annex 1, reference 19). The ADI was based on a no-
observed-adverse-effect level (NOAEL) of 5% (equivalent to 2500 mg/kg 
bw per day) derived from a chronic dietary toxicity study in rats (Hansen 
et al., 1966), with no explanation for the 200-fold uncertainty factor. More 
recent studies, including studies on absorption and excretion, biochemical 
effects, long- and short-term toxicity, carcinogenicity, genotoxicity, 
reproductive and developmental toxicity, and allergenicity, as well as 
studies on neurobehavioural effects and interaction with the membrane 
protein pannexin 1 (Panx1), have since become available.
Brilliant Blue FCF has been evaluated by the present Committee at 
the request of the Forty-eighth Session of the Codex Committee on Food 
Additives (FAO/WHO, 2016). Almost all of the new data were provided 
by the sponsor. Only eight additional publications were identified in a 
5Brilliant Blue FCF (addendum)
literature search in Embase, PubMed and Scopus using the substance name, 
synonyms and the CAS number as search terms. The pre-1969 studies 
described below were considered by the Committee at the thirteenth 
meeting in 1969 (Annex 1, reference 19).
1.1 Chemical and technical considerations
Brilliant Blue FCF consists mainly of disodium 3-[N-ethyl-N-[4-[[4-[N-
ethyl-N(3-sulfobenzyl)amino]phenyl](2-sulfophenyl)methylene]-2,5-
cyclohexadiene-1-ylidene]ammoniomethyl]benzenesulfonate and its 
isomers, together with subsidiary colouring matters, as well as sodium 
chloride and/or sodium sulfate as the principal uncoloured components. 
It is manufactured by condensing 2-formylbenzenesulfonic acid with a 
mixture of 3-[(N-ethyl-N-phenylamino)methyl]benzenesulfonic acid and 
its 2- and 4-isomers to form the leuco base precursor. Oxidation of the 
leuco base precursor with either chromium- or manganese-containing 
compounds produces the dye, which is isolated as the disodium salt. 
The dye contains not less than 85% total colouring matters. Impurities 
include unreacted starting material and reaction by-products (~2%), 
subsidiary colouring matters (≤6%), residual leuco base precursor (≤5%), 
unsulfonated primary aromatic amines (≤0.01% calculated as aniline), 
lead (≤2 mg/kg), chromium (≤50 mg/kg) and manganese (≤100 mg/kg).
2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and excretion
Brilliant Blue FCF was administered orally to rats as a 2% aqueous solution 
at 200 mg per rat. Almost the entire amount was excreted unchanged in 
the faeces within 40 hours. In a later investigation, the colour was found in 
bile in rats, rabbits and dogs after oral administration. In dogs, the amount 
in bile did not exceed 5% of the administered dose (Hess & Fitzhugh, 1953, 
1954, 1955).
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A dose of 0.27 mg/animal (~1.5 mg/kg bw) of 14C-radiolabelled 
Brilliant Blue FCF (14C on central methane; >99% pure) was given by 
gavage to intact (n =  5), bile duct–cannulated (n = 3) or bile duct–ligated 
(n = 5) female Sprague Dawley rats.
Only 0.27% of the dose was absorbed in intact animals and 
2.05% in bile duct–ligated animals, with 91.1% and 97.3%, respectively, 
excreted in the faeces, and 91.7% and 99.4% of the total dose recovered. 
The total absorbed fraction included urinary 14C excretion, expired 14CO2 
and residual radioactivity in internal organs and tissues over 96 hours. 
Biliary excretion was estimated to be 1.32% of the administered dose over 
96 hours. The percentage of radioactivity expired as 14CO2 was 0.04% of 
the dose in intact rats and 0.01% of the dose in bile duct–cannulated rats. 
Results obtained by thin-layer chromatography (TLC) of 24-hour urine 
and bile samples showed that about 95% of the excreted radioactivity 
was unaltered Brilliant Blue FCF and that about 5% was an unidentified 
metabolite or degradation product (Brown et al., 1980).
Almost complete excretion of Brilliant Blue FCF in the faeces 
was reported in another study in male and female rats. Following gavage 
administration of either 0.03 mg/kg bw or 3 mg/kg bw of 14C-labelled 
Brilliant Blue FCF (14C on central methane; radiochemical purity >95% 
by TLC), 99.9% and 95.4%, respectively, was recovered in faeces within 
72 hours. Up to 0.5% was detected in the urine, which was speculated to 
represent cross-contamination of urine with faeces (Phillips et al., 1980).
In the same study, similar patterns of elimination were reported in 
pregnant rats following gavage administration of 3 mg/kg bw on day 8 of 
pregnancy, which was independent of prior 21-day dietary administration 
of unlabelled Brilliant Blue FCF at a dose of 30 mg/kg bw per day. Excretion 
was also almost completely via faeces in male mice and guinea-pigs, 
urinary excretion being less than 1%, regardless of dose level. TLC found 
no evidence of metabolites in rat or guinea-pig faeces. There was evidence 
of slower excretion in mice and guinea-pigs compared to rats.
Lack of gastrointestinal absorption and metabolism was further 
confirmed in situ using isolated loops of small intestine from guinea-pigs 
and mice. Negligible fractions of a 3 mg/kg bw dose were found in the 
bile of rats collected at 5 hours (<0.05%) and in day 11 fetuses (0.0004–
0.0006%) of rats dosed orally on day 8 of gestation (Phillips et al., 1980).
7Brilliant Blue FCF (addendum)
In a more recently published study, the absorption of Brilliant 
Blue FCF on the lingual mucosa after licking lollipops was examined 
using an ex vivo porcine tongue system (Lucová et al., 2013). The 
tongue dorsum was exposed for 20 minutes to human saliva containing 
Brilliant Blue FCF (purity >85% of total colouring matters) at a reported 
concentration of 15 µg/cm2. Fractions were analysed using an ultraviolet-
visible spectrophotometer (limit of quantification: 6.6 ng/mL). Estimated 
distribution of the applied dose at 24 hours was 9.71 µg/cm2 (~65%) 
remaining on the surface, 4.11 µg/cm2 (27%) reaching the squamous 
epithelium and about 34 ng/cm2 diffusing deeper than the surface layers 
(approximately 0.1% in the lamina propria and submucosa as well as 0.1% 
in the receptor fluid), from where it could be systemically bioavailable.
According to Peng et al. (2009), FD&C blue dye No. 1 (Brilliant 
Blue FCF) crosses the blood–brain barrier. However, the authors did not 
substantiate their statement with experimental data or any references. 
Based on a predictive absorption, distribution, metabolism and excretion 
(ADME) analysis (in silico), Park et al. (2009) stated that Brilliant Blue 
FCF may have higher brain permeability than colours such as Allura Red 
AC, amaranth, tartrazine and Sunset Yellow FCF.
In a pharmacokinetic study of biliary excretion in rats, 
spectrophotometry was used to analyse several food colours, including 
Brilliant Blue FCF, for excretion rate and protein binding (Iga, Awazu & 
Nogami, 1971). The average excretion ratios in 4 hours were 94.2%, 96.0% 
and 91.0% at doses of 3, 15 and 30 µmol/L, respectively. Equilibrium 
dialysis methods were used to analyse binding with plasma protein. Three 
millilitres of rat plasma in 30 mL isotonic pH 7.3 buffer solution containing 
Brilliant Blue FCF at a concentration of 1 µmol/mL was dialysed at 37 °C. 
The colour concentration of the buffer solution was determined after 160 
hours of dialysis. The binding ratio of Brilliant Blue FCF with plasma 
protein was 65%.
In further studies, the authors investigated the relationship 
between the biliary excretion behaviour and the elimination from plasma 
of azo dyes and tryphenylmethane dyes in rats (Iga et al., 1971). Binding 
with bovine serum albumin and plasma protein was investigated using 
equilibrium dialysis methods. The analytical methods were the same as 
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described for the earlier study (Iga, Awazu & Nogami, 1971). The binding 
ratios of Brilliant Blue FCF with bovine serum albumin and plasma protein 
after 120 hours of dialysis at 4 °C were 16.2% and 39.7%, respectively.
2.1.2 Biotransformation
14C-Radiolabelled Brilliant Blue FCF (14C on central methane; >99% pure) 
was given by gavage to intact (n = 5), bile duct–cannulated (n = 3) or bile 
duct–ligated (n = 5) female Sprague Dawley rats. TLC of 24-hour urine 
and bile samples showed that about 95% of the excreted radioactivity was 
unaltered Brilliant Blue FCF and about 5% was an unidentified metabolite 
or degradation product (Brown et al., 1980).
Phillips et al. (1980) also used TLC but found no evidence for 
metabolites in rat and guinea-pig faeces. There are, however, no studies 
using more modern techniques to investigate biotransformation or 
identify metabolites.
2.1.3 Effects on enzymes and other biochemical parameters
The effect of Brilliant Blue FCF (among other food colour additives; purity 
not reported) on the activities of human phase I and II metabolic enzymes 
(CYP2A6, CYP3A4, UGT1A6 and UGT2B7) has been examined. Kuno & 
Mizutani (2005) and Mizutani (2009) reported that Brilliant Blue FCF is 
neither a substrate nor an inhibitor of any of the enzymes studied.
Eleven organic synthetic dyes used as food colours, including 
“Brilliant Blue” (purity 90.22%; chemical identity unclear), were tested 
to determine their effect on mitochondrial respiration in mitochondria 
isolated from rat liver and kidney. All food colours tested inhibited 
mitochondrial respiration (state III respiration, uncoupled), as measured 
with α-ketoglutarate or succinate as substrates. The extent of the inhibition 
varied widely, from 100% for erythrosine to 16% for tartrazine, at 
concentrations of 0.1 mg food colour per mg mitochondrial protein. Both 
rat liver and kidney mitochondria showed similar patterns of inhibition 
among the food colours tested. Brilliant Blue showed 78% inhibition 
of state III respiration rates of rat liver and kidney mitochondria with 
succinate as the substrate. The half maximal inhibitory concentration (IC50) 
was 250 and 34 mg/g mitochondrial liver protein with α-ketoglutarate and 
succinate as substrates, respectively, and 28 mg/g mitochondrial kidney 
protein with succinate as substrate (Reyes, Valim & Vercesi, 1996).
9Brilliant Blue FCF (addendum)
In an in vitro study the Xenopus oocyte expression system was used 
to investigate the purinergic P2 receptors that interact with the membrane 
channel protein Panx1 in inflammasome signalling. Brilliant Blue FCF 
was shown to be a selective inhibitor of Panx1 channels, with an IC50 of 
0.27 µmol/L, with no significant effect on the P2X7R receptor observed at 
concentrations as high as 100 µmol/L (Wang, Jackson & Dahl, 2013).
2.2 Toxicological studies
2.2.1 Acute toxicity
The oral median lethal dose (LD50 ) in rats was reported to be higher than 
2000 mg/kg bw (Lu & Lavallee, 1964).
In a dose-range finding experiment performed to identify the 
maximum tolerated dose for an in vivo comet assay, the LD50 in mice was 
higher than 2000 mg/kg bw (Sasaki et al., 2002).
2.2.2 Short-term studies of toxicity
(a) Mice
Mice were given 1200 mg Brilliant Blue FCF (called “Patentblau AE”; 
purity 37% colouring matter, the remainder sodium chloride and some 
sodium sulfate) in feed over 19 days. No adverse effects or other details 
were reported (Gross, 1961).
(b) Rats
Brilliant Blue FCF (purity not reported) tested for toxicity in weanling 
male Wistar rats (n = 5) for 21 days was reported to result in severe growth 
retardation when added to a low fibre diet at a level of 5% (equivalent to 
5 g/kg bw, based on a conversion factor of 0.1). Addition of dietary fibre 
from edible burdock roots was reported to protect against this toxic effect 
(Tsujita et al., 1979).
Brilliant Blue FCF was tested for toxicity in male rats as part of 
two mixtures with tartrazine, Sunset Yellow and carmoisine (mixtures A 
and B) added to the diet for 30 or 60 days at a dose level for the combined 
mixture of 800 mg/kg bw per day (Aboel-Zahab et al., 1997). Neither the 
composition of the mixtures nor the concentration of each colour were 
specified. The Committee noted that this study cannot be considered 
10
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relevant for the evaluation of Brilliant Blue FCF because the investigation 
of mixtures of colours makes it impossible to attribute any effects directly 
to the test substance.
A substance described as “Brilliant blue (blue dye, N0.2) of the 
Imperial Chemicals Industries (ICI, England), from Cairo Food, Lona 
Company, Giza, Egypt” (purity not reported), which might be Brilliant 
Blue FCF, was tested in male Sprague Dawley albino rats (10/group) at 
a single dietary concentration of 124 mg/kg diet for 42 days, along with 
other food additives (tartrazine, carmoisine, trans-anethole propylene 
glycol and vanillin and their combinations).
Significant decreases in body weight, haemoglobin concentrations 
and red blood cell counts were reported for all treatment groups. Other 
changes reported include significant decreases in blood and liver levels 
of reduced glutathione and activities of glutathione-S-transferase and 
superoxide dismutase; and significant increases in activities of serum 
alanine aminotransferase, aspartate aminotransferase and alkaline 
phosphatase and in blood levels of bilirubin, urea, creatinine, total protein 
and albumin. No effects on relative liver, kidney or heart weights were 
found (El-Wahab & Moram, 2013).
The Committee noted that the reliability of this study was limited 
because the identity and purity of the substance were unclear.
(c) Dogs
Twelve beagle dogs, 6–7 months of age, were fed Brilliant Blue FCF (purity 
not reported) at 0.0, 1.0% or 2.0% in the diet for up to 1 year (groups 
comprised one male and one female in the control group, two males and 
two females in the 1% group, and four males and two females in the 2% 
group). One dog at 2% died after 17 days and another at 1% after 46 weeks. 
Both deaths were attributed to viral infections. No clinical signs, gross 
lesions or microscopic pathology findings were attributed to the Brilliant 
Blue FCF exposure (Hansen et al., 1966).
11
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2.2.3 Long-term studies of toxicity and carcinogenicity
(a) Mice
Groups of 57 male and 43 female mice were given Brilliant Blue FCF in 
the diet at 1 mg per day, and observed over 500–700 days. No evidence of 
carcinogenicity was found (Waterman & Lignac, 1958).
Brilliant Blue FCF (total colour content ≥85%; subsidiary colours 
≤6%; sum of volatile matter chlorides and sulfates ≤15%) was given to 
ASH/CS1 mice (n = 48 males and 50 females) in the diet for up to 80 weeks 
at concentrations of 0, 0.015%, 0.15% or 1.5% (equivalent to 0, 20, 200 and 
2000 mg/kg bw per day).
Significantly reduced body weight was reported, mainly in females 
at the highest dose. It was not clear if this was because of reduced feed 
consumption due to lower palatability of the test diet. No treatment-
related changes in haematological parameters were observed in samples 
taken on weeks 13, 26 or 52 (10 mice/sex) and week 80 (all surviving 
mice). On week 13, significant reductions in reticulocyte counts were 
noted in males at 0.15% and both sexes at 1.5%. The low-dose group was 
not examined at this time point. At the highest dose, a significant decrease 
in the relative stomach weight of male mice and a significant increase in 
the relative brain weight of females, which appeared to be the result of the 
reduced female body weight, were reported. Complete histopathological 
examination of the control and high-dose animals was performed, but 
only the liver, kidney and selected tissues were examined in animals of the 
lower dietary levels, as was warranted by macroscopic observations. An 
increased incidence of glomerulonephritis was reported in all treated male 
but not female animals relative to the control group; the trend was not 
dose-dependent (14/44 in controls, 24/34 low dose, 17/30 mid dose, 24/44 
high dose). An increased incidence of mild liver changes in male mice at 
the highest dose level was also observed (incidence of foam cells was 13/44 
versus 2/44 in controls; incidence of fatty change was 11/44 versus 3/44 
in controls). A statistically nonsignificant increase in reticulolymphatic 
tumours (lymphosarcoma and reticulum cell neoplasm) was noted 
at the highest dose level (8/44 versus 4/44 in controls) in male mice. A 
number of tumours observed randomly in single treated animals (but 
not in the controls) included squamous cell carcinoma of the stomach, 
thyroid adenoma, adrenal tumours, mesenteric lipoma and squamous 
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cell carcinoma of the skin. All of these tumours were considered to occur 
spontaneously and not be treatment related. The incidence of kidney 
tumours was increased in the 0.15% dietary group (six adenomas and one 
adenocarcinoma) compared with the control group and the high dietary 
group (only a single animal in each). No kidney tumours were identified 
in the low-dose group of males or any treated females. The authors noted 
that although kidney tumours are unusual in most strains of mice, they are 
common in the ASH/CS1 strain.
It was concluded that Brilliant Blue FCF was not carcinogenic in 
mice. The NOAEL was 0.15% (equivalent to 200 mg/kg bw per day) based 
on the slight reduction in weight gain and changes in organ weights of 
doubtful significance and some liver effects at the highest dose (Rowland 
et al., 1975).
The Committee noted that the study was performed before 
Organisation for Economic Co-operation and Development (OECD) 
guidelines and good laboratory practice (GLP) requirements were 
established and that its reliability was limited (e.g. only summary tables 
were available with no data on individual animals; the males were weighed 
individually while the females were weighed in caged groups of five).
Brilliant Blue FCF was given to Charles Rivers CD-1 mice (60/sex 
per group; 4 weeks old) in the diet for 24 months (104 weeks) at 0, 0.5%, 
1.5% or 5% (equal to 0, 661, 2064 and 7354 mg/kg bw per day for males 
and 0, 819, 2562 and 8966 mg/kg bw per day for females, respectively). 
Separate male and female control groups (n = 60/sex) were used (Borzelleca, 
Depukat & Hallagan, 1990). The test material was reported to be certified 
by the United States Food and Drug Administration (USFDA) as Brilliant 
Blue FCF at 90% purity with the remaining 10% consisting of subsidiary 
colours, volatile chlorides and sulfates, and uncombined intermediates. 
Animals were monitored for clinical signs of toxicity twice daily, at least 
every 5 hours. Body weights and feed consumption were measured 
weekly for the first 14 weeks, biweekly on weeks 16–26 and monthly 
thereafter. Detailed physical examinations and palpation for masses were 
conducted weekly. Haematological parameters were evaluated at 3, 6, 12, 
18 and 24 months (10/group, randomly selected). All animals that died 
spontaneously, were euthanized in a moribund condition or were killed 
as scheduled were necropsied, and organs were weighed. Histological 
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examinations were conducted on all animals from the two control groups 
and the highest dose group.
 At the end of the study, 25 and 23 males survived in the control 
groups and 25, 28 and 33 in the low-, middle- and high-dose groups, 
respectively; and 24 and 31 females survived in the control groups and 31, 
28 and 31 in the treatment groups, respectively. Blue staining of the hair, 
exposed skin and faeces was reported in all treatment groups, but there 
were no overt signs of treatment-related toxicity. There were no changes in 
feed consumption. The lower body weights (P  < 0.01) recorded in different 
periods in both sexes at 1.5% or 5% were attributed to the replacement of 
caloric dietary content with the non-nutrient Brilliant Blue FCF. Except 
for occasional statistically significant decreases in mean haemoglobin, 
haematocrit and leukocyte counts, considered of no toxicological relevance, 
there were no treatment-related changes in haematological parameters.
Overall, there were no toxicologically relevant adverse effects from 
Brilliant Blue FCF exposure in the diet. Lifetime incidence of neoplasms 
in mice treated with Brilliant Blue FCF in the diet did not differ from 
the incidence in control groups. Except for an increased incidence of 
haemangiomas in females at 5%, the incidence rates of various lesions in 
mice in the 0.5% and 1.5% treatment groups were similar to the incidence 
rates in the controls. However, these changes were not statistically 
significant in the adjusted Fisher trend test.
It was concluded that there were no treatment-related neoplasms. 
The NOAEL was 5%, the highest dose tested (equal to 7354 mg/kg bw 
per day for males and 8966 mg/kg bw per day for females) (IRDC, 1981a; 
Borzelleca, Depukat & Hallagan, 1990). The Committee noted that survival 
at the end of the study was about 50% in both control and treatment 
groups. The Committee further noted that the study was performed before 
OECD guidelines were established but that the study was in compliance 
with USFDA GLP Regulations of 20 June 1979.
(b) Rats
Brilliant Blue FCF was administered at a dietary level of 4% to five male 
and five female rats for 600 days. Gross staining of the glandular stomach 
and some granular deposits in the stomach were observed, but no tumours 
(Willheim & Ivy, 1953).
14
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
5,
  2
01
8
Safety evaluation of certain food additives   Eighty-fourth  JECFA
Eighty-five rats were fed a diet containing 0.1% of Brilliant Blue 
FCF for their lifespan. The daily exposure was 10–15 mg. No tumours 
were found (Klinke, 1955).
Groups of 15 male and 15 female Wistar rats were given diets 
containing 0, 0.3% and 3% of Brilliant Blue FCF for 75 weeks (Mannell, 
Grice & Allmark, 1962). There were no adverse effects on growth, and the 
haematological findings were within normal ranges.
In its previous evaluation at the thirteenth meeting (Annex 1, 
reference 19), the Committee established an ADI of 0–12.5 mg/kg bw 
based on a 2-year toxicity study in which 24 male and female weanling 
Osborne–Mendel rats, evenly divided by sex, were fed a diet containing 0, 
0.5%, 1.0%, 2.0% or 5.0% Brilliant Blue FCF (purity not reported) (Hansen 
et al., 1966). The NOAEL was 5.0% (equivalent to 2500 mg/kg bw per day), 
the highest dose tested.
In a chronic toxicity study with a reproductive phase and in utero 
exposure phase, Charles Rivers CD rats (n = 60/sex per group; ~4 weeks 
old) received Brilliant Blue FCF in the diet for 17 weeks at 0, 0.1%, 1% 
or 2% (calculated to provide 0, 50, 514 and 1073 mg/kg bw per day in 
males and 0, 62, 631 and 1318 mg/kg bw per day in females). Separate 
male and female control groups (n = 60/sex) were used (IRDC, 1981b; 
Borzelleca, Depukat & Hallagan, 1990). These animals were designated the 
F0 generation. One male and one female from the same treatment group 
for 15 consecutive days after 62 days of exposure to Brilliant Blue FCF. The 
chronic exposure phase was conducted on randomly selected F1  animals 
(two F1 rats/sex per litter) assigned to the control and treatment groups 
(70/sex per group) at the same dietary levels as the F0 parental animals. 
The reproductive and developmental outcomes of this study are described 
below (section 2.2.5(a)). A minimum of 30 months (120 weeks) of exposure 
was required for the chronic exposure phase or until reduction in survival 
reached 12 rats/sex in any group. The maximum exposure was 116 weeks 
for F1 males and 111 weeks for F1 females.
The test material was the same as that used in the mouse study, 
namely USFDA-certified Brilliant Blue FCF (purity 90% with the 
remaining 10% consisting of subsidiary colours, volatile chlorides 
and sulfates, and uncombined intermediates). F0 and F1 animals were 
monitored for clinical signs of toxicity twice daily, at intervals at least 5 
15
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hours apart. Body weights and feed consumption were measured weekly 
for the first 14 weeks, biweekly on weeks 16–26, and monthly thereafter. 
Body weights were also recorded on gestation days 0, 6, 15 and 21 for 
F0 females and on lactation days 0, 4, 14 and 21 for F0 females and F1 
offspring. Physical examination and palpation for masses were conducted 
weekly. Haematological parameters were evaluated at 3, 6, 12, 18 and 24 
months and at the end of the study (116 and 111 weeks for males and 
females, respectively) (10/group, randomly selected). Clinical chemistry 
and urine analysis were performed on samples collected after 25 months 
for males and 26 months for females. All animals that died spontaneously, 
were euthanized in a moribund condition or were killed as scheduled 
were necropsied, and their organs were weighed. All animals from the two 
control groups and the highest dose group were histologically examined as 
were randomly selected animals from the other treatment groups (10/sex 
per group) at the interim kill at 12 months.
At the end of the study, 18 and 13 males survived in the control groups 
and 12, 12 and 18 in the low-, middle- and high-dose groups, respectively; 
and 28 and 24 females survived in the control groups and 23, 28 and 10 
in the treatment groups, respectively (414 were killed in extremis or died 
spontaneously or accidentally prior to the end of the study). Blue staining 
of the hair, exposed skin and faeces was reported in all treatment groups, 
but no signs of overt toxicity related to treatment were reported. Except for 
reduced body weights in females in the 2% dose group from week 90 to the 
end of the study (15% reduced terminal body weight, P < 0.01, from week 
102), there were no significant differences in body weight between treated 
and control animals. Despite the relatively high mortality observed, there 
was no dose-related trend in either males or females, although survival 
of high-dose females was significantly decreased (P < 0.01) compared to 
the control groups (10/60 in the high-dose group versus 28/60 in control 
group 1 and 24/60 in control group 2). None of the differences between 
control and treated animals in haematological, clinical chemistry or urine 
analysis parameters were statistically significant or considered treatment 
related. A slight increase in feed consumption in males and females at the 
2% dose level was significant (P < 0.05) on random weeks. No treatment-
related gross or histological changes were found at necropsy or follow-
up histological evaluation either at the interim kill or at the end of the 
study. Lifetime incidence of neoplasms in treated rats did not differ 
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from the incidence in control groups. Microscopic examination of the 
macroscopically observed masses in animals at 0.1% and 1% Brilliant Blue 
FCF revealed only random lesions that were considered spontaneous.
It was concluded that there were no treatment-related neoplasms. 
The NOAEL was the highest dose tested in males (equivalent to 1073 mg/
kg bw per day) and the middle dose in females (equivalent to 631 mg/kg 
bw per day) based on decreased mean body weight and survival at the 
highest dose level. The Committee noted that the study was performed 
before OECD guidelines were established but that it was in compliance 
with USFDA GLP Regulations of 20 June 1979.
 2.2.4 Genotoxicity
No mutagenic activity has been observed with Brilliant Blue FCF in several 
in vitro mutagenicity studies conducted in Salmonella typhimurium, 
Bacillus subtilis and Escherichia coli (Auletta, Kuzava & Parmar, 1977; 
Brown, Roehm & Brown, 1978; Bonin & Baker, 1980; Haveland-Smith 
& Combes, 1980; Kawachi et al., 1980; Bonin, Farquharson & Baker, 
1981; Ishidate et al., 1984). Positive findings were reported in two in vitro 
chromosomal aberration assays (Kawachi et al., 1980; Ishidate et al., 1984), 
one in vitro micronucleus assay (Kus & Eroglu, 2015) and one in vitro 
comet assay (Pandir, 2016), but these studies had some shortcomings.
Negative results were obtained in vivo in a micronucleus assay in 
bone marrow (Hayashi et al., 1988) and a comet assay in the stomach, 
colon, liver, kidney, bladder, lung, brain and bone marrow of mice (Sasaki 
et al., 2002). The Committee noted that while these two in vivo studies 
are not fully compliant with the current versions of OECD guidelines 474 
and 489, respectively, they were sufficiently reliable to be considered in the 
assessment.
The results of these studies are summarized in Table 1.
Based on the available data, the Committee concluded that there is 
no concern with respect to genotoxicity of Brilliant Blue.
2.2.5 Reproductive and developmental toxicity
(a) Reproductive toxicity
In a 3-generation reproductive toxicity study, Brilliant Blue FCF (purity 
92%) was given in the diet to male and female Long–Evans rats at 
concentrations calculated to provide dose levels of 0, 10, 100, 300 or 1000 
17
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Test system Test object Concentration Result Reference
In vitro
Reverse mutation Salmonella. typhimurium TA98, 
TA100
100–10 000 μg/platea,b Negative Bonin & Baker (1980)
S. typhimurium TA98, TA100 320, 1 000, 3 200, 10 000 μg/platec Negative
S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538
320, 1 000, 3 200, 10 000 μg/platec,d Negative
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538
10, 100, 1 000, 10 000 μg/plateb,c,d Negative Bonin, Farquharson & 
Baker (1981)
320, 1 000, 3 200, 10 000 μg/platec,d,e Negative
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538 
50, 250, 1 000 μg/platec,d Negative Brown, Roehm & Brown 
(1978)
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538
1, 10, 100, 1 000, 10 000 μg/platec,d Negative Auletta, Kuzava & Parmar 
(1977)
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537, TA92, TA94
Up to 5 000 μg/plated,f Negative Ishidate et al. (1984)
Reverse mutation S. typhimurium TA98 Not reported Negative Kawachi et al. (1980)
Reverse mutation S. typhimurium TA1538 10 mg/mLd,g Negative Haveland-Smith & 
Combes (1980)
Reverse mutation Bacillus subtilis (rec assay) Not reported Negative Kawachi et al. (1980)
Reverse mutation Escherichia coli WP2 trp uvrA 10 mg/mLd,h Negative Haveland-Smith & 
Combes (1980)
Chromosomal 
aberration test
Chinese hamster fibroblast cell 
line (CHL)
Up to 5 000 μg/mLh Positivei Ishidate et al. (1984)
Chromosomal 
aberration test
Hamster lung fibroblasts Not reported Positivej Kawachi et al. (1980)
Micronucleus assay Human lymphocytes 10, 20, 30, 40 mg/mLk Positivel Kus & Eroglu (2015)
Comet assay Human sperm cells 50, 100, 200, 500 µg/mLl Positivem Pandir (2016)
In vivo
Bone marrow 
micronucleus assay
ddY Mice (M) 500, 1 000, 2 000 mg/kg bwn Negative Hayashi et al. (1988o)
1 010 mg/kg bw per dayp Negative
Comet assay ddY Mice (M) 2 000 mg/kg bwq,r Negatives Sasaki et al. (2002)
bw: body weight; M: male; OECD: Organisation for Economic Co-operation and Development; S9: 9000 × g supernatant fraction from liver homogenate; USFDA: United 
States Food and Drug Administration
a Range finder.
b Plate incorporation method.
c With and without S9.
d Material supplied by USFDA.
e Four samples from different suppliers tested, detailed results for one sample reported.
f The preincubation method was used in the presence of S9.
g Fluctuation test with 72–96 hour incubation at 37 °C.
h Treated for 24 hours and 48 hours; D20 (dose at which aberrations were found in 20% of cells): 4.45 mg/mL; frequency of cells with aberrations per unit dose: 3.
I Gaps not excluded from the evaluation; cytotoxicity not reported; purity not reported.
j No details were reported.
k Without S9.
l Incubated continuously for 72 hours at 37 °C; does not comply with OECD study design (cells were exposed for 72 hours; only 500 cells/concentration analysed; purity 
not reported; no positive control; identity of negative control not reported). Increase of micronucleus frequency was accompanied by cytotoxicity.
m High % tail DNA in all control groups (>50%); purity not reported.
n Single intraperitoneal administration with sampling 26 hours later.
o Appears by the synonym CI Acid Blue 9 (the CAS No. 3844-45-9 complies with the JECFA specification); 1000 polychromatic erythrocytes (PCEs) scored per animal.
Table 1
Genotoxicity of Brilliant Blue fCf in vitro and in vivo
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mg/kg bw per day. In each generation, 10 males and 20 females were 
treated with the same dose range of Brilliant Blue FCF or vehicle control. 
Dose formulations were adjusted for body weights. The first generation 
of parents (F0) was mated twice; one of the second generation of parents 
(F1b) was mated three times, and one of the third generation of parents 
(F2b) was mated once (offspring: F3a). Dams were allowed to raise their F2a 
and F2b offspring to weaning. The F1b dams were killed on gestation day 19 
after the third mating and their uterine contents were examined. Offspring 
that were not selected for subsequent mating were killed at weaning and 
necropsied. Parental body weights, feed consumption, offspring survival 
and growth were recorded. F1b and F3a animals (5/sex per dietary dose level) 
were necropsied, and certain tissues were preserved. Histopathological 
examination of selected tissues of control and high-dose F1b and F3a animals 
was undertaken.
The mean body weights of the high-dose groups was lower than 
that of the control group in nursing offspring and in F1 and F2 males and 
females. There were no differences between treated and control animals 
in adult mortality, mating success, pregnancy and fertility rates, length 
of gestation period, offspring survival or sex, litter survival or necropsy 
findings in the animals killed on gestation day 19. Macroscopic and 
microscopic examinations of F1b and F3a animal tissues showed no 
treatment-related findings. Survival rates were compared using the chi-
square test, but no other statistical analyses were shown (BioDynamics 
Inc., 1971). The Committee noted that the study was performed before 
OECD guidelines or GLP requirements were established, but the study 
design was based on a USFDA-approved protocol.
A single-generation reproductive toxicity study was conducted as 
part of a chronic toxicity study in rats (IRDC, 1981b; Borzelleca, Depukat & 
Hallagan, 1990). The test material was USFDA-certified Brilliant Blue FCF 
of 90% purity with the remaining 10% consisting of subsidiary colours, 
Table 1 (continued)
p Four daily intraperitoneal administrations with sampling 24 hours after the final administration.
q Administered via oral gavage.
r Groups of animals were killed 3 or 24 hours after single dose administration.
s Tissues examined included glandular stomach, colon, liver, kidney, bladder, lung, brain and bone marrow; four animals per dose group; 50 nuclei per organ per animal 
measured.
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volatile chlorides and sulfates, and uncombined intermediates. Brilliant 
Blue FCF was given to 60 animals/sex per group (~100 days of age) for 62 
days at dietary levels of 0, 0.1%, 1% and 2% (equivalent to 0, 50, 514 and 
1073 mg/kg bw per day for males and 0, 62, 631 and 1318 mg/kg bw per 
day for females, respectively). One male and one female from the same 
treatment group were mated for 15 consecutive days. Body weights of the 
dams were recorded on gestation days 0, 4, 14 and 21.
There were no differences between controls and treated animals 
in fertility, gestation, parturition, lactation, pup survival through weaning 
or number of live and stillborn pups. Dam mortality was not treatment 
related. One female in the 0.1% group, one male and one female in the 
1.0% group, and one male in the 2.0% group died.
The NOAELs for reproductive end-points were 1073 mg/kg bw per 
day for males and 1318 mg/kg bw per day for females, the highest dose 
levels tested. The Committee noted that the study was performed before 
OECD guidelines were established but that it was in compliance with 
USFDA GLP Regulations of 20 June 1979.
Brilliant Blue FCF (purity >85%) was tested for reproductive 
toxicity and the potential induction of neurobehavioural effects in 
Crlj:CD1 mice (10/sex per group; 5 weeks of age at treatment start) at 
dietary levels of 0, 0.08%, 0.24% and 0.72% (equivalent to 111–407, 347–
1287 and 1032–3856 mg/kg bw per day). Administration commenced 4 
weeks prior to mating (F0 mice mated at 9 weeks of age for 5 days) and 
continued through gestation (14 days), lactation (from birth to weaning, 
~4 weeks) and through to 4–11 weeks of age in the F1 generation. Selected 
reproductive and neurobehavioural parameters were measured.
There were no significant differences between control and treated 
F0 mice in body weights or reproductive success, except for significantly 
increased average body weight of dams in the high-dose group in the 
second week of lactation. No treatment-related differences were observed 
in offspring survival, body weights or neurobehavioural parameters 
(Tanaka et al., 2012).
The authors concluded that the high dose of Brilliant Blue FCF 
resulted in a few significant effects on behavioural development and 
no significant effects on reproduction. The Committee noted that the 
study was not performed according to GLP and did not meet current 
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OECD guidelines (e.g. only some selected reproductive parameters were 
measured).
(b) Developmental toxicity
Brilliant Blue FCF (purity 92%) was given to pregnant Long–Evans rats by 
oral gavage (in 0.5% methylcellulose at 1 mL/100 g bw) from gestation day 
6 to 15 at 0, 200, 600 or 2000 mg/kg bw per day (n = 22–24/group). Three 
vehicle control groups (n = 22 each) were included and a positive control 
group of animals (n = 22) treated with 30 mg/kg bw per day of Trypan Blue 
(injected subcutaneously from day 7 through day 9). Dams that survived 
to the end of the treatment period were killed on day 20. The number of 
corpora lutea recorded and uterine contents examined. All fetuses were 
examined for malformations and about two thirds were examined for 
skeletal ossification, variations and anomalies. Statistical comparisons 
between test and vehicle control groups were made with chi-square test, 
t-test or F-test, as appropriate.
There was no evidence of fetal toxicity or any developmental 
abnormalities that could be attributed to the administration of Brilliant 
Blue FCF (BioDynamics Inc., 1972b).
In a parallel developmental toxicity study, Brilliant Blue FCF 
(purity 92%, the same batch as in the rat study described above) was 
given orally (in 0.5% methylcellulose at 1 mL/kg bw) to pregnant New 
Zealand White rabbits on gestation days 6–18 at 0, 20, 60 or 200 mg/kg 
bw per day (n = 18, 19 and 15, respectively). Three vehicle control groups 
(n = 15–17/group) were included and a positive control group of animals 
(n = 15) treated with 150 mg/kg bw per day of thalidomide. Rabbits that 
survived to the end of the study were killed on day 20. The number of 
corpora lutea were recorded and uterine contents examined. All fetuses 
were weighed, examined macroscopically for externally visible defects and 
visceral anomalies and examined for skeletal ossification, variations and 
anomalies. Statistical comparisons between test and vehicle control groups 
were made with chi-square test, t-test or F-test, as appropriate.
There was no evidence of fetal toxicity or anomalies that could be 
attributed to the administration of Brilliant Blue FCF (BioDynamics Inc. 
1972a).
The Committee noted that these two studies were performed before 
OECD guidelines and GLP requirements were established. The protocols 
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were, however, based upon segment II (Teratology Study) of the USFDA 
“Guidelines for Reproduction Studies for Safety Evaluation of Drugs for 
Human Use” from 1966.
2.2.6 Special studies
(a) Allergenicity
Brilliant Blue FCF (purity not reported) did not cause significant 
degranulation or histamine release from rat mast cells as demonstrated in 
vitro and ex vivo using mast cells harvested from the peritoneal cavity of male 
Sprague Dawley rats (Kreindler, Slutsky & Haddad, 1980). The rats were 
given the colour in drinking-water for 3 months at concentrations found in 
coloured soft drinks. The degranulation was investigated microscopically 
and the histamine release was assayed spectrophotofluorometrically. The 
authors concluded that Brilliant Blue FCF does not release histamine by an 
immunological mechanism.
No evidence of sensitization potential was found when Brilliant 
Blue FCF was tested in a local lymph node assay (SCCNFP, 2004).
(b) Neurotoxicity
Brilliant Blue FCF (purity not reported) was among other food colours 
evaluated in neuroblastoma cells in vitro for synergistic effects on 
developmental neurotoxicity parameters (Lau et al., 2006). Inhibition of 
neurite outgrowth over 24 hours was used as a marker of developmental 
neurotoxicity. Neurite outgrowth length was reduced in cells treated with 
Brilliant Blue FCF (0.05–500 nmol/L) in combination with L-glutamic acid 
(0.5–100 μmol/L), although each of them alone resulted in relatively weak 
inhibition of neurite outgrowth. The authors concluded that the combined 
treatment produced a synergistic inhibitory effect.
Park et al. (2009) examined the potential developmental toxicity in 
the central nervous system of Brilliant Blue FCF (purity not reported) as 
a single substance or in combination with other food colours by assessing 
neural progenitor cell survival and proliferation in vitro and the numbers 
of new neuronal progenitor cells in young ICR mice in vivo. Cells in culture 
were treated with Brilliant Blue FCF at concentrations of 100 nmol/L 
to 1 mmol/L at 10-fold increments for 12, 24 or 48 hours. Cell toxicity 
and proliferation were measured with the MTT assay. Only the highest 
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concentration resulted in reduced cell proliferation and survival after 48 
hours of exposure. Cell death was also noted at the highest concentration 
after 12 and 24 hours and at the second highest concentration after 24 
hours.
In the second part of the study, male mice (5 weeks old) were 
treated with Brilliant Blue FCF by oral gavage for 2 weeks, at 0.426, 
4.26 or 42.6 mg/kg bw per day (equal to 10-, 100- and 1000-fold the 
estimated daily dietary exposure to Brilliant Blue FCF of consumers in 
the Republic of Korea, that is, ~4% of ADI of 12.5 mg/kg bw per day). 
New neuronal growth was evaluated in brain sections following staining 
for bromodeoxyuridine (BrdU; 100 mg/kg bw per day) administered 
by intraperitoneal injections twice daily for 3 days; the mice were killed 
1 day after the last injection. There were no effects on body weight. No 
differences in BrdU incorporation were noted in animals treated with 
Brilliant Blue FCF alone. Decreased staining, implying reduced neuronal 
growth, was reported in animals treated with binary combinations of 1 
mmol/L of each colour, including Brilliant Blue FCF with tartrazine, for 
48 hours. The combination of Brilliant Blue FCF and tartrazine resulted in 
significantly decreased numbers of newly generated cells in adult mouse 
hippocampus at the highest dose (42.6 mg/kg bw per day Brilliant Blue 
FCF and 147.6 mg/kg bw per day tartrazine). According to the authors, 
this indicates adverse actions on hippocampal neurogenesis. However, it 
is not clear to what extent this effect was due to Brilliant Blue FCF (Park 
et al., 2009).
In a reproductive toxicity study in Crlj:CD1 mice (10/sex per 
group; 5 weeks of age at the start of treatment) (described in section 2.2.5), 
Tanaka et al., (2012) tested Brilliant Blue FCF (purity >85%) for potential 
induction of neurobehavioural effects at dietary levels of 0, 0.08%, 0.24% 
or 0.72% (equivalent to 111–407, 347–1287 and 1032–3856 mg/kg bw per 
day). Administration commenced 4 weeks prior to mating (F0 mice mated 
at 9 weeks of age for 5 days) and continued through gestation (14 days), 
lactation (from birth to weaning, ~4 weeks) and through to 4–11 weeks of 
age in the F1 generation.
Statistically significant trends of increased movement time 
(P = 0.019) in the exploratory behaviour test was noted in F0 females after 3 
weeks of treatment. However, there was a trend to decreased average time 
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of rearing (P = 0.027). A significant trend (P < 0.01) of delayed surface 
righting in F1 males and females was observed on postnatal day 4, and 
the difference was also significant between both the high-dose male and 
female offspring and control groups. However, when the same test was 
run on postnatal day 7, there were no significant differences for either sex. 
There were also no effects in the inclined plane test (postnatal days 4 and 
7), in cliff avoidance (postnatal day 7), in the swimming test (postnatal day 
7) or olfactory orientation (postnatal day 14). The authors also described 
some statistically significant trends in exploratory behaviour in F1 males 
and females, although they noted that the effects in males appeared 
inconsistent (Tanaka et al., 2012).
The Committee noted that the study was not performed according 
to GLP and did not meet the 2007 OECD Test Guideline 426 (e.g. 
concerning the number of animals per group).
In a study examining the association of artificial colour exposure 
and behavioural and learning outcomes, Brilliant Blue FCF (purity not 
reported) was included in a mixture with eight other colouring agents 
(erythrosine, Ponceau 4R, Sunset Yellow, Allura Red, amaranth, tartrazine, 
azorubine and Indigo Carmine) given by oral gavage to female Wistar 
Han rats (n = 15/group), each at a dose equal to their respective ADI. The 
animals received a dose of 12.5 mg/kg bw per day of Brilliant Blue FCF. 
The dams were treated for 1 week prior to mating, 5 days during mating 
and throughout pregnancy (with males untreated except for during the 
mating period). F1 offspring were weaned 1 month after birth. At 12 weeks 
of age, the brains of the F1 generation were isolated and tested for protein 
expression of the subunits NR2A and NR2B of the N-methyl-D-aspartate 
receptors and subunits a4, b2 and a7 of the nicotinic acetylcholine receptors 
(nAChRs) in brain tissue homogenates (hippocampi) by Western blotting 
and image density analysis.
In males, protein expression levels of NR2B and nAChR b2 was 
significantly increased (17% and 6.7%, respectively), whereas expression 
of nAChR a4 was significantly decreased (5.67%) compared with controls 
(P < 0.05). In contrast, a 14% decrease in NR2B protein levels was reported 
in females (P < 0.05). However, it is not clear to what extent the observed 
effects were due to Brilliant Blue FCF (Ceyhan et al., 2013).
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In a developmental neurobehavioural study, Brilliant Blue FCF 
(purity not reported) was given to female Wistar albino rats (n = 15/group) 
before and during gestation in a mixture of eight other colouring agents 
(erythrosine, Ponceau 4R, Sunset Yellow, tartrazine, amaranth, Allura Red, 
azorubine and Indigo Carmine). The mixture was given in water by oral 
gavage at concentrations calculated to deliver a dose of each colouring 
agent equivalent to their NOAEL; for Brilliant Blue FCF, the dose was 600 
mg/kg bw per day. The effects of the mixture on spatial working memory in 
offspring was assessed using the Morris water maze test, and behavioural 
and locomotor effects were assessed using the open-field and forced-swim 
tests.
No adverse effects were reported on spatial working memory and 
no depressive behaviour was reported in offspring. A few parameters of 
locomotor activity were significantly increased including “latency to locate 
the visible platform” (a measure of motivation) and forced-swim test 
parameters; anxiolytic-like effect in the open-field test; and mobility time 
in the forced-swim test. The authors suggested that the findings implied a 
sex-related increase in motility and a decrease in motivation and anxiety. 
It is, however, not clear to which extent the effects observed were due to 
Brilliant Blue FCF (Doguc et al., 2015).
(c) Skin cancer
Brilliant Blue FCF was tested for skin carcinogenicity in Swiss Webster mice 
(50/sex per group), among other colouring substances (Carson, 1984). 
Brilliant Blue FCF (0.1 mL of a 1% aqueous suspension) was applied to 6 
cm2 of clipped skin twice per week for 18 months. Untreated and vehicle 
negative controls were included. The treatment with Brilliant Blue FCF did 
not increase the incidence of skin neoplasms compared to control animals, 
unlike treatment with the positive control, 3,4-benzopyrene in acetone, 
which did. It was concluded that Brilliant Blue FCF is unlikely to cause 
skin cancer as a result of repeated dermal exposure.
2.3 Observations in humans
Two out of 24 urticaria patients reported sensitivity to “Brilliant Blue” 
(purity not reported, chemical identity unclear) when tested using a patch 
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test for allergic response to drug excipients. The condition of these patients 
was exacerbated by treatment with antihistamines (Shah, 2010).
No evidence of skin irritation or sensitization was reported in 207 
human volunteers who underwent daily skin applications of a 5% aqueous 
solution of Brilliant Blue FCF or its aluminium lake. Testing included an 
induction phase of three applications per week for 3 weeks, followed by a 
challenge application 12 days later (BIBRA, 1990).
Three cases of chronic, unexplained pruritic skin disorders 
responded to medication changes related to the presence of Brilliant 
Blue FCF (Swerlick & Campbell, 2013). Because these medications also 
contained other dyes and excipients, it is not clear to what extent the 
response observed was due to Brilliant Blue FCF.
There are several reports in which the use of Brilliant Blue FCF in 
enteral feeding solutions has been associated with toxicity, including 12 
deaths (WHO, 2003; Maloney & Brand, 2016). Its use in enteral feeding 
solutions was to facilitate detection and/or monitoring of pulmonary 
aspiration in patients fed via an enteral feeding tube. Some of the reported 
cases were associated with serious complications such as refractory 
hypotension, metabolic acidosis and death. A drip-chamber dye pellet 
tubing system that delivers 10 mg of dye per hour was used in several 
cases (Maloney & Brand, 2016). In a case with sepsis who developed green 
urine, serum and skin while receiving enteral feedings tinted with Brilliant 
Blue FCF, the concentrations of Brilliant Blue FCF in serum and urine 
samples were 10 and 100 µg/mL, respectively (Maloney & Brand, 2016). A 
causal relationship between systemic absorption of Brilliant Blue FCF and 
the reported outcomes has not been definitively established (WHO, 2003).
3. Dietary exposure
The Committee prepared a review of dietary exposure of Brilliant Blue 
FCF based on information from the European Food Safety Authority 
(EFSA, 2010); the Council of Scientific and Industrial Research (CSIR), 
Food Standards Australia New Zealand (FSANZ, 2012); India (Dixit et 
al., 2011; Dixit, Khanna & Das, 2013); the Kuwait Institute for Scientific 
Research (Husain et al., 2006); Konkuk University, Republic of Korea (Ha 
et al., 2013); and USFDA (Doell et al., 2016) (Table 2).
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Organization 
(reference)
Concentration 
data Sampling strategy Consumer groups
Food consumption 
data
Estimates of 
dietary exposure
USFDA
(Doell et al., 2016)
Analytical levels in 
foods
Targeted selection 
using label and/or 
colour 
USA population
2 years and older;
children 2–5 years;
boys 13–18 years)
Individual dietary 
records
food diaries.
2 days;
10–14 days
Mean;
P90 scenariosa,b,c
EFSA
(EFSA, 2010)
Budget method; 
MPLs; use levels in 
foods
Adults;
Children 1–5 years
(United Kingdom: 
1.5–4.5 years)
Individual dietary 
records or 24-hour 
recall (depending on 
survey),
2–7 days
Mean;
P95
or P97.5 scenariosa,b,c
FSANZ
(FSANZ, 2012)
Analytical levels in 
foods in combination 
with use levels (for 
confectionery)
Targeted selection 
using label and/or 
colour 
2 years and above;
2–5 years; 6–12 
years; 13–18 years;
19–24 years; 25 
years and above
24-hour recall,
2 days
Mean;
P90 scenariosb,c
Konkuk University, 
Republic of Korea
(Ha et al., 2013)
Analytical levels in 
foods
Market share 1–2 years; 3–6 years; 
7–12 years; 13–19 
years; 20–29 years; 
30–49 years; 50–64 
years; 65 years 
and above; male; 
female; upper 95th 
consumers
24-hour recall Mean;
P95 scenariosb
CSIR, India
(Dixit et al., 2011; 
Dixit, Khanna & Das, 
2013)
Analytical levels in 
foods
Targeted selection 
using colour in 
combination with 
market share
4–6 years; 7–9 years; 
10–12 years; 13–15 
years; 16–18 years
Limited household 
survey; food 
frequency recall
Mean;
P95 scenariosb
Kuwait Institute for 
Scientific Research 
(Husain et al., 2006)
Analytical levels in 
foods
Targeted selection 
using label and/or 
colour
5–14 years (one year 
per group, male or 
female)
24-hour recall;
2 days
Mean;
Scenariosb
Table 2
summary information on studies of dietary exposure to Brilliant Blue fCf
CSIR: Council of Scientific and Industrial Research; FSANZ: Food standards Australia New Zealand; EFSA: European Food Safety Authority; MPL: maximum permitted 
level; USFDA: United States Food and Drug Administration; P90: 90th percentile; P95: 95th percentile; P97.5: 97.5th percentile
a The lowest analytical value for the colour additive was assigned to each food code.
b The analytical results were averaged for a given food code.
c The highest analytical value for the colour additive was assigned to each food code.
Since these studies were based on individual dietary records, 
analytical levels in foods or reported use levels, the Committee did not 
consider it necessary to include dietary exposure estimates based on the 
budget method, poundage data or diet models.
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3.1 Assessments based on individual dietary records
3.1.1 Exposure estimates reported by USFDA
Brilliant Blue FCF is approved in the USA for general use in food at 
levels consistent with good manufacturing practice (GMP). In a study 
completed by the USFDA (Doell et al., 2016), approximately 600 samples 
from 52 broad food categories were analysed for Brilliant Blue FCF (Harp, 
Miranda-Bermudez & Barrows, 2013). Samples were selected based on a 
previous survey on food labels. Brilliant Blue FCF was found in products 
in 36 of the 52 food categories at concentrations ranging from the limit of 
detection (LOD; 1 mg/kg) to over 10 000 mg/kg (in the category “Frostings 
and Icings”; the second highest value (233 mg/kg) was found in the 
category “Ice Cream Cones”). If Brilliant Blue FCF was not included in the 
ingredient list, it was presumed it was not present in the food. However, 
if it was declared on the label, but the result for the colour was below the 
LOD, Brilliant Blue FCF was presumed present in the food at the LOD.
Two different sets of food consumption data from 2007–2010 
were used for the dietary exposure estimates: a 2-day and a 10- to 14-day 
dietary exposure survey for the United States population. Three population 
groups were used for the exposure estimate: the overall population 2 years 
and older; children aged 2–5 years; and teenage boys aged 13–18 years. 
Exposures were estimated based on “eaters-only”, that is, individuals in 
the population who consumed one or more of the included foods over the 
survey period. Three different exposure scenarios were performed: (1) a 
low-exposure scenario, where the lowest analytical value for Brilliant Blue 
FCF was assigned to the corresponding food code in the consumption 
survey; (2) an average-exposure scenario, where the analytical results 
were averaged for a given food code; and (3) a high-exposure scenario, 
where the highest analytical value was assigned to each food code. Dietary 
exposures were estimated at the mean and at the 90th percentile for each 
population for each food category (Table 3).
For all three groups “Juice Drinks” were the main contributor (20–
25% of total exposure). Other major contributing food groups were “Ice 
Cream Cones”, “Soft Drinks”, “Breakfast Cereal” and “Decoration/Chips 
for Baking”.
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3.1.2 Exposure estimates reported by EFSA
The EFSA Panel on Food Additives and Nutrient Sources added to Food 
(ANS) has re-evaluated the safety of Brilliant Blue FCF when used as a 
food additive (EFSA, 2010). A tiered approach was used.
Dietary exposure estimates using a budget method or maximum 
permitted levels (MPLs) of use are not included in the review since a more 
refined estimate using maximum use levels or maximum level determined 
by analysis was available (Table 4).
Refined exposure estimates were performed using national 
consumption data from a United Kingdom consumption survey (Tennant, 
2008). For children (1–10 years old), estimates have been calculated for 
the United Kingdom (Tennant, 2008) and for 11 European countries as 
part of the EXPOCHI consortium (Belgium, Cyprus, the Czech Republic, 
Finland, France, Germany, Greece, Italy, the Netherlands, Spain and 
Sweden) (Huybrechts et al., 2011). The United Kingdom population was 
selected as representative of adult European Union consumers for Brilliant 
Blue FCF exposure estimates because this survey likely represented the 
highest exposed population in the European Union.
In the refinement using the maximum reported use levels (Table 4) 
made available by the United Kingdom Food Standards Agency (FSA), the 
Study / 
Population 
age in years % Eaters
Dietary exposure (mg/kg bw per day)
Low-exposure scenario Average-exposure scenario High-exposure scenario
Mean P90 Mean P90 Mean P90 
NHANES 2-day food consumption data
≥2 92 0.01 0.03 0.02 0.05 0.04 0.09
2–5 96 0.04 0.07 0.07 0.1 0.1 0.2
Boys 13–18 93 0.02 0.03 0.02 0.05 0.04 0.1
NET-NID 10- to 14-day food consumption data
≥2 99 0.01 0.02 0.02 0.04 0.04 0.06
2–5 100 0.02 0.04 0.04 0.07 0.1 0.1
Boys 13–18 100 0.01 0.03 0.02 0.04 0.04 0.06
Table 3
eaters-only exposure to Brilliant Blue fCf for the United states population based on 
nHAnes 2-day and net-nID 10- to 14-day food consumption data
bw: body weight; NET-NID: National Eating Trends – Nutrient Intake Database; NHANES: National Health and Nutrition Examination Survey; P90: 90th percentile
Source: Doell et al. (2016)
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Food group
Maximum permitted 
level (mg/L)a
Maximum reported use 
level (mg/L)
Beverages
Fruit wines, cider and perry 200 5b
Nonalcoholic flavoured drinks 100 65b
Liquid food supplements/dietary integrators 100 100c
Spirituous beverages 200 200b
Aromatized wines, aromatized wine-based drinks and aromatized wine-product 
cocktails
200 200c
Foodstuffs
Complete formulas and nutritional supplements for use under medical supervision 50 20b
Complete formulas for weight control intended to replace total daily food intake or 
an individual meal
50 50c
Soups
Flavoured processed cheese 100 100c
Fish paste and crustaceans paste
Smoked fish
Savoury snack products and savoury coated nuts
Meat and fish analogues based on vegetable proteins
Desserts including flavoured milk products 150 0.1b
Edible ices 150 145b
Fine bakery wares 200 200b
Candied fruit and vegetables, Mostarda di frutta 200 200c
Preserves of red fruits
Extruded or expanded savoury snack products
Pre-cooked crustaceans 250 250c
Confectionery 300 300b
Mustard 300 300c
Fish roe
Solid food supplements/dietary integrators
Sauces, seasonings, pickles, relishes, chutney and piccalilli 500 500c
Salmon substitutes
Surimi
Decorations and coatings 500 500b
Edible cheese rind and edible casings Quantum satis 100d
Edible casings Quantum satis 500d
a According to the European Parliament and Council Directive 94/36/EC.
b Maximum use level or maximum level determined by analysis.
c Maximum permitted level.
d Quantum satis data.
Source: EFSA (2010)
Table 4
Maximum permitted levels of use and maximum reported use levels of Brilliant Blue fCf in 
beverages and foodstuffs used for the refined exposure assessment
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Food Safety Authority of Ireland (FSAI), the Union of European Beverage 
Associations (UNESDA) and the Confederation of the Food and Drink 
Industries of the European Union (CIAA), the dietary exposure estimate 
for Brilliant Blue FCF showed a mean dietary exposure for the adult 
population of the United Kingdom of 0.6 mg/kg bw per day and of 3.0 mg/
kg bw per day for high-level consumers (97.5th percentile exposure from 
beverages plus per capita average from the rest of the diet).
The mean dietary exposure of European children (aged 1–10 years 
and weighing 16–29 kg) ranged from 0.2 to 2.1 mg/kg bw per day, and from 
0.6 to 4.8 mg/kg bw per day at the 95th percentile. The main contributors 
to the total anticipated mean exposure to Brilliant Blue FCF (>10% in all 
countries) were nonalcoholic beverages (13–53%), fine bakery wares (12–
64%) and sauces, seasonings, pickles, relishes, chutney and piccalilli (14–
60%). Confectionery accounted for 19–24% of exposure in two countries, 
while extruded or expanded savoury snack products accounted for 17% of 
exposure in one country.
3.1.3 Exposure estimates based on individual dietary records (FSANZ)
FSANZ has published an analytical survey to quantify actual levels of 
permitted synthetic colours in foods and beverages in Australia. Brilliant 
Blue is permitted at 70 mg/L in beverages and 290 mg/kg in other foods. 
In 2006, 396 samples were collected and analysed for added colours. These 
results were combined with results of a South Australian survey of synthetic 
colours in foods, sampled in 2004, to give information for a total of 651 
samples (FSANZ, 2008). The dietary exposure estimates for children have 
been updated (FSANZ, 2012) using food consumption data from the 2007 
Australian Children’s Nutrition and Physical Activity Survey and updated 
information on typical use level data from the confectionery industry. A 
comparison of the FSANZ 2008 analytical data with the concentrations 
provided by industry showed only showed negligible differences.
The FSANZ 2008 survey did not specifically analyse for synthetic 
colours in the “lake” form. Lake colours are formed when a synthetic dye is 
combined with a metallic salt substrate such as aluminium hydroxide. Due 
to their insolubility in water and stability in light, lake colours are generally 
used to colour the coating of panned sugar confectionery (Downham & 
Collins, 2000). After the publication of the added colours survey (FSANZ, 
2008), industry provided FSANZ with concentration data on the usage of 
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lake colours in confectionery. These concentration data were used in the 
revised dietary exposure estimates for children aged 2–16 years (Table 5).
The main contributors in the four age groups were (in varying order 
within each age group) flavoured milk (14–25%); ice cream and edible ices 
(11–25%); soft drinks (12–30%); and cakes, muffins and pastries (11–15%).
3.1.4 Exposure estimates based on individual dietary records (Others)
The dietary exposure to Brilliant Blue FCF in the Republic of Korea 
was estimated based on food consumption data for consumers and 
concentrations in processed foods (Ha et al., 2013). Brilliant Blue FCF was 
found in samples of biscuits, candies, chocolate, chewing gum, ice cream, 
beverages, pickled vegetables and liquor. For the average consumer in 
the Republic of Korea (using average concentrations of all samples in a 
food group), the estimated mean and 95th percentile for dietary exposure 
were 0.01 and 0.03 mg/kg bw per day, respectively. For a high-exposure 
consumer (using the average of positive samples), the estimated mean and 
95th percentile for dietary exposure were 0.05 and 0.12 mg/kg bw per day, 
respectively.
Brilliant Blue FCF is permitted in specific foods in levels up to 
100 mg/kg in India. Dietary exposures to Brilliant Blue FCF for children 
in 16 states of India from selected food groups (bakery products, 
beverages, candyfloss, chewing gums, coated candies, hard-boiled sugar 
confectioneries, jam and jellies, ice candy/ice creams, mouth fresheners 
and sugar toys) have been estimated (Dixit et al., 2011). A limited 
household survey on the food consumption patterns of 518 subjects was 
conducted and the exposure to colours was assessed through the food 
frequency recall method. Estimated dietary exposure for Brilliant Blue 
FCF (average consumption, average concentration values) for children 
aged 4–6, 10–12, 13–15 or 16–18 years were 0.1 mg/kg bw per day while 
for children aged 7–9 years the estimated dietary exposure was 0.2 mg/
kg bw per day. Estimated dietary exposure (high consumption, high 
concentration values) for children aged 4–6, 7–9, 10–12, 13–15 or 16–18 
years were 0.4–1.0 mg/kg bw per day.
Dietary exposure to Brilliant Blue FCF in school children in Kuwait 
from selected food groups (biscuits, cakes and ice cream, candy, chips 
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and puffed snacks, chocolates, drinks and juices, chewing gum, jelly and 
lollypops) have been estimated (Husain et al., 2006). Consumption was 
estimated from a 24-hour dietary recall involving 3142 male and female, 
Kuwaiti and non-Kuwaiti, children between the ages of 5 and 14 years 
enrolled in private and public, primary and intermediate schools. A total 
of 344 foodstuffs were analysed for their contents of artificial food colour 
additives, including Brilliant Blue FCF. The estimated dietary exposure 
(average values) of Brilliant Blue FCF for children aged 5–14 years (in 
age groups of one year, male or female) was 0.1–2.4 mg/kg bw per day. 
Children aged 6 years had the highest estimated exposure (1.7–2.4 mg/kg 
bw per day) while children aged 13 and 14 years had the lowest (0.1–0.23 
mg/kg bw per day). The Committee noted that this study had been used 
in estimating dietary exposures to tartrazine at a previous meeting (82nd 
meeting) where the Committee dismissed the relevance of the study as not 
being representative. The current Committee considered that, although 
the survey was not nationally representative, it was of positive value in 
the assessment of Brilliant Blue FCF and therefore its results are included 
herein.
3.2 Evaluation of estimates of dietary exposure
Estimates of dietary exposure to Brilliant Blue FCF published by EFSA, 
FSANZ, India, Kuwait, the Republic of Korea and USFDA are summarized 
in Table 6.
Table 5
estimated dietary exposures (consumers only) to Brilliant Blue fCf for Australian consumers
bw: body weight; P90: 90th percentile
a  Consumers as a % of total respondents.
b  FSANZ (2008).
c  FSANZ (2012).
Age group 
(years)
Consumers
Mean colours scenario 
(mg/kg bw per day)
Maximum colours scenario 
(mg/kg bw per day) 
n %a Mean P90 Mean P90 
≥ 2b 7 761 56 0.01 0.03 0.05 0.12
2–5c 1 086 92 0.02 0.05 0.1 0.24
6–12c 1 956 94 0.02 0.04 0.07 0.17
13–16c 1 090 89 0.01 0.03 0.05 0.11
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Mean High percentile Mean High percentile
USFDA
(Doell et al., 2016)
Consumers only, population ≥2 years Consumers only, children 2–5 years
2-day food 
consumption data
Average-exposure scenario 0.02 0.05a 0.07 0.10a
High-exposure scenario 0.04 0.09a 0.10 0.20a
10–14-day food 
consumption data
Average-exposure scenario 0.02 0.04a 0.02 0.04a
High-exposure scenario 0.04 0.06a 0.04 0.06a
FSANZ
(FSANZ, 2012)
Consumers only, population ≥2 years Consumers only, children 2–5 years
Mean colours scenario 0.01 0.03a 0.02 0.05a
Maximum colours scenario 0.05 0.12a 0.10 0.24a
EFSA
(EFSA, 2010)
Population ≥18 years Children 1–10 years
Maximum reported use levels 0.06 3.0b 0.2–2.1 0.6–4.8c
Konkuk University, 
Republic of Korea
(Ha et al., 2013)
Consumers
0.01 0.03c – –
CSIR, India
(Dixit et al., 2011)
Children 4–18 years
Average-exposure scenario – – 0.1–0.2 –
High-exposure scenario – – – 0.4–1.0c
Kuwait Institute for 
Scientific Research 
(Husain et al., 2006)
Children 5–14 years
Average-exposure scenario – – 0.1–2.4 –
The estimates of dietary exposure to Brilliant Blue FCF calculated 
by EFSA (4.8 mg/kg bw per day, 95th percentile) were much higher than 
those of USFDA and FSANZ (both 0.2 mg/kg bw per day for children at 
the 90th percentile) and the Republic of Korea (0.03 mg/kg bw per day at 
the 95th percentile for whole population). Estimates for India and Kuwait 
were also lower than the EFSA estimates, but higher than the estimates 
from USFDA and FSANZ. The Committee concluded that the higher 
values in the EFSA estimates were due to the use of maximum reported 
Table 6
estimated dietary exposures to Brilliant Blue fCf based on individual dietary records (mg/
kg bw per day)
CSIR: Council of Scientific and Industrial Research; EFSA: European Food Safety Authority; FSANZ: Food Safety Australia New Zealand; USFDA: United States Food and 
Drug Administration
a 90th percentile.
b 97.5th percentile exposure from beverages plus per capita average from the rest of diet.
c 95th percentile.
34
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
5,
  2
01
8
Safety evaluation of certain food additives   Eighty-fourth  JECFA
use levels, as opposed to the use of the analysed levels for foods in the 
other studies.
4. Comments
4.1 Biochemical aspects
When Brilliant Blue FCF was administered orally to rats, almost the entire 
dose was excreted unchanged in the faeces within 40 hours. The colour was 
also found in the bile of rats, rabbits and dogs after oral administration. 
Only 5% of the dose administered was excreted in the bile of dogs (Hess 
& Fitzhugh, 1953, 1954, 1955). In other studies, absorption of Brilliant 
Blue FCF was about 0.5% in rats (Brown et al., 1980; Phillips et al., 1980), 
with more than 99% of total intake excreted in the faeces and less than 
1% recovered in the urine. Results of TLC of urine and bile samples 24 
hours after ingestion showed that about 95% of excreted radioactivity 
was unaltered 14C-radiolabelled Brilliant Blue FCF and that about 5% was 
unidentified metabolite(s) or degradation product(s). Mass spectrometric 
analysis was, however, not used.
An ex vivo porcine tongue system showed that about 0.2% of 
Brilliant Blue FCF diffused through the surface oral mucosa layers (Lucová 
et al., 2013).
Equilibrium dialysis methods have demonstrated that Brilliant 
Blue FCF binds to rat plasma protein (Iga, Awazu & Nogami, 1971; Iga et 
al., 1971). The extent of binding of Brilliant Blue FCF with plasma protein 
was 65% after 160 hours of dialysis at 37 °C.
In an in vitro study in which the Xenopus oocyte expression system 
was used for pharmacological investigations on purinergic P2 receptors 
that interact with the membrane channel protein Panx1 in inflammasome 
signalling, Brilliant Blue FCF was shown to be a selective inhibitor of 
Panx1 channels, with an IC50 of 0.27 µmol/L; no significant effect on the 
P2X7R receptor was observed at concentrations as high as 100 µmol/L 
(Wang, Jackson & Dahl, 2013). The Committee was aware that Panx1 
activation/inhibition is one of several signalling pathways involved in 
various physiological processes at the cellular level (e.g. immune function) 
and that there are many exogenous and endogenous modulators of these 
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pathways. Interactions of substances with P2 receptors and Panx1 are an 
active area of research, particularly in development of drug treatments for 
diverse chronic diseases. The Committee noted that a similar pattern of 
channel inhibition was observed with Fast Green FCF, and further research 
may clarify if the inhibition of Panx1 observed in an in vitro system has 
any relevance for the safety assessment for substances in food.
4.2 Toxicological studies
The acute toxicity of Brilliant Blue FCF is low. The LD50 in mice (Sasaki et 
al., 2002) and rats (Lu & Lavallee, 1964) was higher than 2000 mg/kg bw.
In a 1-year dietary study, 12 dogs were fed Brilliant Blue FCF 
(purity not reported) at 0%, 1% or 2%. No clinical signs, gross lesions or 
microscopic pathological findings were attributed to exposure to Brilliant 
Blue FCF (Hansen et al., 1966).
The long-term toxicity of Brilliant Blue FCF was investigated in 
three studies in mice and five in rats.
No evidence of treatment-related carcinogenicity was found when 
male and female mice were fed Brilliant Blue FCF at a dose of 1 mg/kg bw 
per day over 500–700 days (Waterman & Lignac, 1958).
The administration of Brilliant Blue FCF to male and female mice 
for up to 80 weeks in the diet at concentrations of 0%, 0.015%, 0.15% or 
1.5% (equivalent to 0, 20, 200 and 2000 mg/kg bw per day, respectively) 
resulted in slight reduction in weight gain and increased incidence of foam 
cells in the liver at the highest dose (Rowland et al., 1975). The NOAEL 
was 0.15% (equivalent to 200 mg/kg bw per day).
In a long-term toxicity study in which Brilliant Blue FCF was fed to 
male and female mice for 24 months (104 weeks) at dietary concentrations 
of 0%, 0.5%, 1.5% or 5% (equal to 0, 661, 2064 and 7354 mg/kg bw per 
day for males and 0, 819, 2562 and 8966 mg/kg bw per day for females, 
respectively), the NOAEL was 5% (equal to 7354 mg/kg bw per day), 
the highest concentration tested (IRDC, 1981a; Borzelleca, Depukat & 
Hallagan, 1990). The Committee noted that the survival at the end of the 
study was about 50% in both control and treated groups.
When Brilliant Blue FCF was fed to male and female rats at a 
dietary level of 4% for 600 days, there were no treatment-related tumours 
(Willheim & Ivy, 1953). In another long-term toxicity study in which rats 
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were fed a diet containing 0.1% Brilliant Blue FCF over their lifetime (daily 
intake 10–15 mg), no treatment-related tumours were found (Klinke, 
1955). Similarly, when male and female rats were fed diets containing 0%, 
0.3% or 3% Brilliant Blue FCF for 75 weeks, no treatment-related adverse 
effects were observed on tumour incidence, growth or haematological 
findings (Mannell, Grice & Allmark, 1962).
In its previous evaluation at the thirteenth meeting (Annex 1, 
reference 19), the Committee established an ADI of 0–12.5 mg/kg bw 
based on a 2-year toxicity study in which male and female rats were fed 
a diet containing 0%, 0.5%, 1.0%, 2.0% or 5.0% Brilliant Blue FCF. The 
NOAEL was 5.0% (equivalent to 2500 mg/kg bw per day), the highest 
concentration tested (Hansen et al., 1966).
In a long-term toxicity study that included an in utero exposure 
phase, Brilliant Blue FCF was fed to the F0 rats for up to 17 weeks at levels 
of 0%, 0.1%, 1% or 2% (calculated to provide doses of 0, 50, 514 and 1073 
mg/kg bw per day for males and 0, 62, 631 and 1318 mg/kg bw per day 
for females, respectively). The F1 animals were administered Brilliant Blue 
FCF at the same dose levels for up to 116 weeks for males and 111 weeks 
for females. The NOAEL was 1% (equal to 631 mg/kg bw per day), based 
on 15% decreased mean terminal body weight and decreased survival of 
female rats at the highest dose level (IRDC, 1981b; Borzelleca, Depukat & 
Hallagan, 1990).
The Committee concluded from these studies in mice and rats that 
there is no concern with respect to carcinogenicity of Brilliant Blue FCF.
No mutagenic activity has been observed with Brilliant Blue FCF 
in several in vitro mutagenicity studies conducted in S. typhimurium, 
B. subtilis and E. coli. Positive findings were reported in two in vitro 
chromosomal aberration assays, one in vitro micronucleus assay and one 
in vitro comet assay in mammalian cells, but these studies had a number 
of shortcomings (Kawachi et al., 1980; Ishidate et al., 1984; Kus & Eroglu, 
2015; Pandir, 2016). In contrast, negative results were obtained in an in 
vivo micronucleus assay in bone marrow (Hayashi et al., 1988) and a 
comet assay in the stomach, colon, liver, kidney, bladder, lung, brain and 
bone marrow of mice (Sasaki et al., 2002). Based on the available data, the 
Committee concluded that there is no concern with respect to genotoxicity 
of Brilliant Blue FCF.
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No treatment-related adverse reproductive effects were found in a 
single-generation study in male and female rats fed Brilliant Blue FCF at 
doses up to 1318 or 1073 mg/kg bw per day, respectively (IRDC, 1981b; 
Borzelleca, Depukat & Hallagan, 1990). Similarly, no treatment-related 
adverse effects were seen in a 3-generation study in rats treated with 
Brilliant Blue FCF at doses up to 1000 mg/kg bw per day (BioDynamics 
Inc., 1971). In developmental toxicity studies, no adverse effects were 
reported in rats treated with Brilliant Blue FCF at doses up to 2000 mg/kg 
bw per day (BioDynamics Inc., 1972a) or in rabbits at doses up to 200 mg/
kg bw per day (BioDynamics Inc., 1972b).
Other studies have reported no evidence for allergenicity 
(Kreindler, Slutsky & Haddad, 1980), skin irritation (BIBRA, 1990), dermal 
sensitization (BIBRA, 1990) or skin cancer (Carson, 1984) as a result of 
treatment with Brilliant Blue FCF.
In a one-generation study on neurobehavioural development 
in mice (Tanaka et al., 2012), Brilliant Blue FCF was given in the diet 
at concentrations of 0%, 0.08%, 0.24% or 0.72% (equal to 0, 111–407, 
347–1287 and 1032–3856 mg/kg bw per day, respectively, exposure 
depending on gestational age). The high dose of Brilliant Blue FCF 
resulted in a few statistically significant effects on neurobehavioural 
development (exploratory behaviour and surface righting response). 
However, the Committee noted that the effects on exploratory behaviour 
were inconsistent and that there were no effects from exposure to Brilliant 
Blue at any dose in several other neurobehavioural tests in this study. The 
Committee concluded that the findings were not robust enough to be used 
in the safety assessment.
4.3 Observations in humans
Case reports describe the use of Brilliant Blue FCF in enteral feeding 
solutions associated with discoloration of skin, urine and serum and 
toxicity, including 12 deaths (WHO, 2003; Maloney & Brand, 2016). The 
Committee noted that these case reports relate to seriously ill patients, 
particularly those with increased gut permeability (e.g. patients with 
sepsis), and that a causal relationship with Brilliant Blue FCF has not been 
established.
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4.4 Assessment of dietary exposure
Estimates of dietary exposure to Brilliant Blue FCF published by EFSA 
(EFSA, 2010), FSANZ (FSANZ, 2012), the USFDA (Doell et al., 2016), 
India (Dixit et al., 2011), Kuwait (Husain et al., 2006) and the Republic of 
Korea (Ha et al., 2013) were available to the Committee. The estimate of 
dietary exposure to Brilliant Blue FCF calculated by EFSA (4.8 mg/kg bw 
per day for children at the 95th percentile) was much higher than those 
of the USFDA and FSANZ (both 0.2 mg/kg bw per day for children at the 
90th percentile) and the Republic of Korea (0.03 mg/kg bw per day for the 
whole population at the 95th percentile). Estimates from India and Kuwait 
were also lower than the EFSA estimates, but higher than the estimates 
from the USFDA and FSANZ. The Committee considered that the higher 
values in the EFSA estimates were due to the use of maximum reported use 
levels, whereas the other studies used mean analysed levels. The Committee 
concluded that the use of the more conservative EFSA estimate of 5 mg/
kg bw per day should be considered in the safety assessment for Brilliant 
Blue FCF.
5. evaluation
The Committee concluded that the available data support the revision of 
the ADI for Brilliant Blue FCF and that the study on long-term toxicity in 
rats should be considered as the pivotal study (IRDC, 1981b; Borzelleca, 
Depukat & Hallagan, 1990). In this study, a NOAEL of 631 mg/kg bw 
per day was identified, based on a 15% decrease in mean terminal body 
weight and decreased survival of females at 1318 mg/kg bw per day. The 
Committee established an ADI of 0–6 mg/kg bw based on this NOAEL 
by applying an uncertainty factor of 100 for interspecies and intraspecies 
differences.
The Committee noted that the conservative dietary exposure 
estimate of 5 mg/kg bw per day (95th percentile for children) is less than 
the upper limit of the ADI of 0–6 mg/kg bw established for Brilliant Blue 
FCF and concluded that dietary exposure to Brilliant Blue FCF for children 
and all other age groups does not present a health concern.
The previous ADI of 0–12.5 mg/kg bw was withdrawn.
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At the present meeting, the existing specifications for Brilliant 
Blue FCF were revised, and a maximum limit for manganese was added. 
High-performance liquid chromatography (HPLC) methods were added 
for determining subsidiary colouring matters and organic compounds 
other than colouring matters. The method of assay was changed to visible 
spectrophotometry, and spectrophotometric data were provided for the 
colour dissolved in water or aqueous ammonium acetate.
The specifications were revised, and a Chemical and Technical 
Assessment was prepared.
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1. explanation
β-Carotene-rich extract from Dunaliella salina is a natural orange food colour. 
It is used in a wide range of food and beverages as a colour, including cider, 
malt beverages, water-based flavoured drinks, margarines, cheeses, cake fillings, 
custards, yogurts, processed nuts, precooked pastas and noodles and other 
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products. Intended use levels of the product range from 20 to 1200 mg/kg, 
depending on the food item or category.
Carotenes from natural sources (including carotenes from D. salina) were 
reviewed at the thirty-first, thirty-fifth and forty-first meetings of the Committee 
(Annex 1, references 77, 88 and 107). At the thirty-first meeting, the Committee 
concluded that the group acceptable daily intake (ADI) of 0–5 mg/kg body 
weight (bw) established by the eighteenth Committee for the sum of the synthetic 
carotenoids β-carotene, β-apo-8′-carotenal and β-apo-8′-carotenoic acid methyl 
and ethyl esters was not applicable to natural carotenes as they did not comply 
with the specifications for β-carotene. At the thirty-fifth and forty-first meetings, 
the Committee considered the available data inadequate to establish an ADI 
for the dehydrated algal carotene preparations or for the vegetable oil extract of 
D. salina. At the fifty-seventh meeting, the group ADI for synthetic β-carotene 
was extended to include β-carotene from Blakeslea trispora (Annex 1, reference 
154).
The Committee was asked by the Forty-eighth Session of the Codex 
Committee on Food Additives (FAO/WHO, 2016) to evaluate carotenes from 
D. salina. New short-term animal studies as well as studies on genotoxicity and 
developmental toxicity were submitted. A comprehensive literature search was 
conducted on carotenes from D. salina using the search terms “beta-carotene”, 
“Dunaliella salina” and “D. salina” in PubMed. The Committee also considered 
a limited number of publications on β-carotene from other sources that became 
available since the previous evaluation. In light of the information submitted, the 
Committee limited the assessment to a vegetable oil preparation of a β-carotene-
rich d-limonene extract of D. salina, hereafter referred to as D. salina d-limonene 
extract.
1.1 Chemical and technical considerations
β-Carotene-rich d-limonene extract of D. salina is produced from D. salina, an 
extreme halotolerant alga that inhabits natural and human-made salt lakes and 
ponds. The carotene-rich alga is harvested and concentrated, and the carotenoids 
are extracted using an essential oil rich in d-limonene. The resulting extract is 
saponified, purified, centrifuged, evaporated and finally mixed with a vegetable oil 
to obtain a commercial product with a carotene content of about 30% by weight. 
β-Carotene accounts for more than 95% of the carotene content of the extracted 
material as a mixture of trans and cis  isomers in a ratio of approximately 2:1 
by weight. The remainder of the carotene content includes α-carotene, lutein, 
zeaxanthin and cryptoxanthin. In addition to the colour pigments and vegetable 
oil used for standardization, d-limonene extracts of D. salina contain lipids and 
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other fat-soluble components naturally occurring in the source material, such 
as fatty acids, long-chain alcohols, alkenes and waxes. The composition of these 
fat-soluble components is primarily a mixture of fatty acids common to vegetable 
oils used in foods.
Carotenoids are naturally occurring pigments that are responsible for the 
bright colours of various fruits and vegetables, including citrus fruits, carrots and 
tomatoes. β-Carotene, a provitamin A, is the most common of these carotenoids, 
consisting of an unsaturated chain containing identical substituted ring structures 
at each end.
2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and metabolism
Several studies have shown that rodents absorb very little intact β-carotene 
compared with humans. The main site of carotenoid metabolism by 
β-carotene-15,15′-dioxygenase in rodents is the intestinal mucosa. Activity of 
15,15′-dioxygenase enzyme in rat intestine homogenates was reported to be 750 
nmol/min per mg homogenate protein (During, Albaugh & Smith, 1998; During 
et al., 1999). β-carotene is also metabolized in peripheral tissues such as lung, 
kidney, liver and fat (Wang et al., 1992; Redlich et al., 1996). Serum β-carotene 
levels in rats fed a diet containing 2.4 or 12.7 mg of β-carotene for 14 days were 
very low (0.5 to 0.6 μg/dL), and no β-carotene was found in the liver or adipose 
tissue This level is reportedly about 1/1000th that of humans (Ribaya-Mercado 
et al., 1989).
 
(a) Ferret
White et al. (1993) investigated the use of the ferret as an animal model for the 
bioavailability of natural and synthetic β-carotenes in foods. Male, de-scented 
8-week-old ferrets (n = 26) were maintained on a pelleted purified ferret diet with 
negligible carotenoid and vitamin A content. The diet was formulated to contain 
nutrient concentrations similar to those in published, commercial ferret diets, 
but to allow depletion of baseline tissue carotenoid and vitamin A stores. Feed 
and fluid intakes were measured daily. After consuming the purified diet for 16 
days, four ferrets were randomly selected to determine baseline liver β-carotene 
and vitamin A stores. The remaining ferrets were randomly assigned to one of 
three groups (n = 7 or 8/group). For 10 days, the ad libitum tap water intake was 
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replaced with daily intake of 85 mL of one of three test beverages containing 18 
µmol/L all-trans-β-carotene from natural or synthetic sources: Group 1 received 
100% carrot juice with added L-ascorbic acid (0.078 mmol/L) filtered and diluted 
50% (volume per volume) with water; Group 2 received a suspension of cold 
water-dispersible β-carotene beadlets in a mixed juice beverage; and Group 3 
received a suspension of cold water-dispersible β-carotene beadlets in water. 
Ingestion of 85 mL of each beverage resulted in daily intake of 1.5 µmol of all-
trans-β-carotene for all three groups.
There was no detectable α- or β-carotene in the sera or livers of any of the 
baseline group animals. All three groups accumulated β-carotene in liver after 
the 10-day treatment. However, total accumulation of β-carotene in sera, livers 
and adrenals of ferrets that consumed the carrot juice was significantly lower 
than that in the other two groups (White et al., 1993).
The mean vitamin A concentration in liver of the ferrets in the baseline 
group (killed after the initial 16-day consumption of the low vitamin A diet) 
was 0.50 ± 0.07 µmol/g. There were no significant differences between the three 
treatment groups in liver vitamin A concentrations or liver vitamin A stores at 
the end of the 10-day treatment period. The mean total liver vitamin A stores of 
animals that ingested the all-trans-β-carotene in the carrot juice, mixed juice and 
cold water vehicles (Groups 1, 2 and 3, respectively) were 19.2 ± 2.3, 21.3 ± 2.1 
and 21.1 ± 2.3 µmol/g, respectively (Table 1).
(b) Cow (preruminant calf)
Poor et al. (1992) evaluated the preruminant calf as an animal model for the study 
of human carotenoid metabolism. Fifteen newborn male Holstein calves were fed 
a carotenoid-free milk replacer diet to maintain them in the preruminant state. 
After a 7-day adjustment period, three calves were euthanized. The remainder 
received a single oral dose of β-carotene (20 mg of water-soluble beadlets). 
Blood samples were collected periodically, and tissue samples were collected at 
termination after 1, 3, 6 and 11 days post dosing (n = 3 animals/group).
Serum β-carotene concentrations peaked between 12 and 30 hours 
post dosing and declined slowly afterwards. Serum data were fitted to a two-
compartment model and yielded an elimination constant. Adrenal tissue 
showed significant concentrations of β-carotene at 24 hours post dosing, and 
levels remained elevated at 264 hours. Liver, spleen and lung β-carotene levels 
were significantly elevated 24 hours post dosing and rapidly declined thereafter. 
Adipose and kidney peak β-carotene concentrations were observed at 72 and 144 
hours post dosing, respectively.
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The authors concluded that the preruminant calf may be a suitable model 
for the study of absorption and metabolism of carotenoids in humans (Poor et 
al., 1992).
(c) Human
Human volunteers (12 male and 20 female) ate a low-carotene diet for 10 days. 
The volunteers were randomly assigned to five groups. Two groups received three 
capsules daily containing vegetable oil extracts of Dunaliella salina providing 8 or 
24 mg β-carotene and 1.1 or 3.2 mg α-carotene, respectively; two groups received 
quantities of carrots that provided similar amounts of β-carotene and 6.3 and 
18.9 mg α-carotene, respectively; and the remaining group received placebo 
(vegetable oil) capsules. The volunteers were treated for 7 days followed by a 
depletion phase of 7 days.
All volunteers in the treatment groups showed an increase in serum 
concentration of α- and β-carotenes, with half-lives averaging 7.8 and 12.4 days, 
respectively. Serum vitamin A levels remained unchanged throughout the study 
(Jensen et al., 1985).
Levels of β-carotene, retinol and α-tocopherol in lung tissues and 
bronchoalveolar cells from 21 patients undergoing open lung surgery were 
determined with reverse-phase high-performance liquid chromatography. 
The dietary exposure to β-carotene, retinol and α-tocopherol of each patient 
was assessed using a semiquantitative dietary questionnaire. Serum and 
bronchoalveolar tissue samples were obtained at the time of surgery.
Dietary and serum levels of carotenoids, β-carotene, retinol and 
α-tocopherol were consistent with previously reported values. Lung tissue levels 
of total carotenoids, β-carotene, retinol and α-tocopherol were 0.34 ± 0.36, 0.13 
± 0.27, 0.15 ± 0.06 and 9.60 ± 4.86 µg/g tissue, respectively. Lung tissue levels of 
total carotenoids, β-carotene and α-tocopherol (but not retinol) correlated well 
Group Serum (µmol/L) Liver (nmol/g) Adrenal (nmol/g) Total liver vitamin A (µmol/g)
1 0.305 ± 0.135 2.00 ± 1.04 0.83 ± 0.98 19.2 ± 2.3
2 0.972 ± 0.127 10.27 ± 0.97 6.54 ± 0.92 21.3 ± 2.1
3 1.081 ± 0.135 9.38 ± 1.04 4.56 ± 0.98 21.1 ± 2.3
Table 1
serum and tissue concentrations of all-trans-β-carotene in ferrets after 10-day treatment
Source: White et al. (1993)
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with their serum levels, suggesting that serum and bronchoalveolar cell levels of 
these nutrients could be used to predict lung tissue levels (Redlich et al., 1996).
Stahl, Schwarz & Sies (1993) studied the uptake of all-trans-β-carotene, 
9-cis-β-carotene and α-carotene from a natural carotene preparation from 
Dunaliella salina in humans.
All-trans-β-carotene and α-carotene were absorbed well. Serum peak 
concentrations occurred between 24 and 48 hours. The mean increase in serum 
concentration of α-carotene was 5.6% of the increase of the all-trans-β-carotene, 
consistent with the composition of these carotenoids in the test substance; 9-cis-
β-carotene was not detected in human serum, even after repeated dosing. The 
authors suggested that this could be due to preferential absorption of all-trans-
β-carotene, rapid distribution of 9-cis-β-carotene in tissue or the presence of 
isomerase activity that can convert 9-cis to all-trans-β-carotene (Stahl, Schwarz 
& Sies, 1993).
Gaziano et al. (1995) compared the absorption of all-trans-β-carotene 
and 9-cis-isomers from synthetic β-carotene and from oil-extracted β-carotene 
from Dunaliella salina after administration of these test substances over 30 days 
in 24 study participants. After an initial loading dose of 100 mg/person per day 
for 6 days, the participants received either 66 or 100 mg/day of β-carotene from 
Dunaliella salina or 50 mg/day of synthetic β-carotene for an additional 23 days. 
The levels of β-carotene in plasma were determined on days 8, 15, 22 and 29.
Irrespective of the source of β-carotene, serum levels of all-trans-β-
carotene, 9-cis-β-carotene and total β-carotene increased significantly. In the 
group receiving β-carotene from Dunaliella salina, total β-carotene increased from 
0.29 to 1.16 µmol/L, and the all-trans isomer accounted for 93% of the increase. 
In the group receiving synthetic β-carotene, total β-carotene increased from 
0.27 to 1.89 µmol/L, with the all-trans-β-carotene accounting for 93.8% of this 
increase. Low-density lipoprotein was isolated from 16 of the study participants 
on day 29 of the study and analysed for β-carotene, lycopene, α-tocopherol 
and ubiquinol-10. There was a strong correlation between the change in total 
β-carotene concentration in plasma and the change in total β-carotene in isolated 
low-density lipoprotein (Gaziano et al., 1995).
Over a period of 5 months, von Laar et al. (1996) studied the absorption 
and steady state levels of synthetic β-carotene and natural β-carotene (extracted 
from Dunaliella salina) in serum of 14 patients with erythropoietic porphyria. 
Blood samples were drawn on days 0, 30 and 150, and β-carotene levels in sera 
were determined.
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Levels of β-carotene on day 0 in patients who received β-carotene from 
D. salina varied between 0.6 and 1.4 nmol/mL (mean: 1.1 nmol/mL). On day 
30, the mean value had risen to 4.6 nmol/mL and did not significantly increase 
by day 150. A similar pattern was observed in patients who received synthetic 
β-carotene. The authors reported no significant differences between the two 
sources of β-carotene on the therapeutic effect. No adverse reactions were 
reported (von Laar et al., 1996).
The activity of β-carotene-15,15′-dioxygenase, the primary enzyme 
responsible for oxidative cleavage of β-carotene to retinal, was measured in a 
study using two different human cell lines and human small intestine and liver 
preparations. β-Carotene-15,15′-dioxygenase activity in small intestinal mucosa 
preparations from five adults (44–89 years old) was 97.4 ± 39.8 pmol/hour 
per mg protein and from an infant (17 months old) was 20 pmol/hour per mg 
protein. No activity was detected in adult stomach tissue. The β-carotene-15,15′-
dioxygenase activity in a subcellular preparation of human liver was reported to 
be 62 pmol/hour per mg protein in normal adult liver and 7 pmol/hour per mg 
protein for a liver exhibiting gross pathology. The maximum capacity of carotene 
cleavage by this 15,15′-dioxygenase was estimated to be 12 mg/day (one fifth by 
small intestine and four fifths by liver), assuming an optimal 15,15′-carotene/
retinal cleavage ratio of 1:2 (During, Albaugh & Smith, 1998; During et al., 2001).
2.1.2 Effects on enzymes and other biochemical parameters
Wang et al. (1999) studied the effects of β-carotene alone, or in combination 
with cigarette smoke, on β-carotene and retinoid concentrations in serum and 
lung and expression of genes for retinoic acid receptors (RARs) and activator 
protein-1 (encoded by the c-Jun and c-Fos  genes) in ferrets. Twenty-four male 
adult ferrets were randomly assigned to one of four groups (6 animals/group) 
as follows: (1) chronic exposure to cigarette smoke for 6 months; (2) β-carotene 
supplementation at 2.4 mg/kg bw per day for 6 months; (3) combination cigarette 
smoke and β-carotene supplementation (at 2.4 mg/kg bw per day) for 6 months; 
and (4) control (no smoke treatment and basal level of β-carotene, at 0.16 mg/kg 
per day).
The carotene concentration increased in plasma and lung tissue in the 
β-carotene supplemented group to 22-fold higher than the control group. The 
increase was significantly lower (8% over the control group) in the ferrets treated 
with both smoke and β-carotene. The same pattern of response was observed in 
lung tissue. Levels of β-carotene in lung after 6 months of treatment were 9 ± 1, 
2618 ± 171 and 171 ± 22 pmol per 100 mg lung tissue in the control, β-carotene 
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supplemented and smoke-plus-β-carotene supplemented groups, respectively. 
The pathological evaluation of lung sections from the four groups showed that 
smoke exposure caused a mild aggregation and proliferation of macrophages in 
the lung tissue of ferrets. However, localized proliferation of alveolar type II cells 
and alveolar macrophages, and keratinized squamous epithelium were observed 
in all ferrets given the high-dose β-carotene supplement both with and without 
smoke, as compared with the control group and the group exposed to smoke alone. 
Keratinized squamous metaplasia was confirmed by immunohistochemistry 
with anti-keratin antibody in the lung sections of all ferrets given either high-
dose β-carotene alone or high-dose β-carotene with smoke exposure. Analysis 
of RAR expression and activator protein-1 expression in the lung homogenate 
tissue showed that RARβ expression, but not RARα or RARγ, was decreased in 
all three treatment groups (smoke exposure, 18%; high-dose β-carotene, 62%; 
both, 73%) compared with the control group. Expression of c-Jun and c-Fos was 
up-regulated 3- to 4-fold in ferrets given a β-carotene supplement and exposed to 
smoke compared with the control animals.
The authors concluded that diminished retinoid signalling, resulting 
from the suppression of RARβ expression and overexpression of activator 
protein-1, could be a mechanism to enhance lung tumorigenesis after high-dose 
β-carotene supplementation and exposure to tobacco smoke (Wang et al., 1999).
2.2 Toxicological studies
At the forty-first meeting, JECFA evaluated acute toxicity studies in mice and 
rats treated with dried Dunaliella by gavage; short-term toxicity studies in mice 
and rats fed diets supplemented with dried Dunaliella bardawil and a maize 
oil extract of Dunaliella; a multigeneration reproductive toxicity study in rats 
raised on diets containing dehydrated D. bardawil; and a bacterial mutagenicity 
test in five strains (Annex 1, reference 107). New data available for the present 
assessment are discussed in the following sections.
2.2.1 Acute toxicity
No new acute toxicity studies were available.
2.2.2 Short-term studies of toxicity
In a 90-day toxicity study that complied with Organisation for Economic Co-
operation and Development (OECD) Test Guideline 408 and good laboratory 
practices (GLP), Leuschner (2006a) treated Charles River rats (n = 10/sex per 
group) by gavage with a 0, 318, 954 or 3180 mg/kg bw per day vegetable oil 
preparation of D. salina d-limonene extract (containing 31% carotenes; calculated 
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from doses of 0, 100, 300 and 1000 mg/kg bw per day carotenes using a correction 
factor of 3.18). Study parameters included behaviour, external appearance, faeces, 
motility, functional observations, growth, feed and water intake, haematology, 
clinical biochemistry, urine analysis, ophthalmology, fertility and reproduction, 
organ weights and histopathology.
There were no test substance–related deaths. Treatment had no effect on 
functional observation parameters or on body weight, body weight gain, feed 
and drinking-water consumption or haematological or biochemical parameters. 
Ophthalmological examination of ocular structures found no lesions. No test 
substance–related effect was noted on the estrus cycle or spermatogenesis or on 
relative and absolute organ weights. No test substance–related histopathological 
findings were noted. Histomorphological examination of organs in high-dose 
rats showed superficial erosion of the mucosa with neutrophilic granulocytes 
and haemorrhages in the fundus region of the stomach in 1/10 males and 5/10 
females. This was considered to be a local effect caused by the application of large 
amounts of the test substance.
The no-observed-adverse-effect level (NOAEL) was 3180 mg/kg bw per 
day of D. salina d-limonene extract, the highest dose tested (Leuschner, 2006a).
In a 90-day feeding study, Kuroiwa et al. (2006) fed Fischer rats (n = 10/
sex per group) diets containing 0 (control), 0.63%, 1.25%, 2.5% or 5% Dunaliella 
carotene extracted from Dunaliella alga. The authors reported the average daily 
intakes of Dunaliella carotene to be 0, 352, 696, 1420 and 2750 mg/kg bw per day 
for males and 0, 370, 748, 1444 and 2879 mg/kg bw per day for females. The test 
substance was prepared from a stock solution of Dunaliella carotene extracted 
with soybean oil and containing 31.4% β-carotene that was mixed with basal 
powder and fed, ad libitum, for the duration of the study. The test substance and 
the diets were prepared weekly.
No mortality or treatment-related clinical signs were observed 
throughout the experimental period. Yellowish to reddish brown faeces were 
noted at 1.25% and higher, but no pigmentation was macroscopically observed 
at necropsy in the gastrointestinal tract, adipose tissue or other organs. Males 
at 2.5% and 5% showed a slight (6%) but significant (P  <  0.05) reduction in 
body weight gain compared with the control group from week 5 to the end of 
the experiment. Feed intake in affected animals was not significantly different 
from controls. Organ weight measurements and histopathological evaluations 
found no treatment-related differences in toxicological end-points in any of the 
treatment groups and all were within standard values. A statistically significant 
increase in platelet counts was observed in males at 1.25% and 5% (P < 0.01) 
and in females at 2.5% (P < 0.05) and 5% (P < 0.001), but these changes were 
not considered toxicologically significant because they were within the typical 
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range for current toxicology studies. Slight but statistically significant increases 
in serum total cholesterol and calcium levels occurred in all treated males and 
females, with a dose-dependent trend in males, but all levels were within the 
stated control ranges for these end-points in this laboratory and were considered 
not toxicologically significant.
The study authors considered the NOAEL to be 1.25% (696 mg/kg bw 
per day) in males based on growth suppression observed at the 2.5% dose level, 
and 5% (2879 mg/kg bw per day) in females, the highest dose tested (Kuroiwa et 
al., 2006).
The Committee considered this decrease in body weight gain to not be 
biologically relevant because the magnitude of the change in body weight was 
slight (<10%). The Committee considered the NOAEL to be 5% in the diet (2750 
mg/kg bw per day for males and 2879 mg/kg bw per day for females), the highest 
dose tested.
2.2.3 Long-term studies of toxicity and carcinogenicity
Long-term toxicity or carcinogenicity studies of D. salina d-limonene extract 
have not been performed.
2.2.4 Genotoxicity
In a GLP-compliant study conducted in accordance with OECD Guideline 471, 
Stien (2006) tested D. salina d-limonene extract (carotenoid content of 31.43%) 
with five Salmonella typhimurium strains (TA98, TA100, TA102, TA1535 and 
TA1537) in two separate experiments both with and without metabolic activation. 
Preliminary plate incorporation and preincubation tests, without metabolic 
activation, were performed in test strain TA100 using 10 concentrations of the test 
substance per test, ranging from 0.158 to 2500 μg/plate in the plate incorporation 
test and from 0.0316 to 500 μg/plate in the preincubation test.
Cytotoxicity (scarce background lawn and reduction of the number of 
revertants) was noted at concentrations of 158 μg/plate and higher in the plate 
incorporation test and 316 μg/plate and higher in the preincubation test. As a 
result, 316 μg/plate was chosen as the highest concentration for the main study.
No mutagenic effect was observed in the main study using five 
concentrations of D. salina d-limonene extract ranging from 3.16 to 316 μg/plate 
in any of the five test strains in plate incorporation and preincubation tests with 
and without metabolic activation (Stien, 2006).
Leuschner (2006b) tested D. salina d-limonene extract (carotenoid 
content of 31.43%) in a gene mutation assay in cultured mammalian cells (L5178Y 
TK+/−) both with and without metabolic activation. In a preliminary experiment, 
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cytotoxicity (decreased cell survival) was noted at 208 μg/mL without metabolic 
activation but not with metabolic activation. As a result, 208 μg/mL was chosen 
as the highest concentration for the main experiments.
In two independent experiments, both carried out with and without 
metabolic activation, a concentration range of D. salina d-limonene extract at 
13–208 μg/mL was found to be negative with respect to increasing the mutation 
frequency in the L5178Y TK+/− mammalian cell mutagenicity test, whereas the 
positive controls showed potent mutagenic effects.
These findings indicate that d-limonene extract from D. salina was not 
genotoxic under the conditions of this assay (Leuschner, 2006b).
In a GLP-compliant study conducted in accordance with OECD Guideline 
474, Weimans (2002) determined the ratio of polychromatic erythrocytes (PCEs) 
to normochromatic erythrocytes (NCEs) in an in vivo mouse bone marrow 
micronucleus test of D. salina d-limonene extract (carotenoid content 31.12%). 
The ratio of PCEs to NCEs in the bone marrow indicated cell toxicity. Mice in two 
groups of 10 animals (n = 5/sex) were each orally dosed with the test substance 
at 2000 mg/kg bw. They were killed 24 or 48 hours after administration. A limit 
test was considered sufficient since the test substance produced no adverse 
toxic effects in rat tests available at that time or in vitro genotoxicity tests. The 
test substance was formulated in sesame oil, which was also used as a negative 
control. Cyclophosphamide at a dose level of 30 mg/kg bw was used as positive 
control.
No systemic toxic symptoms were observed at any time during the study. 
All animals survived to scheduled death. No indication of bone marrow toxicity 
was noted in any group treated with the test substance. The highest ratio of PCE/
NCE, 1.0, was observed in females after 24 hours and in males after 48 hours. 
Positive and negative controls gave expected results. Statistical analysis of the 
data showed no significant increase (Wilcoxon matched pairs test, P > 0.05) of the 
micronuclei ratio per 2000 PCEs. Under the conditions of the test, there was no 
evidence of either an aneugenic or clastogenic effect of the test substance leading 
to micronucleus formation in PCEs of treated mice 24 hours or 48 hours after 
oral administration of D. salina d-limonene extract at 2000 mg/kg bw (Weimans, 
2002).
2.2.5 Reproductive and developmental toxicity
No reproductive toxicity studies were available for D. salina d-limonene extract.
The effect of orally administered D. salina d-limonene extract was 
evaluated during the critical phase of organogenesis in a study with a protocol 
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that followed OECD Test Guideline 414. Leuschner (2007) administered D. 
salina d-limonene extract in soybean oil by oral gavage to pregnant CD/Crl:CD 
(SD) dams (n = 25/group) at dose levels of the active ingredient β-carotene of 
0, 318, 954 or 3180 mg/kg bw per day of the extract (calculated from doses of 
β-carotene of 0, 100, 300 or 1000 mg/kg bw per day using a correction factor 
of 3.18) from gestation day 6 to 19 (determined by presence of vaginal plug). 
Parameters investigated included mortality, functional observations, growth, 
feed and water consumption and, at necropsy, uterus and carcass weights and 
effects on fetuses including embryo/fetal survival or fetal body weights.
No maternal or developmental toxicity was observed at any dose level.
The NOAEL for maternal toxicity was 3180 mg/kg bw per day (1000 mg/
kg bw per day, expressed as total carotenes), the highest dose tested. The NOAEL 
for developmental toxicity was 3180 mg/kg bw per day (1000 mg/kg bw per day, 
expressed as total carotenes), the highest dose tested (Leuschner, 2007).
2.3 Observations in humans
A human study investigating the potential effect of β-carotene supplementation 
in reducing cancer risk in high-risk individuals included 29 133 male smokers (1 
pack/day for an average of 36 years) who received daily doses of 20 mg β-carotene 
for 5–8 years. After 2 years of treatment, median serum β-carotene levels had 
increased 17.5-fold in participants receiving the supplement compared with 
controls. Study participants receiving β-carotene had significantly higher lung 
cancer incidence (18%) and mortality (8%) compared with controls (Alpha-
Tocopherol, Beta Carotene Cancer Prevention Study Group, 1994).
In a similar study, 18 314 participants with a higher risk of cancer, 
including smokers, former smokers and asbestos-exposed male workers, received 
daily doses of 30 mg β-carotene and 25 000 International Units of vitamin A or 
controls. After 5 years of treatment, median serum β-carotene levels had increased 
12-fold in the supplement group. After a 4-year follow-up, lung cancer incidence 
was significantly increased (28%) in smokers and asbestos workers receiving the 
supplement; overall, 17% more deaths were observed in this group (Omenn et 
al., 1996a,b).
A systematic review and meta-analysis of nine randomized controlled 
trials investigating β-carotene supplementation and cancer risk was subsequently 
conducted. Thirty-one articles met the initial inclusion criteria for the literature 
search, and 13 of these were retained for the meta-analysis. The data included 
in the meta-analysis covered a total of 180 702 study participants and 1852 
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lung cancer cases. The analysis showed no increase in incidence of lung cancer 
in heavy smokers receiving supplemental doses of β-carotene from 6 to 15 mg/
day for about 5–7 years. There was a low but significant increase in relative 
risk for individuals receiving supplemental β-carotene at 20–30 mg day (or in 
combination with other antioxidants) compared with those receiving the placebo. 
This effect was not observed in lower dose groups (Druesne-Pecollo et al., 2010).
3. Dietary exposure
The Committee considered dietary exposure to β-carotene from D. salina 
d-limonene extract assuming its uses as a food additive in the same food 
categories and at the same maximum use levels (β-carotene basis) as previously 
evaluated β-carotene additives.
JECFA evaluated carotenoids at several previous meetings, but dietary 
exposure (specifically to lutein, a naturally occurring carotenoid) was discussed 
only at its sixty-third meeting in 2004 (Annex 1, reference 173). Based on dietary 
exposure data from a number of studies in North America and the United 
Kingdom, the Committee reported that the exposure to lutein from natural 
sources was in the range of 1–2 mg per day. In 2012, European Food Safety 
Authority (EFSA) evaluated the use of β-carotenes (E 160a (i) and E 160a (ii)) 
as a food additive (EFSA, 2012). Based on European food consumption data 
and usage data of β-carotene reported by the Natural Food Colours Association 
(NATCOL), mean and high (97.5th percentile) exposures of 0.06 and 0.11 mg/kg 
bw per day, respectively, were estimated for United Kingdom adults. Assuming a 
mean adult body weight of 60 kg, these exposures equalled 3.6 and 6.6 mg/day, 
respectively. For children, the corresponding mean and high exposure estimates 
ranged from 0.03 to 0.22 and 0.09 to 0.43 mg/kg bw per day, respectively, across 
European countries. Using a mean body weight of 15 kg, mean and high exposures 
of 0.5‒3.3 and 1.4‒6.5 mg/day, respectively, were calculated.
EFSA also reported mean exposure estimates to β-carotene from the diet 
derived from the European Nutrition and Health Report 2009 (Elmadfa, 2009; 
referenced in EFSA, 2012). This report provided mean exposure estimates to 
β-carotene from nine European countries (Czech Republic, Denmark, Finland, 
Germany, Ireland, Italy, Norway, Poland and Sweden) for children aged 4–6 
years and from 13 European countries (Austria, Czech Republic, Denmark, 
Finland, Germany, Hungary, Ireland, Italy, Lithuania, Poland, Spain, Sweden 
and the United Kingdom) for adults. These estimates were based on different 
methods of assessing food consumption. The mean β-carotene exposure via the 
diet ranged from 1.1 to 3.9 mg/day for children and 1.4 to 5.6 mg/day for adults. 
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No data were provided for high-level consumers. EFSA estimated that in view 
of the large standard deviations reported for the mean exposures, the dietary 
β-carotene exposure from the diet would very likely be considerably higher at 
high percentiles reaching 10 mg/day. Based on these results, EFSA concluded 
that the amount of β-carotene likely to be ingested from the diet would be in the 
range of 5–10 mg/day (EFSA, 2012).
The Committee did not calculate international estimates of dietary 
exposure to β-carotene from D. salina d-limonene extract using either the 
Global Environment Monitoring System – Food Contamination Monitoring and 
Assessment Programme (GEMS/Food) cluster diets or the FAO/WHO Chronic 
Individual Food Consumption Database – Summary statistics (CIFOCOss) 
database. The reason for this was that the proposed use of β-carotene from D. 
salina d-limonene extract by the sponsor was not expected to change the current 
exposure to β-carotene through the diet. In addition, only maximum use levels 
were available which, if used in an assessment, would potentially have resulted in 
very high, unrealistic exposure estimates based on the assumption that all foods 
consumed within the 79 food categories would contain β-carotene from D. salina 
d-limonene extract at the maximum use level.
Instead, the Committee conducted a literature review of the exposure 
to β-carotene from the diet, covering the last 10 years. As chemical analyses 
of β-carotene in food cannot distinguish β-carotene added to food from that 
which occurs naturally, these exposure estimates reflect total dietary exposure 
to β-carotene. The results are listed in Table 2. Due to differences in the way the 
exposure to β-carotene has been estimated (e.g. 24-hour recall, food frequency 
questionnaire, dietary record), the exposures cannot be compared across 
countries. Overall, the mean or median exposure to β-carotene ranged from 
1.4 to 11 mg/day in adults. For children, data from Europe showed a maximum 
mean exposure of 7.3 mg/day; globally, few data were available for children’s 
dietary exposures (Table 2). For high-percentile consumers of foods containing 
β-carotene, exposures were as high as 13.7 mg/day (adults in Europe). Based on 
this review, the Committee concluded that a high daily exposure to β-carotene of 
15 mg (0.25 mg/kg bw for a 60 kg individual) was most appropriate for use in a 
safety assessment.
D. salina d-limonene extract also contains other non-carotene 
components, including vegetable oil, algal lipids and d-limonene. Vegetable oil 
is a natural component of food and therefore of no toxicological concern. Algal 
lipids are estimated to be present in the extract in the range of 20‒35%. Assuming 
a high exposure to β-carotene of 15 mg/day, that this exposure comes completely 
from D. salina d-limonene extract and that the material contains 30% β-carotene, 
the exposure to algal lipids would be maximally 18 mg/kg (0.3 mg/kg bw per 
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day for a 60 kg individual). d-Limonene is estimated to be present at lower levels 
in the extract, not more than 0.3%. Based on the same assumptions as for algal 
lipids, the exposure to limonene would be maximally 0.2 mg/day (0.003 mg/kg 
bw per day for a 60 kg individual).
4. Comments
4.1 Biochemical aspects
β-Carotene is absorbed and detected in human serum and liver when consumed 
as an extract from D. salina or as synthetic β-carotene (Redlich et al., 1996). 
Country / region Population group
Mean age or age 
range (years)
Exposure (mg/day)
ReferenceMean High
Australiaa Adults 54.8b 5.1–5.3c,d – Hodge et al. (2009)
China Adults 60.6b 4.6–5.0c 8.9–9.2c,e Chen et al. (2015)
China Adults (females) 48.2 6.5 – Wang et al. (2014)
Czech Republic Adults 58.2b 4.5–5.6c,d – Stepaniac et al. (2016)
Europef Children 4–6 1.1–3.9 2.9–10.3e Elmadfa (2009)
Adults – 1.4–5.6 2.4–13.7e
France Adults 50.4b 3.6– 4.2c – Lassale et al. (2016)
Italy Infants and toddlers 0–3 1.2 3.9g Sette et al. (2010)
Children 3–10 2.1 5.5g
Adolescents 10–18 2.4–2.6c 6.0–6.3c,g
Adults 18–65 3.0–3.1c 7.2–7.3c,g
Elderly adults ≥65 3.2–3.4c 7.4–7.8c,g
Japan Adults – 1.6–3.0 4.2–6.4e Yabuta et al. (2016)
Poland Children 10–12 7.3d – Kopeć et al. (2013)
Poland Adults 57.6b 6.9–8.0c,d – Stepaniac et al. (2016)
Republic of Korea Adults (female) 60.6 5.0 12.5e Kim et al. (2016)
Russian Federation Adults 58.2b 8.7–10.8c,d – Stepaniac et al. (2016)
Spain Adults 18–64 1.5 – Beltrán-de-Miguel, Estévez-Santiago & 
Olmedilla-Alonso (2015)
a  Includes people living in Australia, but born in Australia, Greece, Italy and the United Kingdom.
b  Average age of males and females, respectively.
c  Range refers to exposure estimates for males and females.
d  Reported exposure is median (50th percentile, P50).
e  Estimated by the Committee as mean exposure + 2 × standard deviation.
f  For children, Czech Republic, Denmark, Finland, Germany, Ireland, Italy, Norway, Poland and Sweden were included. For adults, Austria, Czech Republic, Denmark, 
Finland, Germany, Hungary, Ireland, Italy, Lithuania, Poland, Spain, Sweden and the United Kingdom were included.
g  The 95th percentile of exposure.
Table 2
Dietary exposures to β-carotene as reported in the literature
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Peak levels of β-carotene in human serum occur between 24 and 48 hours after 
ingestion (Stahl, Schwarz & Sies, 1993). Absorption appears to be linear when 
doses up to 30 mg are ingested, but the degree of absorption decreases at higher 
concentrations (Woutersen et al., 1999). Absorption of β-carotene varies between 
10% and 90% in humans and is dependent on various conditions, such as the 
food matrix and nutritional status of the individual (Wang et al., 1993; von 
Laar et al., 1996; Woutersen et al., 1999). In humans, the major storage sites for 
carotenoids are the liver and adipose tissue, and hepatic and adipose tissue levels 
tend to correlate with serum levels (Gaziano et al., 1995; Redlich et al., 1996). In 
human serum, most of the β-carotene is present as the all-trans isomer, in spite 
of significant intake of the 9-cis isomer (Stahl, Schwarz & Sies, 1993; Rock, 1997; 
Woutersen et al., 1999).
In contrast to humans, mice, rats, hamsters and rabbits have very low 
levels of serum and tissue β-carotene due to the very high activity of intestinal 
β-carotene-15,15′-dioxygenase that efficiently converts β-carotene to retinal 
(During, Albaugh & Smith, 1998; Woutersen et al., 1999; During et al., 2001). On 
this basis, the Committee concluded that these species are not suitable models for 
the evaluation of β-carotene in humans.
The toxicokinetics of β-carotene in ferrets and preruminant calves have 
been shown to be similar to the absorption of β-carotene in humans. Ferrets that 
consumed 18 µmol/L of β-carotene as a suspension in water for 16 days after a 
β-carotene elimination period of 10 days were shown to accumulate β-carotene 
in serum, liver and adrenal tissue (White et al., 1993). β-Carotene was also 
significantly increased in liver, spleen, lung and serum of preruminant calves fed 
a single oral dose of 20 mg. Serum levels were still elevated 264 hours post dosing 
(Poor et al., 1992).
4.2 Toxicological studies
At the present meeting, the Committee evaluated two new 90-day studies in rats, 
in vitro and in vivo genetic toxicity assays and a developmental toxicity study 
in rats conducted using a D. salina d-limonene extract. The Committee deemed 
these studies useful for evaluating the toxicity of the non-β-carotene portion of 
the extract.
In a 90-day study submitted to the Committee for this evaluation, rats were 
treated by gavage with D. salina d-limonene extract (containing 31% carotenes) 
at doses of 0, 318, 954 or 3180 mg/kg bw per day (calculated from doses of 0, 
100, 300 and 1000 mg/kg bw per day carotenes using a correction factor of 3.18). 
Superficial erosion of the mucosa with infiltration of neutrophilic granulocytes 
and haemorrhages in the fundus region of the stomach were observed in one 
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female and five males in the high-dose group (Leuschner, 2006a). The Committee 
concluded that the findings in the fundus were most likely due to a local effect 
of the high concentration of the test material given as a bolus, and identified the 
NOAEL to be 3180 mg/kg bw per day of D. salina d-limonene extract, the highest 
dose tested.
In another 90-day study, rats were fed diets containing 0, 0.63%, 
1.25%, 2.5% or 5% of an oil extract of carotenes from Dunaliella alga (species 
not specified). The Committee noted that although the test substance was not 
specified, based upon the reported percentage of β-carotene (31.4%) and the 
description of the material, this is likely a D. salina d-limonene extract. The 
average doses of the Dunaliella carotene extract were reported as 0, 352, 696, 
1420 and 2750 mg/kg bw per day for males and 0, 370, 748, 1444 and 2879 mg/kg 
bw per day for females (Kuroiwa et al., 2006). Although the authors identified a 
NOAEL of 1.25% based on a 6% reduction in body weight gain in males at 2.5% 
and 5%, the Committee considered this not to be a toxicologically relevant effect. 
The Committee concluded that the NOAEL was 5% (2750 mg/kg bw per day) of 
Dunaliella extract, the highest concentration tested.
No long-term toxicity and carcinogenicity studies were available for D. 
salina d-limonene extract.
The D. salina d-limonene extract tested negative in genotoxicity assays, 
including the bacterial reverse mutation assay in five strains of S. typhimurium, 
the forward gene mutation assay in cultured mammalian cells (TK+/− L5178Y) 
with and without metabolic activation and an in vivo mouse bone marrow 
micronucleus test. No concerns for genotoxicity were identified (Leuschner, 
2006b,c; Stien, 2006).
No reproductive toxicity studies were available for the D. salina 
d-limonene extract.
D. salina d-limonene extract (carotene content 31%) was administered to 
pregnant rats from gestation day 6 to 19 by oral gavage at doses of 0, 318, 954 or 
3180 mg/kg bw per day of the extract (calculated from doses of 0, 100, 300 and 
1000 mg/kg bw per day carotenes using a correction factor of 3.18). No maternal 
or developmental toxicity was observed (Leuschner, 2007).
4.3 Observations in humans
No studies were available on the D. salina d-limonene extract.
The Committee noted two independent trials of heavy smokers (at least 
1 pack/day for 36 years on average) who received β-carotene supplements. In the 
first study, participants received β-carotene (20 mg/day) supplementation, with 
or without α-tocopherol supplementation (Alpha-Tocopherol, Beta Carotene 
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Cancer Prevention Study Group, 1994). In the second study, participants 
received β-carotene (30 mg/day) + retinol (25 000 International Units of vitamin 
A) (Omenn et al., 1996a,b). Both studies showed increased, rather than the 
hypothesized decreased, incidence of lung cancer. A subsequent systematic 
review of nine randomized clinical trials showed no increase in the incidence of 
lung cancer in heavy smokers at supplemental doses of β-carotene from 6 to 15 
mg/day for about 5–7 years (Druesne-Pecollo et al., 2010).
4.4 Assessment of dietary exposure
The Committee considered dietary exposure to β-carotene from D. salina 
d-limonene extract assuming its uses as a food additive in the same food 
categories and at the same maximum use levels (β-carotene basis) as previously 
evaluated β-carotene additives. The Committee concluded that dietary exposure 
to β-carotene would not change, as the extract will provide β-carotene at a level 
equivalent to that from other β-carotene food additives.
The Committee therefore reviewed dietary exposures to β-carotene 
reported in the literature. Estimates of dietary exposure from the following 
regions/countries were included in this review: Australia (Hodge et al., 2009), 
China (Wang et al., 2014; Chen et al., 2015), the Czech Republic (Stepaniak et al., 
2016), “Europe” (Elmadfa, 2009; referenced in EFSA, 2012), France (Lassale et 
al., 2016), Italy (Sette et al., 2010), Japan (Yabuta et al., 2016), Republic of Korea 
(Kim et al., 2016), Poland (Kopeć et al., 2013; Stepaniak et al., 2016), Russian 
Federation (Stepaniak et al., 2016) and Spain (Beltrán-de-Miquel, Estévez-
Santiago & Olmedilla-Alonso, 2015). As chemical analyses of β-carotene in food 
cannot distinguish β-carotene added to food from that occurring naturally, these 
dietary exposure estimates reflect total dietary exposure to β-carotene.
Overall, mean or median dietary exposures to β-carotene ranged from 
1.4 to 11 mg/day in adults. For children, data from Europe showed a maximum 
mean exposure of 7.3 mg/day; globally, few data were available for children’s 
dietary exposures. For high-percentile consumers of foods containing β-carotene, 
dietary exposures were as high as 13.7 mg/day (adults in Europe).
The Committee concluded that a high daily dietary exposure to β-carotene 
of 15 mg (0.25 mg/kg bw for a 60 kg individual) is appropriate for use in safety 
assessment. Using this dietary exposure estimate and the assumptions that all 
the β-carotene in the diet comes from this extract and that the extract contains 
30% β-carotene, 35% algal lipids (upper level of a range of 20–35%) and 0.3% 
d-limonene (maximum amount), dietary exposure to the other toxicologically 
relevant constituents of this extract would be 18 mg/day (0.3 mg/kg bw per day 
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for a 60 kg individual) for algal lipids and 0.2 mg/day (0.003 mg/kg bw per day 
for a 60 kg individual) for d-limonene.
5. evaluation
The Committee noted that the total dietary exposure to β-carotene is not expected 
to increase when D. salina d-limonene extract is used as a food colour.
The Committee has also considered the basis for the ADI established for 
the group of carotenoids by the Committee at the eighteenth meeting. The group 
ADI (0–5 mg/kg bw) was derived using a four-generation study in rats with a 
NOAEL for β-carotene of 50 mg/kg bw per day with application of a safety factor 
of 10 because of the natural occurrence of carotenoids in the human diet and the 
low toxicity observed in animal studies. This ADI applies to the use of β-carotene 
as a colouring agent and not to its use as a food supplement.
Data that have become available since the previous evaluation show large 
differences in absorption of β-carotene between rodent species and humans. 
Specific β-carotene-15,15′-dioxygenase activity with β-carotene as substrate 
in the intestine of rodents is nearly 1 million-fold higher than that of humans. 
The Committee considered that rodents are inappropriate animal models for 
establishing an ADI for β-carotene because of the virtual absence of systemic 
absorption in rodents.
The Committee noted that the toxicity of the other components of the 
D. salina d-limonene extract can be evaluated using the results of rodent studies. 
The D. salina d-limonene extract used in the toxicological studies contained 
β-carotene at approximately 30%, algal lipids at 20–35% and diluent vegetable 
oil at 35–50%. The D. salina d-limonene extract did not show genotoxicity in 
the evaluated studies. Short-term toxicity studies in rats give a NOAEL equal 
to 3180 mg/kg bw per day, the highest dose tested. No effects were observed in 
a developmental toxicity study in rats. No long-term toxicity or reproductive 
studies have been conducted with the D. salina d-limonene extract. Correction 
of the dose used to derive the NOAEL for D. salina d-limonene extract of 3180 
mg/kg bw per day for the percentage of the algal component (20–35%) gives an 
adjusted NOAEL of 636–1113 mg/kg bw per day for the algal lipid component of 
the test substance. The margin of exposure for the algal lipid component in the 
D. salina d-limonene extract is 2120–3710 using a dietary exposure of 18 mg/day 
(0.3 mg/kg bw per day). The Committee concluded that dietary exposure to the 
algal component of the extract does not pose a health concern.
The Committee concluded that there was no health concern for the 
use of β-carotene-rich extract from D. salina when used as a food colour and in 
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accordance with the specifications established at this meeting. This conclusion 
was reached because total dietary exposure to β-carotene will not increase and 
there are no toxicity concerns for the non-carotene components of the extract. 
The Committee emphasized that this conclusion applies to the use of this extract 
as a food colour, not as a food supplement.
A specifications monograph and a Chemical and Technical Assessment 
were prepared.
5.1 Recommendations
The Committee recommends that the group ADI for the sum of carotenoids, 
including β-carotene, β-apo-8′-carotenal and β-apo-8′-carotenoic acid methyl 
and ethyl esters, be re-evaluated in light of evidence that shows very low 
absorption of β-carotene in rodents and rabbits in contrast to humans.
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1. explanation
Fast Green FCF (Chemical Abstracts Service No. 2353-45-9; INS No. 143) is a 
dye with a synthetic triphenylmethane base structure permitted as a food colour 
in Japan, the USA and other regions. It is used for colouring breakfast cereals, 
cakes and cupcakes, drink mixers and frozen treats.
The Committee previously evaluated Fast Green FCF at its thirteenth, 
twenty-fifth, twenty-ninth and thirtieth meetings (Annex 1, references 20, 56, 
70 and 73). At its thirteenth meeting, the Committee established an acceptable 
daily intake (ADI) of 0–12.5 mg/kg body weight (bw) based on a long-term 
feeding study in rats. At its twenty-fifth meeting, the ADI of 0–12.5 mg/kg 
bw was made temporary pending the results of adequate long-term feeding 
studies and a multigeneration reproduction/teratogenicity study. At the twenty-
ninth meeting, two long-term toxicity and carcinogenicity studies and a three-
generation reproductive study became available. It was noted that a mouse oral 
carcinogenicity study was negative but that in the rat study an increased incidence 
of urothelial hyperplasia and/or neoplasia of the bladder was observed at the 
highest dose level. The biological significance of observed differences in benign 
and malignant tumours at other sites was considered questionable since, apart 
from the bladder, complete histopathological examination was not performed 
on the low- and intermediate-dose groups. The temporary ADI was extended to 
permit complete histopathological examination of all groups of rats and biometric 
examination of the data. At its thirtieth meeting, a review of the histopathological 
data from the rat oral carcinogenicity study was performed from which it was 
concluded that inappropriate statistical tests had been performed on some of the 
data by the testing laboratory. The Committee concluded that Fast Green FCF 
was noncarcinogenic in rats and established an ADI of 0–25 mg/kg bw, based on 
a long-term study of toxicity in rats.
At the present meeting, the Committee re-evaluated this colour at the 
request of the Forty-eighth Session of the Codex Committee on Food Additives 
(FAO/WHO, 2016). In response to the Committee’s request for further data, new 
studies on genotoxicity and neurological effects were submitted. The Committee 
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also considered other related information which has become available in the 
literature since its last evaluation.
The search of the scientific literature was conducted in March 2017 using 
the PubMed database of the United States National Library of Medicine. Use of 
the linked search terms “Fast Green” and “toxicity” yielded 32 references, some of 
which had been evaluated by previous Committees or identified by the sponsor. 
Several other studies used Fast Green FCF as a marker in their methodology 
(e.g. staining); only one of these references, Ashida et al. (2000), was considered 
relevant for the present assessment.
The previous monograph has been expanded and is reproduced in this 
consolidated monograph. References from 1986 onward were not considered 
by the previous Committees. References from before 1986 that had not been 
evaluated by the previous Committees are indicated in the text.
1.1 Chemical and technical considerations
Fast Green FCF consists mainly of disodium 3-[N -ethyl-N-[4-[[4-[N-ethyl-N-(3- 
sulfobenzyl)amino]-phenyl](4-hydroxy-2-sulfophenyl)methylene]-2,5-
cyclohexadien-1-ylidene]ammoniomethyl]-benzenesulfonate and its isomers, 
together with subsidiary colouring matters, as well as sodium chloride and/or 
sodium sulfate as the principal uncoloured components. It is manufactured by 
condensing 2-formylhydroxybenzenesulfonic acid with a mixture of 3-[(N-ethyl-
N-phenylamino)methyl]benzenesulfonic acid and its 2- and 4-isomers to form 
the leuco base precursor. Oxidation of the leuco base precursor with either 
chromium- or manganese-containing compounds produces the dye, which 
is purified to contain not less than 85% total colouring matters and isolated as 
the disodium salt. Impurities include unreacted starting material and reaction 
by-products (approximately 2%), subsidiary colouring matters (≤6%), residual 
leuco base precursor (≤5%), unsulfonated primary aromatic amines (≤0.01% 
calculated as aniline), lead (≤2 mg/kg), chromium (≤50 mg/kg) and manganese 
(≤100 mg/kg).
2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and excretion
No new information has been published since the previous evaluations.
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Rats and dogs were given 200 mg Fast Green FCF orally. In the rat, almost 
all the administered colour was excreted unchanged in faeces collected over 36 
hours, and no colour was found in the urine. In the dog, the amount of Fast 
Green FCF in bile never exceeded 5% of the administered dose. It was concluded 
that the quantity found in the bile provides a reasonable estimate of the amount 
absorbed from the gastrointestinal tract (Hess & Fitzhugh, 1953; 1954; 1955).
Following intravenous injection of Fast Green FCF in rats, over 90% of 
the colour was excreted in the bile within 4 hours (Iga, Awazu & Nogami, 1971). 
Fast Green FCF was found to have a high binding affinity for plasma protein, and 
it was suggested that the binding ratio with plasma protein was also one of the 
factors in the biliary excretion (Gangolli, Grasso & Golberg, 1967; Iga, Awazu & 
Nogami, 1971; Gangolli et al., 1972).
2.1.2 Biotransformation
No data were available.
2.1.3 Effects on enzymes and other biochemical parameters
In an in vitro study, the Xenopus oocyte expression system was used to investigate 
the purinergic P2 receptors that interact with the membrane channel protein 
pannexin 1 (Panx1) in inflammasome signalling. Fast Green FCF was shown 
to be a selective inhibitor of Panx1 channels, with a half maximal inhibitory 
concentration (IC50) of 0.27 µmol/L. Fast Green FCF did not significantly inhibit 
the P2X7R receptor (Wang, Jackson & Dahl, 2013). The Committee was aware 
that Panx1 activation/inhibition is one of several signalling pathways involved in 
various physiological processes at the cellular level (e.g. immune function) and 
that there are many exogenous and endogenous modulators of these pathways. 
Interactions of substances with P2 receptors and Panx1 are an active area of 
research, particularly in development of drug treatments for diverse chronic 
diseases. The Committee noted that a similar pattern of channel inhibition was 
observed with Brilliant Blue FCF. Further research may clarify if the inhibition 
of Panx1 observed in in vitro is relevant for the safety assessment of substances 
in food.
2.2 Toxicological studies
2.2.1 Acute toxicity
Studies of acute toxicity of Fast Green FCF administered to rats and dogs by the 
oral route are summarized in Table 1.
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2.2.2 Short-term studies of toxicity
No new short-term toxicity studies have been published since the previous 
evaluations.
(a) Dogs
Four beagle dogs per group, equally divided by sex, were fed Fast Green FCF at 0, 
1.0% or 2.0% in the diet (equal to 0, 269 and 695 mg/kg bw per day) for 2 years. 
Histopathology findings attributable to Fast Green FCF were limited to green 
blobs of pigment in the renal cortical tubular epithelial cytoplasm of one male 
dog at the high-dose level. One female dog at the high-dose level showed slight 
interstitial nephritis and slight bone marrow hyperplasia (Hansen et al., 1966).
2.2.3 Long-term studies of toxicity and carcinogenicity
No new long-term toxicity studies have become available since the previous 
evaluations.
(a) Mice
Groups of 50 male and 50 female C3HeB/FeJ mice were fed diets containing 1.0% 
or 2.0% Fast Green FCF (equivalent to 1500 or 3000 mg/kg bw per day) for 2 years; 
100 mice of each sex served as controls. After 78 weeks, 56 control animals, 27 
animals in the 1.0% treatment group and 17 animals in the 2.0% treatment group 
were still alive. Microscopic examination found no treatment-related lesions.
The no-observed-adverse-effect level (NOAEL) was 2.0% in the diet 
(equivalent to 3000 mg/kg bw per day), the highest dietary concentration tested 
(Hansen et al., 1966).
Groups of 60 (120 controls) male and female Charles River CD1 mice 
were fed diets containing Fast Green FCF at 0, 0.5%, 1.5% or 5.0% (equal to 0, 
842, 2465 and 8806 mg/kg bw per day for males and 0, 1141, 3392 and 11 805 
mg/kg bw per day for females) from 43 days of age for approximately 24 months. 
Haematological examinations of 10 animals/sex per group were undertaken at 
Species Sex Route LD60  (mg/kg bw) Reference
Rat Male Oral >2 000 Lu & Lavallee (1964)
Dog Unknown Oral >200 Radomski & Deichmann (1956)
Table 1
Acute toxicity of fast Green fCf
bw: body weight; LD50: median lethal dose
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3, 6, 12 and 18 months. All animals that died or were euthanized in a moribund 
condition and all the animals that survived to study end underwent detailed 
necropsy. The following tissues from all the animals from the control and 5% dose 
group were examined: adrenals, aorta, bone and marrow (femur), brain (three 
sections), eyes (with optic nerve), gall bladder, gastrointestinal tract (oesophagus, 
stomach, duodenum, ileum, caecum, colon), heart, kidneys, liver, lung, lymph 
nodes (mesenteric and mediastinal), mammary gland, nerve (sciatic), ovaries, 
pancreas, pituitary, prostate, salivary gland, seminal vesicles, skeletal muscle, 
skin, spinal cord, spleen, testes with epididymides, thymus, thyroid/parathyroid, 
trachea, urinary bladder, uterus and gross lesions/tissue masses. In addition, gross 
changes/tissue masses of all animals in the lower-dose groups were examined 
histopathologically.
No treatment-related effects on mortality were observed. The mean body 
weights of females in the 5% dose group were consistently lower than that of 
controls (10% at termination of the study). The mean body weights of males in 
the 5% dose group were lower than controls at weeks 52 and 78 (5% and 6%, 
respectively) and in the 1.5% dose group at week 78 (6%). Slight reductions 
in haemoglobin, haematocrit and erythrocyte counts were noted in the high-
dose males at 18 months but no other consistent or dose-related haematological 
changes were observed. Histopathological examination did not find any 
treatment-related lesions, and the incidence, origins and histology of benign and 
malignant neoplasms did not differ significantly between controls and treated 
animals.
The previous Committee concluded that the NOAEL was 5% Fast Green 
FCF in the diet, the highest dose tested. The present Committee noted that the 
mean body weights of females in the 5% dose group were consistently lower than 
that of controls after the study start, indicating an adverse effect at this dose.
The present Committee concluded that the NOAEL was 1.5% (equal to 
3392 mg/kg bw per day) based on the lower body weights observed at 5% (equal 
to 11 805 mg/kg bw per day) in females (Hogan & Knezevich, 1981).
The Committee noted that the study was performed before the establishment 
of Organisation for Economic Co-operation and Development (OECD) guidelines 
and the requirement for good laboratory practices (GLP). The study was, however, 
inspected by a quality assurance unit and met the requirements established by the 
United States Food and Drug Administration (USFDA).
(b) Rats
Groups of 50 weanling Osborne-Mendel rats, evenly divided by sex, were fed 
diets containing 0, 0.5%, 1.0%, 2.0% or 5.0% of Fast Green FCF (equivalent to 0, 
250, 500, 1000 and 2500 mg/kg bw per day) for 2 years. No effects on growth or 
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mortality were observed. Microscopic examination found no treatment-related 
lesions.
The NOAEL was 5.0% in the diet (equivalent to 2500 mg/kg bw per day), 
the highest dietary concentration tested (Hansen et al., 1966).
The Committee noted that the study was performed before OECD 
guidelines and GLP requirements were established.
Fast Green FCF was fed at a dietary level of 4.0% (equivalent to 2000 mg/
kg bw per day) to five male and five female rats for 18–20 months. This procedure 
resulted in gross staining of the forestomach, glandular stomach, small intestine 
and colon. Granular deposits were noted in the stomach. No tumours were 
observed (Willheim & Ivy, 1953).
A carcinogenicity study with an in utero phase was carried out in 
Charles River albino rats. Groups of 60 (120 controls) male and female rats of 
the F0 generation were fed diets containing 0, 1.25%, 2.5% or 5.0% Fast Green 
FCF (equal to 0, 722, 1486 and 3184 mg/kg bw per day for males and 0, 926, 
1863 and 4021 mg/kg bw per day for females) for 2 months prior to mating 
and throughout gestation and lactation. Following the reproductive phase, a 
maximum of four animals of each sex per litter were randomly selected from the 
F1 generation for the long-term carcinogenicity study. Groups of 70 animals/sex 
per group were given Fast Green FCF in the diet at the same concentrations as the 
parent generation. An interim kill of 10 animals/sex per group was carried out 
after 12 months; the remaining animals continued to receive the test diets for 29 
months (males) or 31 months (females). Haematological and clinical chemistry 
tests and urine analysis were performed on 10 rats/sex per group at 3, 6, 12, 18 
and 24 months. All the animals that died or were euthanized in a moribund 
condition during the study and all F1 animals killed at interim and terminal kills 
were necropsied. The following tissues from these animals as well as all survivors 
from the control and 5% dose groups were examined: adrenals, aorta, bone and 
marrow (femur), brain (3 sections), eyes (with optic nerve), gastrointestinal 
tract (oesophagus, stomach, duodenum, ileum, caecum, colon), heart, kidneys, 
liver, lung, lymph nodes (mesenteric, mediastinal), mammary gland, nerve 
(sciatic), ovaries, pancreas, pituitary, prostate, salivary gland, seminal vesicles, 
skeletal muscle, skin, spinal cord, spleen, testes with epididymides, thymus, 
thyroid/parathyroid, trachea, urinary bladder, uterus and gross lesions/tissue 
masses. In addition, gross changes/tissue masses in all animals in the lower-dose 
groups and, subsequently, bladder of males at 1.25% and 2.5% also underwent 
histopathological examination.
During the premating period, no treatment-related effects were seen 
on mortality or body weight gain, but there was a dose-related increase in 
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feed consumption. There were no treatment-related effects on the number of 
successful pregnancies or pup viability at birth, but pup mortality was increased 
in the 5% dose group during lactation days 4–14. The Committee noted that this 
was due to high mortality in one litter (i.e. all 13 pups of one dam died). Mean 
pup weight was reduced in all treatment groups at the end of the lactation period, 
most markedly in the high-dose group.
In the F1 generation, mortality was slightly higher in all treatment groups 
than in controls but not in a dose-related manner. Mean body weights of males 
at 2.5% and 5% were lower than controls at week 1 (about 5%), consistent with 
the lower mean pup weight noted for these groups prior to random selection 
of offspring for the F1 generation. Mean body weights of males at 5% remained 
consistently lower than controls throughout the study (10% at study termination) 
despite their elevated feed intake. Mean body weights for all groups of treated 
females were comparable to controls in the first year of the study. Mean body 
weights of the females at 5% were lower (9%) than controls after 78 weeks; mean 
body weights of the females at 2.5% were lower (7%) than controls after 2 years. 
As with males, feed consumption in the high-dose females was higher than in 
controls. As there was no dose-dependency in the decrease in body weights in 
either males or females, the Committee considered these effects on body weight as 
not adverse. Fasting blood glucose levels were elevated in females in all treatment 
groups at 3 and 12 months, females at 1.25% and 2.5% at 18 months and males in 
all treatment groups at 12 and 18 months.
At the interim (12-month) kill, the mean absolute and relative thyroid 
weights were elevated in the high-dose males while the relative kidney weights 
were elevated in the high-dose females. At study end, the relative thyroid weights 
were elevated in males at 2.5% and 5% and females at 5%; relative kidney weights 
were elevated in both sexes at 5% and females at 2.5%. No treatment-related effects 
were seen in urine analyses or haematological, physical or ophthalmological 
examinations.
Histopathological examination found an increased incidence of 
urothelial hyperplasia in treated males and of urinary bladder transitional cell/
urothelial neoplasms in males at 5%. Nonstatistically significant increases in 
testicular Leydig cell tumours and neoplastic nodules in the liver (now called 
hepatocellular adenomas) were also observed. Time-to-tumour analyses of 
pathology incidence data confirmed the increased incidence of bladder tumours, 
and the incidence of several other tumour types showed statistically significant 
treatment-related differences, including neoplastic nodules in liver (males and 
females), female mammary adenomas and pituitary adenomas, male parathyroid 
adenomas, male thyroid medullary carcinomas, female uterine leiomyosarcomas 
and male testicular interstitial/Leydig cell tumours.
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In nonneoplastic pathology, chronic nephropathy was a common finding 
in all groups but the severity was greater in females at 5%. Other lesions did not 
appear to be related to treatment (Knezevich & Hogan, 1981).
At the twenty-ninth meeting, the Committee noted an increased incidence 
of urothelial hyperplasia and/or neoplasia of the bladder in the Knezevich & Hogan 
(1981) study. However, the biological significance of the differences observed 
in benign and malignant tumours at other sites was considered questionable 
since, apart from the bladder, complete histopathological examination was not 
performed on the low- and intermediate-dose groups.
A review of the histopathological data from the Knezevich & Hogan 
(1981) study concluded that the testing laboratory had performed inappropriate 
statistical tests to analyse some of the data. After conducting appropriate statistical 
procedures, the reviewers concluded that there were no significant differences in 
tumour incidence between combined control groups and the high-dose group 
with respect to tumours of the liver, testes or thyroid; data on the tumours in the 
tissues from the low- and intermediate-dose groups were not examined. In a blind 
review of the slides of the bladders from all dose groups, only three proliferative 
lesions – two benign (papilloma) and one malignant (carcinoma) lesion – were 
observed in bladders of male rats in the high-dose group and a treatment-related 
increase in the incidence or severity of transitional cell hyperplasia was not 
detected. The presence of only three neoplasms in the high-dose male group, 
two of which were questionable, and the absence of evidence of a preneoplastic 
process in the hyperplasia indicated lack of a neoplastic effect of Fast Green 
FCF on the bladder (Dua, Chowdury & Moch, 1982; O’Donnell, 1982; USFDA, 
1982a,b).
Based on this information, the Committee concluded at its thirtieth 
meeting that Fast Green FCF is noncarcinogenic in this species. Therefore, the 
NOAEL was identified as 5.0% in the diet (equal to 3184 mg/kg bw per day for 
males and 4021 mg/kg bw per day for females), the highest dietary concentration 
tested (Knezevich & Hogan, 1981). The present Committee concurred with this 
conclusion.
The Committee noted that although the study was performed before 
OECD guidelines and GLP requirements were established, it met USFDA quality 
assurance requirements.
Eighteen weanling Osborne-Mendel rats of both sexes received weekly 
subcutaneous injections of approximately 30 mg (1 mL of a 3% aqueous solution) 
of Fast Green FCF for 94–99 weeks. Subcutaneous fibrosarcomas were noted at 
the site of injection in 15 animals (Nelson & Hagan, 1953; Hansen et al., 1966).
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Two groups of 16 female rats (control groups of 10 rats) were given 
subcutaneous injections of 0.5 mL of a 3% or 6% solution of Fast Green FCF in 
distilled water (15 or 30 mg, respectively, per injection). The colour used in the 
experiment was certified as 92% pure and was supplied as the disodium sulfonate 
salt. The 10 control rats were given distilled water injections. At first, injections 
of 6% were given 3 times a week; after 17 weeks it became necessary to reduce 
the dose to 3%, and both groups were given injections of 3% twice weekly for 
9 more weeks. For the remaining 22 weeks, both groups were usually injected 
once a week, although occasionally two injections a week were tolerated. Growth 
inhibition was observed. Of the 16 animals at 6% Fast Green FCF solution, 13 
had fibrosarcomas; 10 of the 12 animals at 3% Fast Green FCF also developed 
fibrosarcomas. None of the controls had neoplastic tissue at the site of injection 
(Hesselbach & O’Gara, 1960).
Subcutaneous injection of 1 mL of a 0.8% solution of Fast Green FCF in 
distilled water twice weekly (no further details given) resulted in histopathological 
changes suggestive of subsequent sarcoma formation that was not associated with 
chemical carcinogenic potential (Grasso & Golberg, 1966).
The Committee previously concluded, at its thirteenth, twenty-fifth 
and twenty-ninth meetings, that the production of local sarcomata at the site 
of subcutaneous injection in rats is not considered to constitute evidence of 
carcinogenicity by the oral route.
(c) Hamsters
No tumours were produced in 12 hamsters injected subcutaneously with 1 mg of 
Fast Green FCF dissolved in 0.1 mL water for 330 days (Price et al., 1978).
2.2.4 Genotoxicity
The results of in vitro and in vivo genotoxicity tests of Fast Green FCF are 
summarized in Table 2 and described in detail below. Although 10 of the 18 
available genotoxicity tests were negative, four in vitro and four in vivo studies 
yielded positive results.
An Ames test and an in vitro chromosomal aberration assay were 
positive only in a crude sample when Fast Green FCF samples of different 
purities were assessed. However, no information on cytotoxicity was given, only 
100 metaphases were scored and gaps were not excluded from the evaluation. The 
authors also stated that a sample of Fast Green FCF, purity 90.7%, was negative in 
the in vitro chromosomal aberration assay (Ishidate et al., 1984).
The Committee concluded that this study did not indicate a concern for 
genotoxicity.
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End-point Test system Concentration or dose Result Reference
In vitro
Reverse mutation Salmonella typhimurium 
TA98, TA100, TA1535, TA1537, 
TA1538
50, 250, 1 000 μg/plate Negativea Brown, Roehm & Brown 
(1978)
S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538
50, 250, 1 000 μg/plate Negativeb Bonin, Farquharson & 
Baker (1981)c
S. typhimurium TA92, TA94, 
TA98, TA100, TA1535, TA1537 
1, 2, 5, 10 mg/plate Positive in one crude 
sampled
Ishidate et al. (1984)
S. typhimurium TA98, TA100 Unknown Negativee Kawachi et al. (1980)c
Escherichia coli Unknown Negativef Rosenkranz & Leifer 
(1980)
DNA damage Bacillus subtilis 17A, 45AT 1 mg/mL Negativeg Kada, Tutikawa & Sadaie 
(1972)
B. subtilis Unknown Negativeh Kawachi et al. (1980)
Gene conversion Saccharomyces cerevisiae BZ34 5 mg/mL Negativei Sankaranarayanan & 
Murthy (1979)
Chromosomal 
aberrations 
Chinese hamster fibroblast 
cell line 
3 doses, up to 4 mg/mL Positive in one crude 
samplej
Ishidate et al. (1984)
Chinese hamster ovary cell line 20 μmol/L Positivek Au & Hsu (1979)
Hamster lung fibroblasts Unknown Negativel Kawachi et al. (1980)
Cell 
transformation
Fischer rat embryo cells 1, 10, 100 μg/mL Positive at 1 μg/mL in 
the second experiment 
onlym
Price et al. (1978)
In vivo
Bone marrow 
micronucleus 
induction
Male Swiss albino mice 100, 200, 400, 800 mg/kg bw Positiven Misra & Misra (1986)
Male ddY mice 250, 500, 1 000, 2 000 mg/kg bw Negativeo Hayashi et al. (1988) 
Chromosomal 
aberrations 
Male Swiss albino mice 1 (plus 1 mg/kg bw nitrite), 2 
mg/kg bw
Positivep Giri et al. (1986)
Male Swiss albino mice 250 (plus nitrite at 250 mg/kg 
bw), 500, 500 (plus nitrite at 500 
mg/kg bw), 1 000 mg/kg bw
Positiveq Das & Giri (1988)
Sister chromatid 
exchange 
Male Swiss albino mice 5, 5 (plus nitrite at 5 mg/kg 
bw),10, 12.5 (plus nitrite at 12.5 
mg/kg bw), 25, 25 (plus nitrite at 
25 mg/kg bw), 50, 50 (plus nitrite 
at 50 mg/kg bw), 100 mg/kg bw
Positiver Giri & Mukherjee (1990)
DNA damage Male ddY Mice 2 000 mg/kg bw Negatives Sasaki et al. (2002)
Table 2
Genotoxicity of fast Green fCf in vitro and in vivo
bw: body weight. S9: 9000 × g supernatant fraction from liver homogenate
a  Plate tests were performed with and without S9 mix.
b Plate tests were conducted with and without S9 mix.
c Not evaluated by previous Committees.
d  Plate tests were conducted with and without S9 mix. Fast Green FCF samples were tested and only a crude sample was positive by inducing 347 revertants in TA100 
at 10 mg/plate with S9 mix.
e With and without metabolic activation.
f DNA-polymerase-deficient E. coli was used to determine the DNA-modifying activity.
g The bacterial DNA repair tests were conducted by rec-assay.
h The bacterial DNA repair tests were conducted by rec-assay with and without metabolic activation.
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Another in vitro chromosomal aberration assay found chromosome 
damage, but only summary data were given, there was no information on purity 
and it was unclear whether gaps were excluded from the evaluation. The authors 
indicated that this damage was probably due to the impurities in the sample, but 
did not identify the impurities (Au & Hsu, 1979).
Fast Green FCF gave positive results in an in vitro cell transformation 
study at the lowest concentration tested (1 μg/mL) but not at 10 or 100 μg/mL, 
and only in the second experiment (Price et al., 1978).
For three nonstandard in vivo assays performed in the same laboratory, 
chromosomal aberrations were reported with Fast Green FCF alone or in 
combination with nitrite (Giri et al., 1986; Das & Giri, 1988; Giri & Mukherjee, 
1990). The Committee noted that the purity of Fast Green FCF was not reported 
in these publications and that in two of these studies no positive control was used.
An in vivo bone marrow micronucleus assay also showed positive results 
after intraperitoneal administration in male Swiss albino mice of Fast Green FCF 
at up to 400 mg/kg bw. In this study, no positive control was used, the purity of 
Fast Green FCF was not stated and intraperitoneal administration at 800 mg/kg 
bw resulted in all the animals dying (Misra & Misra, 1986).
In an attempt to duplicate these results, Hayashi et al. (1988) found 
consistently negative results in an in vivo bone marrow micronucleus assay 
after single intraperitoneal injections of Fast Green FCF (89.2% purity) of up to 
2000 mg/kg bw into male ddY mice and after 4 injections at 24-hour intervals of 
the test substance at 250 mg/kg bw. A more recent and well conducted in vivo 
comet assay on murine tissues (glandular stomach, colon, liver, kidneys, urinary 
Table 2 (continued)
i The gene conversion assay in diploid yeast was conducted without metabolic activation.
j The cells were exposed to three Fast Green FCF samples for 24 and 48 hours with no metabolic activation systems were applied. Only a crude sample was positive at 
2 and 4 mg/mL at 24 and 48 hours.
k The mean number of breaks per metaphase induced by Fast Green FCF was 0.36 at 20 μmol/L for 5 hours. No positive control was used.
l Tests were conducted with and without metabolic activation.
m Two experiments were conducted, and only one had positive results.
n No positive control substance was used and the purity of Fast Green FCF was unknown.
o The purity of Fast Green FCF was 89.2%. Mitomycin C (2 mg/kg bw) was used as the positive control. Evidence of genotoxicity was assessed based on increased 
frequency of micronucleated polychromatic erythrocytes (MNPCEs) for each animal (1000 polychromatic erythrocytes [PCEs] per animal were examined).
p Bone marrow chromosomes were examined following 30-day oral treatment of mice with Fast Green FCF with and without nitrite. A significant increase in the 
frequency of chromosomal aberrations was found with the dye-treated and dye-plus-nitrite-treated groups when compared with the controls. No positive control 
was used.
q Bone marrow chromosomes were examined following 90-day oral treatment of mice with Fast Green FCF with and without nitrite. A significant increase in the 
frequency of chromosomal aberrations was found with the dye-treated and dye-plus-nitrite-treated groups when compared with the controls. No positive control 
was used.
r Sister chromatid exchange (SCE) in mouse bone marrow cells was studied after intraperitoneal injection of Fast Green FCF with and without nitrite. Mitomycin C 
(2.5 mg/kg bw) was used as the positive control. A significant increase in SCE frequency was found with the dye-treated and dye-plus-nitrite-treated groups when 
compared with the controls.
s The comet assay was performed in isolated nuclei from the glandular stomach, colon, liver, kidney, urinary bladder, lung, brain and bone marrow of mice.
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bladder, lungs, brain and bone marrow) found clearly negative results 3 and 24 
hours after treatment (Sasaki et al., 2002).
The Committee noted that the Hayashi et al. (1988) and Sasaki et al. 
(2002) in vivo studies were not fully compliant with the current versions of the 
OECD guidelines 474 and 489, respectively. However, they were considered 
sufficiently reliable to be used in this assessment.
Given that all of the genotoxicity studies with positive test outcomes had 
limitations in experimental design and reporting, and an in vivo mouse bone 
marrow micronucleus assay and an in vivo mouse tissue comet assay were clearly 
negative, the Committee concluded that there is no safety concern with respect 
to genotoxicity of Fast Green FCF.
2.2.5 Reproductive and developmental toxicity
No new reproductive and developmental toxicity studies have become available 
since the previous evaluations.
(a) Multigeneration reproductive toxicity
A 3-generation reproduction study was carried out on Fast Green FCF in Long–
Evans rats at dose levels of 0, 10, 100, 300 or 1000 mg/kg bw per day. The F0 parents 
(10 males, 20 females) were given Fast Green FCF in the diet 2 weeks before the 
first mating and continued to be treated daily throughout the gestation, lactation 
and post-weaning phases for three successive generations. The F0 rats were mated 
twice. F1a litters were necropsied at weaning, and selected F1b animals (10 males, 
20 females) were used for subsequent breeding. Following an 80-day growth 
period, F1b animals were mated 3 times and their offspring treated identically to 
the F1a and F1b generations. Following the third mating, half of the pregnant F1b 
dams were killed on gestation day 19, the uterine contents were examined for 
total embryos/resorption sites and the number of corpora lutea per ovary were 
recorded. The remaining F1b dams were allowed to deliver normally (F2c) and 
were killed at weaning. The F2b animals were mated once and allowed to raise 
their offspring (F3a) to weaning when both parents and offspring were killed.
Gross necropsies were performed on all parent animals and on F1a, F2a, F2c 
and F3a offspring at weaning. Selected tissues from five animals of each sex/dose 
from the F1b parents and the F3a generation at weaning were fixed at necropsy, and 
the following tissues examined histopathologically from the control and high-
dose group: stomach, ileum, jejunum, colon, liver, spleen, heart, lungs, adrenals, 
kidneys, urinary bladder, thyroid, ovaries and uterus or testes.
No treatment-attributable effects were observed with respect to feed 
consumption, body weight, adult mortality, mating performance, pregnancy and 
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fertility rates, gestation length, litter survival, resorption rates, necropsy findings 
or offspring survival, weights and sex. There were no treatment-attributable 
macroscopic or microscopic tissue abnormalities of either F1b or F3a animals.
The NOAEL for reproductive toxicity was 1000 mg/kg bw per day, the 
highest dose tested (Smith, 1973).
The Committee noted that no information on the developmental toxicity 
of Fast Green FCF was available. However, information on the developmental 
toxicity of a structurally closely related substance (Brilliant Blue FCF, which 
differs only by one OH group) was available. No developmental toxicity of 
Brilliant Blue FCF was reported in rats at doses up to 2000 mg/kg bw per day or 
in rabbits at doses up to 200 mg/kg bw per day (BioDynamics Inc., 1972a,b). The 
Committee concluded there is no concern with respect to  developmental toxicity 
of Fast Green FCF.
2.2.6 Special studies
(a) Effects on hepatic function
The influence of a mixture of six commonly used artificial  food colours, 
erythrosine, Allura Red, new coccine (Ponceau 4R), Brilliant Blue, tartrazine 
and Fast Green (FCF), on the toxicity of the carcinogenic heterocyclic amine 
3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) was investigated using 
primary cultured rat hepatocytes. Hepatocytes were isolated from rats fed a 
diet containing the mixture of the food colours at concentrations of half their 
respective ADIs for 4 weeks. Trp-P-1 was applied to the cultured hepatocytes at 
various concentrations for 12 hours.
The mixture of food colours did not affect the Trp-P-1-induced decrease 
in cell viability or protein and DNA synthesis, but slightly augmented the Trp-
P-1-induced decrease in gluconeogenesis and ureogenesis. Ashida et al. (2000) 
suggested that the daily intake of artificial food colours may impair hepatic 
functions such as gluconeogenesis and ureogenesis when liver cells are exposed 
to dietary carcinogens such as Trp-P-1.
The Committee noted that the use of mixtures in these studies does not 
permit ascribing any observed effects to individual components.
(b) Neurological effects
Fast Green FCF was tested for its effect on synaptic events in whole-cell voltage 
clamped hippocampal interneurons using the patch clamp technique. The assay 
was performed on freshly isolated tissue from male Wistar rats and maintained 
in artificial cerebrospinal fluid (NaCl at 120 mmol/L, KCl at 3.5 mmol/L, CaCl2 
at 2.5  mmol/L, MgSO4 at 1.3  mmol/L, NaH2PO4 at 1.25  mmol/L, NaHCO3 at 
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25 mmol/L and glucose at 25 mmol/L). Miniature synaptic events were recorded 
in whole-cell voltage clamped hippocampal interneurons of the stratum radiatum 
of the CA1 hippocampus area.
Fast Green FCF added at concentrations of 0.1, 0.3 or 1 mg/mL (0.125, 
0.375 and 1.2 mmol/L, respectively) reduced the frequency of synaptic activity 
in a dose-dependent manner. Frequency was reduced to 21% of the control 
frequency at 1 mg/mL (1.2 mmol/L). The effect was reversible upon removal of 
the test substance. The half maximal effective concentration (EC50) was estimated 
to be 200 mg/mL (250 mmol/L). No effect was detected on the magnitude of 
current or the decay time constant. Van Hooft (2002) suggested that Fast Green 
FCF may inhibit the release of neurotransmitters at a presynaptic level.
The Committee noted that Fast Green FCF is poorly absorbed and 
that the colour was only active at high concentrations in vitro. The Committee 
concluded that these results are not relevant to the present evaluation.
2.3 Observations in humans
No data were available.
3. Dietary exposure
The Committee reviewed dietary exposures for Fast Green FCF based on 
individual dietary records from the USFDA (Doell et al., 2016) and Konkuk 
University, Republic of Korea (Ha et al., 2013). In these studies, Fast Green FCF 
was detected in only a few food groups – mainly in the ice cream group – and 
the exposure estimates reflect use in only these foods (Table 3). Fast Green FCF 
was included in the analytical programs of studies in Australia (FSANZ, 2008) 
and Kuwait (Husain et al., 2006), but it was not detected and no dietary exposure 
estimates were reported. The USFDA analysed 44 food samples for Fast Green 
FCF; the colour was detected in two food groups (cereal and sherbet) at levels of 
1.9–2.9 mg/kg (Harp, Miranda-Bermudez & Barrows, 2013).
Since the exposure estimates from the USA and the Republic of Korea 
were based on only a few findings in a limited number of food groups, the 
Committee performed a conservative dietary exposure assessment using the 
FAO/WHO Chronic Individual Food Consumption Database – Summary 
statistics (CIFOCOss) database and Codex maximum levels.
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3.1 Assessments based on model diets
3.1.1 Exposure estimates based on CIFOCOss database
The CIFOCOss database1 currently contains summary statistics from 55 surveys 
from 36 countries, each with survey durations of 2 days or more. The countries, 
grouped in 17 Global Environment Monitoring System – Food Contamination 
Monitoring and Assessment Programme (GEMS/Food) clusters diets (WHO, 
2012), are culturally and economically comparable. The database provides 
summary statistics of food categorization, grouped in three tiers, with more than 
600 items at the most detailed tier. The food categories from the Codex General 
Standard for Food Additives (GSFA) (FAO/WHO, 2015) were matched with the 
CIFOCOss detailed food groups to assign the Codex maximum levels for the 
calculations. These assignments are listed in Table 4.
The mean and the 95th percentile of the dietary exposure were calculated 
within each survey, age class and CIFOCOss food group. For each survey a mean 
and a high exposure were calculated. The high exposure was calculated as the sum 
of the 95th percentile exposure for the food group with the highest 95th percentile 
exposure and the mean exposure for each of the remaining food groups. For each 
age group, Table 5 lists the number of clusters and surveys included in the ranges 
given for the mean and the high exposure estimates. The high value of 12 mg/kg 
Table 3
studies reviewed for the present assessment of dietary exposure to fast Green fCf
USFDA: United States Food and Drug Administration; P90: 90th percentile; P95: 95th percentile
a 90th percentile.
b 95th percentile.
c The lowest analytical value for the colour additive was assigned to each food code.
d The analytical results were averaged for a given food code.
e The highest analytical value for the colour additive was assigned to each food code.
Organization
Concentration 
data
Sampling 
strategy Consumer groups
Food consumption 
data
Estimates 
of dietary 
exposure Scenarios
USFDA (Doell et 
al., 2016)
Analytical levels 
in foods
Targeted 
using label 
and/or colour 
USA population
≥2 years;
children 2–5 years;
boys 13–18 years
Individual dietary 
records and food 
diaries 2 days;
10–14 days
Mean
P90a
P95b
Lowc
Mediumd
Highe
Konkuk University, 
Republic of Korea 
(Ha et al., 2013)
Analytical levels 
in foods
Market share 1–2 years; 3–6 years; 7–12 
years; 13–19 years; 20–29 years; 
30–49 years; 50–64 years; ≥65 
years; male; female; upper 95th 
consumers
24-hour recall Mean
P95b
Mediumd
1 Detailed data (January 2017) were made available to the Committee by the World Health Organization.
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CIFOCOss food group GSFA code
Codex maximum levels 
(mg/kg or mg/L)
Dairy-based desserts (e.g. pudding, fruit or flavoured yogurt) 01.7 100
Fat-based desserts excluding dairy-based dessert products 02.4
Edible ices, including sherbet and sorbet 03
Bullets or lollipop 05.2
Cakes, cookies and pies (e.g. fruit-filled or custard types) 07
Meat from mammals other than marine mammals, nes 08.1 100
Game (mammalian) meat
Beef and other bovines meat
Goat and other caprines
Horse and other equines
Kangaroo meat
Pork and other porcines
Rabbit meat
Sheep and other ovines
Poultry meat, nes
Game (poultry) meat
Chicken meat
Duck meat
Goose meat
Quail meat
Turkey meat
Unprocessed meat and offals, nes
Processed meat and meat products, nes 08.2 100
Fish-based composite food 10.4
Dietary supplements, food supplements 13.6 600
Flavoured milk 01.1.4 100
Canned or bottled (pasteurized) fruits 04.1.2.4 200
Jams, jellies, marmalades 04.1.2.5 400
Other processed fruits (excluding dried and juice), nes 04.1.2.8 100
Papaya, dried Average of 04.2.2.3, 
04.2.2.4 and 04.2.2.7
200a
Raspberries, red, black, dried
Pulses processed, nes
Roots and tubers processed
Roots and tubers other processed, nes
Brassica vegetables, head cabbages, flowerhead cabbages, processed
Bulb vegetables, processed
Fruiting vegetables, other than cucurbits, processed
Leafy vegetables, processed
Legume vegetables, processed
Root vegetables, processed
Table 4
food groups and Codex maximum levels of fast Green fCf used in the CIfoCoss calculations
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CIFOCOss: Chronic Individual Food Consumption Database – Summary statistics; GSFA: General Standard for Food Additives; nes: not elsewhere specified
a Average of 04.2.2.3 (300 mg/kg), 04.2.2.4 (200 mg/kg) and 04.2.2.7 (100 mg/kg).
Table 5
exposure estimates for fast Green fCf per age group based on CIfoCoss database and 
Codex maximum levels
bw: body weight; CIFOCOss: Chronic Individual Food Consumption Database – Summary statistics; No.: number
a  Ages not defined in the version of CIFOCOss database available.
Table 4 (continued)
CIFOCOss food group GSFA code
Codex maximum levels 
(mg/kg or mg/L)
Other vegetables, nes, other processing
Other vegetables, unprocessed, nes
Strawberry, dried 04.2.2.7 100
Processed fish and fish products (including molluscs, crustaceans and echinoderms) 09.2.4.1 100
Tuna, preserved
Salmon, preserved
Smoked, dried, fermented, and/or salted fish and fish products, including molluscs, 
crustaceans and echinoderms
09.2.5
Mayonnaise 12.6.1 100
Mustard sauce
Sauces and like products, nes
Energy drinks 14.1.4 100
Isotonic drink
Nonalcoholic (“soft”) beverages, nes
Distilled spirituous beverages containing more than 15% alcohol 14.2.6 100
Beer and malt beverages, nes 14.2.7
Beer of barley
Beer of maize
Alcoholic beverages, nes
Populationa No. of clusters No. of surveys
Range for mean 
exposure across 
dietary surveys  
(mg/kg bw per day)
Range for high-level 
exposure across 
dietary surveys  
(mg/kg bw per day)
Adults 5 19 0.49–1.5 1.0–4.8
Adolescents 5 17 0.50–2.9 1.2–12
Children 7 30 0.25–2.7 1.0–7.5
Toddlers 4 9 0.93–2.8 2.1–8.7
Infants 1 2 0.19–0.37 0.57–6.9
bw per day for adolescents is strongly influenced by the contribution of United 
Kingdom adolescent consumers of nonalcoholic soft drinks.
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For each age group, Table 6 lists the CIFOCOss food group contributing 
most to the total mean exposure within each survey, the range of these 
contributions and the number of surveys included in this range. Only food groups 
that contributed at least 10% to the total mean exposure are included in the table.
3.2 Assessments based on individual dietary records
3.2.1 Exposure estimates reported by USFDA
In a study completed by the USFDA (Doell et al., 2016), approximately 600 
commercially available food samples from 52 broad categories were analysed 
for Fast Green FCF (and other synthetic colours) using a validated liquid 
chromatography method with photodiode array detection (Harp, Miranda-
Bermudez & Barrows, 2013). Samples were selected based on a previous survey of 
food labels. Fast Green FCF was found in products in two of the 52 food categories 
at concentrations just over the limit of detection (LOD; 1 mg/kg) to 1.2 mg/kg (in 
the categories “Cakes and cupcakes” and “Ice Cream, frozen yogurt, sherbet”). 
Two different sets of food consumption data from 2007–2010 were used for the 
dietary exposure estimates: a 2-day and a 10- to 14-day dietary exposure survey 
for the United States population. Three population groups were used for the 
exposure estimate: United States population 2 years and older, children 2–5 years 
and teenage boys aged 13–18 years. Exposures were estimated based on “eaters 
Populationa
Food group contributing most to the mean 
exposure No. of surveys
Range of contributions 
(%)
Adults Beer and malt beverages, nes 10 9–44
Nonalcoholic (“soft”) beverages, nes 7 12–57
Diet beverages 2 22–24
Adolescents Nonalcoholic (“soft”) beverages, nes 13 17–100
Roots and tubers other processed, nes 1 39
Children Nonalcoholic (“soft”) beverages, nes 20 7–100
Roots and tubers other processed, nes 3 31–43
Canned or bottled (pasteurized) fruits 2 1–13
Other vegetables, unprocessed, nes 1 30
Toddlers Nonalcoholic (“soft”) beverages, nes 6 2–30
Roots and tubers other processed, nes 2 37–38
Canned or bottled (pasteurized) fruits 1 13
Infants Roots and tubers other processed, nes 1 62
nes: not elsewhere specified; No.: number
a  Ages not defined in the version of CIFOCOss database available.
Table 6
food groups contributing most to total mean exposure to fast Green fCf
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only” (individuals in the population who consumed one or more of the included 
foods over the survey period). Three different exposure scenarios were performed 
but showed no difference in exposure to Fast Green FCF. Dietary exposures were 
estimated at the mean and at the 90th percentile for each population for each 
food category (Tables 7 and 8).
The “Frozen dairy dessert/Sherbet” food group was the dominant 
contributor (95–97% of total exposure) to exposure to Fast Green FCF in the 
USA population. Table 8 lists the major contributing food groups for the three 
age groups.
3.2.2 Exposure estimates reported by Konkuk University, Republic of Korea
The dietary exposure to Fast Green FCF in the Republic of Korea was estimated 
based on food consumption data for consumers and concentrations in processed 
foods (Ha et al., 2013). Fast Green FCF was found in 2/40 samples of ice cream. For 
the average consumer in the Republic of Korea (using the average concentration 
of all samples in a food group), the estimated mean and 95th percentile for 
dietary exposure were both below 0.001 mg/kg bw per day. For a high exposure 
consumer (using the average concentration of positive samples), the estimated 
mean and 95th percentile for dietary exposure were 0.001 and 0.003 mg/kg bw 
per day, respectively.
The dietary exposure estimates based on the CIFOCOss model diets and 
Codex maximum levels uses a very conservative approach and shows mean dietary 
exposures 0.5–1.5 mg/kg bw per day for adults and 0.3–3 mg/kg bw per day for 
toddlers, children and adolescents. Ranges for high exposures (in mg/kg bw per 
day) were 1–5 for adults, 1–9 for toddlers and children, and 0.5–12 for adolescents.
3.3 Evaluation of estimates of dietary exposure
Using the CIFOCOss data for adolescents, the dietary exposure is estimated to be 
12 mg/kg bw per day (95th percentile).
The USFDA assessments based on USA food consumption data and 
analytical levels estimate mean dietary exposure in the range 0.01–0.04 mg/
kg bw per day for children aged 2–5 years, teenage boys aged 13–18 years and 
the population aged 2 years and older. The 90th percentile exposures were in 
the range of 0.02–0.09 mg/kg bw per day. The estimates were derived from a 
generally lower-bound approach and were based on foods found to contain Fast 
Green FCF, which can explain the differences with the conservative approach of 
the CIFOCOss model.
The Committee concluded that the higher dietary exposure estimates 
prepared using the CIFOCOss model were due to the use of Codex maximum 
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levels as opposed to mean analysed levels for all foods used by the USFDA and 
the Republic of Korea.
The Committee concluded that the conservative estimate of 12 mg/kg bw 
per day, prepared using the CIFOCOss model, should be considered in the safety 
assessment for Fast Green FCF.
4. Comments
4.1 Biochemical aspects
Absorption of orally administered Fast Green FCF was shown to be less than 5%; 
almost all the administered colour was excreted unchanged in the faeces of the 
rats (Hess & Fitzhugh, 1953, 1954, 1955).
Food group
% of total exposure per population group
Population ≥2 years Children 2–5 years Boys 13–18 years
Frozen dairy dessert/Sherbet 95 97 97
Drink mixers 2 – –
Breakfast cereal 1 1 1
Cake and cupcakes 1 1 –
Table 7
estimated daily exposure to fast Green fCf for the United states population based on 
nHAnes food consumption data, 2007–2010
bw: body weight; NHANES: National Health and Nutrition Examination Survey
a  Individuals who consumed one or more of the included foods over the survey period.
Source: Doell et al. (2016)
Age–sex group (years) % eatersa
Estimated exposure (mg/kg bw per day)
2 days food consumption 10–14 days food consumption
Mean 90th percentile Mean 90th percentile 
Children (2–5) 15 0.04 0.09 0.02 0.03
Boys (13–18) 14 0.03 0.06 0.01 0.02
Population (≥2) 15 0.02 0.04 0.01 0.02
Table 8
Major contributors to fast Green fCf exposure in the UsA population based on the 2-day 
mean average-exposure scenario
Source: Doell et al. (2016)
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In an in vitro study, in which the Xenopus oocyte expression system was 
used for pharmacological investigations on purinergic P2 receptors that interact 
with the membrane channel protein Panx1 in inflammasome signalling, Fast 
Green FCF was shown to be a selective inhibitor of Panx1 channels, with an IC50 of 
0.27 µmol/L, and did not significantly inhibit the P2X7R receptor (Wang, Jackson 
& Dahl, 2013). The Committee was aware that Panx1 activation/inhibition is one 
of several signalling pathways involved in various physiological processes at the 
cellular level (e.g. immune function) and that there are many exogenous and 
endogenous modulators of these pathways. Interactions of substances with P2 
receptors and Panx1 are an active area of research, particularly in development of 
drug treatments for diverse chronic diseases. The Committee noted that a similar 
pattern of channel inhibition was observed with Brilliant Blue FCF, and further 
research may clarify if the inhibition of Panx1 observed in an in vitro system has 
any relevance for the safety assessment for substances in food.
4.2 Toxicological studies
Fast Green FCF has low oral acute toxicity in rats (Lu & Lavallee, 1964) and dogs 
(Radomski & Deichmann, 1956).
A short-term study of toxicity revealed no compound-related effects in 
dogs fed Fast Green FCF at 0%, 1.0% or 2.0% of the diet (equal to 0, 269 and 695 
mg/kg bw per day, respectively) for 2 years (Hansen et al., 1966).
Two previously reviewed long-term studies of oral toxicity showed no 
compound-related effects in mice and rats. The NOAEL was 2% Fast Green FCF 
in the diet (equivalent to 3000 mg/kg bw per day) in mice and 5.0% (equivalent 
to 2500 mg/kg bw per day) in rats (Hansen et al., 1966).
No treatment-related increase in tumour incidence was found in a 
mouse carcinogenicity study (Hogan & Knezevich, 1981). At the twenty-ninth 
meeting, the Committee concluded that the NOAEL was 5% Fast Green FCF in 
the diet, the highest dose tested. The present Committee noted that the mean 
body weights of females in the 5% dose group were consistently lower than those 
of controls after the commencement of the study (−10% compared with relevant 
controls at termination of the study). The Committee considered this decrease 
in body weights to be a treatment-related adverse effect and concluded that the 
NOAEL was 1.5% Fast Green FCF (equal to 3392 mg/kg bw per day), based on 
the lower body weights observed at 5% (equal to 11 805 mg/kg bw per day) in 
females.
A carcinogenicity study in rats reported an increased incidence of 
urothelial hyperplasia and/or neoplasia of the bladder (Knezevich & Hogan, 
1981). However, a peer review of the histopathological data showed that Fast 
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Green FCF is noncarcinogenic in this species (Dua, Chowdury & Moch, 1982; 
O’Donnell, 1982; USFDA, 1982a,b). The previous Committee agreed with this 
conclusion at its thirtieth meeting and concluded that the NOAEL in this dietary 
study was 5% Fast Green FCF (equal to 3184 mg/kg bw per day), the highest 
dose tested (Annex 1, reference 73). The present Committee concurred with this 
conclusion.
Whereas 10 of the 18 available genotoxicity tests were negative, four in 
vitro and four in vivo studies yielded positive results. Given that all of the studies 
with positive test outcomes had several limitations in experimental design and 
reporting, whereas an in vivo mouse bone marrow micronucleus assay (Hayashi 
et al., 1988) and an in vivo mouse tissue comet assay (Sasaki et al., 2002) were 
clearly negative, the Committee concluded that there is no concern with respect 
to genotoxicity of Fast Green FCF.
No reproductive toxicity was reported at doses up to 1000 mg/kg bw per 
day over three generations of rats (Smith, 1973).
No developmental toxicity studies were available. However, information 
on the developmental toxicity of the structurally related substance Brilliant Blue 
FCF, which differs from Fast Green FCF by a single hydroxyl group, was available. 
No developmental toxicity was reported in rats treated with Brilliant Blue FCF at 
doses up to 2000 mg/kg bw per day or in rabbits at up to 200 mg/kg bw per day 
(BioDynamics Inc. 1972a,b). Based on these findings, the Committee concluded 
that there is no concern for developmental toxicity for Fast Green FCF.
4.3 Observations in humans
No data were available.
4.4 Assessment of dietary exposure
Estimates of dietary exposure to Fast Green FCF published by the Republic 
of Korea (Ha et al., 2013) and the USFDA (Doell et al., 2016) were available. 
Because the estimates were based on only a few findings in  a limited number 
of food groups, the Committee conducted a conservative assessment using the 
CIFOCOss database and Codex maximum levels.
Dietary exposure to Fast Green FCF was estimated to be 12 mg/kg bw 
per day for  adolescents, the age group with the highest exposure, at the 95th 
percentile. This estimate was much higher than those of both the USFDA (0.09 
mg/kg bw per day for children at the 90th percentile) and the Republic of Korea 
(0.003 mg/kg bw per day for the whole population at the 95th percentile). The 
Committee concluded that these differences were due to the use of Codex 
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maximum levels, in contrast to the estimates from the USFDA and the Republic 
of Korea, which used mean analysed levels for all foods.
The Committee concluded  that the conservative estimate of 12 mg/kg 
bw per day, prepared using CIFOCOss data, should be considered in the safety 
assessment for Fast Green FCF.
5. evaluation
The Committee at previous meetings concluded that Fast Green FCF is not 
carcinogenic. The evidence newly available at this meeting indicates that there 
is no concern with respect to genotoxicity of Fast Green FCF. The ADI of 0–25 
mg/kg bw established previously by the Committee was based on a long-term rat 
dietary study in which a NOAEL of 5% Fast Green FCF (equivalent to 2500 mg/
kg bw per day), the highest concentration tested, was identified (Hansen et al., 
1966).
The Committee concluded that the new data that had become available 
since the previous evaluation gave no reason to revise the ADI and confirmed 
the ADI of 0–25 mg/kg bw. The Committee noted that the conservative dietary 
exposure estimate for Fast Green FCF of 12 mg/kg bw per day (95th percentile for 
adolescents) was below the upper bound of the ADI. The Committee concluded 
that dietary exposures to Fast Green FCF for adolescents and all other age groups 
do not present a health concern.
At the present meeting, the existing specifications for Fast Green FCF 
were revised, and a maximum limit for manganese was added. High-performance 
liquid chromatography (HPLC) methods were added to determine subsidiary 
colouring matters and organic compounds other than colouring matters. The 
assay method was changed to visible spectrophotometry, and spectrophotometric 
data were provided for the colour dissolved in water or aqueous ammonium 
acetate.
The specifications monograph was revised, and a Chemical and Technical 
Assessment was prepared.
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1. explanation
Gum ghatti (Chemical Abstracts Service [CAS] No. 9000-26-6), also known as 
Indian gum, ghatti gum or gum ghati, is the dried gummy exudate from wounds 
in the bark of Anogeissus latifolia Wallich (family Combretaceae), a large tree 
native to India and Sri Lanka (Al-Assaf, Phillips & Amar, 2009). Gum ghatti is 
used as a thickening agent and stabilizer. It is permitted as a food additive in the 
USA.
Gum ghatti was previously evaluated at the twenty-sixth and twenty-
ninth Joint FAO/WHO Expert Committee on Food Additives (JECFA) meetings 
(Annex 1, references 59 and 70). Heavy metal specifications were revised at the 
fifty-seventh JECFA meeting (Annex 1, reference 154). No acceptable daily intake 
(ADI) could be established at the twenty-sixth or twenty-ninth meetings because 
of insufficient data, but the Committee did not make specific recommendations 
for further studies; no monographs were prepared.
At the present meeting, the Committee evaluated gum ghatti at the 
request of the Forty-eighth Session of the Codex Committee on Food Additives 
(FAO/WHO, 2016). A toxicological dossier was submitted. Two new 90-day rat 
studies as well as genotoxicity studies have become available since the previous 
evaluations. To address any data gaps for gum ghatti, the safety data on other 
polysaccharide-based gums were considered based on their similar general 
structure, chemical and functional properties, technical uses, lack of absorption 
as intact substances and their metabolism in the lower gastrointestinal tract.
A comprehensive literature search up to April 2017 was performed in 
PubMed and TOXLINE using the following search terms: “gum ghatti”/“ghati”, 
“ghatti”/“ghati gum”, “gatifolia”, “CAS no 9000-28-6”, “toxicity”, “mutagenicity”, 
“teratologic”, “evaluation”. Although the search resulted in five additional papers, 
these did not add further relevant data to those submitted to the Committee for 
this meeting.
1.1 Chemical and technical considerations
Unprocessed gum ghatti occurs as both amorphous “tears” of various sizes and as 
broken irregular pieces. It is light to dark brown in colour, has little or no odour 
and is available commercially in the form of brown tears or grey to reddish-
grey powder. The product in commerce is manufactured by collecting the dried 
translucent exudate as tears, partially dissolving these in water and filtering. The 
final product is sterilized and dried to a gummy, lump form, or spray-dried to a 
powder form.
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Gum ghatti consists mainly of a calcium salt (or occasionally magnesium) 
salts of high molecular weight and water-soluble complex polysaccharides. The 
hydrolysis of the polysaccharide yields L-arabinose, D-galactose, D-glucuronic 
acid and D-mannose, and small amounts of D-xylose and L-rhamnose. The 
reported average molar ratio of the various units is L-arabinose:D-galactose:D-
glucuronic  acid:D-mannose:D-xylose:L-rhamnose = 40:25:20:7:1:1 (Sakai et al., 
2013). Gum ghatti also contains protein-bound arabinogalactan units, tannins 
and moisture. The average molecular weight of gum ghatti is in the order of 
several hundred kDa (Kang et al., 2015).
2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and excretion
Data on the absorption, distribution and excretion of gum ghatti were not 
available at the last evaluation by the Committee, and no additional information 
has become available since. However, based on its chemical composition, it is 
reasonable to assume that gum ghatti, like similar gums, will not be significantly 
degraded or absorbed in the stomach or small intestine. Instead, it is probable 
that gum ghatti, like gum arabic, passes into the caecum where it is enzymatically 
degraded and fermented by the microflora in the large intestine to hydrogen 
gas, carbon dioxide and short chain fatty acids, which can be absorbed and 
metabolized (Ali, Ziada & Blunden, 2009).
Gum arabic has been found to be fermented mainly to acetate, propionate 
and butyrate, which can be absorbed and metabolized by normal metabolic 
pathways. Short chain fatty acids have been found to significantly affect intestinal 
and liver metabolism as sources of energy or metabolic effectors (Ali, Ziada & 
Blunden, 2009).
2.1.2 Biotransformation
No information was available.
2.1.3 Effects on enzymes and other biochemical parameters
No information was available.
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2.2 Toxicological studies
2.2.1 Acute toxicity
No new information was available on acute toxicity. One study that included 
a test of acute toxicity had not been previously described (Newell & Maxwell, 
1972). Male Sprague Dawley rats (n = 10; 200–250 g) were fasted overnight prior 
to administration of gum ghatti suspended in corn oil at a dose of 10 000 mg/kg 
body weight (bw). There were no deaths and no symptoms were observed except 
for a “transient depression of the rats” for a few hours after dosing.
The Committee noted that this study was performed prior to the 
introduction of good laboratory practice (GLP) regulations and the report was 
very limited.
2.2.2 Short-term toxicity
Male Sprague Dawley rats (200–250 g; non-fasted) were administered gum ghatti 
suspended in corn oil at a daily dose of 5000 mg/kg bw for 5 days. No unusual or 
adverse effects were observed (Newell & Maxwell, 1972).
The Committee noted that this study was performed prior to GLP and 
the report was very limited.
Two 90-day rat studies were performed in compliance with GLP and 
quality assurance (QA) and in accordance with Organization for Economic Co-
operation and Development (OECD) Test Guideline 408. The test substance, 
Gatti Gum SD (previously called Gatifolia SD), a grey to reddish-grey spray-
dried powder, was mixed with basal diet AIN-93M. Because the test substance 
was found to be stable in the prepared feed for only 58 days, two batches of feed 
containing the test substance were prepared for both studies. Five lots of the test 
substance were prepared, analysed and certified in accordance with specifications 
and standards for food additives in Japan. Six sugar components in each lot were 
characterized; the total sugar composition was 84.2–86.5%.
In the first study, Davis & Lea (2011; also described in Maronpot et al., 
2013) administered gum ghatti in a purified basal diet, AIN-93M, to Sprague 
Dawley rats (n = 10/sex per group) at concentrations of 0 (control), 0.5%, 1.5% 
and 5% (equal to 0, 337, 1018 and 3044 for males and 0, 396, 1149 and 3308 mg/
kg bw per day for females, respectively). The dose levels were selected from a 
previous 14-day dose range–finding study (Davis & Lea, 2014).
No clinical signs of toxicity were observed in any of the animals and all 
animals survived to study end. After 90 days of treatment, the animals were killed 
and all major tissues were fixed for analysis.
There were no differences in mean feed consumption and body weight 
gains between the treatment and control groups. No significant differences were 
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found in ophthalmologic and neurological observations, urine analyses or blood 
clotting times.
In haematological analyses, there was a statistically significant increase 
in monocyte concentration in each of the treated groups of female rats compared 
with controls. The increases were above historical control values but were not 
dose-related, being of similar magnitude in each treated group. In contrast, a 
statistically significant, dose-dependent decrease in monocyte concentration was 
observed in male rats. A decrease in albumin level was observed in male rats 
in the 0.5% and 5% dietary dose groups. Although statistically significant, this 
decrease was slight and not dose-dependent.
An increase in mean ovary weight was observed at the 0.5% dose 
level (relative mean weight) and at 5% (absolute and relative mean weights). A 
decrease in absolute brain weight in male rats was observed at the 5% dose level. 
The Committee considered these effects not treatment related because they were 
not dose related, not observed in both sexes and/or not accompanied by any 
histopathological correlates.
In both males and females, exposure to 5% gum ghatti in the diet was 
significantly associated with increased empty and full caecal weights. This 
increase was apparent both in absolute and relative tissues weights. In addition, 
a significant association with increased empty caecal weights was observed in 
females at 0.5%. Minimal to moderate histopathological changes were observed 
in the caecum of high-dose males; 6/10 displayed minimal to mild caecal 
mucosal hyperplasia and/or minimal to mild crypt elongation. No lesions were 
found in female rat caeca. In 2/10 female rats exposed to 5% gum ghatti in the 
diet, moderate inflammation of the colon with loss of mucosa, haemorrhage and 
necrosis was diagnosed as ulcerative colitis. No significant lesions were observed 
in the colon of the male rats.
Because of the lesions observed in the colon of female rats, fixed colon 
wet tissues from all male and female rats were thoroughly re-examined in a peer 
review to see if any additional lesions could be identified. Moderate lymphoid 
hyperplasia was observed in one male control and in one male at 5% gum ghatti in 
the diet. In addition, one female control rat displayed minimal congestion of the 
mucosa. In the three remaining high-dose rats, no significant lesions were found 
in the colon. No lesions other than those identified in the initial histopathology 
evaluation were found. Microscopic evaluation of tissues in all other investigated 
organs found no significant lesions in the high-dose (5%) animals.
The effects on caecal weights seen in both sexes at 5% gum ghatti in the diet 
have been reported in other toxicity studies of poorly digestible polysaccharides 
and gum products (Tulung, Rémésy & Demigné, 1987; Wyatt et al., 1988; Levrat et 
al., 1991; Doi et al., 2006; Ali, Ziada & Blunden, 2009; Hagiwara et al., 2010). The 
increase in caecal weights is considered to be the result of absent or incomplete 
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absorption of gum in the small intestine leading to microbial fermentation of the 
gum in the caecum and colon (Newberne, Conner & Estes, 1988). The ulcerative 
colitis observed in 2/10 female rats at 5% was not seen in any other dose group 
or in males, and no reason could be identified for the occurrence of ulcers in 
females only. Other effects on monocytes, albumin, brain and ovarian weight 
were either sporadic and/or did not show a dose-response relationship.
Based on the results of this study a no-observed-adverse-effect level 
(NOAEL) of 3044 mg/kg bw per day, the highest dose tested, was identified for 
male rats, and of 1149 mg/kg bw per day for female rats, based on the incidence 
of ulcerative colitis observed at the highest dose (3308 mg/kg bw per day).
In order to evaluate  the  relevance  of the  focal colonic 
ulcerations,  the  possible role of the  AIN-93M diet and  the possibility that 
intrinsically susceptible littermates had been randomly assigned to the same 
group, Davis (2012; also described in Maronpot et al., 2013) conducted a study in 
female Sprague Dawley rats (n = 20/group) to compare two different basal diets 
(AIN-93M and NIH-07), with a focus on histopathology of colon. The female 
rats were fed diets containing 0 (control) or 5% gum ghatti, equal to 0 or 3671 
mg/kg bw per day for rats given the AIN-93M diet and 3825 mg/kg bw per day 
for rats given the NIH-07 diet.
The study parameters were essentially the same as in the Davis & Lea 
(2011) study (described above) except that neurological assessments and urine 
analyses were not carried out and histopathological assessment was restricted 
to caecum and colon. To circumvent the possibility that intrinsically susceptible 
littermates could have been randomly assigned to the same group, rats ordered 
for the second study were specifically requested to be non-littermates.
No clinical signs of toxicity were observed in any of the animals and 
all animals survived the 90-day treatment. There were no associations between 
exposure to gum ghatti and feed consumption, body weight gain, tissue weights 
or ophthalmological parameters.
Haematological analysis found that prothrombin time was significantly 
decreased in rats administered 5% gum ghatti in the AIN-93M diet, while 
activated partial thromboplastin time and red blood cell distribution width 
were significantly increased compared to control rats fed the AIN-93M diet. 
In contrast, no differences in haematological end-points were observed in the 
female rats fed the NIH-07 diet. In the initial 90-day study, the only change noted 
in females exposed to 5% gum ghatti in the AIN-93M diet was an increase in 
monocytes.
In clinical chemistry analyses, chloride and alkaline phosphatase levels 
increased significantly and potassium, albumin and phosphorus levels decreased 
significantly in treated females fed the AIN-93M diet compared with the controls. 
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In treated females fed the NIH-07 diet, globulin levels were significantly decreased 
and calcium levels increased. The clinical chemistry changes were not consistent 
across the groups in the two studies, however (AIN-93M diet versus NIH-07 diet 
in this, the Davis, 2012, study versus AIN-93M in the initial, Davis & Lea, 2011, 
study). This indicates that the changes may not be related to gum ghatti exposure.
Pituitary gland weight was significantly increased in treated animals fed 
the AIN-93M diet compared with controls; however, no change in pituitary gland 
weight was observed in treated rats fed the NIH-07 diet or in the initial Davis & 
Lea, 2011, study.
As in the first study, empty caecal weights (absolute and relative) were 
increased in treated animals in both AIN-93M and NIH-07 diets compared with 
their respective controls. Full caecal weights (absolute and relative) were also 
increased in treated rats fed the AIN-93M diet compared with rats fed the carrier 
diet alone, but not in treated rats fed the NIH-07 diet. Histopathological changes 
were not apparent in the caecum of animals from any dose group.
A focal colonic ulcer associated with an acute inflammation was found in 
one of the control rats. The histology of this ulcer was similar to those observed 
in the first study. A common observation in all groups in the second study was 
focal lymphoid hyperplasia of the colon; it was found in 5/20 rats fed the AIN-
93M diet alone, 5/20 rats fed the AIN-93M diet with 5% gum ghatti, 2/20 rats fed 
the NIH-07 diet alone and in 3/20 rats fed the NIH-07 diet with 5% gum ghatti. 
The severity of this lesion ranged from minimal to marked, with no apparent 
association with gum ghatti exposure.
A panel of experts in a post-study pathology working group examined 
the colon lesions and 50% of the colon and caecum sections from both 90-day 
studies. The expert group reached the conclusion that the ulceration of the 
colon was a sporadic event that was not associated with exposure to gum ghatti 
and that the caecal changes diagnosed in 6/10 male rats in the first study were 
“normal variations”. The caecal changes could not be confirmed as being caecal 
crypt hyperplasia and/or crypt elongation; rather, they may have been affected by 
variable handling of the tissues while fixing, trimming, embedding and preparing 
of tissue sections. Moreover, the pathology expert group did not find the increase 
in caecal weight toxicologically relevant.
The Committee considered the increase in caecal weight at the 5% dose 
of gum ghatti in both 90-day studies to be an adaptive effect in the rat that has no 
relevance to humans. Based on the results of these two studies, a NOAEL of 3044 
mg/kg bw per day, the highest dose tested in male rats, was identified (equal to 
2590 mg/kg bw per day after correcting for purity).
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2.2.3 Long-term studies of toxicity and carcinogenicity
No information was available.
2.2.4 Genotoxicity
New information has become available since the last evaluations by the Committee 
at the twenty-sixth and twenty-ninth meeting. The results of these newly available 
genotoxicity studies as well as the results of older studies are summarized in Table 
1.
No evidence for genotoxic potential of gum ghatti was found in several 
in vitro or in vivo studies at concentrations or dose levels that met or exceeded 
the levels suggested in OECD guidelines.
It should be noted that the older genotoxicity studies of gum ghatti 
(Newell & Maxwell, 1972; Mortelmans, 1981; Prival, Simmon & Mortelmans, 
1991) were conducted prior to OECD guidelines and were generally not certified 
for compliance with GLP and QA, whereas the newer genotoxicity studies 
(Swarts, 2010a,b; Davis & Hobbs, 2011; also reported in Hobbs et al., 2012) were 
all performed according to OECD guidelines and were certified for compliance 
with GLP and QA.
2.2.5 Reproductive and developmental toxicity
(a) Multigeneration studies
No information was available.
(b) Developmental toxicity
No new information has become available since the last evaluation. The results 
of the previously submitted studies are summarized below as no toxicological 
monographs were prepared following the Committee’s previous evaluations of 
gum ghatti.
Food and Drug Research Laboratories Inc. (1972a) investigated the 
developmental toxicity effects of gum ghatti on four animal species: mice, rats, 
hamsters and rabbits. In each study, gum ghatti (described as “fine tan powdered 
material”; purity not specified) was administered daily to the female animals by 
oral intubation gavage using anhydrous corn oil as vehicle, at a volume of 1.0 mL/
kg bw. The day of mating was considered to be gestation day 0. Gum ghatti was 
administered daily during major organogenesis, defined as the period between 
implantation and closure of the hard palate. In each study, the controls were 
described as “sham treated”; the report does not specify whether this means the 
controls received the vehicle.
Groups of pregnant albino CD-1 mice (n = 20–21/group) were 
administered 0, 17, 80, 370 or 1700 mg/kg bw per day of gum ghatti (purity not 
105
Gum ghatti
End-point Test system
Route of 
administration Concentration Result Reference
In vitro
Reverse mutation Salmonella typhimurium TA98, 
TA100, TA1535, TA1537, TA1538, 
Escherichia coli WP2uvrA
– 0.3–100 µg/plate, 
±S9
Negativea Mortelmans (1981); 
Prival, Simmon & 
Mortelmans (1991)
Forward and 
reverse mutations
Host-mediated assay, related in 
vitro tests (mouse) S. typhimurium 
G-46, TA1530
– 5% w/v Negative Newell & Maxwell 
(1972)b
Recombination 
frequency
Host-mediated assay, related in 
vitro tests (mouse) Saccharomyces 
cerevisiae D-3
– 1% w/v Negative Newell & Maxwell 
(1972)b
Adverse effects 
on metaphase 
chromosomes
Cytogenetic assay WI-38 cells 
(human embryonic lung)
– 0.16–16 µg/mL Negative Newell & Maxwell 
(1972)b
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA97a, E. coli WP2uvrA, 
pKM101
– 125–6 000 µg/plate, 
±S9
Negativec Swarts (2010a); 
Hobbs et al. (2012)
Chromosomal 
aberration 
Chinese hamster ovary cells (CHO) – 1 000–6 000 µg/
mL, ±S9
Negativec,d Swarts (2010b); 
Hobbs et al. (2012)
In vivo
Chromosomal 
aberration in germ 
cells
Dominant lethal test
Rat
Oral 30, 2 500, 5 000 mg/
kg bw
Negative Newell & Maxwell 
(1972)b
Adverse effects 
to metaphase 
chromosomes
Cytogenetic assay (bone marrow)
Rat 
Oral 30, 2 500, 5 000 mg/
kg bw
Negative Newell & Maxwell 
(1972)b
DNA damage 
Micronucleus 
induction
Comet/micronucleus combination 
assay B6C3f1 Mouse; male
Oral 1 000, 1 500, 2 000 
mg/kg bw
Negative Davis & Hobbs 
(2011); Hobbs et al. 
(2012)
Table 1
Genotoxicity of gum ghatti in vitro and in vivo
bw: body weight; S9: 9000 × g supernatant fraction from rat liver homogenate; w/v: weight per volume
a Plate incorporation method.
b Methodologies used to conduct the tests in Newell & Maxwell (1972) are described in the reference (IACM, 1972).
c Preincubation method used.
d In the in vitro chromosomal aberration study in Chinese hamster ovary cells (CHO), a statistically significant increase in the polyploidy index after 4 hours of exposure 
was reported, but only at a single dose (1000 mg/mL) with metabolic activation. In addition, a weak but significant increasing trend in polyploidy index was found 
after continuous exposure for 19 hours, but this was not accompanied by any significant increases in any single treatment culture, relative to vehicle controls. These 
results were considered by the study authors to be incidental findings and not an indication of a true positive response. The results did not demonstrate any decrease 
in viable cell counts or mitotic index, or any increase in chromosome aberrations (as measured by the percentage of damaged cells in each culture) for any of the 
treatment cultures compared to vehicle controls (Swarts, 2010b; also reported in Hobbs et al., 2012).
stated) on gestation days 6–15. Aspirin at 150 mg/kg bw per day was given to 
the positive controls. Body weights were recorded on gestation days 0, 6, 11, 
15 and 17. All animals were observed daily for appearance and behaviour with 
particular attention paid to feed consumption in order to better recognize any 
abnormalities resulting from anorexic effects in the pregnant animal. On gestation 
day 17, all mice underwent caesarean section under anaesthesia. The numbers of 
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implantation sites, resorption sites and live and dead fetuses and body weights 
of the live pups were recorded. The urogenital tract of each dam was examined 
in detail for anatomical normality. All fetuses underwent gross examination 
for external congenital abnormalities; one third of the fetuses from each litter 
were examined for visceral abnormalities, and the remaining two thirds were 
examined for skeletal defects.
There were no treatment-related adverse effects in the dams; on the 
numbers of implantations, resorptions or live or dead fetuses; or on the frequency 
of external, soft tissue or skeletal tissue abnormalities in mice treated with gum 
ghatti at up to the highest dose (1700 mg/kg bw per day) relative to sham-treated 
controls (Food and Drug Research Laboratories Inc., 1972a).
The Committee noted that no soft tissue abnormalities were recorded 
for the positive controls, although the dose of aspirin may have been too low to 
induce abnormalities.
In the same study, groups of pregnant albino Wistar-derived rats (n = 
20–24/group) were administered 0, 17, 80, 370 or 1700 mg/kg bw per day of gum 
ghatti (purity not stated) on gestation days 6–15. Aspirin at 250 mg/kg bw per day 
was given to the positive controls. Body weights were recorded on gestation days 
0, 6, 11, 15 and 17. All animals were observed daily for appearance and behaviour 
with particular attention paid to feed consumption in order to better recognize 
any abnormalities resulting from anorexic effects in the pregnant animal. On 
gestation day 20, all the rats underwent caesarean section under anaesthesia. 
The numbers of implantation sites, resorption sites and live and dead fetuses and 
the body weights of the live pups were recorded. The urogenital tract of each 
dam was examined in detail for anatomical abnormalities. All fetuses underwent 
gross examination for external congenital abnormalities. One third of the fetuses 
from each litter were examined for visceral abnormalities, and the remaining two 
thirds were examined for skeletal defects.
Between gestation days 9 and 19, there were four, zero, one, one and 
five maternal deaths at 0, 17, 80, 370 and 1700 mg/kg bw per day, respectively. 
In the 48–72 hours prior to death (between gestation days 9 and 19), severe 
diarrhoea and urinary incontinence with anorexia were observed in the dams 
that died. Pathological investigations of the viscera revealed a marked petechial 
haemorrhage in the mucosa of the small intestine, but no other findings. 
According to the authors, there were no adverse effects on the dams at the lower 
doses of 17, 80 and 370 mg/kg bw per day.
The number and type of abnormalities in fetal soft and skeletal tissues in 
the high-dose group did not differ from the number found to occur spontaneously 
in the sham-treated controls. There were no treatment-related adverse effects on 
numbers of implantations, resorptions or live or dead fetuses or seen in gross, 
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soft tissue or skeletal tissue examinations relative to sham-treated controls at any 
dose, including in surviving rats at the highest dose (Food and Drug Research 
Laboratories Inc., 1972a).
The Committee noted that the positive control group showed an 
increased number of resorptions, a reduced number of live fetuses, reduced fetal 
weights and increases in soft tissue and skeletal abnormalities.
Groups of golden hamsters (n = 20/group) were administered 0, 17, 80, 
370 or 1700 mg/kg bw per day of gum ghatti (purity not stated) on gestation 
days 6–10. Aspirin at 250 mg/kg bw per day was given to the positive controls. 
Body weights were recorded on gestation days 0, 8, 10 and 14. All animals were 
observed daily for appearance and behaviour with particular attention paid to 
feed consumption in order to better recognize any abnormalities resulting from 
anorexic effects in the pregnant animal. On gestation day 14, all the hamsters 
underwent caesarean section under anaesthesia. The numbers of corpora lutea, 
implantation sites, resorption sites and live and dead fetuses and body weights 
of the live pups were recorded. The urogenital tract of each dam was examined 
in detail for anatomical abnormalites. All fetuses underwent gross examination 
for external congenital abnormalities. One third of the fetuses from each litter 
were examined for visceral abnormalities, and the remaining two thirds were 
examined for skeletal defects.
There were, according to the authors, no treatment-related adverse effects 
on the dams, on the number of implantations, resorptions or live or dead fetuses 
or on gross, soft tissue or skeletal abnormalities in hamsters treated with gum 
ghatti up to 1700 mg/kg bw per day relative to sham-treated controls (Food and 
Drug Research Laboratories Inc., 1972a). The Committee noted that soft tissue 
abnormalities were reported in one hamster treated at 370 and one at 1700 mg/
kg bw per day gum ghatti and in one positive control.
Groups of pregnant Dutch Belted rabbits (n = 15/group) were 
administered 0, 7, 33, 150 or 700 mg/kg bw per day of gum ghatti (purity not 
stated) on gestation days 6–18. In addition, 6-amino nicotinamide at 2.5 mg/kg 
bw (administered once, on gestation day 9) was given to the positive controls. 
Body weights were recorded on gestation days 0, 6, 12, 18 and 29. The appearance 
and behaviour of all the animals were observed daily with particular attention to 
feed consumption in order to better recognize any abnormalities resulting from 
anorexic effects in the pregnant animal. On gestation day 29, all the pregnant 
rabbits (n = 12) underwent caesarean section under anaesthesia and the numbers 
of corpora lutea, implantation sites, resorption sites and live and dead fetuses and 
body weights of the live pups were recorded. The urogenital tract of each doe was 
examined in detail for anatomical abnormalities and all the fetuses were examined 
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for external congenital abnormalities. The live fetuses in each litter were placed 
in an incubator for 24 hours to assess neonatal survival, after which the surviving 
pups were killed and examined for visceral abnormalities (by dissection). The 
fetuses were then cleared of cellular matter in potassium hydroxide, stained with 
Alizarin Red S dye and examined for skeletal defects.
At the highest dose (700 mg/kg bw per day), following severe diarrhoea 
and urinary incontinence with anorexia, 10/12 pregnant rabbits died between 
gestation day 10 and 18, and 10 aborted. There were no gross pathology findings 
in the few surviving does except for haemorrhagic spots in the small intestine. 
At the second highest dose (150 mg/kg bw per day), 5/14 pregnant does died 
between gestation day 12 and 20, and five aborted. At mid dose (33 mg/kg bw per 
day), 3/14 pregnant does died between gestation day 16 and 26, and four aborted. 
At the lowest dose (7 mg/kg bw per day), no deaths or abortions were observed. 
It should be noted that 3/13 sham-treated does died between gestation day 13 and 
14, and three aborted. All the dams that died aborted prior to death.
At 33, 150 and 700 mg/kg bw per day, 21%, 36% and 83%, respectively, of 
the pregnant rabbits died. In addition, 23% of the sham-treated does died.
According to the authors, up to 33 mg/kg bw per day of the test material 
had no discernible effect on nidation or on maternal and fetal survival. However, 
at 150 and 700 mg/kg bw per day, significant maternal toxicity ensued and a 
majority of the animals died. It was concluded that the test substance was not a 
teratogen in the rabbit (Food and Drug Research Laboratories Inc., 1972a).
The Committee noted that only two high-dose pregnant does survived 
to term and that three sham-treated pregnant does died. An increase in both soft 
tissue and skeletal abnormalities was observed in the positive control group.
2.3 Observations in humans
No information was available.
3. Dietary exposure
3.1 Exposure assessment
The Committee evaluated dietary exposure information from a submission 
provided by a sponsor and prepared estimates of dietary exposure from potential 
use scenarios.
109
Gum ghatti
3.1.1 Budget method
The Committee concluded that no screening by the budget method would be 
appropriate for this assessment.
3.1.2 Production volume data
The sponsor’s submission to the Committee stated that the global production 
of gum ghatti was estimated to be 1  000  000–1  500  000  kg. As gum ghatti is 
used in several industry applications other than as a food additive, only a small 
fraction of the gum ghatti currently produced is expected be used in food (Ido et 
al., 2008). A personal communication included with the submission stated that 
internal industry estimates suggest that current global production volumes for 
food use is 50 000–60 000 kg.
With a conservative estimate of global production volume for food use of 
100 000 kg (taking into account incomplete reporting), and the consumer “eaters-
only” population is assumed to be 10% of the total population in countries where 
gum ghatti is known to be currently approved (as noted above), then the dietary 
exposure can be estimated as follows:
[100  000 kg*1 × 109 µg/kg]/[(395 × 106 persons)*365 days] = 694 µg/
person per day,
or, for a 60 kg individual:
[694 µg/person per day]/[60 kg bw per person] = 11.6 µg/kg bw per day.
The Committee noted that this very low estimate of dietary exposure 
reflects the current low usage of gum ghatti in food. It would be unrealistic as a 
measure of long-term consumption by consumers of food products containing 
gum ghatti.
3.2 International estimates of dietary exposure
As with other gums with similar technical effects, gum ghatti is used only in 
processed food products. Therefore, the Committee concluded that the use of 
commodity-based food consumption information from the Global Environment 
Monitoring System – Food Contamination Monitoring and Assessment 
Programme (GEMS/Food) would not be appropriate for this evaluation.
110
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
5,
  2
01
8
Safety evaluation of certain food additives   Eighty-fourth  JECFA
3.3 National estimates of dietary exposure
No national estimates of exposure were submitted to the Committee and no 
reports were found in the literature.
The submission reviewed by the Committee noted that gum ghatti is 
used in a number of countries. The only reported use levels were from the USA, 
however, and the Committee was unable to find any information on usual use in 
the other countries. In the USA, gum ghatti is generally recognized as safe for use 
in foods at the maximum usage levels (see Table 2).
Gum Ghatti is also used as a flavouring ingredient in the USA, although 
at significantly lower use levels (Burdock, 2009).
3.4 Exposure scenario based on submitted use levels
The submission to the Committee contained two reports outlining use levels for 
gum ghatti in a number of General Standard for Food Additives (GSFA) food 
categories (Tables 3 and 4). The Committee prepared an estimate of exposure 
based on these levels.
Table 3 contains use levels for foods in GSFA categories 1.1.4 “Flavoured 
fluid milk drinks” and categories 14.1 and 14.2 (various beverage categories). The 
maximum use level for milk beverages was 150 mg/L; for nonalcoholic beverages, 
100 mg/L; and for alcoholic beverages, 300 mg/L. Using food consumption 
data from the USA, the Committee completed a scenario assessment of dietary 
exposure by assuming 250 g/day consumption of milk beverages (95th percentile); 
900 g/day of nonalcoholic beverages (95th percentile); and 750 g/day of alcoholic 
beverages (95th percentile). The Committee estimated dietary exposure to gum 
ghatti would be 350 mg/day or 6 mg/kg bw per day for a 60 kg individual1.
Table 4 contains a more extensive list of foods potentially containing 
gum ghatti. Additional food categories include dairy- and fruit-based desserts, 
candies, pastas and prepared noodles, bakery wares, seasonings and spices, 
comminuted meat products and food for special dietary uses and supplements. 
The Committee concluded that only consumption of pre-cooked pastas and 
noodles and similar products containing gum ghatti at the proposed use level 
of 6000 mg/kg would result in a dietary exposure different from that in the 
scenario discussed above. The exposure to gum ghatti from consumption of 60 g 
of prepared noodles1 containing the maximum level would be approximately 360 
mg/day (6 mg/kg bw per day for a 60 kg individual). Addition of this exposure 
1 Food consumption data taken from the reported 95th percentile levels in the USA from the NPD Group’s 
National Eating Trends survey (proprietary data from the United States Food and Drug Administration 
provided to the Committee).
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GSFA Food category 
Concentration in final food product (mg/L)
Mean Max.
1.1.4 Flavoured fluid milk drinks 5.0 150.0 
14.1 Non-alcoholic ("soft") beverages 5.0 100.0
14.1.2 Fruit and vegetable juices 5.0 100.0
14.1.4 Water-based flavoured drinks, including "sport," "energy" or 
"electrolyte" drinks and particulated drinks
5.0 100.0
14.1.4.1 Carbonated water-based flavoured drinks 5.0 100.0
14.1.4.3 Concentrates (liquid or solid) for water-based flavoured drinks 5.0 100.0
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic 
counterparts
10.0 300.0
14.2.1 Beer and malt beverages 10.0 300.0
14.2.6 Distilled spirituous beverages containing more than 15% alcohol 10.0 300.0
Food (as served) % in final food product Function
Beverages and beverage bases, nonalcoholic 0.2 Emulsifier and emulsifier salt
All other food categories 0.1 Emulsifier and emulsifier salt
GSFA Food 
category 
no. GSFA Food category description
Max. use level 
(mg/kg final food 
product)
01.0 Dairy products and analogues, excluding products of food category 02.0
01.1.2 Dairy-based drinks, flavoured and/or fermented (e.g. chocolate milk, cocoa, eggnog, drinking yoghurt, 
whey-based drinks)
150
1.7 Dairy-based desserts (e.g. pudding, fruit or flavoured yoghurt) 36
04.0 Fruits and vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe 
vera), seaweeds, and nuts and seeds
04.1.2.9 Fruit-based desserts, including fruit-flavoured water-based desserts 80
05.0 Confectionery
05.2.1 Hard candy 800
05.2.2 Soft candy 80
06.0 Cereals and cereal products, derived from cereal grains, from roots and tubers, pulses, legumes and 
pith or soft core of palm tree, excluding bakery wares of food category 07.0
Table 2
Maximum usage levels generally recognized as safe for gum ghatti in food in the UsA
Table 3
Use levels of gum ghatti in foods in GsfA categories 1.1.4 “flavoured fluid milk drinks” and 
categories 14.1 and 14.2 (various beverage categories)
Table 4
Use levels of gum ghatti in foods potentially containing gum ghatti per GsfA food category
GSFA: General Standard for Food Additives; max.: maximum
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to that from the uses modelled above results in a conservative dietary exposure 
estimate of 12 mg/kg bw per day.
The Committee used the European Food Safety Authority (EFSA) Food 
Additive Intake Model (Version 1.0) with the use levels from Table 3 to estimate 
dietary exposure to gum ghatti. The results are shown in Table 5. The estimated 
exposure for adults was 6 mg/kg bw per day.
Finally, the Committee considered, in light of the scant information 
available on the current uses of gum ghatti, a scenario in which gum ghatti would 
Table 4 (continued)
GSFA Food 
category 
no. GSFA Food category description
Max. use level 
(mg/kg final food 
product)
06.4.3 Pre-cooked pastas and noodles and like products 6 000
07.0 Bakery wares
7.2 Fine bakery wares (sweet, salty, savoury) and mixes 40
08.0 Meat and meat products, including poultry and game
08.3.2 Heat-treated processed comminuted meat, poultry and game products 42
12 .0 Salts, spices, soups, sauces, salads and protein products
12.2.1 Herbs and spices 600
12.2.2 Seasonings and condiments 350
13 .0 Foodstuffs intended for particular nutritional uses
13.3 Dietetic foods intended for special medical purposes (excluding products of food category 13.1) 10 000
13.5 Dietetic foods (e.g. supplementary foods for dietary use) excluding products of food categories 13.1– 
13.4 and 13.6
120
13.6 Food supplements 77 660
14 .0 Beverages, excluding dairy products
14.1 Non-alcoholic (“soft”) beverages 100
14.1.2 Fruit and vegetable juices 100
14.1.3 Fruit and vegetable nectars
14.1.4 Water-based flavoured drinks, including "sport", “energy” or "electrolyte" drinks and particulated 
drinks
100
14.1.4.1 Carbonated water-based flavoured drinks 48
14.1.4.2 Non-carbonated water-based flavoured drinks, including punches and ades 136
14.1.4.3 Concentrates (liquid or solid) for water-based flavoured drinks 240
14.1.5 Coffee, coffee substitutes, tea, herbal infusions and other hot cereal and grain beverages, excluding 
cocoa
20
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts 300
14.2.1 Beer and malt beverages 300
14.2.6 Distilled spirituous beverages containing more than 15% alcohol 300
14.2.7 Aromatized alcoholic beverages (e.g. beer, wine and spirituous cooler-type beverages, low-alcoholic 
refreshers)
32
GSFA: General Standard for Food Additives; max.: maximum; no.: number
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substitute directly for other food gums in processed foods. At the seventy-first 
JECFA meeting, the dietary exposure to OSA-modified gum arabic was estimated 
at “less than 20 mg/kg bw per day”; this was reaffirmed at the eighty-second 
meeting.
3.5 Conclusion
The Committee considered that a dietary exposure of 12 mg/kg bw per day was 
suitable for use in a safety assessment of gum ghatti.
4. Comments
4.1 Biochemical aspects
Absorption, distribution, metabolism and excretion data on gum ghatti were not 
available. However, similar to other gums and dietary fibres, gum ghatti is unlikely 
to be significantly digested or absorbed in the stomach or small intestine. Based 
on its chemical composition, gum ghatti is expected to be enzymatically degraded 
and fermented by the microflora in the large intestine to hydrogen gas, carbon 
dioxide and short-chain fatty acids, which can be absorbed and metabolized (Ali, 
Ziada & Blunden, 2009).
Populationa
Range for mean across dietary surveys 
(mg/kg bw per day)
Range for high level across dietary surveys 
(mg/kg bw per day)
Min. Max. Min. Max.
Toddlers 0.216 3.033 1.263 25.805
Children 0.193 3.410 0.490 15.240
Adolescents 0.168 0.648 0.339 9.518
Adults 0.175 0.849 0.567 6.011
Elderly adults 0.145 0.476 0.287 6.187
Table 5
Dietary exposure estimates using the efsA food Additive Intake Model (Version 1.0) and 
use levels from table 3
bw: body weight; EFSA: European Food Safety Authority; max.: maximum; min.: minimum
a  European country population group descriptors have the following definitions: infants, <12 months; toddlers, 12–35 months; other children, 3–9 years; adolescents, 
10–17 years; adults, 18–64 years; elderly adults, 65–74 years; very elderly adults, ≥75 years.
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4.2 Toxicological studies
In an acute toxicity study in male rats (Newell & Maxwell, 1972), no deaths were 
reported at 10 000 mg/kg bw, the highest dose tested.
Two new 90-day studies of the toxicity of gum ghatti (purity 85%) have 
been performed in rats.
In the first study (Davis & Lea, 2011), rats were fed a basal diet (AIN-
93M) containing 0%, 0.5%, 1.5% or 5% gum ghatti (equal to 0, 337, 1018 and 
3044 mg/kg  bw  for males and 0, 396, 1149 and 3308 mg/kg  bw  per day for 
females, respectively).  Although haematological and clinical chemistry effects 
were observed, they were not dose related, not found in both sexes and/or not 
correlated with any histopathological findings.
Increased caecal weights were observed in the male and female rats at 5% 
gum ghatti. In addition, in 6 out of 10 high-dose males, minimal to mild mucosal 
hyperplasia and/or minimal to mild crypt elongation were observed in the 
caecum, whereas no lesions were found in the caecum of female rats. In 2/10 
high-dose females, ulcerative colitis  was observed in the colon; no significant 
lesions were observed in the colon of male rats.
In order to evaluate  the relevance of the ulcerative colitis,  the possible 
role of the AIN-93M diet and the possibility that intrinsically susceptible litter-
mates had been randomly assigned to the same group, a second study tested 
two different basal diets (AIN-93M and NIH-07) containing 0 or 5% gum ghatti 
(equal to 0 and 3671 mg/kg bw per day for rats fed the AIN-93M diet and 0 and 
3825 mg/kg bw per day for rats fed the NIH-07 diet) (Davis, 2012). The study 
deviated from OECD Test Guideline 408, as only one dose was tested in only one 
sex (female) and the histopathological examination did not include the full range 
of recommended organs, because the aim of this second study was to follow up 
on the observations reported in female rats at the highest dose in the first study.
Increased empty  caecal  weights were observed in animals exposed to 
gum  ghatti  in both diets. Full  caecal  weights  (absolute and relative) were  also 
increased in rats exposed to gum ghatti in the AIN-93M diet but not the NIH-07 
diet. Focal lymphoid hyperplasia of the colon was observed in all study groups, 
but there was no association with the dietary exposure to gum ghatti, and the 
authors concluded that these findings were incidental and not treatment related. 
A pathology working group  subsequently  concluded that the ulcerative colitis 
observed in the colon of the female rats was a sporadic event not associated with 
the dietary exposure to gum ghatti and that the caecal changes in male rats could 
not be confirmed as caecal  crypt hyperplasia/crypt elongation (Maronpot et 
al., 2013).
The Committee noted that the effects on caecal weights observed in both 
sexes at 5% gum ghatti have also been reported in other toxicity studies of poorly 
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digestible polysaccharides and gum products (Tulung, Rémésy & Demigné, 1987; 
Wyatt et al., 1988; Levrat et al., 1991; Doi et al., 2006; Ali, Ziada & Blunden, 2009; 
Hagiwara et al., 2010). The increase in caecal weight is considered to be the result 
of microbial fermentation of undigested and unabsorbed gum in the lower large 
intestine (Newberne, Conner & Estes, 1988). The  Committee considered this 
increase in caecal weight at 5% dietary gum ghatti to be an adaptive, rather than 
adverse, response. Based on the results of the new 90-day studies (Davis & Lea, 
2011; Davis, 2012), the Committee identified a NOAEL of 3044 mg/kg bw per day 
(equal to 2590 mg/kg bw per day, corrected for purity), the highest dose tested.
No long-term studies of the toxicity or carcinogenicity  of gum  ghatti 
were available.
In vitro and in vivo genotoxicity studies have recently been conducted. 
These, together with earlier in vitro and in vivo studies, showed no evidence for a 
genotoxic potential of gum ghatti. The Committee concluded that there were no 
genotoxicity concerns for gum ghatti.
No reproductive toxicity studies were available for gum ghatti.
Studies on developmental toxicity of gum ghatti administered by oral 
gavage were performed in mice, rats, hamsters and rabbits (Food and Drug 
Research Laboratories, Inc., 1972a). In mice and hamsters dosed at 0, 17, 80, 370 
or 1700 mg/kg bw per day, there were no treatment-related adverse effects on 
the dams. There were also no treatment-related adverse effects on the numbers 
of implantations, resorptions or live and dead fetuses or on the frequency of 
external, soft tissue or skeletal abnormalities.
In the rat, there were four, zero, one, one and five maternal deaths at 
0, 17, 80, 370 and 1700 mg/kg bw per day, respectively. Severe diarrhoea and 
urinary incontinence with anorexia were observed in the 2–3 days prior to death. 
Petechial haemorrhage was observed in the mucosa of the small intestine of the 
dams that died. There were no treatment-related adverse embryo-fetal effects at 
any dose, including in those rats that survived at the highest dose tested.
In the rabbit study, there were 15 animals per dose group. There were 3, 
0, 3, 5 and 10 maternal deaths in the 0, 7, 33, 150 and 700 mg/kg bw per day dose 
groups, respectively. As with rats, severe diarrhoea and urinary incontinence with 
anorexia were observed in the 2–3 days prior to death. In addition, all animals 
aborted prior to death. Petechial haemorrhage was observed in the mucosa of 
the small intestine of the does that died. There were no treatment-related adverse 
embryo-fetal effects at any dose, including in the two pregnant rabbits that 
survived at the highest dose tested.
These developmental toxicity studies were performed prior to OECD 
guidelines or GLP standards and do not comply with several modern standards/
guidelines: the purity of the substance was not stated; the treatment period covered 
the major phase of organogenesis but did not extend to the end of gestation; and 
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the rationale for dose selection in all four studies was not presented. In addition, 
none of the study reports presented the clinical observations, feed consumption, 
gravid uteri weights or statistical analyses of the results. The Committee 
also noted that there were maternal deaths at high doses in mice, rats and, in 
particular, rabbits in developmental toxicity studies on other gums conducted by 
the same laboratory at about the same time, in which the test substance was also 
administered by oral gavage. The Committee considered that this may have been 
due to the difficulty of administering high concentrations of viscous substances 
by gavage. They further noted that no treatment-related adverse maternal or 
developmental effects were reported in surviving high-dose animals in studies 
on gum ghatti and other gums. Despite the deficiencies in the study methods 
and reporting and the occurrence of maternal deaths, there were no effects on 
embryo-fetal growth or development at doses up to 1700 mg/kg bw per day.
In view of  the gaps in the database for gum  ghatti (i.e. the absence 
of any long-term toxicity or carcinogenicity studies,  the limitations of the 
developmental toxicity studies and  the lack of any reproductive  studies), the 
Committee considered data on structurally related gums. The gum most closely 
related to gum ghatti is gum arabic (also known as gum acacia); the two gums 
have similar monosaccharide profiles with respect to L-arabinose, L-rhamnose, 
D-galactose and D-glucuronic acid (Pitthard & Finch, 2001; Akiyama, Yamazaki 
& Tanamoto, 2011).
Developmental  toxicity  studies  on other gums in mice, rats, hamsters 
and rabbits (Food and Drug Research Laboratories Inc., 1972b) were 
conducted  by the same laboratory that conducted the  developmental  toxicity 
studies on gum ghatti. As such, they may have had similar limitations. A more 
recent combined fertility and developmental toxicity study  of gum  arabic  in 
rats  (Collins et al., 1987)  was  previously evaluated by the Committee, which 
considered that this study did not give cause for concern about the safety of gum 
arabic (Annex 1, reference 89). EFSA (2017) also described more recent fertility 
studies in rats (Morseth & Ihara, 1989; Huynh et al., 2000) and considered that 
these studies did not give cause for concern about the safety of gum arabic. Based 
on the combined fertility and developmental toxicity study in rats (Collins et al., 
1987), an overall NOAEL of 10 647 mg/kg bw per day (the highest dose tested) was 
identified for reproductive, developmental and parental effects. The Committee 
noted that reproductive and developmental toxicity studies on other gums (carob 
bean gum [FAS 16], cassia gum [FAS 62], gellan gum [FAS 28], guar gum [FAS 
8], karaya gum [FAS 24], tara gum [FAS 21], tragacanth [FAS 20], xanthan gum 
[FAS 21]) also previously evaluated by the Committee (Annex 1, references 39, 
57, 72, 74, 84, 95 and 197) did not raise any health concerns for reproductive or 
developmental effects.
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Overall, the Committee concluded that there were no health concerns 
for gum ghatti regarding reproductive or developmental effects.
Previously evaluated carcinogenicity studies of gum arabic in mice and 
rats  conducted by the United States National Toxicology Program  (National 
Toxicology Program, 1982) found  no indications  of any treatment-related 
increases  in  tumour  incidence at dietary gum arabic concentrations of 2.5% 
and 5.0% (equivalent to 1250 and 2500 mg/kg bw per day for rats and 3750 and 
7500 mg/kg bw per day for mice). The Committee noted that other previously 
evaluated chronic toxicity/carcinogenicity studies in mice and rats (carob bean 
gum, gellan gum, guar gum, tara gum, xanthan gum) also raised no health 
concerns regarding carcinogenic potential.
4.3 Observations in humans
No observations of gum ghatti in humans were available. However, three human 
studies on gum arabic found that daily ingestion by adults of up to 30 g (equivalent 
to  500  mg/kg  bw  per day for a 60 kg individual)  over 18–21  days  was well 
tolerated (Ross et al., 1983; Sharma, 1985; Cherbut et al., 2003). Furthermore, 
Ross et al.  (1983) found that gum arabic could not be detected in the stool, 
indicating complete fermentation in the colon.
4.4 Assessment of dietary exposure
The Committee received one assessment of dietary exposure to gum ghatti from 
the sponsor and prepared estimates of dietary exposure based on model diets and 
potential use scenarios using food consumption data from the European Union 
and the USA.
The sponsor’s submission noted that gum ghatti is used in a number 
of countries. The only use levels reported were from the USA. The Committee 
was unable to find information on the typical use levels in other countries. The 
submission to the Committee contained two reports outlining use levels for gum 
ghatti in a number of GSFA food categories. The Committee prepared estimates 
of dietary exposure based on these levels.
One report contains use levels for foods in GSFA categories 1.1.4 
“Flavoured fluid milk drinks” and categories 14.1 and 14.2 (various beverage 
categories). The maximum use level for the milk beverages was 150 mg/L; for 
nonalcoholic beverages, 100 mg/L; and for alcoholic beverages, 300 mg/L. Using 
food consumption data from the USA, the Committee completed a scenario 
assessment of dietary exposure by assuming 250 g/day consumption of milk 
beverages (95th percentile), 900 g/day nonalcoholic beverages (95th percentile); 
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and 750  g/day of alcoholic beverages (95th percentile). The estimated dietary 
exposure to gum ghatti would be 350 mg/day or 6 mg/kg bw per day for a 60 kg 
individual. The use of these maximizing assumptions in the preparation of the 
estimate from these three broad food groups results in a highly conservative 
estimate of chronic dietary exposure to gum ghatti.
The second report contains a more extensive list of foods potentially 
containing gum ghatti. The Committee concluded that only consumption of 
noodles containing gum ghatti at a use level of 6000 mg/kg would result in a 
dietary exposure different from that in the scenario discussed above. The exposure 
to gum ghatti from consumption of 60 g of prepared noodles containing the 
maximum level would be approximately 360 mg/day (6 mg/kg bw per day for 
a 60 kg individual), doubling the previous scenario estimate (12 mg/kg bw per 
day).
The Committee also used the EFSA Food Additive Intake Model (Version 
1.0) with the use levels from the sponsor’s report to estimate dietary exposure to 
gum ghatti. The estimated exposure for adults was 6 mg/kg bw per day.
The Committee considered that a dietary exposure of 12 mg/kg bw per 
day was suitable for use in a safety assessment of gum ghatti.
5. evaluation
Because limited toxicological data on gum ghatti were available, ADIs were not 
established at previous meetings (Annex 1, references 59 and 70). The present 
Committee evaluated two new 90-day studies in rats that did not show adverse 
effects at doses up to 3044 mg/kg bw per day, the highest dose tested (equal to 
2590 mg/kg bw per day when corrected for purity). The Committee took into 
account the lack of systemic exposure to gum ghatti because of its high molecular 
weight and polysaccharide structure, its lack of toxicity in short-term studies, the 
lack of concern for genotoxicity and the absence of treatment-related adverse 
effects in studies of gum arabic and other polysaccharide gums with a similar 
profile.
The Committee concluded that gum ghatti is unlikely to be a health 
concern and established an ADI “not specified” for gum ghatti that complies with 
the specifications.
Therefore, the Committee concluded that the estimated dietary exposure 
to gum ghatti of 12 mg/kg bw per day does not represent a health concern.
The specifications were revised based on submitted information and 
available literature. An high-performance liquid chromatography (HPLC) method 
for the identification of the gum constituents was added to replace the thin-layer 
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chromatography method. One identity method, using a mercury-containing 
reagent, was removed. L-Rhamnose was added as one of the constituents of gum 
ghatti, based on current literature reports.
The specifications were revised, and a Chemical and Technical Assessment 
was prepared.
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1. explanation
Jagua (Genipin–Glycine) Blue (Chemical Abstracts Service [CAS] No. 1314879-
21-4) is the product of the reaction between stoichiometric equivalents of genipin 
extracted from the unripe Genipa americana Linne (Rubiaceae) fruit and glycine, 
resulting in a blue-coloured genipin–glycine polymer and dimers. This report 
refers to the blue-coloured genipin–glycine polymer and dimer content of Jagua 
(Genipin–Glycine) Blue as the “blue polymer” content. Genipa americana fruit 
has traditionally been used for the preparation of juices, jellies, marmalades and 
liquors (Ramos-de-la-Peña et al., 2015).
Jagua (Genipin–Glycine) Blue is permitted for use as a food colour in 
Colombia.
Jagua (Genipin–Glycine) Blue has not been evaluated previously by the 
Committee. It was on the agenda at the request of the Forty-eighth Session of the 
Codex Committee on Food Additives (FAO/WHO, 2016).
The sponsor provided a dossier containing chemical, technical, dietary 
exposure and toxicological data, including unpublished in vitro studies, 
genotoxicity studies and in vivo toxicological studies in rats and dogs.
At the present meeting, the Committee reviewed a series of unpublished 
studies relevant to the human health risk assessment of Jagua (Genipin–Glycine) 
Blue. A comprehensive literature search of peer-reviewed literature on Genipa 
americana or the structurally related colour Gardenia Blue was undertaken 
in PubMed; 54 records were retrieved, but only two suitable publications on 
Gardenia Blue were identified. One suitable reference, a long-term toxicity study 
on Gardenia Blue, was identified and added to the toxicological data submitted 
to the Committee for this meeting. A literature search of articles published since 
1900 on the occurrence of and dietary exposure to Jagua (Genipin–Glycine) 
Blue was conducted in Web of Science using the search terms “Jagua”, “Genipa”, 
“Jenipapo” and “‘Huito” in the areas “Food science technology”, “Nutrition 
dietetics”, “Plant sciences” and “Chemistry”. A total of 164 records were retrieved, 
but none were relevant in relation to occurrence in food or dietary exposure to 
Jagua (Genipin–Glycine) Blue.
The name was changed from “Jagua extract” to “Jagua (Genipin–Glycine) 
Blue” because the name “Jagua extract” was not adequately descriptive.
1.1 Chemical and technical considerations
Genipa americana L. is a small to medium-sized tree (UNCTAD, 2005) that 
belongs to the Rubiaceae family and is native to central and tropical South 
America (Djerassi, Gray & Kincl, 1960; Ueda, Iwahashi & Tokuda, 1991). The 
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plant yields edible berries referred to as jagua fruit, chipara, guayatil, maluco, 
caruto or huito (Ramos-de-la-Peña et al., 2015) in Spanish and as genipap in 
English.
The unripe jagua fruit contains high levels of a cyclopentan-[C]-pyran 
skeleton class of compound, called iridoids (Dinda, Debnath & Harigaya, 
2007a,b). Genipin is a unique iridoid in its ability to crosslink with primary amines 
present in amino acids and proteins, in the presence of oxygen, to produce high 
molecular weight water-soluble blue pigments (Touyama et al., 1994a,b; Fujikawa 
et al., 1987; Paik et al., 2001; Park et al., 2002; Cho et al., 2006; Lee, Lee & Jeong, 
2009).
Jagua (Genipin–Glycine) Blue is a deep blue/black colour obtained by 
treating peeled and ground pulp of unripe fruits of G. americana L. with water. 
The resulting juice is filtered and treated with a stoichiometric amount of glycine 
based on the concentration of genipin in the water extract; it is heated at 70 °C for 
2 hours, until the blue colour is completely formed. The product is centrifuged, 
concentrated and/or dried. Unreacted genipin is considered an impurity of Jagua 
(Genipin–Glycine) Blue. The liquid product is obtained by concentrating the 
Jagua (Genipin–Glycine) Blue up to 20–50°Bx and formulating with food-grade 
glycerine or other permitted food additives. Alternatively, a powder is obtained, 
after concentrating the Jagua (Genipin–Glycine) Blue to 20°Bx, mixing with a 
food-grade carrier, then spray-drying and sieving.
The Jagua (Genipin–Glycine) Blue product in commerce contains a blue 
polymer (20–40%) and three blue dimers (approximately 1.5%) as colouring 
matters. The remaining components of the product are carbohydrates (>55%), 
protein (approximately 7%) and water (approximately 5%). The blue polymer 
composed of repeating dimers has the molecular formula (C27H25O8N2)n and 
an average molecular weight of 6000 Da. The molecular formulae of the three 
identified dimers are C28H28O8N2 (CAS No. 1313734-13-2), C27H25O8N2 (CAS No. 
104359-67-3) and C27H24O8N2 (CAS No. 1313734-14-3). The blue polymer and the 
three dimers have been identified by nuclear magnetic resonance spectroscopy 
(NMR (1H, 13C)), infrared spectroscopy (IR), mass spectroscopy (MS) and high-
performance liquid chromatography (HPLC). The Jagua (Genipin–Glycine) Blue 
is stable and has no decomposition products under normal storage conditions.
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2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and excretion
In a study that was not compliant with good laboratory practices (GLP), the 
permeability of Jagua Blue (batch 5314034; 200 mg/mL, equivalent to 67.5 
mg/mL, expressed as “blue polymer”) was assessed across Caco-2 epithelial 
monolayers. Ranitidine (10 µmol/L) was used as a low permeability control; 
talinolol (10 µmol/L) as a P-gp efflux control; and warfarin (10 µmol/L) as a 
high permeability control for apical to basolateral transport. Lucifer Yellow, a 
nonpermeable dye, was used in control wells to verify that the monolayer was 
properly formed. Receiver side buffer was sampled and evaluated by the sponsor 
using ultraviolet–visible spectroscopy. Control media were analysed using liquid 
chromatography–tandem mass spectrometry. The apparent permeability rate 
coefficient for Jagua (Genipin–Glycine) Blue was lower than the rate coefficient 
for the low permeability control, ranitidine, suggesting poor passive absorption. 
However, some efflux at a single concentration was seen, suggesting that some 
of the blue-coloured material in the test article may be a substrate for an efflux 
transporter (Gilbert, 2015).
As part of a 90-day repeated-dose study in dogs (section 2.2.2(b)), Jagua 
(Genipin–Glycine) Blue (33.79%) chromophores were monitored in plasma 
using a low sensitivity spectrophotometric (590 nm) assay (analytical range 1–2.5 
mg/mL). There was no detectable activity in any of the plasma samples at any 
time on day 1 or day 91 after daily dosing with extracts containing up to 338 mg/
kg body weight (bw) of “blue polymer” (Mancari, 2016).
2.1.2 Biotransformation
No information was available.
2.2 Toxicological studies
2.2.1 Acute toxicity
A group of female Wistar Crl:WI(Han) rats (n = 5; 9–10 weeks) were treated with 
Jagua (Genipin–Glycine) Blue (33.05% active component; batch no. 5313014) by 
gavage at a dose of 2000 mg/kg bw (equal to 660 mg/kg bw on a “blue polymer” 
basis). The test item, provided to the laboratory as a dark blue solid, was 
suspended in sterile water at a concentration of 0.2 g/mL and administered at a 
dose volume of 10 mL/kg bw. The study was certified as compliant with GLP and 
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quality assurance (QA). It was performed in accordance with Organisation for 
Economic Co-operation and Development (OECD) Test Guideline 420.
No abnormal clinical signs were observed during the study. All five 
animals survived until the end of the study, and no signs of toxicity were observed. 
No treatment-related macroscopic findings were noted at necropsy.
The oral median lethal dose (LD50) was greater than 2000 mg/kg bw 
(equal to 660 mg/kg bw on a “blue polymer” basis; Allingham, 2014a).
2.2.2 Short-term studies of toxicity
(a) Rats
In a dose range –finding study, Allingham (2014b) administered Jagua (Genipin–
Glycine) Blue (batch no. 5313014) to groups of Wistar Crl:WI(Han) rats (n = 
3/sex per group; 9–10 weeks at study start) by gavage at 0, 10, 50, 100, 500 or 
1000 mg/kg bw per day (equal to 0, 3, 17, 33, 165 and 330 mg/kg bw per day on 
a “blue polymer” basis) for 28 days. High-performance liquid chromatography 
with ultraviolet detection (HPLC-UV) determined the blue polymer content to 
be 33.05% of the extract. The study was described as conforming with GLP, but it 
was not audited by a QA unit. The study conformed to the OECD Test Guideline 
408. Observations included clinical signs, body weights, feed consumption, 
functional observational battery, haematology, clinical chemistry, urine analysis, 
organ weights and macroscopic pathology.
There were no deaths during the study. There were no effects on body 
weight gain or feed consumption. Effects on piloerection are listed in escalating 
dose order: slight (1, 2, 1, 3, 3, 3 males and 0, 0, 0, 1, 2, 3 females) or moderate 
(0, 0, 0, 3, 3, 1 male animals only). Some animals were also noted to move their 
bedding immediately after test substance administration (0, 0, 0, 2, 1, 3 males and 
0, 0, 1, 3, 3, 1 females). Other clinical findings were sporadic and were assumed to 
not be treatment related. Dark discoloration of the kidneys and testes at 1000 mg/
kg bw per day were attributed to the intense colour of the test item.
This study (Allingham, 2014b) was used to determine the high dose (1000 
mg/kg bw per day of Jagua (Genipin–Glycine) Blue) for the 90-day repeated-dose 
rat study described below.
Allingham et al. (2014) administered Jagua (Genipin–Glycine) Blue 
(batch no. 5313014) to groups of Wistar Crl:WI(Han) rats (n = 10/sex per group; 
7–8 weeks at study start) by gavage at 0, 100, 300 or 1000 mg/kg bw per day 
(equal to 0, 33, 99 and 330 mg/kg bw per day on a “blue polymer” basis) for 90 
days. An additional five male and five female rats were observed for a further 
28 days following the last dose. These recovery group animals were also treated 
at the highest dose. The doses were measured and verified in study weeks 1, 
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5, 9 and 13 using HPLC-UV (590  nm) to detect the “blue polymer” content, 
which represented 33.05% of the extract. The study was certified as GLP and 
QA compliant and conformed with OECD Test Guideline 408. Observations 
included clinical signs, body weight, feed consumption, functional observational 
battery, motor activity, ophthalmoscopy, haematology, clinical chemistry, urine 
analysis, organ weights and macroscopic and microscopic pathology (Allingham 
et al., 2014).
There were no deaths during the study. Mid-dose females were reported 
to have higher feed consumption on days 15–21 (36.4 g/day vs 21.2 g/day for 
controls), though the study did not report the statistical significance of this finding. 
High-dose males had a slight (8%) yet significant lower body-weight gain at the 
end of the recovery period. Discoloured faeces were noted in all treatment groups 
from day 32 (for the high-dose animals) and day 56 (for the low-dose animals) 
until the end of the treatment period; the discoloration was presumed to be due to 
the colour of the test article. Additional cage-side observations included transient 
crust (one control male, one recovery group male, two high-dose males, five high-
dose females), alopecia (two recovery group males, five recovery group females, 
one low-dose female, four high-dose females) and a transient necrosis of the left 
shoulder in a single control male. The study authors concluded that these effects 
were not treatment related. No significant findings were seen in the functional 
observational battery. No statistically significant differences in haematological 
values were reported. The only statistically significant differences in clinical 
chemistry values were lower alkaline phospatase activity in recovery group males 
and higher urea levels in high-dose females compared with controls. The report 
authors noted that the values were within the range for historical controls. Results 
from urine analysis tests were similar in control and treated animals except for 
one mid-dose male with elevated bilirubin (2 mg/dL), erythrocytes (250 cells/
µL) and leukocytes (500 cells/µL) and low pH (5). The report authors noted that 
the changes were not associated with any clinical biochemistry, haematological 
or macro/histopathological changes and concluded that these changes were not 
treatment related.
Pathological findings included dilated pelvis in control (7/20), low-dose 
(4/20), mid-dose (11/20) and high-dose (8/20) animals. One control animal 
had an enlarged kidney; one mid-dose male, four high-dose males and four 
high-dose females had dark discoloration on a kidney; one control had a red 
discoloration on the thymus and red discoloration on axillary lymph nodes; one 
low-dose male and one high-dose male had dark discoloration on the liver; one 
high-dose male had an enlarged liver; and one mid-dose male had dark foci on 
the lungs. Five control, three low-dose, two mid-dose and two high-dose females 
had fluid distension of the uterus/cervix, with one at the low dose and one at the 
high dose having it in both horns, and one mid-dose female having two horns 5 
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mm in diameter. One control, one low-dose and one mid-dose female had a small 
uterus/cervix. One mid-dose female had a black focus on mucosa of the fundus 
of the stomach. The findings were not dose dependent and control animals were 
similarly affected. The findings were of low incidence and related to the estrus 
state of the animals (small or fluid filled findings in the uterus). The study authors 
did not consider these findings to be treatment related.
Changes in organ weights were as follows: statistically significant 
decreases in absolute kidney weight in low-dose males (89% of control weight) 
and mid-dose males (90% of control weight), but not in the high-dose groups nor 
relative to body weight; statistically significant increases in brain weights relative 
to body weight in low-dose males (11% above controls), but not mid-dose or 
high-dose animals. Adrenal gland weights in high-dose females were slightly yet 
statistically significantly lower than that of controls (83% of controls) compared 
with brain weights of the respective animals. There were no histopathological 
correlates to the change in adrenal gland weights and male animals were 
unaffected. Slightly lower absolute thyroid/parathyroid gland weights (~67% 
of controls; not statistically significantly) were observed in male but not female 
high-dose animals. No treatment-related alterations were observed in the 
thyroid/parathyroid glands (macroscopically or microscopically) at the end of 
the treatment period. All recorded histopathological findings were within the 
range of spontaneous background alterations in Wistar rats of these ages. The 
changes were considered not toxicologically relevant because they were not dose 
responsive, not seen in both sexes or not related to histopathological correlates.
The NOAEL was 330 mg/kg bw per day of Jagua (Genipin–Glycine) Blue 
on a “blue polymer” basis, the highest dose tested (Allingham et al., 2014).
(b) Dogs
Mancari (2016) administered Jagua (Genipin–Glycine) Blue (batch no. 5314034; 
33.79% “blue polymer” as determined by HPLC-UV [590 nm]) to groups of beagle 
dogs (n = 3/sex per dose) by gavage at 0, 250, 500 or 1000 mg/kg bw per day in 
water (0, 85, 169 and 338 on a “blue polymer” basis) for 90 days. The measured 
doses on two occasions were found to be 102.3–104.1% and 92.9–94.2% of the 
expected value. The study was certified as following OECD GLP, but it deviated 
from OECD Guideline No. 409, which recommends using a minimum of four 
animals per sex per dose. Furthermore, clinical chemistry and urine analysis 
were performed at the beginning and end of the study rather than monthly or 
additionally at the midway point, as recommended; the dogs were around 1 year 
old at study initiation, when the guideline recommends starting by 9 months 
of age; and the epididymis, thymus and uterus were collected, preserved and 
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examined at necropsy, but not weighed. Nevertheless, the Committee considered 
these deviations to be minor and not affecting the validity of the study.
Study observations included clinical signs, body weights, feed 
consumption (qualitative), ophthalmoscopy, electrocardiography, haematology, 
clinical chemistry, urine analysis, organ weights and macroscopic and microscopic 
pathology.
There were no deaths during the study. Clinical signs noted were blood 
in urine and faeces in one mid-dose male on day 2 and one low-dose male on day 
42. Blue faeces were observed throughout the study in all treated animals, which 
was assumed to be due to the colour of the test article.
One high-dose male lost approximately 15% of its body weight, but 
other variations in body weight were small and there was no dose relationship. 
No treatment-related ophthalmoscopic or electrocardiographic changes were 
noted. Compared with pretest values, a 26%, 8%, 9% and 18% decrease in white 
blood cells was observed in control, low-, mid- and high-dose males, respectively, 
and in high-dose females (20%), with inter-animal variability. This decrease in 
white blood cells was due to a decrease in both lymphocytes and neutrophils. 
Lymphocytes were also decreased by 11% in low-dose females and by 12% in mid-
dose females. An approximate 10% decrease in red blood cells, haemoglobin and 
haematocrit was observed in both sexes at the high dose. Compared with pretest 
values, red blood cells, haemoglobin and haematocrit decreased by 5–11%, 4–10% 
and 5–14%, respectively, in high-dose animals, and all post-test values were above 
the 5th percentile for the historical controls. Prothrombin time and prothrombin 
time ratio were significantly increased in high-dose females (P < 0.01; Dunnett 
test), though values remained within the normal range for dogs (Sodikoff, 1995). 
Prothrombin time also increased in mid-dose males (P < 0.05; Dunnett test). No 
other changes in coagulation parameters were observed. A 1.7-fold increase in 
total cholesterol was recorded in one high-dose female. A slight to marked dose-
related increase in total serum bilirubin (from 0–0.09 at pretest to 0.1–0.28 mg/
dL on day 88) was seen in both sexes at all doses; changes for mid- and high-dose 
females were significant (P < 0.05 and P < 0.01, respectively, Cochran–Cox test) 
and changes for high-dose males were significant (P < 0.05; Dunnett test). The 
authors noted that the test results may have been affected by the colour of the test 
article: most of the treated animals at all doses had green urine and the intensity 
of the colour correlated with treatment dose.
The Committee noted that the change in colour of urine and serum 
bilirubin that the study author attributed to the colour of the test article suggests 
that a coloured component of the test substance was absorbed. All microscopic 
findings recorded were reported to be within the range of spontaneous background 
alterations that may be recorded in beagle dogs of this age.
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The NOAEL was the highest dose tested, 338 mg/kg per day on a “blue 
polymer” basis (Mancari, 2016).
2.2.3 Long-term studies of toxicity and carcinogenicity
There were no long-term studies of Jagua (Genipin–Glycine) Blue.
Gardenia blue is also a genipin–amino acid/peptide polymer, and is 
expected to have a structure similar to Jagua (Genipin–Glycine) Blue. One 104-
week toxicity study in F344 rats of a blue polymer derived from geniposide 
extracted from Gardenia jasminoides was reported in the literature (Imazawa 
et al., 2000), and it has been included in this monograph for read-across of the 
findings.
Geniposide and eight other iridoid forms were extracted from G. 
jasminoides with methanol. The glucosides were mixed with defatted soybean 
protein and treated with β-glycosidase and protease in a buffer solution, resulting 
in a blue polymer with a melting-point of 118–120 °C and molecular weight of 
15 600 ± 400. The test article was not further described in terms of its composition, 
polymer structure, blue polymer content or impurities.
Fischer 344/DuCrj (F344) rats (n = 50/sex per dose; 6 weeks old) were 
exposed to the blue polymer at concentrations of 0, 2.5% and 5% in the diet 
(equal to 0, 1077 and 2173 mg/kg bw in males and 0, 1267 and 2533 mg/kg bw 
in females). The study was not reported as compliant with OECD guidelines 
or GLP. Feed consumption was measured once every 5 weeks and body weight 
was measured once a week for the first 5 weeks and every 5 weeks thereafter. 
The surviving rats were killed at 104 weeks after an overnight fast. Haematology 
measurements included white blood cells, red blood cells, haemoglobin, 
haematocrit and platelets. At necropsy, brain, submaxillary gland, lungs, heart, 
liver, spleen, adrenal glands, kidneys and testes were weighed. Tumours, major 
organs and tissues fixed in formalin and paraffin and stained for histopathological 
examination. There was no reported change in mean body weight or survival. 
Survival rates for the 0, 2.5% and 5% dose groups were 68%, 68% and 52% in 
males and 88%, 82% and 74% in females, respectively. No changes were found 
in organ weights except for a significant increase in left lung weight in males in 
the 5% group. The report noted some unspecified and occasional variation from 
controls, but these changes were neither consistent nor dose related. Faeces, but 
not urine, in treated animals were reported as blue. No treated group showed 
significant increases in tumour incidence over the control.
The NOAEL was 5% in the diet (2173 mg/kg bw per day in males and 
2533 mg/kg bw per day in females), the highest dose tested (Imazawa et al., 2000).
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2.2.4 Genotoxicity
The genotoxicity of Jagua (Genipin–Glycine) Blue has been investigated in 
three genotoxicity studies. A bacterial reverse mutation assay was conducted 
in accordance with OECD Test Guideline 471, an in vitro mouse lymphoma 
assay in accordance with OECD Test Guideline 476 and an in vivo mammalian 
micronucleus induction assay in accordance with OECD Test Guideline 474. All 
studies were certified for compliance with GLP and QA.
No genotoxic potential of Jagua (Genipin–Glycine) Blue was identified. 
The results from three genotoxicity studies with Jagua (Genipin–Glycine) Blue 
are summarized in Table 1.
2.2.5 Reproductive and developmental toxicity
No information was available.
2.2.6 Special studies
(a) Allergenicity
Jagua (Genipin–Glycine) Blue was tested for the presence of 26 known and 
characterized contact allergens by gas chromatography–mass spectrometry. 
None were detected (Arnoult, 2013).
(b) In vitro studies
Jagua (Genipin–Glycine) Blue was found not to penetrate the skin in an in vitro 
percutaneous penetration assay (Lati, 2013); to be a nonirritant in a hen egg 
chorioallantoic membrane assay; and to be nonphototoxic in an in vitro 3T3 
NRU phototoxicity test (Parmantier, 2013a,b).
The Committee did not find the tests pertinent for evaluating the risk of 
use of Jagua (Genipin–Glycine) Blue as a food colourant.
2.3 Observations in humans
A QA-compliant repeated insult patch test was conducted to determine the 
irritation and/or sensitization potential of Jagua (Genipin–Glycine) Blue after 
repeated application, under occlusive patch test conditions, to the skin of 52 
volunteers with self-perceived sensitive skin. Approximately 0.2 mL of a 1.5% 
solution of Jagua (Genipin–Glycine) Blue in distilled water was applied to the 
skin for 24 hours, with 24–48 hour intervals between applications, for a total of 
nine applications. No dermatitis or allergic contact dermatitis was seen in any of 
the volunteers during the induction or challenge phases of the study (Hollenback, 
Miller & Erianne, 2013).
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The Committee did not find the tests pertinent for evaluating the risk of 
use of Jagua (Genipin–Glycine) Blue as a food colourant.
3. Dietary exposure
3.1 Introduction
Estimates of dietary exposure to Jagua (Genipin–Glycine) Blue prepared by the 
sponsor, based on dietary data for the USA population, and estimated use levels 
and use frequencies were made available to the Committee. In addition, the 
Committee completed a conservative assessment using the WHO/FAO Chronic 
Individual Food Consumption Database – Summary statistics (CIFOCOss) and 
End-point Test system 
Route of 
administration Concentration/dose Result Reference 
In vitro
Reverse mutation Salmonella typhimurium 
TA98, TA100, TA102, TA1535 
and TA1537 
– 3.16–5 000 μg/plate, ±S9 Negativea Kraft (2013) 
Gene mutation Mouse lymphoma L5178Y 
TK+/− cells 
– First experiment:
500–4 250 μg/mL, −S9
250–5 000 μg/mL, +S9  
Second experiment:
100–3 250 μg/mL, −S9
600–5 000 μg/mL, +S9 
Negativeb Trenz (2013) 
In vivo 
Micronucleus 
induction 
Mouse; male and female Single 
Intraperitoneal 
400, 1 000 and 2 000 mg/kg bw Negativec Wessels 
(2013)
Table 1
Genotoxicity of Jagua (Genipin–Glycine) Blue in vitro and in vivo
bw: body weight; TK: thymidine kinase; S9: 9000 × g supernatant fraction from liver homogenate
a Two separate experiments were performed. The first experiment used the plate incorporation method and the second experiment the preincubation method. 
Cytotoxicity was noted in the plate incorporation method assays using strains TA1537 at 2500 µg/plate without metabolic activation, strains TA98 and TA1535 
at ≥2500 µg/plate without metabolic activation. Cytotoxicity was also noted in the preincubation method assays using strain TA100 at ≥316 µg/plate without 
metabolic activation, strain TA1537 at ≥100 µg/plate without metabolic activation and strain TA1537 at ≥2500 µg/plate with metabolic activation.
b Two separate experiments were performed. Relative total growth was reduced at the highest concentrations in both experiments. The global evaluation factor was 
not exceeded and no dose–response relationship was observed. Colony sizing showed no clastogenic effects with or without metabolic activation. Positive responses 
were obtained for appropriate positive controls (methyl methanesulfonate [MMS] and ethyl methanesulfonate [EMS] without activation and benzo[a]pyrene with 
activation).
c The dose of 2000 mg/kg bw was determined to be the maximum tolerated dose in a preliminary toxicity test. Moderate transient toxicity was observed in the highest 
test group and mild to moderate in the mid-dose test group. Micronuclei were examined in peripheral blood drawn at 44 hours and also for the control and high-dose 
group at 68 hours.
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proposed maximum use levels provided by the sponsor. No actual use data were 
presented or found in the literature.
3.2 Dietary exposure assessment
3.2.1 Assessments based on model diets
(a) Exposure estimates based on CIFOCOss database
The CIFOCOss database1 currently contains summary statistics from 55 surveys 
from 36 countries, each with survey durations of 2 days or more. The countries 
are grouped into 17 Global Environment Monitoring System (GEMS) clusters 
(WHO, 2012) that are culturally and economically comparable. The database 
provides summary statistics of food categorization, grouped in three tiers, with 
more than 600 items at the most detailed tier. The food categories provided as 
examples for proposed uses by the sponsor were matched with the CIFOCOss 
detailed food groups to assign the maximum proposed use levels for the 
calculations. These assignments are listed in Table 2.
The mean and the 95th percentile of the dietary exposure were calculated 
within each survey, age class and CIFOCOss food group. For each survey, a 
mean and a high exposure were calculated. The high exposure was calculated 
as the sum of the 95th percentile exposure, for the food group with the highest 
95th percentile exposure, and the mean exposure for each of the remaining 
food groups. For each age class, Table 3 lists the number of clusters and surveys 
included in the ranges given for the mean and the high exposure estimates.
For each age group, Table 4 lists the CIFOCOss food group contributing 
most to the total mean exposure within each survey, the range of these 
contributions and the number of surveys included in this range. Only food groups 
that contributed at least 10% to the total mean exposure are included in the table.
3.2.2 Assessments based on individual dietary records
(a) Exposure estimates based on Brazilian consumption data
The sponsor submitted estimates on dietary exposure from Jagua (Genipin–
Glycine) Blue (“Jenipapo Concentrate”) based on average consumption data from 
Brazil (whole population), submitted by the Instituto Brasileiro de Geografia 
e Estatística (IBGE) and proposed use levels. The estimated average dietary 
exposure at 100% use in proposed food items was 32.7 mg/day as Jagua (Genipin–
Glycine) Blue (corresponding to 13 mg/day calculated as “blue polymer” from 
Jagua (Genipin–Glycine) Blue, using a conversion factor of 0.4). The proposed 
1 Detailed data (January 2017) were made available to the Committee by the World Health Organization.
135
Jagua (Genipin–Glycine) Blue
CIFOCOss food group Sponsor-proposed food group
Proposed 
maximum use 
level (mg/kg or 
mg/L)a
Dairy-based desserts (e.g. pudding, fruit or flavoured yoghurt) Average of yoghurt, pudding 180
Yoghurt, cheese and milk-based dessert for infants and young 
children
Baby food 120
Food for infants and small children, nes
Ready-to-eat meal for infants and young children
Cereal-based food for infants and young children
Fruit juice and herbal tea for infants and young children
Bullets or lollipop Candy 120
Cream Cream 240
Edible ices, including sherbet and sorbet Ice cream
Dairy products, nes Dairy-based drinks, flavoured and/or fermented (e.g. 
chocolate milk, cocoa, eggnog, drinking yoghurt, 
whey-based drinks) (GMP)
Fermented milks (plain) Flavoured milk 120
Chantilly
Flavoured milk
Other cocoa products (including chocolate), nes Cocoa and chocolate products (GMP) 240
Cocoa butter
Cocoa mass
Processed nuts, including coated nuts and nut mixtures (with 
e.g. dried fruit)
Nougats and marzipans (GMP) 240
Tree nuts, processed, nes
Fruit juice, nes Fruit drinks 40
Vegetable juice, nes
Cakes, cookies and pies (e.g. fruit-filled or custard types) Jams
Gelatins
120
Gum
Sugar products and confectionaries, nes
Other processed fruits (excluding dried and juice), nes
Canned or bottled (pasteurized) fruits
Jams, jellies, marmalades
Other processed fruits (excluding dried and juice), nes
Diet beverages Soft drink 40
Nonalcoholic (“soft”) beverages, nes Energy drink
Energy drinks Sport drink
Isotonic drink
Soy drink Soy milk 120
Soy milk powder
Table 2
food groups and maximum use levels of “blue polymer” from Jagua (Genipin–Glycine) Blue 
used in the CIfoCoss calculations
CIFOCOss: Chronic Individual Food Consumption Database – Summary statistics; GMP: good manufacturing practices; nes: not elsewhere specified
a Recalculated from total Jagua (Genipin–Glycine) Blue to “blue polymer” from Jagua (Genipin–Glycine) Blue using 0.4 as a conversion factor.
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bw: body weight; CIFOCOss: Chronic Individual Food Consumption Database – Summary statistics
a  Ages in years were not defined in the available version of CIFOCOss database.
Table 3
exposure estimates for “blue polymer” from Jagua (Genipin–Glycine) Blue per age group 
based on CIfoCoss database and maximum use levels proposed by sponsor
Populationa
Food group contributing most to the mean 
exposure Number of surveys Range of contributions (%)
Adults Fermented milks (plain) 6 22–47
Nonalcoholic (“soft”) beverages, nes 3 25–63
Diet beverages 2 27–30
Adolescents Nonalcoholic (“soft”) beverages, nes 8 28–74
Edible ices, including sherbet and sorbet 2 6–22
Fermented milks (plain) 1 31
Children Fermented milks (plain) 5 21–43
Nonalcoholic (“soft”) beverages, nes 5 52–64
Edible ices, including sherbet and sorbet 2 10–34
Fermented milks (plain) 1 83
Fruit juice, nes 1 70
Toddlers Ready-to-eat meal for infants and young children 3 41–49
Soy drink 2 3–14
Dairy products, nes 1 18
Fermented milks (plain) 1 60
Food for infants and small children, nes 1 61
Fruit juice and herbal tea for infants and young 
children
1 10
Infants Fermented milks (plain) 1 41
Ready-to-eat meal for infants and young children 1 47
Populationa Number of clusters Number of surveys
Range for mean 
exposure across 
dietary surveys (mg/kg 
bw per day)
Range for high-level 
exposure across 
dietary surveys (mg/kg 
bw per day)
Adults 5 19 0.18–0.7 0.46–1.5
Adolescents 5 17 0.25–1.6 0.69–5.1
Children 7 30 0.07–3.8 0.57–9.8
Toddlers 4 9 1.68–3.6 3.79–10.9
Infants 10 2 2.42–3.7 7.69–12.4
Table 4
food groups contributing most to total mean exposure to “blue polymer” from Jagua 
(Genipin–Glycine) Blue
nes: not elsewhere specified
a Ages in years were not defined in the available version of CIFOCOss database.
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use frequency of 30% reduces the exposure to 3.9 mg/day (calculated as “blue 
polymer” from Jagua (Genipin–Glycine) Blue).
(b) Exposure estimates based on USA consumption data
The sponsor submitted estimated daily exposures to Jagua (Genipin–Glycine) 
Blue in selected foods based on foods reported to be consumed in the What 
We Eat in America (WWEIA) dietary component of the National Health and 
Nutrition Examination Surveys (NHANES) 2009–2012.
The amounts of coloured food consumed were reduced using expectations 
of use frequencies based on flavour and food types. The list of all food codes 
reported consumed in NHANES 2009–2012 that would fall into the target food 
types was reviewed. When available, the flavours specified for foods under each 
food type were used to identify which foods can be found to be blue coloured 
or potentially blue coloured. When flavours were not specified for foods under 
a given food type, all foods for that food type were conservatively assumed to be 
coloured blue. Baby products were excluded from selection.
Furthermore, the amounts of coloured food consumed were reduced 
based on expectations of the portion of food items that would be coloured (e.g. for 
candy-coated candies with chocolate or non-chocolate interiors, it was assumed 
that 50% of the weight of the candy was the coating that could be coloured).
Finally, the expected use level was reduced from the maximum proposed 
use level to a lesser level, based on the intensity of the colour of the representative 
products.
Estimated dietary exposures based on these assumptions are shown in 
Table 5.
3.3 Evaluation of estimates of dietary exposure
The dietary exposure estimate for “blue polymer” from Jagua (Genipin–Glycine) 
Blue based on the CIFOCOss model diets and proposed maximum use levels 
uses a very conservative approach and shows mean exposures (in mg/kg bw per 
day) in the range of 0.2–0.7 for adults, 0.3–2 for adolescents, 0.07–4 for children 
and 2–4 for toddlers. Ranges (in mg/kg bw per day) for high exposures were 
0.5–2 for adults, 0.7–5 for adolescents, 0.6–10 for children and 4–11 for toddlers.
The assessment based on Brazilian consumption data and proposed use 
levels estimated the dietary exposure at 4 mg/day for the whole population.
The dietary exposure estimates based on USA food consumption data 
and proposed use levels, refined with assumptions of expected use levels and use 
frequencies, were significantly lower. The estimated daily mean exposure was 0.2 
mg/kg bw per day for children, and 0.06 mg/kg bw per day for adolescents and 
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Table 5
estimated daily exposure to “blue polymer” from Jagua (Genipin–Glycine) Blue from 
proposed uses based on 2-day food consumption data from nHAnes 2009–12
bw: body weight; NHANES: National Health and Nutrition Examination Surveys
a Submitted data were recalculated from total Jagua (Genipin–Glycine) Blue to “blue polymer” from Jagua (Genipin–Glycine) Blue using 0.4 as conversion factor.
Age–sex group (years) % eaters
Estimated exposure (mg/kg bw per day)a
Mean 90th percentile
Children (2–5) 90 0.17 0.37
Teenage boys (13–18) 85 0.06 0.14
Population (≥2) 76 0.06 0.14
for the general population 2 years and older. The 90th percentile estimates were 
0.4 mg/kg bw per day for children, and 0.14 mg/kg bw per day for adolescents 
and for the general population 2 years and older.
Using the CIFOCOss data from USA for children less than 6 years old, 
the dietary exposure is estimated at 11 mg/kg bw per day (95th percentile).
The estimates of the dietary exposure for “blue polymer” from Jagua 
(Genipin–Glycine) Blue calculated by this method were much higher than those 
of the sponsor (0.4 mg/kg bw per day for children at the 90th percentile). The 
Committee concluded that this was due to the use of reduction factors for use 
levels and use frequencies by the sponsor.
4. Comments
4.1 Biochemical aspects
The molecular weight and chemical properties of the “blue polymer” of Jagua 
(Genipin–Glycine) Blue suggest that the polymer is unlikely to be absorbed 
intact from the gastrointestinal tract. A size distribution analysis showed that less 
than 1.5% of the mixture contained dimers with molecular weights of around 
500 Da, which could be absorbed. An in vitro study using a Caco-2 cell intestinal 
barrier model showed that “blue polymer” has poor passive penetration, but 
there is some evidence to suggest that a small proportion of Jagua (Genipin–
Glycine) Blue, possibly the smallest coloured molecular species (such as genipin–
glycine dimers (molecular weight approximately 500 Da) or other coloured low 
molecular weight components), was actively transported (Gilbert, 2015). No “blue 
polymer” was detectable in the plasma of dogs in an oral gavage repeated-dose 
study (tested up to 338 mg/kg bw per day, limit of quantification 1 mg/mL) on 
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day 1 or 91 following dosing with Jagua (Genipin–Glycine) Blue (Mancari, 2016). 
No investigations into biotransformation of the “blue polymer” were undertaken.
4.2 Toxicological studies
Results from an oral gavage acute toxicity test in the rat showed no adverse effects 
at the highest tested dose of 660 mg/kg bw (Allingham, 2014b).
Results from oral gavage 90-day repeated-dose toxicity studies in rats 
and dogs showed no adverse effects at 330 mg/kg bw per day or 338 mg/kg bw 
per day of “blue polymer”, respectively, the highest doses tested (Allingham et al., 
2014; Mancari, 2016). The dog study deviated from the relevant OECD guideline, 
but the Committee considered these deviations to be minor and to not affect the 
validity of the study. The Committee noted that in dogs the urine was coloured 
green with an intensity that appeared to be in proportion to the administered 
dose, and there was an increase in measured serum bilirubin values attributed 
to the interference of the test article with the analytical method, suggesting that 
some of the “blue polymer” had been absorbed from the gastrointestinal tract. 
Green-coloured urine was not observed in rats. In 90-day animal studies, all 
treated animals had faeces that were coloured blue, which is consistent with poor 
absorption of the high molecular weight component of the “blue polymer” from 
the gastrointestinal tract.
There were no long-term toxicity or carcinogenicity studies available 
on Jagua (Genipin–Glycine) Blue. To address the data gap, one non-GLP 
carcinogenicity study in rats on a structurally related genipin-based blue polymer 
from Gardenia jasminoides (Gardenia Blue) was considered. The Gardenia Blue 
used in the study was formed from a mixture of genipin and a protease digest of soy 
proteins, resulting in different amino acids attached to genipin. The Committee 
noted that the purity of blue polymer in the Gardenia Blue was not described. At 
concentrations up to 5% in the diet (equal to 2173 mg/kg bw per day in the males 
and 2533 mg/kg bw per day in the females), there were no treatment-related 
adverse effects or changes in tumour incidence (Imazawa et al., 2000).
There was no evidence of genotoxicity of Jagua (Genipin–Glycine) Blue 
in vitro, with bacterial reverse mutation assays and a mouse lymphoma assay, or 
in vivo, with a mouse micronucleus assay. The Committee concluded that there 
was no concern with regard to genotoxicity.
No reproductive or developmental toxicity studies on Jagua (Genipin–
Glycine) Blue were available; there were also no available reproductive or 
developmental toxicity studies on Gardenia Blue.
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4.3 Observations in humans
No relevant human studies were available.
4.4 Assessment of dietary exposure
Estimates of dietary exposure to Jagua (Genipin–Glycine) Blue prepared by 
the sponsor based on dietary data for the United States population, estimated 
use levels and use frequencies were available to the Committee. Additionally, 
a conservative assessment using the CIFOCOss database and maximum use 
levels provided by the sponsor was performed by the Committee. The 95th 
percentile estimates of dietary exposure for Jagua (Genipin–Glycine) Blue on a 
“blue polymer” basis calculated by the Committee were 11 mg/kg bw per day for 
children and 5 mg/kg bw per day for adolescents. These estimates were much 
higher than those calculated by the sponsor. The difference between the sponsor’s 
estimates and the Committee’s estimates was due to the use by the sponsor of 
lower use levels and use frequencies.
The Committee concluded that the conservative estimate of 11 mg/kg bw 
per day for children and 5 mg/kg bw per day (for adolescents), prepared using 
the CIFOCOss model, should be considered in the safety assessment for Jagua 
(Genipin–Glycine) Blue on a “blue polymer” basis.
5. evaluation
The Committee noted that in 90-day toxicity studies with Jagua (Genipin–
Glycine) Blue in the dog and rat, no treatment-related adverse effects were found 
at the highest doses tested; in addition, genotoxicity tests were negative and no 
treatment-related adverse effects were observed in a carcinogenicity study with 
the structurally related food colour, Gardenia Blue. Based on the coloration 
of the urine in the dogs and the increase in serum bilirubin test values, which 
was attributed to interference of the test article with the analytical method, the 
Committee concluded that some component of the Jagua (Genipin–Glycine) 
Blue is absorbed and excreted, most likely the dimers or other coloured low 
molecular weight component; the dimers make up less than 1.5% of Jagua 
(Genipin–Glycine) Blue. However, the Committee noted that the highest doses 
tested in both 90-day studies were only 330 and 338 mg/kg bw per day (expressed 
on a “blue polymer” basis) in rats and dogs, respectively. The Committee was 
concerned that the possible effects of the low molecular weight species that could 
be absorbed would not have been adequately investigated.
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A comparison of the dietary exposure estimate (11 mg/kg bw per 
day) with the NOAEL from the 90-day studies of oral toxicity in rats and 
dogs (approximately 330 mg/kg bw per day) gives a margin of exposure of 
approximately 30.
Because of the limited biochemical and toxicological database and the 
low margin of exposure, the Committee was unable to complete the evaluation 
for Jagua (Genipin–Glycine) Blue.
A new tentative specifications monograph and a Chemical and Technical 
Assessment were prepared.
The Committee raised concern regarding potential toxicity of low 
molecular weight fraction of the total colouring matter in Jagua (Genipin–Glycine) 
Blue. The Committee recommends additional biochemical and toxicological 
information (e.g. absorption, distribution, metabolism and excretion studies, 
long-term toxicity, carcinogenicity, reproductive and developmental toxicity 
studies), including the use of higher doses of the “blue polymer”, including the 
dimers, in order to complete an evaluation of the safety of Jagua (Genipin–
Glycine) Blue.
To support the above, additional information is required on:
 ■ Characterization of the low molecular weight components of the 
“blue polymer”.
 ■ A validated method for the determination of dimers.
 ■ Data on concentrations of dimers from five batches of the commercial 
product.
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1. explanation
Metatartaric acid (Chemical Abstracts Service No. 56959-20-7/39469-81-3; INS 
No. 353), a polymer of L(+)-tartaric acid, is used as a food additive in winemaking 
in the following countries and regions: Argentina, Australia, Brazil, Canada, Chile, 
the European Union, New Zealand, Norway, Paraguay, the Russian Federation, 
South Africa, Turkey and Uruguay.
Metatartaric acid, which was not previously evaluated by the Committee, 
was evaluated at the request of the Codex Committee on Food Additives 
(CCFA) at its Forty-eighth Session (FAO/WHO, 2016). It is proposed for use 
in winemaking at a level of good manufacturing practice. The data that were 
submitted in response to the call for data related to its use as a food additive in 
winemaking only.
The safety of L(+)-tartaric acid and DL-tartaric acid and their sodium 
and potassium salts was evaluated at the seventeenth and twenty-first meetings 
of the Committee (Annex 1, references 32 and 44). At its seventeenth meeting, 
the Committee established a group acceptable daily intake (ADI) of 0–30 mg/kg 
body weight (bw) for L(+)-tartaric acid and its sodium, potassium, potassium–
sodium salts, expressed as L(+)-tartaric acid. Specifications were available to the 
Committee for L(+)-tartaric acid (only interim additional data were available; no 
further action was taken) at its nineteenth meeting (Annex 1, reference 38). At 
its twenty-first meeting, the Committee reaffirmed the ADI for the L(+)-tartrate 
monosodium salt and the existing specifications for L(+)-tartaric acid, but did 
not establish an ADI for monosodium DL-tartrate.
L(+)-Tartaric acid, the naturally occurring form of tartaric acid, occurs 
in many fruits and wines. Tartrate crystals (potassium bitartrate and calcium 
tartrate) develop naturally in wine and are the major cause of sediment in bottled 
wines. In order to prevent sedimentation, metatartaric acid has been used in wine 
since 1955 (OIV, 2012, 2017; Guise et al., 2014).
147
Metatartaric acid
At the present meeting, the Committee reviewed a short-term toxicity 
study and a genotoxicity study of metatartaric acid. A literature search was 
conducted in a number of databases for articles from 1950 to 6 April 2017. The 
keywords used in the searches included “metatartaric acid” OR “tartaric acid” 
OR “tartrate” AND “toxicology” OR “toxicity”. References were retrieved for 
“metatartaric acid” from PubMed (5 records), Web of Science (11 records), 
MEDLINE (6 records), Scopus (Elsevier; 6 records) and AGRIS (10  records); 
none were retrieved from Embase/Cochrane Library/Directory of Open 
Access Journals/GIM/CINAHL. However, none of these retrieved studies were 
considered relevant for the safety assessment of metatartaric acid. References 
retrieved for “tartaric acid” and “tartrate” from PubMed (63 records), BIOSIS (163 
records), MEDLINE (195 records), CINAHL (94 records), AGRIS (94 records), 
Embase (47 records), Cochrane Library (16 records), Directory of Open Access 
Journals (32 records) and GIM (4 records) identified three other toxicity studies.
The previous monograph on L(+)- and DL-tartaric acid has been expanded 
and is reproduced in this consolidated monograph that includes metatartaric 
acid and L(+)-tartaric acid/tartrate. Studies on L(+)- and DL-tartaric acid from 
1977 onward had not been previously reviewed by the Committee.
1.1 Chemical and technical considerations
Metatartaric acid is typically manufactured using L(+)-tartaric acid from natural 
sources. It is formed by the intermolecular esterification between the carboxylic 
group of one L-tartaric acid unit and the secondary alcohol group of another 
molecule of L-tartaric acid, which may be followed by further intermolecular 
and intramolecular esterification reactions (Sprenger et al., 2015). The primary 
components of metatartaric acid are the L-tartaric acid monomer, ditartrate 
monoester and diester, and polyester chains of varying degrees of polymerization. 
The average molecular weight range has been determined in commercial products 
to be 2.2–8.9 kDa, with a polydispersity index up to 50. Metatartaric acid is used 
as a stabilizer and sequestrant in wine to prevent growth and precipitation of 
potassium bitartrate and calcium tartrate crystals (Marchal & Jeandet, 2009). 
Stability studies in wine indicated that it undergoes hydrolysis to tartaric acid 
over time, but the rate of hydrolysis is dependent on pH and storage temperature 
(Ribéreau-Gayon et al., 2006; Morello, 2012).
Metatartaric acid is produced by heating L-tartaric acid from grapes 
at 150–170  ºC under atmospheric or reduced pressure for less than 1 hour 
(Ribéreau-Gayon et al., 2006). This process produces a colourless liquid, which 
is cooled, dried and ground into an off-white powder. Variations in production 
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temperature, pressure and time allow manufacturers to alter the degree of 
esterification in the final product.
2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and excretion
(a) Metatartaric acid
Metatartaric acid, a dispersed polymer of tartaric acid units linked together 
by ester bonds, is anticipated to undergo rapid enzyme-mediated hydrolysis to 
L(+)-tartaric acid once exposed to carboxylesterases in the gastrointestinal tract 
(Heymann, 1980; Anders, 1989).
(b) L(+)-Tartaric acid
Rats
The excretion of L(+)-tartaric acid in the urine after oral administration was 
investigated in rats, guinea-pigs, rabbits and dogs.
In the rat, 68–99% of a 400 mg/kg bw dose of tartaric acid was recovered 
unchanged.
In the guinea-pig, 13–27% of the dose was recovered from doses ranging 
from 100 to 800 mg/kg bw.
In the rabbit, 90–99% of a 50 mg/kg bw dose was recovered. When 
the dose was raised to 100, 200 or 300 mg/kg bw, 21–23%, 15–26% and 2–3%, 
respectively, was found in urine.
In the dog, doses lower than 600 mg/kg bw were fully excreted in the urine 
(83–100%); with higher doses (600–1500 mg/kg bw), the recovery diminished to 
50–60% and was associated with slight renal changes (Underhill et al., 1931a).
Following oral gavage administration of L(+)-tartaric acid at 1000 mg/
kg bw, Gry & Larsen (1978) determined that the average percentage of tartrate 
recovered in urine was 72.9% in Wistar rats (n = 5/sex), 26% in female Danish 
Landrace pigs (n = 3) and 3.6% in female guinea-pigs (n = 11).
In a study investigating the disposition of monosodium tartrate, two 
groups of male CFY rats (n = 10/group) received either a dose of monosodium 
[14C]L(+)-tartrate or of monosodium [14C]DL-tartrate at 2730 mg/kg bw per day 
by oral intubation for 7 days. Three hours after the last dose, one animal per 
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group was killed and radioactivity was measured in whole blood, plasma, bone 
and kidneys. Thereafter, a rat from each group was killed at intervals over the 
next 12 days. One rat at each kill time underwent whole-body autoradiography.
In a second study, two groups of male rats (n = 8) received either 
monosodium [14C]L(+)-tartrate or [14C]DL-tartrate at 2570 mg/kg bw per day by 
oral intubation for 7 days. All the animals were killed 6 hours after administration 
of the final dose, and the livers and kidneys were removed.
Radioactivity concentrations in plasma following dosing with 
monosodium [14C]L(+)-tartrate at 2730 mg/kg bw declined biphasically, with 
calculated half-lives of 3 and 53 hours, respectively. Whole-body autoradiography 
at 3 hours after monosodium [14C]L(+)-tartrate administration showed most of the 
radioactivity to be in the gastrointestinal tract, liver, kidneys and bone. From 24 to 
192 hours after the last dose, radioactivity was only detected in bone. Dosing with 
monosodium [14C]DL-tartrate at 2730 mg/kg bw resulted in peak plasma levels 3 
hours after the last dose with the half-lives for the biphasic decline in plasma at 
15 and 58 hours. Autoradiography at 3 hours after monosodium [14C]DL-tartrate 
administration showed radioactivity to be mainly in the gastrointestinal tract, 
liver, kidneys and bone. Radioactivity was still detected in bone at 24 hours after 
the last dose and in granular deposits in the kidneys at 192 hours after the last 
dose. At 96 hours after dosing, radioactivity in the kidneys and bones of rats 
treated with [14C]DL-tartrate was twice that of rats treated with [14C]L(+)-tartrate; 
this also corresponded with an increased relative kidney weight. Renal retention 
of tartrate was attributed to precipitation of calcium DL-tartrate in the tubules, 
and histopathological examinations showed crystalluria, which was not observed 
in rats treated with [14C]L(+)-tartrate (Down et al., 1977).
Following administration to rats of a single oral dose of monosodium 
[14C]L(+)-tartrate at 400 mg/kg bw, 70.1% of the radioactivity was excreted in 
urine, 15.6% in expired air and 13.6% in the faeces within 48 hours. Excretion of 
the labelled material in the urine was almost complete within 12 hours and in the 
expired air within 24 hours. After the same dose was administered by intravenous 
injection, 81.8%, 7.5% and less than 1% of the labelled material was excreted 
in urine, expired air and faeces, respectively (Chasseaud, Down & Kirkpatrick, 
1977).
Following administration to rats of a single oral dose of 14C-labelled 
sodium tartrate at 18.8 mg/kg bw, 51.5% of the radioactivity was excreted 
unchanged in urine within 24 hours, 21.8% was expired as CO2 within 6 hours. 
After intraperitoneal injection, 63.1% was excreted in urine within 24 hours and 
9.4% as CO2 within 6 hours. The intestinal absorption in rats was 81% of the 
tartrate dose and the urinary excretion 70% of the dose.
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As a larger portion of the 14C was expired as respiratory CO2 after oral 
or intracaecal administration than after parenteral administration, this indicates 
that some of the tartrate was metabolized in the intestines, probably by bacteria 
in the caecum (Chadwick et al., 1978).
Humans
In contrast to rats, only 12% of an oral dose of sodium tartrate with radioactive 
tracer (2, 5 or 10 g/person; n = 5/group) was recovered unchanged in human 
urine, while 46% of the dose was recovered as expired CO2. Following intravenous 
administration, 63.8% of the dose was recovered in the urine of a single human 
participant, while a further 18% was expired as 14CO2.
The large difference in urinary excretion after oral and intravenous 
administration indicated that only a small proportion of an oral dose is absorbed. 
Since only small amounts of radiolabelled tartrate were recovered in human urine 
following oral administration, tartrate is likely fermented by microorganisms in 
the large intestine (Chadwick et al., 1978).
A study was undertaken to demonstrate the concentration range of 
tartrate in human urine following dietary exposure to 280  mL of grape juice 
containing tartaric acid at 2.0 g/L (i.e. 560 mg, but reported to be 590 mg). Urine 
collected over 24 hours from 23 human volunteers (n = 23; sex not reported) was 
tested for tartrate after 1 day consuming a diet free of tartaric acid followed by 
1 day of the restricted diet plus the grape juice to a total of 560 mg tartaric acid. 
Concentrations of urinary tartrate ranged from 7.4 to 282 μg/mg of creatinine.
The authors concluded that urinary tartrate levels in humans depended 
heavily on the diet and gastrointestinal microflora, and that there was no clinical 
benefit in routinely measuring tartrate levels in urine (Lord, Burdette & Bralley, 
2005).
In a randomized cross-over feeding trial, 21 healthy men consumed a 
single dose of 100, 200 or 300 mL of wine at dinner, followed by a 7-day washout 
period during which the participants avoided consuming wine or grape-based 
products. A strongly significant correlation was found between wine consumption 
and urinary tartaric acid (Regueiro et al., 2014).
In a study using ion-chromatographic determination of L-tartrate in 
urine samples, urinary excretion of tartrate was measured in healthy people 
eating a normal diet (n = 19), in practising vegetarians (n = 26) and in idiopathic 
calcium stone formers (n = 33). The results confirmed the critical dependence 
of tartrate excretion on the composition of the diet, with the excreted tartrate 
151
Metatartaric acid
mainly from dietary sources and entirely exogenous in origin (Petrarulo et 
al.,1991).
2.2 Toxicological studies
2.2.1 Acute toxicity
(a) Metatartaric acid
No information was available.
(b) L(+)-Tartaric acid
Mice
The oral median lethal dose (LD50) of sodium tartrate in mice was reported to be 
4360 mg/kg bw (Locke et al., 1942).
Rabbits
Three out of seven male rabbits died following oral administration of disodium 
tartrate at an average dose of 5290 mg/kg bw, while six male rabbits survived 
an average oral dose of 3680 mg/kg bw (Locke et al., 1942). Renal damage was 
observed only after the intravenous administration of tartaric acid at doses of 
0.2–0.3  g in rabbits and rats (Bodansky, Gold & Zahm, 1942; Gold & Zahm, 
1943).
Dogs
Tartaric acid at a dose of 5000 mg/kg bw was reported to be fatal in a dog when 
administered by stomach tube (Sourkes & Koppanyi, 1950).
2.2.2 Short-term studies of toxicity
(a) Metatartaric acid
In an 18-week oral toxicity study, metatartaric acid (with 27–35% esterified 
tartaric acid) was given to Wistar rats (n = 15/sex per group) in their drinking-
Species Sex Route Test substance LD50 (mg/kg bw) Reference
Mice Not reported Oral Sodium tartrate     4 360 Locke et al. (1942)
Rabbits Male Oral Disodium tartrate >3 680 Locke et al. (1942)
bw: body weight; LD50: oral median lethal dose
Table 1
Acute toxicity of tartaric acid
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water at concentrations of 0, 0.1%, 0.5% or 3.0% (0, 80, 330 and 1810 mg/kg 
bw per day for males and 0, 130, 520 and 2520 mg/kg bw per day for females, 
respectively, based on the animals’ water consumption). Another three groups of 
rats (n = 5/sex per group) were treated similarly for either 2 or 6 weeks.
A urine concentration and dilution test was undertaken at the end of 
weeks 2, 6 and 18. Rats deprived of water for 6 hours were given water at 25 mL/
kg bw. The specific gravity of their urine was measured twice in a 2-hour period 
following this administration of water. At weeks 6 and 18, the specific gravity of 
urine collected during a 4-hour period after 16 hours of water deprivation was 
measured again.
Relative to controls, feed consumption was reduced significantly 
(P < 0.01) in males, by 7% in the middle-dose group and 20% in the high-dose 
group, and in females (P < 0.05), by 6% in the middle-dose group and 9% in the 
high-dose group. Nevertheless, body weights were only reduced (4%; P < 0.001) 
in high-dose male rats. Treated rats also consumed less water; in males, water 
consumption was 19.5%, 35.5% and 45.7% less than controls at the low, mid and 
high dose, respectively, while in females water consumption was 17%, 36% and 
50% less than controls at the low, mid and high dose, respectively.
Relative to controls, all groups of rats treated for 2, 6 or 18 weeks excreted 
less urine, and urine of a higher specific gravity, when deprived of water for 6 hours 
or during the 2-hour period following a water load. In contrast, at week 18 only 
male rats in the middle- and high-dose groups excreted urine of lower specific 
gravity and in larger volumes than control animals in the 16–20 hour period after 
the water load. Urinary constituents were normal in the treated animals. Some 
significant differences in relative organ weights (brain, heart, spleen, kidneys, 
stomach, caecum and gonads) were observed in high-dose male and female 
rats at 6 or 18 weeks; these were related to the low terminal body weights of the 
animals. Both high-dose sexes showed an increase in relative kidney weight but 
without any accompanying histopathological changes. Haematology and blood 
chemistry examinations found no treatment-related adverse effects (Ingram et 
al.,1982).
The Committee noted that most of the observed effects – reduced feed 
and water consumption; reduced body weight; urine with increased specific 
gravity – were directly attributable to the unpalatability of metatartaric acid in 
drinking-water. As a result, the Committee considered that this study was not 
suitable for use in this safety assessment.
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(b) L(+)-Tartaric acid
Rabbit
Three rabbits survived 17 consecutive daily feedings of disodium tartrate at 
an average dosage of 1150 mg/kg bw; three out of six rabbits died after being 
administered average dosages of 3680  mg/kg bw over 6–19 consecutive daily 
feedings (Locke et al., 1942).
Male New Zealand White rabbits (n = 15) fed 7.7% sodium tartrate in the 
diet (equivalent to 2310 mg/kg bw per day) for 22 weeks showed no evidence of 
toxicity either in terms of body and organ weight (testes and thyroid) changes or 
pathology (Packman, Abbott & Harrisson, 1963).
Dog
The test substance, “tartaric acid”, was given in daily oral doses of 990 mg/kg 
bw to each of four dogs for 90–114 days. Casts appeared in the urine of three 
dogs; the blood chemistry remained normal except in one dog that developed 
azotaemia and died within 90 days. Weight changes varied from a weight gain of 
30% to a loss of 32% (Krop & Gold, 1945).
2.2.3 Long-term studies of toxicity and carcinogenicity
(a) Metatartaric acid
No information was available.
(b) L(+)-Tartaric acid
No new long-term toxicity studies were available since the previous evaluation of 
L(+)-tartaric acid.
A previously unpublished 2-year feeding study in rats that supports the 
ADI for tartaric acid had since been published (Hunter et al., 1977). Groups 
of Sprague Dawley rats (n = 35/sex) were fed diets described as containing 
monosodium L(+)-tartrate at concentrations of 0, 25  600, 42  240, 60  160 or 
76 800 mg/kg bw per day (reported to be equal to a dose of L(+)-tartaric acid of 
0, 710, 1220, 1840 and 2460 mg/kg bw per day for males and 0, 930, 1600, 2360 
and 3200 mg/kg bw per day for females, respectively) for 104 weeks.
The survival of rats at 42 240, 60 160 or 76 800 mg/kg bw per day was 
better than that of the controls; this correlated with the lower feed consumption 
of these groups and a reduced body-weight gain. There were no adverse clinical 
signs or ophthalmoscopic changes. Haematology and urology tests did not 
show any treatment-related effects, nor were there any changes in macroscopic 
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pathology or organ weights. Histopathological examination of tissues did not 
show any evidence of toxicity or tumour induction attributable to treatment with 
the test substance. No treatment-related adverse effects were seen, even at the 
highest dose.
However, the Committee noted that the dose conversion reported used 
the molecular weight for disodium tartrate rather than monosodium tartrate 
to calculate the doses of L(+)-tartaric acid. Using monosodium tartrate, the 
Committee calculated the doses to be 0, 770, 1400, 1900 and 2680 mg/kg bw per 
day for males and 0, 1030, 1780, 2630 and 3550 mg/kg bw per day for females, 
respectively. As a result, the Committee concluded that the no-observed-adverse-
effect level (NOAEL) for L(+)-tartaric acid in the study was 2680 mg/kg bw per 
day, the highest tested dose.
2.2.4 Genotoxicity
(a) Metatartaric acid
In a newly submitted in vitro reverse mutation assay, two independent experiments 
were performed. The test system consisted of Salmonella typhimurium TA97, TA98, 
TA100, TA102 and TA1535. Negative-control substances included demineralized 
H2O, dimethyl sulfoxide and ethanol. Positive-control substances in tests without 
metabolic activation were 4-nitro-1,2-phenylenediamine for TA97a, TA98 and 
TA102; and sodium azide for TA100 and TA1535. Positive-control substances in 
tests with metabolic activation were 2-aminoanthracene for TA97, TA100, TA102 
and TA1535, and benzo[a]pyrene for TA98. The supernatant fraction used for 
metabolic activation was from the livers of male Sprague Dawley rats that had 
been treated intraperitoneally with Aroclor 1254 at 500 mg/kg bw.
A test substance is considered to have mutagenic potential in the reverse 
mutation assay if there is a reproducible increase (by at least a factor of 2) in the 
number of revertant colonies per plate. A concentration-related increase over the 
range tested is also taken as a sign of mutagenic activity.
The first experiment was performed using the plate incorporation 
method, with concentrations of 50–5000 µg/plate (actual concentrations ranged 
from 47 to 4709 µg/plate, with or without metabolic activation). The second 
experiment was performed using the preincubation method with concentrations 
of 156–5000 µg/plate (actual concentrations ranged from 157 to 5037 µg/plate, 
with or without metabolic activation). The positive controls produced the 
expected increase in the number of revertants. Results of both experiments were 
negative; metatartaric acid showed no genotoxic potential (Andres, 2016).
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(b) L(+)-Tartaric acid
In two in vitro assays, reverse mutation and chromosomal aberration, L(+)-
tartaric acid showed no genotoxic potential. In contrast, sodium L(+)-tartrate 
was negative in the reverse mutation assay but yielded a positive result in the 
chromosomal aberration test. The Committee noted that potential cytotoxicity 
was not tested and that gaps were counted in the chromosomal aberration test. 
The Committee concluded that these factors call into question the reliability of 
this study. In addition, 1 mg/mL of the related compound, L(+)-tartaric acid, was 
shown to be negative in the same assay.
In an in vivo micronucleus test in mice, sodium L(+)-tartrate was also 
negative using single intraperitoneal doses up to 3600 mg/kg bw (Hayashi et al., 
1988).
The results of the studies are summarized in Table 2.
2.2.5 Reproductive and developmental toxicity
(a) Metatartaric acid
No information was available.
(b) L(+)-Tartaric acid
Teratology studies have been conducted in mice, rats, hamsters and rabbits. The 
highest doses tested were 274 mg/kg bw per day (for 10 days) in mice; 181 mg/kg 
bw per day (for 10 days) in rats; 225 mg/kg bw per day (for 5 days) in hamsters; 
and 215 mg/kg bw per day (for 13 days) in rabbits, administered during the 
period of organogenesis.
Tartaric acid did not produce teratogenic effects in either soft or skeletal 
tissues at the highest doses tested. Likewise, there were no effects on nidation, or 
maternal or fetal survival rates (FDRL, 1973).
2.2.6 Immunotoxicity
The potential immunotoxicity of L-tartaric acid was evaluated in a rapid 
screening protocol in which groups of 30 female CD1 mice were given L-tartaric 
acid orally at doses of 750, 1500 or 3000 mg/kg bw per day for 5 days. A group of 
control animals was also evaluated. The animals received an infectious challenge 
on day 3 of dosing and immunization on day 5. The antibody plaque-forming cell 
response was measured 4 days later. Deaths and survival were monitored for 10 
days after infection.
There were no statistically significant differences in spleen weight, 
thymus weight, spleen cellularity, anti-sheep red blood cell or plaque-forming 
cell response, or death due to Listeria infection between test and control animals 
(Gaworski et al., 1994).
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Table 2
Genotoxicity of L(+)-tartaric acid and sodium L(+)-tartrate
End-point Test substance Test system Concentration Result Reference
In vitro 
Reverse 
mutationa
L(+)-tartaric acidb,c Salmonella typhimurium strains TA92, TA94, 
TA98, TA100, TA102, TA1535, TA1537 
Up to 10.0 mg/plate 
± S9d
Negativee Ishidate et al. 
(1984)
Sodium L(+)-tartratef,g Salmonella typhimurium strains TA92, TA94, 
TA100, TA1535, TA1537 and TA9
Up to 5.0 mg/plate 
± S9d
Negativee Ishidate et al. 
(1984)
Chromosomal 
aberration
L(+)-tartaric acidb,c Chinese hamster fibroblast cell line Up to 1.0 mg/mLh Negative Ishidate et al. 
(1984)
Sodium L(+)-tartratef,i Chinese hamster fibroblast cell line Up to 15.0 mg/mLh Positive Ishidate et al. 
(1984)
In vivo 
Micronucleus Sodium L(+)-tartratef,g Male ddY mice bone marrow cells 0, 900, 1 800, 2 700, 
3 600 mg/kg bwi
Negative Hayashi et al. 
(1988)
bw: body weight; S9: 9000 × g supernatant fraction from liver homogenate
a Using the Ames method.
b Purity of the test substance: 99.9%.
c Solvent: phosphate buffer.
d The S9 was prepared from the liver of Fischer rats pretreated 5 days before with polychlorinated biphenyls (500 mg/kg bw of Kanechlor KC-400 in olive oil, by 
intraperitoneal injection).
e Negative result indicates that no significant increases in the numbers of revertant colonies were detected in any S. typhimurium strains at the maximum dose.
f Purity of the substance: 99.5%.
g  Solvent: physiological saline.
h The cells were exposed to each sample at three different doses for 24 and 48 hours. No metabolic activation systems were applied. The maximum dose of each sample 
was selected by a preliminary test, in which the dose needed for 50% cell-growth inhibition was estimated using a cell densitomer.
i  The test substance was administered in a single intraperitoneal injection, and the sampling time was 26 hours.
2.3 Observations in humans
(a) Metatartaric acid
No information was available.
(b) L(+)-Tartaric acid
A fatal case of tubular nephropathy following accidental ingestion of 30 g tartaric 
acid has been reported (Robertson & Lönnell, 1968).
Sodium tartrate at daily doses of up to 10 or even 20 g has been used in 
medical practice as a laxative. Sodium tartrate was tested as a laxative in a clinical 
study involving daily doses of 10 g given to 26 study participants for an average 
of 11.8 doses; laxative responses occurred in 66% of the participants. The only 
observed side-effects were nausea or vomiting and abdominal cramps (Gold & 
Zahm, 1943).
In a human study involving ingestion of L-tartrate at 225 mg/kg bw per 
day, one volunteer was treated for 2 consecutive days while another was treated for 
4 consecutive days). There was no evidence of renal toxicity: creatinine clearance 
was normal and there was no proteinuria (Chadwick et al., 1978).
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3. Dietary exposure
The sponsor submitted dietary exposure estimates for metatartaric acid in wine 
at a maximum use level of 100 mg/L using the European Food Safety Authority 
Food Additives Intake Model (FAIM, version 1.0). However, the Committee 
considered that this did not reflect long-term dietary exposure to metatartaric 
acid in wine.
Since metatartaric acid is proposed as a winemaking additive, it is 
expected to be consumed by those of drinking age. The legal minimum age for 
drinking alcoholic beverages in most countries is 18 years, but the range is from 
16 to 21 years (IARD, 2016).
The Committee conducted international dietary exposure assessments 
for metatartaric acid in wine using the Global Environment Monitoring System 
– Food Contamination Monitoring and Assessment Programme (GEMS/Food) 
cluster diets database. Per capita wine consumption ranged from 0.24 to 88 g/
day across the 17 cluster diets (WHO, 2012). The per capita dietary exposure 
estimates for metatartaric acid ranged from 0.0004 (G14) to 0.2 mg/kg bw per 
day (G07), assuming a 60 kg average body weight and 100 mg/L of metatartaric 
acid as the maximum use level.
The Committee also prepared international estimates of dietary exposure 
to metatartaric acid using wine (14.2.3.1 “Still grape wine” and 14.2.3.3 “Fortified 
grape wine, grape liquor wine and sweet grape wine”) consumption levels from the 
FAO/WHO Chronic Individual Food Consumption Data – Summary statistics 
(CIFOCOss) database and 100 mg/L of metatartaric acid as the maximum use 
level. Estimates were based on 51 consumption datasets from 19 countries across 
eight GEMS/Food cluster diets (G05, G06, G07, G08, G09, G10, G11 and G15) 
were used.
Table 3 summarizes the exposure estimates to metatartaric acid for 
adults. The mean exposure estimates to metatartaric acid in wine for the adult 
population ranged from 0.000 07 to 0.2 mg/kg bw per day. This range was within 
the range calculated using data from the GEMS/Food cluster diets database. 
The maximum mean dietary exposure estimate to metatartaric acid for adult 
consumers of wine was 0.3 mg/kg bw per day, and the maximum 95th percentile 
dietary exposure estimate for adult consumers of wine was 0.8 mg/kg bw per day.
At the national level, the mean and 95th percentile dietary exposures for 
the United States adult consumers of wine to metatartaric acid were 0.1 and 0.3 
mg/kg bw per day, respectively. The Committee also estimated dietary exposures 
to metatartaric acid using the consumption data of wine for Australian and 
New Zealand adults and the maximum use level of 100 mg/L metatartaric acid. 
The estimated dietary exposures to metatartaric acid for 95th percentile adult 
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consumers of wine were 1.3 mg/kg bw per day for both Australians and New 
Zealanders.
The Committee assumed that metatartaric acid hydrolyses to an 
approximately equivalent concentration of tartaric acid. The Committee noted 
that the dietary exposure to metatartaric acid for the highest 95th percentile adult 
consumers of wine (1.3 mg/kg bw per day, expressed as L(+)-tartaric acid) is 
appropriate for use in this safety assessment.
4. Comments
4.1 Biochemical aspects
(a) Metatartaric acid
Metatartaric acid, a dispersed polymer of tartaric acid units linked together by 
ester bonds, is anticipated to undergo rapid enzyme-mediated hydrolysis to L(+)-
tartaric acid once exposed to carboxylesterases in the gastrointestinal tract.
(b) L(+)-Tartaric acid
The disposition of L(+)-tartaric acid following ingestion appears to differ markedly 
between most of the animal species investigated (rats, rabbits, dogs and pigs) and 
humans. In rats, rabbits, dogs and pigs, most of the ingested tartrate is absorbed 
and excreted unchanged (50–100%) in the urine (Underhill et al., 1931a; Gry 
Group
Mean total population
(mg/kg bw per day)
Mean consumers of wine
(mg/kg bw per day)
95th percentile consumers 
of wine
(mg/kg bw per day)
CIFOCOss 0.000 07–0.2 0.004–0.3 0.02–0.8
Australiana 0.08b – 1.3b
New Zealandc 0.05b – 1.3b
USA adultsd – 0.1 0.3
Table 3
estimates of dietary exposure to metatartaric acid in wine in adults (CIfoCoss data plus 
Committee-prepared estimates)
bw: body weight; CIFOCOss: FAO/WHO Chronic Individual Food Consumption Database – Summary statistics
a 0.05 L/day for mean respondents irrespective of whether they consumed wine, and 0.8 L/day for 95th percentile consumers of wine.
b  Using an average body weight of 60 kg/person.
c 0.03 L/day for mean respondents irrespective of whether they consumed wine, and 0.75 L/day for the 95th percentile consumers of wine. Consumption data from the 
1995 Australian National Nutrition Survey.
d  66 g/day (1.1 g/kg bw per day) for mean USA adult consumers of wine and 200 g/day (3.4 g/kg bw per day) for 95th percentile adult consumers of wine from the 
1997 New Zealand National Nutrition Survey food consumption data.
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& Larsen, 1978). The extent of absorption and urinary excretion of unchanged 
tartrate in guinea-pigs (13–27%) is similar to that observed in humans (12%) 
(Underhill et al., 1931b; Chadwick et al., 1978).
In rats, 15–22% of ingested tartrate was exhaled as carbon dioxide. 
Microbial fermentation was confirmed following intracaecal administration, 
when 66% of the administered dose (18.8 mg/kg bw) was exhaled as radiolabelled 
carbon dioxide, while less than 2% of the administered dose was absorbed and 
excreted in urine (Chasseaud, Down & Kirkpatrick, 1977; Chadwick et al., 1978). 
In rats, the concentration–time curve for radiolabelled L(+)-tartrate suggested a 
short half-life in plasma of around 3 hours (Down et al., 1977).
Apart from its excretion in urine, there is evidence of extensive microbial 
fermentation of L(+)-tartaric acid to carbon dioxide in humans: very little 
unchanged tartrate (<5%) has been detected in faeces. Although the concentration 
of radiolabelled carbon dioxide exhaled by humans 1 hour after intravenous 
dosing was small (18%), suggesting metabolism by tissue enzymes, up to 46% of 
the label was exhaled 4 hours after oral dosing (Chadwick et al., 1978).
4.2 Toxicological studies
(a) Metatartaric acid
No acute toxicity studies were available.
Rats exposed to metatartaric acid in their drinking-water at concentrations 
up to 3.0% for 18 weeks had markedly reduced body weight due to a dose-related 
reduction in feed and water intake, owing to the poor palatability of metatartaric 
acid in water at all concentrations tested (Ingram et al., 1982). As a result, the 
Committee considered this study to be unsuitable for a risk assessment of 
metatartaric acid.
Metatartaric acid was not genotoxic in a reverse mutation assay.
No long-term toxicity and carcinogenicity, reproductive toxicity or 
developmental toxicity studies were available.
(b) L(+)-Tartaric acid
The LD50 of sodium tartrate in mice was reported to be 4360  mg/kg bw; for 
disodium tartrate in male rabbits, it was greater than 3680 mg/kg bw (Locke et 
al., 1942).
The Committee noted that no new long-term toxicity studies had 
become available since the previous evaluation of L(+)-tartaric acid. However, 
the previously unpublished toxicity study that supports the ADI for tartaric 
acid had since been published. In that study, no treatment-related adverse 
effects were observed in rats with diets containing monosodium L(+)-tartrate at 
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concentrations of 0, 25 600, 42 240, 60 160 or 76 800 mg/kg bw (reported to be 
equal to L(+)-tartaric acid doses of 0, 710, 1220, 1840 and 2460 mg/kg bw per 
day for males and 0, 930, 1600, 2360 and 3200 mg/kg bw per day for females, 
respectively) (Hunter et al., 1977). The Committee noted that the conversion 
reported in the publication used the molecular weight for disodium tartrate 
rather than monosodium tartrate to calculate the doses of L(+)-tartaric acid. 
Using monosodium tartrate, the Committee calculated the doses to be 0, 770, 
1400, 1900 and 2680 mg/kg bw per day for males and 0, 1030, 1780, 2630 and 
3550 mg/kg bw per day for females, respectively. The Committee concluded that 
the NOAEL for L(+)-tartaric acid in the study was 2680 mg/kg bw per day, the 
highest tested dose.
In two in vitro assays including reverse mutation (S. typhimurium 
strains TA92, TA1535, TA100, TA1537, TA94 and TA98) and chromosomal 
aberration (Chinese hamster fibroblast cell line), L(+)-tartaric acid showed no 
genotoxic potential at concentrations up to 1 mg/mL. However, although sodium 
L(+)-tartrate was negative in the reverse mutation assay, it was positive in a 
chromosomal aberration test at high concentrations of up to 15 mg/mL (Ishidate 
et al., 1984). The Committee noted that no testing of potential cytotoxicity was 
performed and that gaps had been counted in the chromosomal aberration test. 
The Committee concluded that these factors call into question the reliability of 
this study. In addition, the related compound, L(+)-tartaric acid, at 1 mg/mL was 
shown to be negative in the same assay. Sodium L(+)-tartrate was also negative 
using single intraperitoneal doses up to 3600 mg/kg bw in an in vivo micronucleus 
test in mice (Hayashi et al., 1988).
4.3 Assessment of dietary exposure
The sponsor requested the use of metatartaric acid as a food additive in wine 
at a maximum use level of 100 mg/L. The Committee conducted international 
dietary exposure assessments for metatartaric acid in wine using the GEMS/
Food cluster diets database. The dietary exposure estimates for metatartaric acid 
ranged from 0.0004 (G14) to 0.2 mg/kg bw per day (G7) (per capita), assuming 
a 60 kg body weight and 100  mg/L of metatartaric acid as the maximum use 
level. The Committee also prepared international estimates of dietary exposure 
to metatartaric acid using wine (food category no. 14.2.3.1 “Still grape wine” and 
food category no. 14.2.3.3 “Fortified grape wine, grape liquor wine and sweet 
grape wine”) consumption levels from the CIFOCOss database and 100 mg/L 
of metatartaric acid as the maximum use level. The estimates of mean dietary 
exposure to metatartaric acid for adult consumers of wine ranged up to 0.3 mg/kg 
bw per day, and the highest 95th percentile dietary exposures in adult consumers 
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of wine reached 0.8 mg/kg bw per day. The Committee prepared dietary estimates 
to metatartaric acid in wine using consumption data from the 1995 Australian 
National Nutrition Survey, the 1997 New Zealand National Nutrition Survey and 
the USA National Health and Nutrition Examination Surveys, with the maximum 
use level of 100 mg/L. These estimates were 1.3, 1.3 and 0.3 mg/kg bw per day for 
the 95th percentile exposures for adult consumers of wine, respectively.
The Committee assumed that metatartaric acid hydrolyses to an 
approximately equivalent concentration of tartaric acid. The Committee noted 
that the dietary exposure to metatartaric acid for the highest 95th percentile adult 
consumers of wine (1.3 mg/kg bw per day, expressed as L(+)-tartaric acid) is 
appropriate for use in this safety assessment.
5. evaluation
As metatartaric acid undergoes enzymatic hydrolysis to tartaric acid prior to 
systemic absorption, the biochemical and toxicological data on tartaric acid 
considered at previous meetings are relevant to the safety assessment of the 
metatartaric acid. Additional information to support the safety assessment of 
metatartaric acid includes the absence of any effects in a bacterial reverse mutation 
test. The Committee evaluated a series of studies that had become available since 
L(+)-tartaric acid was last evaluated. The body of evidence suggests no change 
to the group ADI previously established for L(+)-tartaric acid and its sodium, 
potassium and potassium–sodium salts, expressed as L(+)-tartaric acid.
The Committee concluded that metatartaric acid (when used in 
winemaking) should be included in the group ADI of 0–30 mg/kg bw for L(+)-
tartaric acid and its sodium, potassium and potassium–sodium salts, expressed 
as L(+)-tartaric acid.
The Committee noted that the dietary exposure estimate for metatartaric 
acid for adult consumers of wine was 4% of the upper bound of the ADI, and 
concluded that dietary exposure to metatartaric acid in wine at the maximum use 
level of 100 mg/L does not present a health concern.
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1. explanation
Tamarind seed polysaccharide (Chemical Abstract Service [CAS] Number 39386-
78-2) is produced from the hulled seeds of Tamarindus indica Linne. Tamarind 
seed polysaccharide is a xyloglucan. Xyloglucans are a type of dietary fibre 
naturally present in the cell wall of plants and are abundant in rice, vegetables 
and fruits (Shibuya & Iwasaki, 1978; Kato & Matsukura 1994; Kato, 1995; Kato, 
Ito & Watanabe, 2001). Tamarind seed polysaccharide is permitted for use as a 
thickener, stabilizer, emulsifier and gelling agent in a variety of food products in 
China, Japan, the Republic of Korea and the USA.
Tamarind seed polysaccharide (Fig. 1) has not been previously evaluated 
by Joint FAO/WHO Expert Committee on Food Additives (JECFA). The 
Committee evaluated tamarind seed polysaccharide at the request of the Forty-
eighth Session of the Codex Committee on Food Additives (FAO/WHO, 2016). 
A toxicological dossier for tamarind seed polysaccharide was submitted. 
A comprehensive literature search was also conducted. The keywords used in 
the searches included tamarind OR glyloid OR glyate OR Imlees OR Imli or 
Imlis OR 39386-78-2 (CAS Registry Number). The databases searched included 
EMBASE (1974–2017 February 6; 480 records); Ovid MEDLINE (1946–2017 
February 07; 210 records); CAB Abstracts (1973–2017 Week 4), Food Science and 
Technology Abstracts (1969–2017 Week 5)   and Global Health and International 
Pharmaceutical Abstracts (1970–2017 February 07), which retrieved 123 records; 
SCOPUS (to 7 February 2017; 33 records); and Reactions Weekly (Ovid journals; 
1 record). None of the records retrieved added to the toxicological data submitted 
to the Committee for this meeting.
To address any data gaps, the Committee also considered safety data on 
other polysaccharide-based gums on the basis of their similar general structure, 
chemical and functional properties, technical uses, lack of absorption as intact 
substances and metabolism to normal dietary constituents (e.g. short-chain fatty 
acids) as a result of microbial fermentation in the large intestine.
1.1 Chemical and technical considerations
The tamarind tree is a large evergreen widely distributed in subtropical and 
tropical zones (Williams, 2006). T. indica L. is a monotypic genus and belongs to 
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the subfamily Caesalpinioideae of the family Leguminosae (Fabaceae). The seeds 
of the tamarind fruit are smooth, glossy, flattened and oblong-shaped (Duke, 
1981). Tamarind seed polysaccharide is also known as tamarind seed gum, 
tamarind gum, tamarind xyloglucan, tamarind seed xyloglucan and tamarind 
galactoxyloglucan. 
Every part of the T. indica L. tree is used as food or in traditional 
medicine in most tropical countries (De Caluwé, Halamová & Van Damme, 
2010). Traditional uses in food rely on the aroma and flavouring properties of 
the tamarind fruit, in its fresh or dried form. It is also used in herbal medicinal 
therapies (Williams, 2006). 
Tamarind seed polysaccharide is produced from tamarind seeds that are 
sieved and toasted to remove the black testa (seed coat). The light brown tamarind 
kernel obtained is then pulverized and sieved to obtain tamarind kernel powder. 
The kernels contain 65–72% carbohydrate (polysaccharide and free sugars), 15–
23% protein, 4–7% fat, 2–3% ash and 0.7–8% crude fibre, reported on a dry matter 
basis (Duke, 1981). The tamarind kernel powder is treated with methanol, and the 
pH is adjusted during treatment; this is followed by centrifugation to physically 
separate the insoluble tamarind seed polysaccharide from the supernatant, which 
contains the protein, fat and minerals. The polysaccharide is dried, pulverized, 
sieved and mixed with bulking agents to standardize the product. Depending on 
the pH treatment, downstream filtration, and acid or alkali treatment, products 
differing by viscosity can be manufactured. 
Tamarind seed polysaccharide is composed of a linear chain of D-glucose 
units linked by β(1–4) glycosidic bonds. Single D-xylose units are attached to 
about 75% of these D-glucose units via α(1–6) bonds. Single D-galactose units 
are attached to some of the D-xylose units through β(1–2) bonds. The molar ratio 
Fig. 1
structural formula of tamarind seed polysaccharide
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of glucose:xylose:galactose is about 4:3:1 (Gidley et al., 1991). The tendency of 
xyloglucans to self-associate gives rise to a wide range of reported molecular 
weights (400–6000 kDa) (Nishinari et al., 2009). 
2. Biological data
2.1 Biochemical aspects
Absorption, distribution, metabolism and excretion data for tamarind seed 
polysaccharide were not available. Based on the size and chemical composition, 
it was considered that tamarind seed polysaccharide, like other dietary fibres, 
would not be absorbed intact and would not be digested by enzymes in the 
gastrointestinal tract (Cummings & Englyst, 1987). Based on its chemical 
composition, tamarind seed polysaccharide is likely to be degraded and fermented 
by intestinal bacteria in the lower gastrointestinal tract. It has been estimated 
that more than 75% of tamarind seed polysaccharide is fermented (Ministry of 
Health, Labour and Welfare, 2003). 
This fermentation process, similar to that of other nondigestive 
polysaccharides such as locust (carob) bean gum, cassia gum and tara gum, 
would yield hydrogen gas, carbon dioxide and short-chain fatty acids. All of these 
products would be expected to be absorbed, metabolized or excreted. 
Evidence supporting such a fermentation process includes the results of 
a 14-day dietary study in rats, which showed that oligosaccharides of tamarind 
seed polysaccharide generate short-chain fatty acids (specifically, lactic acid, 
propionic acid and butyric acid) in greater amounts in the caeca of test animals 
than is generated by control rats fed a non-fibre diet (Ebihara & Nakamoto, 
1998). In vitro studies demonstrated that human microflora can also degrade 
and ferment tamarind seed polysaccharide (Hartemink et al., 1996). Specific 
bacteria in the large intestine in humans are capable of enzymatic hydrolysis of 
the glucan backbone of xyloglucans, which lead to degradation and subsequent 
fermentation (Hartemink et al., 1996; Larsbrink et al., 2014). 
2.2 Toxicological studies
The toxicological tests summarized below used commercially available products. 
The manufacturing process for tamarind seed polysaccharide product has 
changed with time, such that the earlier products contained about 80% dietary 
fibre and the later products about 85% dietary fibre. The remaining 15–20% of the 
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tamarind seed polysaccharide product consisted of water, carbohydrates, protein 
and fat—normal dietary constituents that are not expected to pose a health 
concern. 
2.2.1 Acute toxicity
Acute oral toxicity studies were conducted with tamarind seed polysaccharide 
(purity: 80.8% tamarind seed polysaccharide) in mice and rats of both sexes. The 
results are summarized in Table 1. The highest dose tested in these studies was 
5000 mg/kg body weight (bw), the limit of the test. 
In all the studies, the animals received a single oral dose of tamarind seed 
polysaccharide after fasting overnight and were observed for 2 weeks (with the 
exception of the 1-week-long Isozaki & Yoshida, 1962–1964, study). No deaths, 
clinical signs of toxicity or gross pathologies were observed in any of the studies. 
Tamarind seed polysaccharide was considered to have very low acute oral toxicity 
in mice and rats. The oral median lethal dose (LD50) in mice and rats was greater 
than 5000 mg/kg bw or 4000 mg/kg bw when corrected for purity.
With one exception (Hachiya et al., 1985), the authors of the studies 
did not provide a statement on good laboratory practice (GLP) or of guidelines 
followed. 
2.2.2 Short-term studies of toxicity
(a) Mice 
In a 13-week range-finding study for a 78-week carcinogenicity study, Sano et al. 
(1996) fed  groups of male and female B6C3F1 mice (10/sex per group; 5 weeks old) 
diets containing tamarind seed polysaccharide (purity: 80.8%) at concentrations 
of 0, 0.625%, 1.25%, 2.5% or 5% for 13 weeks (equal to 0, 1000, 1900, 3900 and 
8200 mg/kg bw per day for males and 0, 1300, 2700, 5400 and 10 600 mg/kg bw 
per day for females, respectively). Although the study was performed prior to 
the establishment of Organisation for Economic Co-operation and Development 
(OECD) GLP or study guidelines, it was considered to be well-conducted. 
Animals were observed daily for mortality and clinical signs of toxicity, 
and were weighed weekly. Feed and water consumption were monitored over a 
2-day period prior to each weighing. Prior to termination, animals were fasted 
overnight and blood samples were collected for haematological and blood 
chemistry measurements. Haematological measures included erythrocyte counts, 
leukocyte counts, haemoglobin concentrations and haematocrit values. Blood 
chemistry parameters assessed included total protein, albumin, albumin/globulin 
ratio, aspartate transaminase, alanine transaminase, alkaline phosphatase, total 
bilirubin and urea nitrogen. At termination, necropsies were conducted, organs 
weighed (brain, heart, liver, spleen, kidneys, adrenals, testes and ovaries) and 
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histopathology performed (on the organs listed above as well as on lymph nodes, 
bone marrow, thymus, tongue, salivary glands, oesophagus, stomach, duodenum, 
jejunum, ileum, caecum, colon, rectum, pancreas, gall bladder, urinary bladder, 
prostate, seminal vesicle, mammary gland, uterus, vagina, femur, sternum, skin, 
subcutis, eyes, Harderian glands, spinal cord and all grossly visible lesions). A 
full histopathological examination was conducted only in control and 5% groups.
There were no deaths or clinical signs of toxicity. No treatment-related 
adverse effects were observed with respect to body weights or feed or water 
consumption. The study authors stated that no haematological treatment-related 
effects were observed (no data were provided). Blood chemistry findings showed 
a very slight but statistically significant decrease in total protein levels in males at 
0.625%, 2.5% and 5% groups (i.e., not in the 1.25% group) compared with controls 
(data not provided). The authors considered these findings not toxicologically 
significant because no other blood chemistry changes were observed. No 
treatment-related changes were observed at necropsy, including gross pathology, 
organ weight or histopathology.
In the absence of any toxicologically relevant findings, the no-observed-
adverse-effect level (NOAEL) was a dietary concentration of 5%, equal to 8200 
and 10 600 mg/kg bw per day for males and females, respectively, or 6600 and 
8600 mg/kg bw per day when corrected for purity (Sano et al., 1996). 
Table 1
Acute toxicity of tamarind seed polysaccharide
Species Sex Route LD50  (mg/kg bw) Reference
Mouse Male Oral >1 500 Isozaki & Yoshida (1962–1964)a
Mouse Male and female Oral >5 000 Hachiya et al. (1985)b
Mouse Male and female Oral >5 000 Noda et al. (1988)c
Mouse Male and female Oral >2 000 Takizawa, Hachiya & Birukawa (1993)d
Rat Male and female Oral >5 000 Hachiya et al. (1985)e
Rat Male Oral >5 000 Noda et al. (1988)f
Rat Male and female Oral >5 000 Noda et al. (1988)g
bw: body weight; LD50: median lethal dose; OECD: Organisation for Economic Co-operation and Development
a  Groups of ICR-JCL male mice (6/group; 30 g bw) received a single oral dose of tamarind seed polysaccharide at 1000 or 1500 mg/kg bw. Animals were observed for 7 
days. 
b  According to the authors, the test was conducted in compliance with United States Environmental Protection Agency or OECD guidelines. Groups of ddY mice (≥5–
10/sex per group; 5–7 weeks old) received a single gavage dose of tamarind seed polysaccharide of up to 5000 mg/kg bw. 
c  Groups of ddY mice (10/sex per group; 4 weeks old) received a single gavage dose of tamarind seed polysaccharide at 0 or 5000 mg/kg bw (vehicle not described). 
d  Groups of ddY mice (5/sex per group; 9 weeks old) received a single gavage dose of tamarind seed polysaccharide at 0 (vehicle: distilled water) or 2000 mg/kg bw.
e  According to the authors, the experiment was conducted in compliance with United States Environmental Protection Agency or OECD guidelines. Groups of Sprague 
Dawley rats (≥5–10/sex per group; 5–6 weeks old) received a single gavage dose of tamarind seed polysaccharide. 
f  Groups of male Wistar rats (5/group; 4 weeks old) received a single gavage dose of tamarind seed polysaccharide at 5000 mg/kg bw. 
g  Groups of Sprague Dawley rats (5/sex per group; 4 weeks old) received a single gavage dose of tamarind seed polysaccharide at a dose of 5000 mg/kg bw.
171
Tamarind seed polysaccharide 
(b) Rats
In a 4-week study, Oka et al. (1962–1964) fed groups of male Donryu rats (10/
group; mean bw 100 g) diets containing tamarind seed polysaccharide (purity: 
80.8%) equivalent to doses of 0, 200 or 2000 mg/kg bw per day. The study was 
conducted prior to the establishment of OECD GLP or study guidance documents. 
The animals were monitored daily for mortality. Feed consumption 
and body weights were measured daily. Immediately prior to termination, 
blood samples were drawn for haematology measures including red blood 
cell concentration, white blood cell concentration, Sahli value (an indication 
of haemoglobin concentration) and haematocrit. Three animals in the control 
group died on day 17 of the study (no explanation for the deaths was given). 
The study authors did not report differences between treated and control 
groups in body weight, feed consumption or haematological measures; the 
graphical data they presented did not show a difference (no statistical analysis 
was provided). At necropsy, a mild pneumonia was seen in two animals dosed 
at 200 and three at 2000 mg/kg bw per day. According to the study authors, no 
treatment-related lesions were observed at necropsy (no data were provided). 
In the absence of any observed toxicity, the NOAEL was 2000 mg/kg bw 
per day, equal to 1620 mg/kg bw per day when corrected for purity (Oka et al., 
1962–1964).
In a 4-week study, groups of Crl:SD CD IGS rats (10/sex per group; 7–8 
weeks old) were given ad libitum diets containing tamarind seed polysaccharide 
(purity: 85.5%; lot number: 12.02.28-1) at concentrations of 0, 40 000, 80 000 
or 120 000 mg/kg feed (equal to 0, 3451, 6739 and 10 597 mg/kg bw per day for 
males and 0, 3602, 7190 and 10 691 mg/kg bw per day for females, respectively). 
The study was conducted according to OECD and United States Food and 
Drug Administration (USFDA) GLP requirements and in compliance with the 
appropriate guidelines. 
Animals were observed at least twice daily for viability and were clinically 
examined prior to the first treatment and weekly thereafter until termination. 
Ophthalmological examinations were conducted according to the guidelines. 
Body weight was recorded on the first day of treatment and weekly thereafter and at 
termination. Body weight gain was calculated at weekly intervals and for the overall 
study. Feed consumption was measured weekly and feed efficiency, including the 
mean daily dietary intakes, were calculated. A functional observational battery 
was performed, and motor activity of all animals was assessed at week 4. Blood 
samples were collected to assess haematology and blood chemistry parameters 
and urine samples for urine analysis at weeks 2 and 4. Vaginal smears from all 
females were assessed microscopically to determine the animal’s estrus stage. At 
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termination, all surviving animals were euthanized and necropsied. A standard 
set of organ wet weights was recorded. Samples of organs and other standard 
tissues as well as organs and tissues from the control and high-dose groups and 
any gross lesions from any group underwent histopathological examination. 
All animals survived until study termination. All clinical observations 
seen in control and treated groups in both sexes were considered incidental and 
neither treatment- nor dose-related. All ophthalmological examinations were 
normal. Mean body weights of treated males and females did not differ significantly 
from those of control groups. However, there was a statistically significant 
decrease in mean body-weight gain in males at 80 000 (−14%; P  <  0.05) and 
120 000 mg/kg feed (−26%; P < 0.001) compared with controls during the first 
week of treatment only. The only statistically significant differences in feed 
consumption and feed efficiency occurred during the first week of treatment when 
mean daily feed consumption decreased in high-dose females (−10%; P < 0.01) 
and mean feed efficiency decreased in high-dose males (−15%; P < 0.001). These 
differences were transient and possibly due to the palatability of the feed; the 
differences were not considered toxicologically relevant. The findings from 
the functional observational battery and the motor activity assessments were 
comparable in treated and control groups. 
Haematological, blood chemistry and urine analysis results were 
comparable in treated and control groups. Statistically significant differences 
between treated and control groups were slight and not dose-dependent. 
Gross necropsy findings occurred in single incidences and/or showed no dose 
relationship. Statistically significant decreases in absolute and relative organ 
weights occurred in adrenals and uterus with oviducts, but these findings were 
all within the range of historical control values found in the literature; were not 
dose-dependent; and were not associated with any clinical or histopathological 
changes. These differences were considered incidental and toxicologically 
insignificant. No microscopic findings were associated with treatment. The 
vaginal smears showed no cyclic changes that could be considered treatment-
related.
In the absence of any toxicologically significant findings, the NOAEL 
for tamarind seed polysaccharide was 120 000 mg/kg feed (equal to 10 597 and 
10 691 mg/kg bw per day for males and females, respectively, or 9113 and 9194 
mg/kg bw per day, when corrected for purity), the highest concentration tested 
(Heimbach et al., 2013; Koetzner, 2013).
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2.2.3 Long-term studies of toxicity and carcinogenicity
(a) Mice
In a 78-week carcinogenicity study, Sano et al. (1996) fed groups of male and 
female B6C3F1 mice (n = 50/sex per group; 6 weeks old) diets containing 
tamarind seed polysaccharide (purity: 80.8%) at concentrations of 0, 1.25% or 5% 
for 78 weeks (equal to 0, 1474 and 6658 mg/kg bw per day for males and 0, 2185 
and 8575 mg/kg bw per day for females). The study was conducted prior to the 
establishment of OECD GLP or study guidelines documents, but was consistent 
with OECD Test Guideline 451 for carcinogenicity (2008). 
Animals were observed daily for mortality and clinical signs of toxicity, 
and weights and feed and water consumption were measured once a week for the 
first 14 weeks and every 2 weeks thereafter. Immediately before termination, all 
animals were fasted overnight and blood samples were collected. Haematological 
parameters assessed included erythrocyte counts, leukocyte counts, haemoglobin 
concentrations and haematocrit values. Blood chemistry and urine analyses were 
not performed. At termination, each animal was necropsied and examined for 
gross changes. Brain, heart, liver, spleen, kidneys, adrenals, testes and ovaries 
were weighed and the organ to body weight ratio calculated for each. Bone 
marrow, caecum, colon, duodenum, eyes, femur, gall bladder, Harderian glands, 
ileum, jejunum, mammary gland, lungs, lymph nodes, oesophagus, pancreas, 
parathyroids, pituitary, prostate, rectum, thymus, thyroids, tongue, trachea, 
salivary glands, seminal vesicle, skin and subcutis, sternum, stomach, urinary 
bladder, uterus, vagina, spinal cord and all grossly visible lesions underwent 
histopathological examination. Missing from the standard suite of organs and 
tissues were the following: cervix, coagulating gland, epididymis, lacrimal gland, 
peripheral nerve and skeletal muscle. All males and females in the control and 5% 
groups underwent complete histological examination; histological examination 
of mice at 1.25% was restricted to spleen, lungs, liver, gall bladder, kidneys and 
all abnormal tissues.
The percentage survival of mice to 78 weeks did not significantly differ 
between treated and control groups. At 0, 1.25% and 5%, 46, 46 and 43 males and 
50, 48 and 48 females survived. There were also no significant differences between 
treated and control groups with respect to clinical signs of toxicity. While mean 
body weights of males did not significantly differ between treated and control 
groups, the mean body weights of females at both doses were lower than that of 
the control group from week 34; by termination at week 78, mean female body 
weights were statistically significantly reduced, in a non-dose-related manner, 
by 11% for the low-dose group and 7% for high-dose group compared with 
the controls (Table 2). The study authors stated that there were no significant 
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differences in feed or water consumption between treated and control groups 
(data not provided). 
Haematological examinations showed a statistically significant decrease 
in the haemoglobin concentration in males at 5% (−5%; no statistics provided); 
the authors considered this not toxicologically significant as there were no 
significant changes in other haematological parameters. No other haematological 
differences were reported.
The absolute organ weight data were not presented. Relative organ weight 
data are shown in Table 2. The organ to body weight ratios in treated males did 
not differ statistically from the controls with the exception of kidney weights in 
the 1.25% dose group (−6%, P < 0.01). However, the difference was considered 
slight, and likely reflected the marginal increase in body weights in this group 
compared with controls. Several organ to body weight ratios were statistically 
significantly increased in females at 1.25% and 5% compared with controls, 
including the brain, heart, liver, spleen and kidneys. The differences were not 
dose-related. The study authors suggested that these differences were due to the 
reduced body-weight gain in the treated females, and the Committee noted that 
the effects on relative organ weights correlated with the non-dose-related effects 
on body weight. Necropsy findings showed no significant difference between 
treated and control groups in terms of gross pathology or histopathology. 
All tumours were consistent with the type, severity and incidence 
expected in aged mice. The incidence of tumours was generally singular, with 
the exception of tumours in the lung, stomach, liver, mammary gland, uterus and 
lymphoma (Table 3). The study authors stated that nonneoplastic lesions in the 
Sex Dose No. of mice
Final body 
weight (g)a
Relative organ weight (%)a
Brain Heart Liver Spleen Kidney
M 0 46 38.8 ± 3.3 1.28 ± 0.12 0.56 ± 0.07 4.4 ± 1.3 0.27 ± 0.12 1.71 ± 0.14
1.25% 46 39.6 ± 4.0 1.26 ± 0.14 0.54 ± 0.08 4.7 ± 1.8 0.29 ± 0.14 1.61 ± 0.19**
5% 43 38.2 ± 3.8 1.32 ± 0.13 0.55 ± 0.07 4.7 ± 1.6 0.27 ± 0.12 1.66 ± 0.16
F 0 50 43.3 ± 7.0 1.25 ± 0.22 0.36 ± 0.06 3.3 ± 0.4 0.27 ± 0.08 0.97 ± 0.15
1.25% 48 38.5 ± 6.5** 1.41 ± 0.24** 0.43 ± 0.11** 3.8 ± 0.9** 0.40 ± 0.48 1.14 ± 0.025**
5% 48 40.2 ± 4.7* 1.33 ± 0.17* 0.40 ± 0.06** 3.6 ± 0.4** 0.31 ± 0.11* 1.04 ± 0.11*
Table 2 
Mean (± sD) terminal body weights and relative organ weights in male and female B6Cf1 
mice per dietary dose of tamarind seed polysaccharide
M: male; F: female; No: number; SD: standard deviation; *: P < 0.05; **: P < 0.01 Student t-test
a Mean ± SD.
Source: Sano et al. (1996)
175
Tamarind seed polysaccharide 
treated groups were similar to those in both male and female controls (no data 
were provided).
Based on the absence of carcinogenicity and dose-related systemic 
toxicity, the NOAEL was 5%, equal to 6658 and 8575 mg/kg bw per day for males 
and females, respectively, or 5380 and 6929 mg/kg bw per day when corrected for 
purity (Sano et al., 1996).
(b) Rats
Groups of Sprague Dawley rats (20/sex per group; 8 weeks old) were given diets 
containing tamarind seed polysaccharide (purity: 80.8%) at concentrations of 0, 
4%, 8% or 12% for 104 weeks (equal to 1.2–2.5, 2.3–5.3 and 3.8–8.3 g/kg bw 
per day for males and 1.4–3.1, 3.0–6.7 and 4.7–9.4 g/kg bw per day for females, 
respectively). The study was not described as having been conducted according 
to GLP or OECD guidelines. 
Species
Incidence per dose and sexa
Male Female
Control 1.25% 5% Control 1.25% 5%
Liver
Hepatocellular adenoma 5 3 6 0 0 0
Hepatocellular carcinoma 3 7 5 0 0 0
Haemangioma 0 2 2 0 0 0
Lung
Adenoma 2 3 0 0 0 2
Adenocarcinoma 1 1 0 0 0 0
Mammary gland
Fibroadenoma NA NA NA 0 2 0
Haematopoietic system
Malignant lymphoma / 
leukaemia
3 1 0 0 NA 0
Stomach 
Papilloma 1 1 2 0 1 0
Uterus
Endometrial stromal polyp NA NA NA 8 4 11
Table 3
Incidence of tumours in male and female B6Cf1 mice  per dietary dose of tamarind seed 
polysaccharide
NA: not assessed
a Number of occurrences observed in all the mice (n = 50, except the females at 5%, where n = 49). Exceptions included sex-specific observations and findings that 
were not seen in the control or high-dose group.
Source: Sano et al. (1996)
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The animals were observed daily for mortality and signs of clinical 
toxicity. Body weight and feed consumption were recorded every fourth week. 
Animals in extremis were euthanized. All animals were necropsied. Organ 
weights were recorded for all animals, and organ to body weight ratios were 
calculated for brain, heart, lung, liver, kidney, spleen, pituitary, thyroid, adrenal 
gland, testis, ovary and uterus. Organ and tissue samples of heart, aorta, lung, liver, 
kidney, urinary bladder, spleen, pancreas, tongue, submaxillary gland, stomach, 
mesentery, thyroid, adrenal, parathyroid, testis, prostate, bone, skeletal muscle, 
colon, ovary, uterus, bone femur and bone marrow were histopathologically 
examined. Blood samples taken by heart puncture at termination were chemically 
analysed for glucose, calcium, inorganic phosphorus, urea nitrogen, creatinine, 
cholesterol, total protein, albumin, albumin/globulin ratio, total bilirubin, 
lactate dehydrogenase, alkaline phosphatase, aspartate aminotransferase, alanine 
aminotransferase, sodium, potassium and chlorine. Additional blood samples 
were taken from amputated tail segments to assess haematological parameters, 
which included red blood cell concentration, haemoglobin concentration, 
haematocrit, clotting time, white blood cell concentration and differentiation of 
white blood cells. Urine samples were collected from animals housed in metabolic 
cages for 18 hours at weeks 6, 19, 31, 43, 57, 67, 85 and 104 for males and 6, 
18, 30, 44, 58, 70, 85 and 103 for females. Urine analysis included assessment of 
urine volume as well as protein, urea nitrogen, creatinine, sodium, potassium and 
chlorine concentrations.
Survival, though poor, did not differ significantly in treated and control 
groups; in the control, 4%, 8% and 12% groups, 25%, 55%, 35% and 55% of males 
and 55%, 65%, 60% and 40% of females, respectively, survived to 104 weeks. No 
explanation was given for the higher than expected death rate in the male control 
group. Almost all animals survived up to week 70, after which survival decreased 
(Table 4). Control group males had the poorest survival; 65% survived at week 
81 whereas all other groups had at least 80% survival. There was no dose-related 
effect on survival. 
The authors stated that no differences in clinical signs of toxicity  between 
the treated and control groups were observed (limited information provided). 
There were no significant differences between the treated and control 
groups with respect to mean body weights and mean feed consumption (feed 
consumption data not provided).
Iida et al. (1978) reported that males consumed between 1.2 and 2.5, 2.3 
and 5.3, and 4.3 and 8.3 g/kg bw per day and females between 1.5 and 3.1, 3.4 and 
6.7 and 5.4 and 9.4 g/kg bw per day, respectively, at 4%, 8% and 12%. Based on 
data in the original laboratory report (Iida et al., 1977), the Committee calculated 
weighted averages for the different dose groups and sexes. Accordingly, at 4%, 8% 
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and 12%, males consumed 1.62, 3.29 and 5.15 g/kg bw per day and females 1.93, 
4.00 and 6.07 g/kg bw per day, respectively. 
Individual and mean body weights and organ weights were presented 
separately for surviving animals and for animals that died during the study. In 
surviving animals, there was no dose-related effect observed with body or organ 
weight differences in either sex.
Histopathological findings were presented for all animals, as well as 
separately for surviving animals and animals that died during the study. All 
effects were age-related and none were treatment-related. Statistically significant 
differences between treated and control male groups were observed in the 
incidences of nephropathy and seminiferous tubule atrophy, but the incidence 
in the treated groups was lower than in the control groups and the effect was 
not dose-related. No other statistically significant differences were observed in 
males. A statistically significant difference between treated and control female 
groups was observed in the incidence of myocardial degeneration. An increased 
incidence was only observed in the 8% dose group and not the higher 12% dose 
group, and therefore the effect was considered not treatment-related. No other 
statistically significant differences between treated and control females were 
observed with respect to histopathological findings. 
Tumour incidences were presented for all animals, as well as separately 
for surviving animals and for most animals that died or were killed in extremis 
during the study. The most frequently  observed tumours were considered age-
related and typical of this strain of rat (e.g. pituitary adenomas, mammary gland 
Weeks
No. of surviving rats
Male Female
Control 4% 8% 12% Control 4% 8% 12%
0–4 20 20 20 20 20 20 20 20
69–72 18 17 19 17 19 18 19 16
73–76 16 17 16 17 19 18 19 16
77–80 13 16 16 17 19 18 19 16
81–84 13 16 16 17 18 17 19 16
85–88 12 14 16 16 18 16 19 15
89–92 11 14 14 16 16 16 17 12
93–96 9 13 9 15 15 14 17 10
97–100 7 11 8 13 13 13 13 10
101–104 5 11 7 11 11 13 12 8
Table 4
survival of rats fed tamarind seed polysaccharide in the diet for 2 years
no: number
Source: Iida et al. (1978)
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tumours). No statistically significant increases in any tumour type were observed 
in treated males or females compared with controls except for the total incidence 
of mammary tumours in females at 4%, which nevertheless was not considered 
treatment-related. 
Haematological assessment showed no statistically significant differences 
between treated and control groups with respect to any measured parameter in 
either sex. Blood chemistry assessment showed a statistically significant decrease 
in alkaline phosphatase activity in males at 12% compared with controls (−9%; 
P < 0.05). Statistically significant decreases in alanine transferase activity and blood 
urea nitrogen in females at 4% and 12% and a statistically significant reduction 
in potassium in females at 8% compared with the controls were observed. The 
study authors considered these changes slight and not toxicologically relevant 
as they were inconsistent with adverse reactions (i.e. decreases were observed). 
Urinary protein decreased statistically significantly in males at 12% compared 
with controls (−46%; P  <  0.05), although this decrease was not considered 
toxicologically relevant. No urine analysis effects were observed in treated 
females. 
Based on the absence of carcinogenicity and lack of dose-related systemic 
toxicity, the NOAEL was the highest concentration tested, equal to 5150 mg/kg 
bw per day for males and 6070 mg/kg bw per day for females, or 4161 and 4904 
mg/kg bw per day, respectively, when corrected for purity (Iida et al., 1978). 
2.2.4 Genotoxicity
The results of four in vitro genotoxicity assays with tamarind seed polysaccharide 
are summarized in Table 5. One bacterial reverse mutation study (Schreib, 2012; 
reported in Heimbach et al., 2013) was conducted in compliance with GLP 
and OECD Test Guideline 471 (1997), whereas another (Miyabe, 1993) was 
conducted in compliance with Japanese Ministry of Labour guidelines. Neither 
Kurita (1993) nor Ishidate, Sofuni & Kishi (1985), respectively, specified if the 
DNA repair assay and chromosomal aberration assay they conducted were GLP 
or guideline compliant. The test results were negative in all the assays. 
Despite the limitations of some of these assays (e.g. solubility at higher 
concentrations), based on the negative results and the absence of chemical 
structural alerts the Committee concluded that there was no genotoxic concern 
with tamarind seed polysaccharide.
2.2.5 Reproductive and developmental toxicity
No data were available from specific studies on reproductive or developmental 
toxicity. Short- and long-term studies in mice and rats found no treatment-
related adverse effects on reproductive tissues. 
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2.2.6 Special studies – Allergenicity
The potential antigenicity of tamarind seed polysaccharide and tamarind kernel 
powder was assessed in sensitized guinea-pigs (Dainippon Pharmaceutical Co., 
Ltd, 1963) and in isolated guinea-pig intestinal tract using the Schultz-Dale 
method (on exposure to an antigen, contraction of smooth muscle, possibly 
due to histamine release, is considered an early step in a general anaphylactic 
reaction) (Geiger & Alpers, 1959).
Guinea-pigs (200–300 g bw; number and sex of animals per group 
and maintenance conditions not stated) were sensitized with tamarind seed 
polysaccharide (2% solution; purity 80%; no more than 3% protein), tamarind 
kernel powder (2% solution of commercial tamarind kernel powder; range of 
protein 16.9–22.7%) or egg albumen (0.2% solution) by three intraperitoneal 
injections of 0.5 mL/animal per day every other day for an unstated number 
of days (possibly 2 days of injections, based on the Schultz-Dale method). The 
animals were subjected to further experimentation 3 weeks after the last injection. 
A group of nonsensitized animals were also included.
Sensitized and nonsensitized guinea-pigs were challenged with a single 
intraperitoneal injection of a 2% tamarind seed polysaccharide or tamarind kernel 
Test system Test object Concentration / dose (purity) Result Reference
Reverse 
mutation 
Salmonella typhimurium TA98, 
TA100, TA1535 and TA1537
Escherichia coli WP2uvrA
0, 10.0, 31.6, 100, 316, 1 000, 2 500 and 5 000 μg/plate
(purity: 85.5%; lot no. 12.02.28-1) 
Negative Schreib (2012)a
Reverse 
mutation
S. typhimurium TA98 and TA100 0, 0.2, 0.5, 1, 2, 5, 10 and 20 mg per plate 
(purity: 80.8%) 
Negative Miyabe (1993)b
DNA repair Bacillus subtilis H17 and M45 15.6, 31.3, 62.5, 125, 250 and 500 μg per disc
(purity: 80.8%)
Negative Kurita (1993)c
Chromosomal 
aberration
Chinese hamster lung derived 
fibroblast cells
Maximum 2.0 mg/mL
(purity: 80.8%) 
Negative Ishidate, Sofuni 
& Kishi (1985)d
DNA: deoxyribonucleic acid
a Plate incorporation and preincubation methods were used with and without metabolic activation (S9 liver microsomal fraction derived from male Sprague Dawley 
rats induced with phenobarbital/β-naphthoflavone). The solvent control was distilled water. A specific positive control was used for each tester strain and for each 
metabolic condition (i.e. with or without metabolic activation). Precipitation was observed in all tester strains when concentrations were 316 µg/plate or higher 
(with or without metabolic activation). No cytotoxicity was observed at any concentration tested.
b Preincubation method used with and without metabolic activation (S9 liver microsomal fraction derived from Sprague Dawley rats induced with phenobarbital/β-
naphthoflavone). The solvent control was distilled water. No positive control was used. Two plates were tested at each concentration of the test material, and six plates 
were used for the solvent control. Summary data were provided. 
c Assay was conducted with and without metabolic activation (S9 liver microsomal fraction derived from male Sprague Dawley rats induced with phenobarbital/β-
naphthoflavone). The solvent control was sterile pure water. A positive control was used with or without metabolic activation (tryptophan pyrolysate 1 and mitomycin 
C, respectively). Detailed data were provided.
d The test material was incubated with the test object for 48 hours. The percentage of chromosomal structural aberrations was determined in 100 metaphases. The 
solvent control was physiological saline. No positive control was used. The authors noted that higher concentrations could not be tested due to problems with 
solubility. Summary data were provided. 
Table 5
results of genotoxicity assays with tamarind seed polysaccharide
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powder solution (0.5 mL/animal). Animals sensitized to tamarind kernel powder 
solution showed signs of mild anaphylactic shock, which included stimulated 
respiration, mild hiccups, incontinence and piloerection. Animals sensitized to 
tamarind seed polysaccharide and nonsensitized animals did not react to any 
challenge (Dainippon Pharmaceutical Co., Ltd, 1963).
Geiger & Alpers (1959) conducted an ex vivo experiment using a 
Magnus instrument and the Schultz-Dale method. Strips of intestinal tract 
from sensitized and nonsensitized guinea-pigs were assessed for their reactivity 
(ability to contract) to solutions of egg albumen, tamarind seed polysaccharide or 
tamarind kernel powder (all treatments used 0.2 mL of 2% solutions). Intestinal 
movements were recorded for 3 minutes after treatment with each of the 
solutions. Intestinal strips from animals sensitized with egg albumen or tamarind 
kernel powder reacted when treated with a corresponding solution. Intestinal 
strips from animals sensitized with tamarind seed polysaccharide did not react 
with a corresponding solution. Intestinal strips from nonsensitized animals did 
not react with any of the test solutions.
The authors of the study concluded that under the test conditions, 
tamarind kernel powder was antigenic and that tamarind seed polysaccharide 
was not. 
The Committee considered the study of poor scientific quality and that it 
did not contribute to this safety assessment.
2.3 Observations in humans
Tamarind kernel powder is used as a sizing agent in textile and paper industries. 
Published case reports describe acute respiratory reactions in industry workers 
after inhalation of tamarind seed kernel powder (Murray, Dingwall-Fordyce & 
Lane, 1957; Tuffnell & Dingwall-Fordyce, 1957). The Committee considered 
these findings not relevant to this dietary exposure assessment. 
No reports were found on food allergies or food intolerance following 
ingestion of tamarind seed polysaccharide. Given its long time use in several 
countries and the absence of reported intolerances or food allergies, either these 
populations have developed tolerance or allergy or intolerance to tamarind seed 
polysaccharide is uncommon.
In a randomized, open-label, parallel group, multicentre, controlled 
clinical study (Gnessi et al., 2015), individuals with acute diarrhoea (50/group) 
ingested two oral capsules containing xyloglucan (origin and description of 
xyloglucan not stated) and gelatine (Tasectan Plus®; 100 mg xyloglucan and 250 
mg gelatine per capsule) every 6 hours for 3 days (to a total of 800 mg xyloglucan 
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per person per day) or another treatment (diosmectite or Saccharomyces 
boulardii). Xyloglucan was well tolerated and not associated with any adverse 
event. 
Due to the insufficient description of the products used in this study, the 
Committee did not consider this study useful for safety assessment.
3. Dietary exposure 
3.1 Dietary exposure estimates
The Committee received an assessment of dietary exposure to tamarind seed 
polysaccharides from one sponsor in response to the call for data. 
3.1.1 Budget method 
The Committee concluded that no screening by the budget method would be 
appropriate for this assessment.
3.1.2 Production volume data
The per capita dietary exposure to tamarind seed polysaccharide in Japan 
was calculated based on the quantity produced in 2011 (787 370 kg), the total 
population of Japan (128 million) and a food wastage rate, assumed to be 20%. 
The body weight used was 55.1 kg, based on the mean body weight of the adult 
Japanese population as specified by the Ministry of Health, Labour and Welfare 
(MHLW) and Food Safety Commission. Dietary exposure was estimated at 13.5 
mg/person per day (0.24 mg/kg bw per day for a person weighing 55.1 kg).
3.2 International estimates of dietary exposure
The Committee concluded that because tamarind seed polysaccharide (like all 
gums used for the same technical effects) is used exclusively in processed foods, 
it would be inappropriate to estimate exposure using the commodity-level food 
consumption data used to derive the Global Environment Monitoring System 
– Food Contamination Monitoring and Assessment Programme (GEMS/Food) 
cluster diets. Therefore, there are no international estimates of exposure for 
tamarind seed polysaccharide. 
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3.3 National estimates of dietary exposure 
Two national estimates of dietary exposure to tamarind seed polysaccharide 
were submitted for review by the Committee: Japan and the USA. For the safety 
assessment, the Committee adjusted the dietary exposure estimates to account 
for the content of tamarind seed polysaccharide in the test articles (85%) using a 
factor of 0.85.
3.3.1 Japan 
Tamarind seed polysaccharide has long been available as a food additive in Japan 
and is used in many food products. The food categories and typical (0.1–0.5%) 
and maximum (0.2– 1.5%) use levels are based on use experience and study 
results for tamarind seed polysaccharide in Japan (Table 6). Tamarind seed 
polysaccharide usage is technologically self-limiting because food products 
become unacceptably viscous at higher usage levels. 
Estimates of dietary exposure to tamarind seed polysaccharide were 
made by combining the use levels with 2014 food consumption data from the 
Japanese National Health and Nutrition Survey (Ministry of Health, Labour and 
Welfare, 2014). In the survey, 3648 households were randomly selected from 300 
districts so that 8047 individuals aged 1 year and older participated. Both the 
typical and the maximum levels were combined with food consumption data 
for each category. The mean estimated dietary exposure per capita of tamarind 
seed polysaccharide was 39.5 mg/person per day (0.72 mg/kg bw per day for an 
individual weighing 55 kg) at the typical use level and 101.9 mg/person per day 
(1.85 mg/kg bw per day for an individual weighing 55 kg) at the maximum use 
level.
A market share factor of 5% was used to make these estimates, based 
on the assumption that tamarind seed polysaccharide production was only 
4.4% of all thickeners produced in Japan. The Committee concluded that the 
use of this factor was inappropriate as it does not take product brand loyalty 
into account. Consequently, the Committee considered the dietary exposures to 
be 20-fold higher than those submitted to the Secretariat: the mean, typical use 
dietary exposure would be 790 mg/person per day (14 mg/kg bw per day) and the 
maximum use dietary exposures would be 2.0 g/person per day (37 mg/kg bw per 
day). After adjusting for the 85% polysaccharide in the test articles, the dietary 
exposures were estimated to be 670 mg per person per day (12 mg/kg bw per day) 
and 1.7 g per person per day (31 mg/kg bw per day).
3.3.2 United States of America
Estimates of exposure to tamarind seed polysaccharide in the USA were prepared 
in a manner parallel to that used for the Japanese assessment. Food consumption 
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Food category
Codex GSFA food 
category number
Typical use level Maximum use level
mg/kg (%) mg/kg (%)
Cereals products Wheat flour / 
flour
Bread (except 
sweet bread)
07.0 3 000 0.3 5 000 0.5
Sweet bread 07.0 3 000 0.3 5 000 0.5
01.7 
02.4 
04.1.2.8 
05.1.3 
10.4
Udon and fresh 
Chinese noodles
06.4 3 000 0.3 5 000 0.5
Instant Chinese 
noodles
06.4 3 000 0.3 5 000 0.5
Pasta 06.4 3 000 0.3 5 000 0.5
Other flour 
products
06.6 3 000 0.3 5 000 0.5
Vegetables Pickles 04.2.2.3 5 000 0.5 10 000 1.0
04.2.2.7 
04.2.2.8
Fruit Jam 04.1.2.5 5 000 0.5 10 000 1.0
04.2.2.8
Fruit juice 
/ fruit 
beverages 
14.1.3 1 000 0.1  2 000 0.2
Fish and 
shellfish
Processed 
fish products
Tsukudani 
(boiled foods in 
sweetened soy 
sauce)  
09.2.4.1 5 000 0.5 10 000 1.0
Meat Meat Ham and 
sausages
08.2.2 3 000 0.3 10 000 1.0
08.3.2
08.3.3
Milk  Milk and 
dairy 
products  
Fermented 
milk and lactic 
acid bacteria 
beverages
01.2.1 1 000 0.1 5 000 0.5
Other dairy 
products
01.4
01.7
03.0 1 000 0.1 5 000 0.5
Confectionery Japanese 
traditional 
confectionery
04.2.2.6 5 000 0.5 15 000 1.5
06.5
Table 6 
food categories and use levels for tamarind seed polysaccharide in Japan
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Table 6 (continued)
Food category
Codex GSFA food 
category number
Typical use level Maximum use level
mg/kg (%) mg/kg (%)
Cakes, buns and 
pastries
07.0 1 000 0.1 5 000 0.5
Cookies 07.0 1 000 0.1 5 000 0.5
Other 
confectionery
04.1.2.5 5 000 0.5 10 000 1.0
Beverages Other 
beverages
Coffee and cocoa 01.1.2 1 000 0.1 2 000 0.2
Seasonings and 
spices
Seasonings Sauces 12.6 5 000 0.5 10 000 1.0
Mayonnaise 12.6 5 000 0.5 10 000 1.0
12.7
Other seasonings 12.5 2 000 0.2 10 000 1.0
12.9.2.3
Spices and 
others
12.4 1 000 0.1 10 000 1.0
GSFA: General Standard for Food Additives
data were taken from the 2003–2006 National Health and Nutrition Examination 
Surveys (NHANES) for all categories of food that might contain tamarind 
seed polysaccharide (CDC, 2006). A total of 16 783 individuals participated in 
the surveys during this period. These data were combined with the proposed 
maximum use levels for each category and summed to give a per capita 
estimate of the mean exposure. Market share was assumed to be 100%, and it 
was also assumed that all foods in each category would contain tamarind seed 
polysaccharide. As almost 100% of those surveyed consumed foods from at least 
one of the food categories in which tamarind seed polysaccharide is intended for 
use, the per capita exposures were identical to those for consumers. 
Tamarind seed polysaccharide exposure is concentrated in three food 
categories: beverages, flour products, and sauces and condiments. The estimated 
mean and 90th percentile daily exposures to tamarind seed polysaccharide were 
reported to be 2.6 and 4.4 g/person per day, respectively. Expressed in terms 
of body weight (60 kg), the estimated mean and 90th percentile daily dietary 
exposures were 45 and 91 mg/kg bw per day, respectively. Adjustment of these 
estimates to account for the 85% content of tamarind seed polysaccharide in the 
test articles gives estimates of 2.2 and 3.7 g/person per day for the mean and 90th 
percentiles, respectively (38 and 77 mg/kg bw per day). The food categories and 
proposed maximum use levels   for this analysis are shown in Table 7.
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Food category Examples
Codex GSFA 
food category 
number
Maximum use 
level (%)
Ice cream Ice cream, sorbet, gelato, frozen yogurt 01.7 
02.4
03.0
0.3
Sauces and condiments Barbecue, steak, demiglace, tomato, chilli, tabasco, curry, teriyaki, tare 
sauces; ketchup; gravy
Tonkatsu, korokke, yakisoba, okonomiyaki sauces
12.6
12.4
12.9.2.3
1.5  
Mayonnaise and dressings Mayonnaise, reduced fat mayonnaise; Caesar, French, Italian, Ranch, 
Thousand Island, wafu dressings
12.6
12.7
1.0
Fruit preserves Fruit spread, jam, jelly, apple sauce 04.1.2.5 0
4.1.2.8 0
4.1.2.9
1.0
Desserts Pudding, Bavarian cream, mousse 01.7
10.4
0.2
Beverages Fruit juice, reduced fat milk, cocoa drink 01.1.2 
06.8.1
14.1.3
14.1.4.2
0.2
Pickles Tsukemono (pickled foods), kimchi, pickled cucumber, pickled olives, 
pickled sauerkraut
04.2.2.3
04.2.2.7
1.0
Tsukudani (boiled foods in 
sweetened soy sauce)
Laver, mushroom and kelp tsukudani 04.2.2.8 1.0
Spreads and fillings Custard cream, spreads 01.6.1 
01.7
02.2.2
02.4
04.1.2.8
04.2.2.6
05.1.3
10.4
0.5
Flour products Bread, pastry, cake, instant noodles, ramen, udon, dough, batter 06.4 
06.6
07.0
0.5
Soups Broth, consommé, creamy soups 12.5 0.2
All other food categories 01.4
01.7
01.6.1 01.6.4
01.6.5
04.1.2.9
05.1.4 05.1.5
05.2.2
05.3 05.4 11.4 
12.6 13.4
13.5
0.5
Table 7
UsA food categories and maximum use levels for tamarind seed polysaccharide
GSFA: General Standard for Food Additives
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4. Comments
4.1 Biochemical aspects
Absorption, distribution, metabolism or excretion data were not available on 
tamarind seed polysaccharide. Based on its size and chemical composition, 
tamarind seed polysaccharide, like other dietary fibres, is not expected to be 
absorbed intact or digested in the gastrointestinal tract (Cummings & Englyst, 
1987). Based on its chemical composition, tamarind seed polysaccharide is 
expected to be enzymatically degraded and fermented by intestinal bacteria in 
the large intestine. The fermentation process would yield hydrogen gas, carbon 
dioxide and short-chain fatty acids, which could be absorbed and metabolized. 
It has been estimated that more than 75% of tamarind seed polysaccharide 
is fermented (Ministry of Health, Labour and Welfare, 2003). This extensive 
fermentation process is similar to that for other nondigestive polysaccharides, 
such as carob bean gum, cassia gum and tara gum.
Evidence supporting such a fermentation process includes the results of 
a 14-day dietary study in rats, which showed that oligosaccharides of tamarind 
seed polysaccharide generate short-chain fatty acids (specifically, lactic acid, 
propionic acid and butyric acid) in the caeca of test animals in greater amounts 
than in control rats fed a non-fibre diet (Ebihara & Nakamoto, 1998). In vitro 
studies demonstrated that human microflora can also degrade and ferment 
tamarind seed polysaccharide (Hartemink et al., 1996). Specific bacteria that 
colonize the large intestine in humans are capable of enzymatic hydrolysis of the 
glucan backbone of xyloglucans, which would lead to fermentation (Hartemink 
et al., 1996; Larsbrink et al., 2014).
4.2 Toxicological studies
All toxicological tests were conducted using a commercial product in which 
the purity of the tamarind seed polysaccharide was between 80% and 85%. The 
remaining 15–20% included water, carbohydrates, protein and fat, which are 
normal dietary constituents that are not expected to pose a toxicological hazard. 
Tamarind seed polysaccharide is of low acute oral toxicity in mice and rats. The 
LD50 in each of these species was greater than 5000 mg/kg bw (4000 mg/kg bw 
when corrected for purity).
No toxicity was observed in a 13-week study in mice at concentrations of 
up to 50 000 mg/kg feed (equal to 8200 mg/kg bw per day, or 6642 mg/kg bw per 
day when corrected for purity) (Sano et al., 1996). There were no toxicologically 
relevant effects in a 4-week dietary study of tamarind seed polysaccharide in rats 
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at concentrations up to 120 000 mg/kg feed (equal to 10 597 mg/kg bw per day, 
or 9113 mg/kg bw per day when corrected for purity) (Heimbach et al., 2013; 
Koetzner, 2013).
Similarly, no toxicologically relevant effects, including treatment-related 
tumours, were observed in a 78-week study in mice at concentrations of up to 
50 000 mg/kg feed (equal to 6658 mg/kg bw per day, or 5380 mg/kg bw per day 
when corrected for purity) (Sano et al., 1996). No treatment-related toxicity, 
including tumours, was observed in a 104-week study in rats at concentrations 
of up to 120 000 mg/kg feed (equal to 5150 mg/kg bw per day, or 4161 mg/kg bw 
per day when corrected for purity) (Iida et al., 1978). The highest doses tested 
in these toxicity studies routinely equalled or exceeded the recommended dose 
limit of 5% of the diet for rodent toxicity studies.
The Committee concluded that the pivotal study was the 104-week study 
in rats (Iida et al., 1978). This was a well-conducted study performed before the 
implementation of GLP. The NOAEL was 5150 mg/kg bw per day (corrected to 
4161 mg/kg bw per day for purity), the highest dose tested.
Tamarind seed polysaccharide tested negative in bacterial reverse 
mutation assays and in an in vitro chromosomal aberration assay. Despite the 
limitations of some of these assays (due to the poor solubility of the test substance 
at higher concentrations), based on the absence of chemical structural alerts and 
negative results, the Committee concluded that for tamarind seed polysaccharide, 
there was no concern with respect to genotoxicity.
No reproductive or developmental toxicity studies were conducted with 
tamarind seed polysaccharide. The Committee noted that histopathological 
analysis of reproductive organs from long-term feeding studies in mice and rats 
did not identify any effects on reproductive tissues. The Committee also noted 
that reproductive and developmental toxicity studies on other polysaccharide 
gums previously evaluated by the Committee did not raise concerns for 
reproductive or developmental effects. For example, when cassia gum was 
assessed in a two-generation reproductive toxicity study in rats, it was shown not 
to cause reproductive toxicity at 50 000 mg/kg feed (equal to 5280 mg/kg bw per 
day), the highest concentration tested. In a developmental toxicity study in rats, 
cassia gum did not cause embryotoxicity or teratogenicity at 1000 mg/kg bw per 
day, the highest dose tested. In a developmental toxicity study in rabbits, cassia 
gum did not cause any adverse effects on dams or numbers of implantations, 
postimplantation losses or fetal defects at 1000 mg/kg bw per day, the highest 
dose tested.
Based on the absence of histopathological effects on reproductive 
tissues in long-term rodent studies, the lack of absorption of intact tamarind 
seed polysaccharide, the degradation and fermentation of tamarind seed 
polysaccharide into normal dietary constituents, and the absence of reproductive 
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or developmental toxicity observed with other polysaccharide gums, the 
Committee concluded that tamarind seed polysaccharide would be unlikely to 
pose a concern with respect to reproductive or developmental toxicity.
4.3 Observations in humans
No reports were found on food allergies or food intolerance to tamarind seed 
polysaccharide, despite its long-term use in several countries.
4.4 Assessment of dietary exposure
The Committee received an assessment of dietary exposure to tamarind seed 
polysaccharide from one sponsor in response to the call for data.
Two national estimates of dietary exposure to tamarind seed 
polysaccharide were included in the sponsor’s submission and reviewed by the 
Committee: from Japan and the USA. These estimates of dietary exposure to 
tamarind seed polysaccharide were made by combining maximum use levels 
(assuming 85% polysaccharide in the commercial product) with 2014 food 
consumption data from the Japanese National Health and Nutrition Survey or 
with 2003–2006 food consumption data from USA National Health and Nutrition 
Examination Surveys. The estimated mean dietary exposure to tamarind seed 
polysaccharide ranged from 31 to 38 mg/kg bw per day, with the 90th percentile 
exposures up to 77  mg/kg bw per day. These estimates are conservative, in 
that it has been assumed that all products that might contain tamarind seed 
polysaccharide would contain the substance at the indicated maximum use levels. 
Tamarind seed polysaccharide would be likely to substitute for other gums.
The Committee concluded that the estimated dietary exposure of 75 mg/
kg bw per day was suitable for use in this safety assessment.
5. evaluation
5.1 Recommendations
The Committee established an acceptable daily intake (ADI) “not specified” for 
tamarind seed polysaccharide. This ADI was based on the absence of toxicity in 
repeated-dose animal studies of tamarind seed polysaccharide. These included 
long-term rodent studies in which mice were fed up to 6658  mg/kg bw per 
day (corrected to 5380  mg/kg bw per day, for purity) and rats were fed up to 
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5150 mg/kg bw per day in rats (corrected to 4161 mg/kg bw per day, for purity). 
In addition, there was no concern regarding genotoxicity. Reproductive toxicity 
and developmental toxicity were not considered a concern based on the lack 
of absorption of intact polysaccharide, the degradation and fermentation of 
tamarind seed polysaccharide into normal dietary constituents, and the absence 
of reproductive and developmental effects in other polysaccharide gums.
The estimated dietary exposure based on proposed uses and use levels 
was 75 mg/kg bw per day. The Committee concluded that this does not present a 
health concern.
A new specifications monograph and a Chemical and Technical 
Assessment were prepared.
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1. explanation
Yeast extracts containing mannoproteins are used as food additives in winemaking. 
Yeast mannoproteins are extracted from purified yeast (Saccharomyces cerevisiae) 
cell walls by enzymatic treatment with β-glucosidase or by physicochemical 
extraction with thermal treatment. Yeast mannoproteins are galactomannans 
consisting almost exclusively of mannose units bound to proteins or peptides.
The name was changed from “yeast mannoproteins” to “yeast extracts 
containing mannoproteins” because the name “yeast mannoproteins” was not 
adequately descriptive. The products in commerce are extracts containing yeast 
components and mannoproteins, and not pure mannoproteins. Yeast extracts 
containing mannoproteins have not been previously evaluated by the Committee. 
The compounds were evaluated at the present meeting at the request of the Forty-
eighth Session of the Codex Committee on Food Additives (FAO/WHO, 2016). 
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) call asked 
for data on yeast mannoproteins in general; however, the only data that were 
submitted related to their use as a food additive in winemaking.
Wine contains significant concentrations of tartrates that can crystallize 
and precipitate during storage, resulting in unwanted sediment. Wine also 
contains small amounts of protein, which can produce a haze. Although yeast 
mannoproteins occur naturally in wine due to yeast fermentation, they are also 
added to inhibit the crystallization of tartrates and stabilize the proteins in the 
wine after bottling and during storage.
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Yeast mannoproteins are approved for treatment of wine in Argentina, 
Australia, Canada, the European Union (Commission Regulation (EC) No. 
2165/2005), New Zealand and the USA.
The sponsor submitted a dossier summarizing technological, 
toxicological and dietary exposure information relevant to the evaluation of yeast 
mannoproteins from S. cerevisiae. In addition, a literature search for toxicity data 
performed using multiple databases and search terms resulted in approximately 
20 other potentially relevant papers. However, because few toxicological studies 
were available for yeast mannoproteins, relevant studies with S. cerevisiae, its 
constituents or substances derived from its fermentation were included in the 
assessment.
1.1 Chemical and technical considerations
Mannoproteins represent a large group of natural compounds from yeast (S. 
cerevisiae) in which polysaccharide chains are bound to proteins and peptides 
by covalent and noncovalent linkages (i.e. ionic interactions). The structures and 
molecular weights of mannoproteins vary, depending on the degree and type of 
glycosylation. The polysaccharide chains consist almost exclusively of mannose 
units linked by α-links forming a long α-1→6 linked backbone containing 
short α-1→2 and α-1→3 linked side-chains. Several of the side-chains may have 
phosphodiester linkages to other mannosyl residues. Yeast mannoproteins 
are extracted from purified yeast cell walls by enzymatic extraction using 
glucan 1,3-β-glucosidase (EC 3.2.1.58) or by thermal treatment. The enzyme 
hydrolyses the yeast cell wall, allowing the mannoproteins to be solubilized. The 
thermal treatment breaks the links with β-glucans in the cell wall to release the 
mannoproteins. The mannoproteins thus solubilized by either treatment are then 
separated from the insoluble cell wall material, concentrated and micro-filtered 
or ultra-filtered. The mannoproteins have molecular weights ranging from 20 
kDa to more than 450 kDa.
There was limited information available to the Committee to fully 
characterize the yeast mannoprotein products in products of commerce. 
Information and data about the chemical composition of the range of commercial 
yeast mannoprotein products are required. There are also limited data available 
on the levels of yeast mannoproteins in wine. Wine contains yeast mannoproteins 
from the fermentation process as well as those added for the purpose of 
precipitating tartrates. This results in potential levels higher than 400 mg/L of 
yeast mannoproteins in the wine.
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2. Biological data
2.1 Biochemical aspects
2.1.1 Absorption, distribution and excretion
In an in vivo study in rats (strain not indicated), Adrian & Frangne (1976) compared 
the digestibility of yeast cell walls in a control diet with one supplemented with 
20% dried yeast cell walls. The digestibility of the supplemented diet was 92%, 
close to that of the control diet. The digestibility of the nitrogenous content was 
particularly high, indicating that cell wall proteins were available to the digestive 
tract proteases.
In an in vitro study, Moine-Ledoux (2003) compared the effect of 
reconstituted intestinal fluid (at pH 7.5 and containing pancreatic enzymes) on 
dry active yeasts, yeast cell walls and mannoproteins. Following incubation in the 
reconstituted intestinal fluid, mannoproteins were released from active dry yeasts 
and yeast cell walls. Further analysis of the mannoproteins in the reconstituted 
intestinal fluid showed that mannoproteins behave like proteins in terms of 
digestibility.
2.1.2 Biotransformation
Once mannoproteins have been hydrolysed by intestinal enzymes, further 
fermentation of the glucomannan moiety can occur through the action of 
bacterial glycoside hydrolases (glucomannanases and endoglucanases) in the 
large intestine (Liu et al. 2010; Bâgenholm 2017). These glycoside hydrolases 
hydrolyse the glycosidic chain into oligo- or monosaccharides, which may be 
subsequently processed in the regular glycosidic pathway into, among others, 
organic acids or alcohols (den Besten et al., 2013a,b).
2.1.3 Effects on enzymes and other biochemical parameters
In a study using immortalized human hepatocytes (Fa2N-4 cells), Schauss 
et al. (2012) found that a fermentation product of S. cerevisiae did not induce 
cytochrome P450 (CYP) CYP1A2 or CYP3A4 messenger ribonucleic acid 
(mRNA) or enzymatic activity and did not interfere with the induction of 
CYP1A2 by omeprazole or of CYP3A4 by rifampin (also known as rifampicin). 
The test article used in this study was described as the product of a proprietary 
fermentation process using S. cerevisiae, involving “both a unique substrate 
and a stress process”. The test article, hereafter referred to as “yeast fermentate 
preparation”, was also tested in several toxicology studies conducted by Schauss 
et al. (2012) (described in section 2.2). The whole liquid fermentate was dried, 
resulting in a product that contained the same nutrient/vitamin profile, cell wall 
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components including mannoproteins, and stress-induced defence metabolites. 
However, a more complete chemical characterization of the test article was not 
available.
2.2 Toxicological studies
2.2.1 Acute toxicity
(a) Acute oral toxicity
In a good laboratory practice (GLP)-compliant study that conformed with 
Organisation for Economic Co-operation and Development Test Guideline 
(OECD TG) 423, Sprague Dawley rats (n = 10/sex) received a single dose of 2000 
mg/kg body weight (bw) of yeast fermentate preparation by gavage.
All treated rats survived to study end at day 15. No body-weight loss was 
noted and feed consumption was similar in treated and control rats. No clinical 
toxicological symptoms were observed and no gross pathological changes were 
found in the organs at necropsy (Schauss et al., 2012).
(b) Dermal irritation
In a GLP-compliant cutaneous irritation study conducted according to OECD 
TG 404, Richeux (2002ba) assessed the acute dermal irritant/corrosive effects of 
mannoproteins enzymatically extracted from S. cerevisiae yeast in albino New 
Zealand White rabbits. The test substance was applied (0.5 g) to the healthy skin 
of the right flank of each animal under a semi-occlusive dressing. On the left 
flank, and under the same conditions, 0.5 mL of distilled water was applied to an 
equivalent area of healthy skin. The cutaneous reactions were evaluated at 1, 24, 
48 and 72 hours after the dressing was removed.
No macroscopic cutaneous reaction (erythema, oedema) was observed 
in any of the animals (Richeux, 2002a).
(c) Eye irritation
In a GLP-compliant ocular irritation study conducted according to OECD TG 
405, Richeux (2002b) assessed the acute irritant/corrosive effect of mannoproteins 
enzymatically extracted from S. cerevisiae yeast by inserting the powder (0.1 g) 
directly into one eye of New Zealand White rabbits. The other eye served as 
control. Ocular reactions were evaluated at 1, 24, 48 and 72 hours after instillation.
Very mild ocular reactions (lachrymation and enanthema), limited to 
the conjunctiva, were observed 1 hour after application. These effects were totally 
reversed after 3 days (Richeux, 2002b).
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2.2.2 Short-term studies of toxicity
González Pereyra et al. (2014) administered a daily dose of 108 viable cells or 
colony forming units (cfu) of S. cerevisiae RC016 suspended in phosphate-
buffered saline (PBS) that was prepared daily to male Wistar rats (n = 6) by gavage 
for 60 days. There were no deaths or signs of illness. No changes were reported 
in the general health status of the animals, including behaviour, activity, posture, 
fur quality, feed and water intake. Histopathological examinations of liver, lungs, 
intestine and testes did not show any differences between treated and control 
animals (González Pereyra et al., 2014).
Schauss et al. (2012) conducted a GLP-compliant 90-day study in 
accordance with OECD  TG 408 in Sprague Dawley rats (n = 80/sex; n  =  20/
group). The animals received by gavage 0, 30, 200 or 1500 mg/kg bw per day of 
a yeast fermentate preparation in water containing 1% methylcellulose. Direct 
ophthalmological examinations were performed on five males and five females 
of each dose group prior to treatment and on all high-dose and control animals 
once during week 11 of treatment. After the last treatment, blood samples were 
taken and examined for haematological and clinical chemistry parameters. Urine 
analysis was carried out once during week 12 on 10 males and 10 females. All 
animals underwent necropsy on day 91 after a 16-hour fast. Organ weights were 
recorded and histopathological examinations performed.
There were no deaths. No treatment-related changes in general state, 
external appearance or behaviour were observed in any of the animals. There 
were no significant differences in body weight or body weight gain compared 
with the controls. Amounts of food and water consumed was similar in all treated 
and control male and female rats. No ophthalmological changes were observed 
in control or high-dose groups. No treatment-related differences in the visual 
(finger approach) or auditory (startle) reactivity, pain perception (tall pinch), 
grip strength or motor activity were observed during examination of male and 
female rats at week 11. No treatment-related effects were observed in red blood 
cells, white blood cells, haemoglobin, haematocrit or platelet count values. 
There were no changes in blood coagulation rates as seen in prothrombin time 
measurements. Clinical chemistry data determined at the end of the 90-day study 
did not indicate any treatment-related toxicity. Individual values and group mean 
values were within physiological ranges. There were no differences in the volume, 
specific gravity or pH of urine between control and treated groups; nor were there 
any differences in glucose, blood or protein concentrations in the urine.
Gross necropsy found no treatment-related lesions. The few sporadic 
pathological changes observed were not treatment related. Internal examination 
showed that subcutaneous tissue, regional lymph nodes, fatty tissue, skeletal 
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muscles, joints and bone system were normal in all animals. No differences in 
the actual organ weights or relative organ weights were noted, and no treatment-
related histopathological findings were observed. The test article was well 
tolerated at all doses for the duration of the 90-day study.
Based on these results, the no-observed-adverse-effect level (NOAEL) 
was 1500 mg/kg bw per day, the highest dose tested.
2.2.3 Long-term studies of toxicity and carcinogenicity
Schauss et al. (2012) conducted a GLP-compliant study, in accordance with 
the OECD TGs 408 and 452, in Sprague Dawley rats (n = 80/sex). The animals 
received 0, 20, 200 or 800 mg/kg bw per day of yeast fermentate preparation by 
gavage for 1 year. In addition to the examinations conducted as described in the 
90-day study by the same authors (section 2.2.2), blood samples were collected 
at weeks 14 and 33 and before necropsy. Urine analysis was performed during 
weeks 13, 32 and 52.
Macroscopic, microscopic, serum chemistry, haematological, and 
histological examinations and urine analysis found no clinically significant results. 
Overall, the test article was well tolerated at all doses. A statistically significant 
decrease in water consumption over nonconsecutive weeks in the highest dose 
group was considered not clinically relevant. The nonneoplastic histopathological 
findings were spontaneous or incidental and typical of this strain of rat. The 
authors considered the low incidence of benign tumours in the female rats to be 
unrelated to treatment because of the lack of statistical significance and because 
the incidences fell within the historical control ranges (6.3–32% for mammary 
gland adenomas and 26.0–92.86% for pituitary adenomas).
Based on the lack of treatment-related results, the NOAEL was 800 mg/
kg bw per day, the highest dose tested.
2.2.4 Genotoxicity
(a) In vitro
No evidence of genotoxicity was seen in a bacterial reverse mutation assay 
performed in accordance with OECD TG 471 on the yeast fermentate preparation 
(Ames test with Salmonella typhimurium strains TA97a, TA98, TA100, and 
TA1535, and Escherichia coli strain WP2 urvA [pKM101+], with and without 
metabolic activation). Similarly, no evidence of genotoxicity was seen in a mouse 
lymphoma cell mutagenicity assay conducted in accordance with OECD TG 476 
(mouse lymphoma L5178Y) (Schauss et al., 2012).
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(b) In vivo 
Madrigal-Santillán et al. (2010) examined the antigenotoxic effects of S. cerevisiae 
and its extracts using micronucleus assay, comet assay and sister chromatid 
exchange in mice. The researchers reported evidence for antimutagenic capacity 
of mannans (mannose with α-1,6 links and α-1,2 and α-1,3 branched side-
chains) and glucans (glucose with links α-1,6 links and β-1,2 and β-1,3) branched 
side-chains) against the genotoxic effects of antineoplastic compounds such as 
cyclophosphamide and mitomycin C (Madrigal-Santillán et al., 2010).
González Pereyra et al. (2014) fed male Wistar rats a commercial basal 
diet that provided a daily dose of 108 viable cells or cfu of S. cerevisiae RC016 
suspended in PBS (prepared daily) for 60 days. Genotoxicity and cytotoxicity 
were evaluated using the bone marrow micronucleus assay and the comet assay. 
Internal organs were macroscopically and microscopically examined.
Dietary administration of S. cerevisiae RC016 did not induce cytotoxicity 
or genotoxicity in rats (González Pereyra et al., 2014).
2.2.5 Reproductive and developmental toxicity studies
No data were available.
2.2.6 Special studies
(a) Allergenicity
A GLP-compliant sensitization study was conducted according to OECD TG 
406 using an extract containing mannoproteins enzymatically extracted from 
S. cerevisiae yeast in albino guinea-pigs (Richeux, 2002c). Preliminary tests 
showed no necrosis after intradermal injection at the highest dose (40%). Topical 
application kept under an occlusive dressing for 24 hours at the maximum dose 
of 100% induced no cutaneous reaction. In contrast, a topical application kept 
under an occlusive dressing for 24 hours at the maximum dose of 100% after 
intradermal induction with physiological serum and topical application of distilled 
water (negative control) induced a slight erythema in two animals treated with 
the highest dose. After the first release phase, a macroscopic cutaneous reaction 
was noted (moderate erythema) in 5% of the animals in the treated group (1/20), 
24 and 48 hours after removal of the occlusive dressing, at the 50% treated site. 
No reaction of cutaneous intolerance was observed in the negative controls or 
the 25% treated group. A second release phase was performed to confirm or 
invalidate these results after 11 days of rest. No macroscopic cutaneous reaction 
was noted following removal of the occlusive dressings.
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Posadas et al. (2010) reported that 10% and 15% administration of 
mannoprotein E1, a mannoprotein-rich product from S. cerevisiae, in a liquid 
diet had a protective effect on intestinal tissue in Wistar rats (n = 58) infected 
with S. typhimurium. This protection was expressed as a lower pro-inflammatory 
response, with decreased production of the pro-inflammatory cytokines 
interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and IL-1β, and 
downregulation of toll-like receptor 5 (TLR5) in gut epithelium, as well as by 
inhibiting apoptosis.
(b) Animal nutrition studies
Póo & Millán (1990) and Aziz et al. (1997) showed that substitution of 50% of 
the protein ration in feed with S. carlsbergensis cells had no metabolic effects. 
Accordingly, in the European Union, S. cerevisiae yeasts or lysates are permitted 
in animal feed for any species, with no restriction on the amounts used (Directive 
82/471/EEC and amendments; European Commission, 1982).
(c) Immune response
In a GLP-compliant study conducted in accordance with United States Food and 
Drug Administration (USFDA) guidelines, a yeast fermentate preparation was 
not mitogenic for human peripheral lymphocytes (Schauss et al., 2012).
Yuan et al. (2015) assessed the effects on immunity and uterine 
inflammation in transition cows of a yeast product derived from S. cerevisiae. 
Barn blocks of multiparous Holstein cows were randomly assigned to one of four 
treatments (n = 10/group) from 21 days before expected parturition to day 42 
postpartum. Rations were supplemented with a product containing yeast culture 
plus enzymatically hydrolysed yeast (YC-EHY) at 0, 30, 60 or 90 g/day throughout 
the experiment. Cows were injected subcutaneously with ovalbumin on day −21, 
−7 and 14 to assess their humoral immune response.
Concentrations of colostrum immunoglobulin G were unaffected by 
treatments. Platelet count was increased by addition of YC-EHY. Increasing 
YC-EHY dose directly correlated with increases in plasma anti-ovalbumin 
immunoglobulin G levels following three ovalbumin challenges, suggesting 
that the treatments resulted in an enhanced humoral immunity. Increasing YC-
EHY dose also correlated with quadratically increased faecal immunoglobulin 
A concentrations during early lactation. Uterine neutrophil counts were much 
greater in samples collected on day 7 than in those collected on day 42 (32.1 versus 
7.6 ± 3.5% of cells), reflecting neutrophil infiltration immediately after calving, 
but no treatment-related effect was detected. Significant day effects were detected 
for mRNA of IL-6, IL-8, neutrophil myeloperoxidase and neutrophil elastase in 
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the uterine samples, reflecting greater abundance of these transcripts collected on 
day 7 than on day 42. The mRNA abundance of neutrophil myeloperoxidase and 
neutrophil elastase increased linearly with YC-EHY dose.
The authors concluded that supplementation with YC-EHY enhanced 
humoral and mucosal immunity and modulated uterine inflammatory signals 
and mammary gland health in transition dairy cows.
2.2.7 Special studies on receptors
Mannose is important in protein glycosylation. Its involvement as a component 
of diverse glycoepitopes in intra- and intercellular immunological processes is 
gaining recognition (Loke et al., 2016). Like other galactomannans, mannoproteins 
can interact with the mannose receptor, a G-coupled protein expressed on the 
cell surface and in the cytoplasm of various cells (Wild, Robinson & Winchester, 
1983; Ezekowitz & Stahl, 1988; Tizard et al., 1989; Takahashi et al., 1998; Régnier-
Vigouroux, 2003). Mannose receptors are also present in a soluble form in 
serum. Mannose receptors are a collectin of the family of C-type lectins, which 
require calcium for efficient binding (Hansen et al., 2016); as mannose receptors 
are capable of specifically recognizing mannose, they are also called mannose-
binding lectin (Loh et al., 2017).
Mannose receptors bind mannose conjugated with structures such as 
polysaccharides and glycoproteins. They also bind free mannose, though less 
efficiently. Mannose receptors are expressed in the gastrointestinal tract and in 
a variety of cells (macrophages, dendritic cells and endothelial cells) in different 
organs (liver, spleen, lung, kidney, muscle, brain and the lymphatic system). 
Consequently, mannosylated proteins and mannose receptors may be involved 
in physiological mechanisms in the following ways:
 ■ Innate immunity: by recognizing and facilitating (acting as an 
opsonin) the uptake by macrophages of microorganisms that express 
mannose on their outer membranes (Cui, Hsu & Mumper, 2003) 
and by activating the complement system (van Asbeck et al., 2008; 
Beltrame et al., 2015), which may in turn induce inflammatory 
reactions (Yamamoto et al., 1997). But mannose receptors also 
facilitate entry of microorganisms (Takahashi et al., 2012; de Pasquale 
et al., 2013; Borggren & Jansson, 2015) into macrophages or dendritic 
cells.
 ■ Specific immunity: as mannose receptors expressed on dendritic cells 
contribute to the regulation of T-cell functionality (Burgdorf, Lukacs-
Kornek & Kurts, 2006; Li et al., 2010; Ramberg et al., 2010; Schuette 
et al., 2016).
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 ■ Intracellular calcium regulation: binding of mannose glycoproteins 
to mannose receptors may result in increased intracellular calcium 
levels (Blackmore & Eisoldt, 1999).
In conclusion, increased intake of mannoproteins may be beneficial 
(impaired fixation of bacteria on gastrointestinal epithelial cells leads to a 
decreasing risk of infection) or detrimental (blockage of mannose receptors on 
macrophages resulting in a decrease in their capacity to eliminate infectious 
organisms that have an outer membrane rich in mannose) (Allavena et al., 2004).
The Committee acknowledged that mannoproteins might have some 
physiological effects following their binding to mannose receptors. However, the 
interpretation and relevance of this effect is still a matter of research and the 
results of studies in this area were not considered in this evaluation.
2.3 Observations in humans
Jensen et al. (2015) studied the anti-inflammatory properties of a dried 
fermentate derived from S. cerevisiae in vitro using cell-based bioassays, and 
in healthy humans using a topical application of the fermentate. Treatment of 
primary human polymorphonuclear cells in vitro resulted in reduced formation 
of reactive oxygen species and migratory activity towards inflammatory mediator 
leukotriene B4. In vivo, inflammatory responses to histamine-induced skin 
inflammation were significantly reduced at the inflamed sites treated with dried 
fermentate compared with the sites treated with placebo based on subjective 
scores of irritation (P < 0.05).
Bansal, Tadros & Bansal (2017) reported a case of allergy to beer, wine 
and cider resulting from immunoglobulin E reactivity to yeasts and moulds. 
The authors concluded that although cases of yeast allergy are extremely rare 
in the medical literature, they may in fact be under-recognized and should be 
considered in patients with reactions to alcoholic beverages and other yeast-
containing products.
2.3.1 Special considerations – History of safe use of baker’s yeast and related 
products
S. cerevisiae and its products have a long history of safe use in foods and beverages 
such as beer, wine and cider, and as a dietary or nutritional supplement (among 
others, Tucker & Woods, 1995; Pretorius, 2000; Zhang et al., 2005; Owens & 
McCracken, 2007; Ciamponi, Duckham & Tirelli, 2012; Salari et al., 2013; 
Marongiu et al., 2015).
The European Food Safety Agency (EFSA) concluded that baker’s yeast is 
nontoxic and nonpathogenic (Pariza & Foster, 1983; Pariza & Johnson, 2001) and 
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that it is not a major food allergen. EFSA included baker’s yeast on the Qualified 
Presumption of Safety (QPS) list (EFSA, 2007).
The USFDA has approved dried yeast as an ingredient in food (21 C.F.R. 
5172.896), and “generally recognized as safe” (GRAS) notices (GRN) have been 
accepted by USFDA with no questions regarding the use of genetically modified 
yeasts as starter cultures for wine (GRAS GRN No. 120 and GRAS GRN No. 175). 
Baker’s yeast extract (21 C.F.R. s184.1933) has been affirmed by the USFDA as a 
GRAS flavouring agent and adjuvant at a level not to exceed 5% in food.
The Committee noted that most of the biological studies reported did 
not consider the variability in the composition of yeast mannoproteins (Lopez-
Solis et al., 2017) and their possible interactions with other wine components 
(Wu, Guan & Zhong, 2015; Mekoue Nguela et al., 2016).
3. Dietary exposure
Yeast extracts containing mannoproteins are proposed for use at a recommended 
use level of 200  mg/L and at a maximum level of 400 mg/L in food category 
14.2.3 “Grape wines” and its subcategories within the Codex General Standard 
for Food Additives (GSFA). Yeast mannoproteins also occur naturally in wine, 
foods including bread, pastries, beer and yeast extracts, and in yeast-containing 
food supplements. The concentration data for yeast mannoproteins naturally 
present in foods, as provided to the Committee, are shown in Table 1.
The Committee evaluated the sponsor’s submission and prepared 
international estimates of dietary exposure to yeast mannoproteins using the 
FAO/WHO Chronic Individual Food Consumption Database – Summary 
Food item
Concentration (mg/kg or mg/L)
Mean High
Beer 192 507
Bread and pastriesa 5 600 8 000
Yeast extracts 100 000 120 000
Wineb 350 500
Yeast-containing food supplements 16 000c
Table 1
Concentrations of yeast mannoproteins naturally present in food
a Based on the assumption that bread contains on average 3.5% yeast and up to 5% yeast (Cofalec, 2017), that 50% of yeast is cell wall and that 34% of the cell wall 
is released as mannoproteins. Note that the submission used a percentage of 16% of yeast mannoproteins in yeast (instead of 17%) to calculate the concentration of 
yeast mannoproteins in bread and pastries.
b Llauberes, Dubourdieu & Villettaz (1987); Dupin et al. (2000).
c The nature of this concentration, i.e. mean or high level, was not specified.
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statistics (CIFOCOss) in combination with the recommended and maximum 
use levels in wine and the background occurrence of yeast mannoproteins in 
wine, bread, pastries and beer. No consumption data on yeast extracts and 
yeast-containing food supplements were available in CIFOCOss. Since yeast 
mannoproteins are present in processed foods, the Committee concluded that 
the use of the commodity-based food consumption information from the GEMS/
Food Database cluster diets would not be appropriate for this evaluation.
3.1 Dietary exposure estimates based on food consumption data
3.1.1 Dietary exposure estimates submitted to the Committee by the sponsor
Two assessments of the dietary exposure to yeast mannoproteins, based on the 
following data, were made available to the Committee by the sponsor:
 ■ French consumption data on bread, pastries, wine and beer in adults, 
assuming a population with a high consumption of bread and wine 
and therefore potentially a high exposure to yeast mannoproteins; 
and
 ■ United States consumption data (90th percentile) on wine, beer, bread 
and pastries in adults, supplemented with estimated consumption of 
yeast extracts and yeast-containing food supplements.
Based on French food consumption data from the 1998–1999 Individual 
and National  French Food Intake (INCA) study on bread, pastries, wine and beer, 
the mean exposure to yeast mannoproteins from food and from yeast extracts 
containing mannoproteins added to wine at a level of 300 mg/L was estimated to 
be 1.7 g/day (Volatier, 2000). In this assessment, a mean background level of yeast 
mannoproteins in wine of 125 mg/L was used based on a French study of the 
presence of yeast mannoproteins in commercial food products (Moine-Ledoux, 
2003). Furthermore, it was assumed that bread and pastries contain 5% yeast 
and that 17% of the yeast consists of yeast mannoproteins. For beer, the mean 
concentration of 192 mg/L (Table 1) was used in the calculations.
Using food consumption data from the United States Department of 
Agriculture’s 1994 and 1995 Continuing Survey of Food Intakes by Individuals 
and 1994 and 1995 Diet and Health Knowledge Survey (Wilson et al., 1997) in 
combination with concentrations (high) of yeast mannoproteins in foods and in 
yeast-containing food supplements (mean or high concentration not specified; 
Table 1), the background exposure to yeast mannoproteins was estimated to be 
3.7 g/day.
Addition of yeast extracts containing mannoproteins to wine at the 
maximum level of 400 mg/L would result in a maximum additional exposure to 
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yeast mannoproteins of 0.02 g/day. This is about 0.5% of the estimated background 
exposure to yeast mannoproteins. The exposure to yeast mannoproteins via 
the intake of yeast-containing food supplements was estimated based on a 
recommended daily intake of 3.5 g according to the packaging label.
3.1.2 Dietary exposure estimates performed by Food Standards Australia New 
Zealand (FSANZ)
FSANZ performed a dietary exposure assessment of yeast mannoproteins for 
the Australian and New Zealand adult populations (≥18 years) based on food 
consumption data from the 1995 Australian National Nutrition Survey and the 
1997 New Zealand National Nutrition Survey (FSANZ, 2008). Estimated mean 
dietary exposures to yeast mannoproteins from all added and background 
sources, including bread, pastries, wine, beer and yeast extracts of were estimated 
to be 0.42 and 0.35 g/day for adults from Australia and New Zealand, respectively. 
For consumers with a high consumption of wine (95th percentile), estimated 
dietary exposures to yeast mannoproteins from wine and other sources were 0.74 
and 0.66 g/day, respectively. FSANZ used 125 mg/L as the mean background 
level of yeast mannoproteins in wine in their assessment and an added amount 
of 300 mg/L in wine in the high consumer scenario. The added amount used to 
assess the mean dietary exposure was not specified (FSANZ, 2008).
In the dietary exposure estimates provided by the sponsor and 
conducted by FSANZ, it was assumed that 100% of the yeast extracts containing 
mannoproteins added to wine was mannoproteins.
3.2 International assessment of the intake conducted by the 
Committee
3.2.1 Background concentration data
The Committee performed an international dietary exposure assessment of yeast 
mannoproteins using the background concentrations of yeast mannoproteins 
in food as listed in Table 1, excluding the concentrations in bread and pastries. 
Based on the assumption that bread contains on average 3.5% yeast (range: 2–5%; 
Cofalec, 2017) and that yeast contains 17% mannoproteins (assuming that 50% 
of yeast is the cell wall and 34% of the cell wall is released as mannoproteins), 
a mean concentration of yeast mannoproteins of 6000  mg/kg was used in the 
exposure assessment. The Committee noted that the background concentration 
of yeast mannoproteins in wine used in these exposure calculations is higher 
than the one used in the exposure calculations performed by the sponsor using 
the French consumption data (section 3.1.1) and by FSANZ (2008; section 3.1.2): 
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350 versus 125 mg/L. The Committee selected the highest reported level as part 
of a conservative approach.
3.2.2 Food consumption data and food mapping
The CIFOCOss1 contains summary statistics of 55 surveys from 36 countries. 
These surveys cover at least 2 survey days. The database provides summary 
statistics of food consumption for about 750 items at a high level of classification. 
The statistics are available for different age groups per survey, ranging from infants 
to very elderly adults. Dietary exposure to yeast mannoproteins was calculated 
using CIFOCOss datasets on food consumption by adolescents (10–18 years), 
adults (18+ years) and the general population (ages not specified).
United States food consumption data were excluded from the exposure 
assessment. For the USA, the only relevant consumption data available in 
CIFOCOss were for the food category 14.2.3.3 “Fortified grape wine, grape liquor 
wine and sweet grape wine”, resulting in very low exposure estimates for yeast 
mannoproteins compared with those of other countries included in CIFOCOss. 
Thai food consumption data for the general population were also not considered; 
no 95th percentile consumers of still grape wine were reported for this country.
Foods with concentration data (Table 1) were mapped to comparable 
food categories in CIFOCOss for the exposure assessment (Table 2). For yeast 
extracts and yeast-containing food supplements, no comparable food categories 
were present in the database. These sources of dietary exposure were therefore 
not considered in the exposure assessment using CIFOCOss.
3.2.3 Mean and high dietary exposure estimates
The Committee calculated a mean and high dietary exposure to yeast 
mannoproteins at a background level or with yeast extracts containing 
mannoproteins added to wine at the recommended or maximum use level. In 
these calculations, the Committee assumed that the yeast extracts (containing 
mannoproteins) were 100% mannoprotein.
(a) Mean dietary exposure
The mean background dietary exposure to yeast mannoproteins was calculated by 
combining a mean consumption of all relevant foods (Table 2) with the respective 
mean background concentration of yeast mannoproteins per food (Table 1), 
except for bread and pastries for which a mean concentration of 6000  mg/kg 
was used (section 3.2.1). The mean exposure to yeast mannoproteins, including 
yeast extracts containing mannoproteins added to wine, was estimated at the 
1 The January 2017 version was made available to the Committee by the World Health Organization.
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recommended use level of 200 mg/L, resulting in overall concentration of yeast 
mannoproteins in wine of 550 mg/L (background + added).
The mean background exposure to yeast mannoproteins ranged from 
0.1 to 21  mg/kg bw per day (Table 3). Addition of yeast extracts containing 
mannoproteins to wine at the recommended level resulted in an increase in the 
mean dietary exposure to yeast mannoproteins of less than 5% (<0.1–4.2%), 
except for adults and elderly adults in Finland. In these two population groups, 
the increase was 14% and 30%, respectively. However, despite this increase the 
overall (background + added) exposure to yeast mannoproteins remained low: 
0.4 and 0.1  mg/kg bw per day, respectively. The exposure varied significantly 
within population groups (Table 3). This reflected differences in the consumption 
of bread and pastries, which contributed at least 90% of the exposure to yeast 
mannoproteins in almost all datasets.
(b) High dietary exposure
The high background dietary exposure was calculated by combining a high 
consumption level (95th percentile of consumers) of “Still grape wine” (food 
category 14.2.3.1), the wine that was consumed at the highest levels, with the 
high background level of yeast mannoproteins in wine of 500 mg/L (Table 1). 
To assess a high exposure, including the addition of yeast extracts containing 
mannoproteins to wine, the maximum use level of 400 mg/L was added to the 
Table 2
Mapping foods to assess the dietary exposure to yeast mannoproteins using CIfoCoss
CIFOCOss: FAO/WHO Chronic Individual Food Consumption Database – Summary statistics
a Foods for which concentrations of yeast mannoproteins were available (Table 1) and could be mapped to comparable food categories within CIFOCOss.
b Level 3 code of CIFOCOss.
Fooda
CIFOCOss
Food codeb Food description
Beer 14.2.1 Beer and malt beverages
14.2.1.1 Beer of sorghum
14.2.1.2 Beer of millet
14.2.1.3 Beer of barley
14.2.1.6 Beer of maize
Bread and pastries 07.2.1 Cakes, cookies and pies (e.g., fruit-filled or custard types)
CP 0179a Wheat white bread
CP 0179b Wheat wholemeal bread
CP 1250 Rye bread
CP 5295 Corn bread
Wine 14.2.3.1 Still grape wine
14.2.3.3 Fortified grape wine, grape liquor wine and sweet grape wine
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high background level of yeast mannoproteins in wine resulting in an overall 
concentration of 900  mg/L. The other wine type coded in CIFOCOss (food 
category 14.2.3.3 “Fortified grape wine, grape liquor wine and sweet grape wine”) 
(Table 2) and the other foods (bread, pastries and beer) were included in the 
high exposure assessment by combining the mean consumption with a mean 
concentration of yeast mannoproteins per food.
The background exposure to yeast mannoproteins of consumers with 
a high wine consumption ranged from 2.5 to 21 mg/kg bw per day (Table 3). 
Addition of yeast extracts containing mannoproteins to wine at the maximum 
level of 400 mg/L resulted in an increase in yeast mannoprotein exposure ranging 
from <1‒30% per dataset (Table 3). The increase was significantly higher only 
among Finnish adults and elderly adults: 72% and 78%, respectively. This large 
increase was due to the relatively high consumption of wine in these two Finnish 
populations relative to the other sources of exposure to yeast mannoproteins. 
However, this increase did not result in an exposure to yeast mannoproteins 
outside the range of exposures estimated for the total group of adults present in 
CIFOCOss (Table 3): 4.3 and 5.0 mg/kg bw per day, respectively. In general, the 
highest increases in exposure were observed in the adult population (on average 
20%) because this population group consumes wine at the highest levels.
Population group
Mean total population
(mg/kg bw per day)
95th percentile consumer of wineb
(mg/kg bw per day)
Background
Background
+ added Background
Background
+ added
Adolescents
(10–18 years)
6.1–21 6.1–21 8.0–21 8.5–21
Adults
(18+ years)c
0.1–13 0.4–13 2.5–15 4.3–18
General populationd 5.1–7.8 5.1–7.8 6.3–11 7.2–13
bw: body weight; CIFOCOss: FAO/WHO Chronic Individual Food Consumption Database – Summary statistics
a Exposure estimates do not include potential exposure via yeast extract and yeast-containing food supplements.
b Based on 95th percentile consumption of food category 14.2.3.1 “Still grape wine” (consumers only) and mean consumption levels of the other relevant foods (total 
population).
c Including the population groups adults, elderly adults and very elderly adults within CIFOCOss;
d Ages included in the general population are not specified within CIFOCOss.
Table 3
estimated exposures to yeast mannoproteins via the dieta at a background level or with 
yeast extracts containing mannoproteins added to wine (background + added) based on 
CIfoCoss data
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(c) Overall
The estimated dietary exposures to yeast mannoproteins at the mean level 
increased less than 5% (relative to background estimates) after the addition 
of yeast extracts containing mannoproteins to wine at the recommended level 
of 200 mg/L. For adult consumers with a high wine consumption, the dietary 
exposure increased 20% on average after the addition of yeast extracts containing 
mannoproteins to wine at the maximum level of 400 mg/L. The highest estimated 
dietary exposure was 21  mg/kg bw per day in adolescents. Exposure to yeast 
mannoproteins was mainly determined by the consumption of bread and pastries, 
due to both the high consumption levels of these foods and a high concentration 
level (6000 mg/kg).
3.2.4 Exposure via yeast extracts and yeast-containing food supplements
The Committee did not consider the possible exposure to yeast mannoproteins 
via the consumption of yeast extracts and yeast-containing food supplements in 
the exposure assessments; no information on the consumption of these foods was 
available in CIFOCOss. To assess the possible exposure to yeast mannoproteins 
via yeast extracts, the Committee used a mean exposure to yeast mannoproteins 
of 0.15 g/day through this source as estimated by FSANZ for the adult populations 
of Australia and New Zealand (FSANZ, 2008). The highest exposure estimated 
to yeast mannoproteins was 21 mg/kg bw per day in adolescents (Table 3). For 
this population group, an additional exposure of about 3 mg/kg bw per day was 
calculated via the consumption of yeast extracts based on an average body weight 
of 52  kg in this population group (EFSA, 2012). Thus, the highest potential 
exposure in adolescents was estimated at 24 mg/kg bw per day.
For yeast-containing food supplements, the sponsor provided an intake 
level of 3.5 g/day (the recommended daily consumption on the packaging label) 
and a concentration level of 16 000 mg/kg (Table 1). However, the Committee 
considered this information to be unreliable, and did not quantify the exposure 
to yeast mannoproteins via this source.
3.3 Overall results of the dietary exposure estimates
Table 4 lists the estimated dietary exposures to yeast mannoproteins using food 
consumption data from France and the USA (as provided by the sponsor), 
those calculated by FSANZ (2008), and those calculated by the Committee. Due 
to the use of different background levels of yeast mannoproteins in wine, the 
exposure results are not completely comparable. In addition, the Committee also 
considered the exposure in adolescents whereas the other exposure estimates 
apply only to adults (≥18 years).
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The exposure based on the United States food consumption data was 
higher than the highest exposure calculated by the Committee. The reason 
for this is that high consumption levels of all foods were combined with high 
concentration levels of yeast mannoproteins (section 3.1). The exposure estimates 
of FSANZ and those based on French consumption data (section 3.1) were 
approximately within the range of the CIFOCOss estimates.
FSANZ (2008) estimated the exposure to yeast mannoproteins via bread 
and pastries by estimating first the consumption of yeast via these two foods 
based on recipes. Subsequently, the amount of yeast mannoproteins consumed 
was estimated by assuming that 17% of the yeast consists of mannoproteins. This 
difference in approach may also have contributed to the lower exposures reported 
by FSANZ (2008) compared with the Committee estimates. JECFA estimated the 
mean consumption of yeast via bread and pastries in adults (including the elderly 
and very elderly) at about 3 g/day within CIFOCOss (based on the assumption 
that bread and pastries contain 3.5% of yeast and an average adult weighs 60 kg). 
The amounts reported by FSANZ were about 1 g/day.
4. Comments
4.1 Biochemical aspects
No relevant absorption, distribution, metabolism or excretion studies were 
available for yeast mannoproteins. The Committee assumed that mannoproteins 
Sourcec
Exposure (mg/kg bw per day)a
Mean High
France 28 –
USA – 62
FSANZ 5.8–7.0 11–12.3
JECFA 3.4–24 7.3–24d
Table 4
estimated dietary exposures to yeast mannoproteins, including via the addition of yeast 
extracts containing mannoproteinsa to wine
bw: body weight; CIFOCOss: FAO/WHO Chronic Individual Food Consumption Database – Summary statistics; FSANZ: Food Standards Australia New Zealand; USA: 
United States of America.
a In all calculations, it was assumed that the yeast extracts (containing mannoproteins) were comprised of 100% mannoproteins.
b Exposure estimates for France and the USA, and of FSANZ were converted to exposure estimates per kg body weight by division with a body weight of 60 kg.
c Exposure estimates for France and the USA (provided by the sponsor), and those of FSANZ relate to adult populations (≥18 years). Exposure estimates calculated by 
the Committee include adolescents (10–18 years), adults (≥18 years) and the general population (age not specified in CIFOCOss).
d Including an additional exposure to yeast mannoproteins of about 3 mg/kg bw per day via the consumption of yeast extracts (section 3.2.4).
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extracted from S. cerevisiae in the test compound will behave similarly to those 
resulting from dietary exposure to the intact yeast or to other glucomannans 
consumed as part of a regular diet. Once mannoproteins have been hydrolysed 
by intestinal enzymes, the carbohydrate moiety can be fermented by intestinal 
microflora in the large intestine into, among others, organic acids or alcohols 
(den Besten et al., 2013a,b; Bâgenholm et al., 2017).
In a study using immortalized human hepatocytes (Fa2N-4 cells), a 
fermentation product of S. cerevisiae did not induce cytochrome P450 (CYP) 
CYP1A2 or CYP3A4 mRNA or enzymatic activity and did not interfere with 
the induction of CYP1A2 or CYP3A4 by omeprazole or rifampin (also known 
as rifampicin), respectively (Schauss et al., 2012). The test article used in this 
study was described as the product of a proprietary fermentation process using 
S. cerevisiae, involving “both a unique substrate and a stress process”. The test 
article, hereafter referred to as “yeast fermentate preparation”, was also tested 
in several toxicology studies. The yeast fermentate preparation is reported to 
contain cell wall components, including mannoproteins, components from the 
medium, fermentative by-products and stress-induced metabolites. However, a 
more complete chemical characterization of the test article was not available.
4.2 Toxicological studies
In male rats given a daily dose of 108 viable cells or cfu of S. cerevisiae RC016 
by oral gavage for 60 days, no treatment-related effects were reported (González 
Pereyra et al., 2014).
In a 90-day study, groups of male and female rats were given 0, 30, 200 or 
1500 mg/kg bw per day of a suspension of yeast fermentate preparation in water 
containing 1% methylcellulose. No deaths occurred, and no treatment-related 
changes in any of the parameters assessed at any dose were observed (Schauss et 
al., 2012).
Schauss et al. (2012) reported a chronic toxicity study in male and female 
rats administered 0, 20, 200 or 800 mg/kg bw per day of a suspension of yeast 
fermentate preparation in water containing 1% methylcellulose. No treatment-
related or clinically relevant findings were reported in any of the parameters 
assessed at any dose.
A yeast fermentate preparation was negative in a bacterial reverse 
mutation assay and in a mouse lymphoma cell mutagenicity test (Schauss et al., 
2012). Bone marrow micronucleus and comet assays were negative in male rats 
given 108 viable cells or cfu of S. cerevisiae RC016 daily for 60 days by oral gavage 
(González Pereyra et al., 2014).
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No data were available regarding the carcinogenicity and reproductive 
or developmental toxicity of material relevant to yeast extracts containing 
mannoproteins.
The only study available with yeast extracts containing mannoproteins 
gave a negative result in a dermal sensitization study conducted on albino guinea-
pigs (Richeux, 2002c).
Owing to the high content of mannose in yeast, the Committee assumed 
that yeast mannoproteins, like other galactomannans, can interact with mannose 
receptors (Tizard et al., 1989). Binding of mannosylated proteins to mannose 
receptors is involved in various physiological mechanisms, including innate and 
specific immunity. The consequence of increased binding of mannoproteins to 
mannose receptors and the relevance of such data are still a matter of research.
4.3 Observations in humans
Yeast fermentate preparation from S. cerevisiae was not mitogenic in human 
peripheral lymphocytes (Schauss et al., 2012).
Bansal, Tadros & Bansal (2017) reported one case of allergy to beer, wine 
and cider resulting from immunoglobulin E reactivity to yeasts and moulds.
4.4 Assessment of dietary exposure
Yeast extracts containing mannoproteins are proposed for use at a recommended 
use level of 200  mg/L and at a maximum level of 400 mg/L in food category 
14.2.3 “Grape wines” and its subcategories within the Codex GSFA. 
Yeast  mannoproteins  also occur naturally in wine, as well as in other foods 
including bread, pastries, beer and yeast extracts, and in food supplements. The 
Committee evaluated the sponsor’s submission and prepared international 
estimates of dietary exposure to yeast  mannoproteins  using the CIFOCOss 
database in combination with the recommended and maximum use levels in 
wine and the background occurrence of yeast mannoproteins in wine, bread, 
pastries and beer. No consumption data on yeast extracts and yeast-containing 
food supplements were available in the CIFOCOss. The dietary exposure was 
calculated using datasets in the CIFOCOss that were related to food consumption 
data for adolescents (10–18 years), adults (18+ years) and the general population 
(ages not specified), assuming that 100% of the yeast extract was mannoproteins.
The mean background exposure to yeast mannoproteins ranged from 
0.1 to 21 mg/kg bw per day. In consumers with high consumption of wine, the 
background exposure ranged from 2.5 to 21 mg/kg bw per day. The highest 
background exposures were calculated for adolescents. Addition of yeast extracts 
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containing mannoproteins to wine at the recommended level resulted in an 
increase in the mean dietary exposure to yeast mannoproteins in the datasets of 
less than 5% (<0.1–4.2%), resulting in a range of exposure of 0.4–21 mg/kg bw 
per day. For consumers with high consumption of wine, the addition of yeast 
extracts containing mannoproteins to wine at the maximum level resulted in an 
increase of dietary exposure of, on average, 20%. The resulting high estimates 
of dietary exposure were 4.3–21 mg/kg bw per day. Dietary exposure to yeast 
mannoproteins was mainly (at least 90% in almost all datasets) determined by 
bread and pastries, due to both high consumption and a high concentration level. 
The additional dietary exposure to yeast mannoproteins via the consumption of 
yeast extract, based on FSANZ data (FSANZ, 2008), was estimated to be about 3 
mg/kg bw per day.
5. evaluation
The Committee noted that very few toxicity studies were available for the range 
of yeast extracts containing mannoproteins on the market. However, consumers 
are exposed to yeast mannoproteins from S. cerevisiae present in wine as well as 
in other fermented foods, including bread, pastries, beer and yeast extracts, and 
in food supplements. Therefore, the Committee considered that it was possible 
to use the available information relating to S. cerevisiae and its constituents 
for this evaluation. No indication of toxicity was identified from the available 
information, including the toxicological studies on one product that was poorly 
characterized (yeast fermentate preparation from S. cerevisiae). However, there 
were no data on reproductive and developmental toxicity or carcinogenicity for 
any relevant yeast preparation.
In addition to the natural presence of yeast mannoproteins in wine 
and the long history of consumption of yeast products in common foods, the 
Committee considered that the tentative product specifications for yeast extracts 
containing mannoproteins indicate that these do not contain chemical residues 
or microbiological contaminants of concern. In addition, the Committee 
estimated that the exposure to yeast mannoproteins due to the addition of yeast 
extracts containing mannoproteins to wine at the maximum level of 400 mg/L 
would result, on average, in a 20% increase in dietary exposure compared to 
the background exposure through the regular diet of 0.4–21 mg/kg bw per day, 
primarily driven by bread and pastries. These conservative dietary exposure 
estimates are based on the assumption that 100% of the yeast extracts containing 
mannoproteins is mannoproteins.
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In considering the data and information regarding yeast and yeast-
derived products, the Committee concluded that it is unlikely that there would 
be a health concern for the use of yeast extracts containing mannoproteins as a 
food additive for oenological uses at maximum use levels up to 400 mg/L for the 
stabilization of wine.
The Committee noted that any change in the uses and/or use levels of 
yeast extracts containing mannoproteins as a food additive will require a new 
evaluation.
A new tentative specifications monograph and a Chemical and Technical 
Assessment were prepared.
In order to remove the tentative designation of the specifications, the 
Committee requires chemical characterization of the product in commerce along 
with data to be able to complete specifications related to the use of yeast extracts 
containing mannoproteins in wine manufacture. The following information is 
required:
 ■ Composition of yeast extracts containing mannoproteins as well as 
the processes used in their manufacture;
 ■ Analytical data from five batches of each commercial product, 
including information related to impurities; and
 ■ Data on concentrations of yeast mannoproteins in wine in which 
yeast extracts containing mannoproteins have been used.
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AnneX 1
reports and other documents resulting from previous 
meetings of the Joint fAo/WHo expert Committee on 
food Additives
1. General principles governing the use of food additives (First report of the Joint FAO/WHO Expert Committee 
on Food Additives). FAO Nutrition Meetings Report Series, No. 15, 1957; WHO Technical Report Series, No. 129, 
1957 (out of print). 
2. Procedures for the testing of intentional food additives to establish their safety for use (Second report of the 
Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Report Series, No. 17, 1958; WHO 
Technical Report Series, No. 144, 1958 (out of print). 
3. Specifications for identity and purity of food additives (antimicrobial preservatives and antioxidants) (Third 
report of the Joint FAO/WHO Expert Committee on Food Additives). These specifications were subsequently 
revised and published as Specifications for identity and purity of food additives, Vol. I. Antimicrobial preservatives 
and antioxidants, Rome, Food and Agriculture Organization of the United Nations, 1962 (out of print). 
4. Specifications for identity and purity of food additives (food colours) (Fourth report of the Joint FAO/WHO Expert 
Committee on Food Additives). These specifications were subsequently revised and published as Specifications 
for identity and purity of food additives, Vol. II. Food colours, Rome, Food and Agriculture Organization of the 
United Nations, 1963 (out of print). 
5. Evaluation of the carcinogenic hazards of food additives (Fifth report of the Joint FAO/WHO Expert Committee 
on Food Additives). FAO Nutrition Meetings Report Series, No. 29, 1961; WHO Technical Report Series, No. 220, 
1961 (out of print). 
6. Evaluation of the toxicity of a number of antimicrobials and antioxidants (Sixth report of the Joint FAO/WHO 
Expert Committee on Food Additives). FAO Nutrition Meetings Report Series, No. 31, 1962; WHO Technical 
Report Series, No. 228, 1962 (out of print). 
7. Specifications for the identity and purity of food additives and their toxicological evaluation: emulsifiers, 
stabilizers, bleaching and maturing agents (Seventh report of the Joint FAO/WHO Expert Committee on Food 
Additives). FAO Nutrition Meetings Series, No. 35, 1964; WHO Technical Report Series, No. 281, 1964 (out of 
print). 
8. Specifications for the identity and purity of food additives and their toxicological evaluation: food colours 
and some antimicrobials and antioxidants (Eighth report of the Joint FAO/WHO Expert Committee on Food 
Additives). FAO Nutrition Meetings Series, No. 38, 1965; WHO Technical Report Series, No. 309, 1965 (out of 
print). 
9. Specifications for identity and purity and toxicological evaluation of some antimicrobials and antioxidants. FAO 
Nutrition Meetings Report Series, No. 38A, 1965; WHO/Food Add/24.65 (out of print). 
10. Specifications for identity and purity and toxicological evaluation of food colours. FAO Nutrition Meetings 
Report Series, No. 38B, 1966; WHO/Food Add/66.25. 
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11. Specifications for the identity and purity of food additives and their toxicological evaluation: some antimicrobials, 
antioxidants, emulsifiers, stabilizers, flour treatment agents, acids, and bases (Ninth report of the Joint FAO/
WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 40, 1966; WHO Technical Report 
Series, No. 339, 1966 (out of print). 
12. Toxicological evaluation of some antimicrobials, antioxidants, emulsifiers, stabilizers, flour treatment agents, 
acids, and bases. FAO Nutrition Meetings Report Series, No. 40A, B, C; WHO/Food Add/67.29. 
13. Specifications for the identity and purity of food additives and their toxicological evaluation: some emulsifiers 
and stabilizers and certain other substances (Tenth report of the Joint FAO/WHO Expert Committee on Food 
Additives). FAO Nutrition Meetings Series, No. 43, 1967; WHO Technical Report Series, No. 373, 1967. 
14. Specifications for the identity and purity of food additives and their toxicological evaluation: some flavouring 
substances and non nutritive sweetening agents (Eleventh report of the Joint FAO/WHO Expert Committee on 
Food Additives). FAO Nutrition Meetings Series, No. 44, 1968; WHO Technical Report Series, No. 383, 1968. 
15. Toxicological evaluation of some flavouring substances and non nutritive sweetening agents. FAO Nutrition 
Meetings Report Series, No. 44A, 1968; WHO/Food Add/68.33.
16. Specifications and criteria for identity and purity of some flavouring substances and non-nutritive sweetening 
agents. FAO Nutrition Meetings Report Series, No. 44B, 1969; WHO/Food Add/69.31. 
17. Specifications for the identity and purity of food additives and their toxicological evaluation: some antibiotics 
(Twelfth report of the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 
45, 1969; WHO Technical Report Series, No. 430, 1969. 
18. Specifications for the identity and purity of some antibiotics. FAO Nutrition Meetings Series, No. 45A, 1969; 
WHO/Food Add/69.34. 
19. Specifications for the identity and purity of food additives and their toxicological evaluation: some food colours, 
emulsifiers, stabilizers, anticaking agents, and certain other substances (Thirteenth report of the Joint FAO/
WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 46, 1970; WHO Technical Report 
Series, No. 445, 1970. 
20. Toxicological evaluation of some food colours, emulsifiers, stabilizers, anticaking agents, and certain other 
substances. FAO Nutrition Meetings Report Series, No. 46A, 1970; WHO/Food Add/70.36. 
21. Specifications for the identity and purity of some food colours, emulsifiers, stabilizers, anticaking agents, and 
certain other food additives. FAO Nutrition Meetings Report Series, No. 46B, 1970; WHO/Food Add/70.37. 
22. Evaluation of food additives: specifications for the identity and purity of food additives and their toxicological 
evaluation: some extraction solvents and certain other substances; and a review of the technological efficacy of 
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Abbreviations used in the monographs 
ADI  acceptable daily intake
ADME   absorption, distribution, metabolism, and excretion
ANS  [EFSA Panel on ]Food Additives and Nutrient Sources added to Food
bw  body weight
CAS  Chemical Abstracts Service
CCFA   Codex Committee on Food Additives
CIFOCOss  FAO/WHO Chronic Individual Food Consumption Database –
  Summary statistics
cfu  colony-forming unit 
CSIR  Council of Scientific and Industrial Research
CYP  cytochrome P450
DNA   deoxyribonucleic acid
EFSA  European Food Safety Authority
F   female
F   generation, e.g. F0, F1a, F1b, F2a, F2b, etc.
FAO   Food and Agriculture Organization of the United Nations
FSANZ  Food Standards Australia New Zealand
GEMS/Food  Global Environment Monitoring System – Food Contamination
  Monitoring and Assessment Programme 
GLP  good laboratory practice
GRAS   Generally Recognized as Safe
GRN  Generally Recognized as Safe (GRAS) notice
GSFA  General Standard for Food Additives
HPLC  high-performance liquid chromatography 
IC50   half maximal inhibitory concentration
INS   International Numbering System for Food Additives
JECFA  Joint FAO/WHO Expert Committee on Food Additives
LD50  median lethal dose 
LOD  limit of detection
M   male
NA  not applicable
nAChR   nicotinic acetylcholine receptor
NCE  normochromatic erythrocytes 
nes   not elsewhere specified
NET-NID  National Eating Trends – Nutrient Intake Database
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NHANES National Health and Nutrition Examination Survey
no./No.  number
NOAEL  no-observed-adverse-effect level
OECD  Organisation for Economic Cooperation and Development
OECD TG Organisation for Economic Co-operation and Development Test
  Guideline
P90  90th percentile
P95  95th percentile
P97.5  97.5th percentile
Panx1   pannexin 1
PBS  phosphate-buffered saline
PCE  polychromatic erythrocytes
PND  postnatal day 
QA  quality assurance 
QPS  [EFSA] Qualified Presumption of Safety 
RAR  retinoic acid receptor
S9  9000 × g supernatant fraction from liver homogenate 
TLC  thin-layer chromatography 
USA  United States of America 
USFDA  United States Food and Drug Administration 
v/v  volume per volume
WHO   World Health Organization
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toxicological information, dietary exposures and 
information on specifications
Food additives evaluated toxicologically and assessed for dietary exposure 
Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological and dietary 
exposure conclusions 
Brilliant Blue FCF Ra The Committee concluded that the available data support the revision of the 
ADI for Brilliant Blue FCF. In a long-term toxicity study in rats, a no-observed-
adverse-effect level (NOAEL) of 631 mg/kg body weight (bw) per day was 
identified, based on a 15% decrease in mean terminal body weight and 
decreased survival of females at 1318 mg/kg bw per day. The Committee 
established an ADI of 0–6 mg/kg bw based on this NOAEL by applying an 
uncertainty factor of 100 for interspecies and intraspecies differences.
The Committee noted that the conservative dietary exposure estimate of 5 mg/
kg bw per day (95th percentile for children) is less than the upper limit of the 
ADI of 0–6 mg/kg bw established for Brilliant Blue FCF and concluded that 
dietary exposure to Brilliant Blue FCF for children and all other age 
groups does not present a health concern.
The previous ADI of 0–12.5 mg/kg bw was withdrawn.
β-Carotene-rich extract from 
Dunaliella salina
N The Committee noted that data have become available since the previous 
evaluation that show large differences in absorption of β-carotene between 
rodents and humans. The Committee considered that rodents are inappropriate 
animal models for establishing an ADI for β-carotene.
The Committee noted that the toxicity of the other components of the 
β-carotene-rich d-limonene extract of D. salina (hereafter referred to as D. 
salina d-limonene extract) can be evaluated using the results of rodent studies. 
A short-term toxicity study in rats gave a NOAEL of 3180 mg/kg bw per day, 
the highest dose tested. No long-term toxicity or reproductive studies have 
been conducted. The D. salina d-limonene extract did not show genotoxicity 
or developmental toxicity. Correction of the NOAEL of 3180 mg/kg bw per day 
for the percentage of the algal component (20–35%) gives an adjusted NOAEL 
of 636–1113 mg/kg bw per day for the algal lipid component of the D. salina 
d-limonene extract. The margin of exposure for this algal lipid component is 
2120–3710 using a dietary exposure of 18 mg/day (0.3 mg/kg bw per day). 
The Committee concluded that exposure to the algal component of the extract 
does not pose a health concern.
The Committee noted that the total dietary exposure to β-carotene is not 
expected to increase when D. salina d-limonene extract is used as a food 
colour.
The Committee concluded that there was no health concern for the 
use of β-carotene-rich extract from D. salina when used as a food 
colour in accordance with the specifications established at this 
meeting. The Committee emphasized that this conclusion applies to the use 
of this extract as a food colour, not as a food supplement.
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Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological and dietary 
exposure conclusions 
Fast Green FCF Ra The ADI of 0–25 mg/kg bw established previously by the Committee was 
based on a long-term rat dietary that identified a NOAEL of 5% Fast Green FCF 
(equivalent to 2500 mg/kg bw per day), the highest concentration tested.
The Committee concluded that the new data that had become available since 
the previous evaluation gave no reason to revise the ADI and confirmed the 
ADI of 0–25 mg/kg bw. The Committee noted that the conservative dietary 
exposure estimate for Fast Green FCF of 12 mg/kg bw per day (95th percentile 
for adolescents) was below the upper bound of the ADI. The Committee 
concluded that dietary exposures to Fast Green FCF for adolescents 
and all other age groups do not present a health concern.
Gum ghatti Rb The Committee took into account the lack of systemic exposure to gum ghatti 
because of its high molecular weight and polysaccharide structure, its lack 
of toxicity in short-term studies, the lack of concern for genotoxicity and the 
absence of treatment-related adverse effects in studies of gum arabic and 
other polysaccharide gums with a similar profile.
The Committee concluded that gum ghatti is unlikely to be of health concern 
and established an ADI “not specified”c for gum ghatti that complies 
with the specifications.
The Committee concluded that the estimated dietary exposure 
to gum ghatti of 12 mg/kg bw per day does not present a health 
concern.
Jagua (Genipin–Glycine) Blue N,T The Committee noted that the highest doses tested in two 90-day toxicity 
studies in rats and dogs were only 330 and 338 mg/kg bw per day (expressed 
on a “blue polymer” basisd), respectively. The Committee was concerned that 
the possible effects of the low molecular weight component of the “blue 
polymer” that could be absorbed were not adequately investigated.
A comparison of the dietary exposure estimate (11 mg/kg bw per day) with the 
NOAEL from the 90-day studies of oral toxicity in rats and dogs (approximately 
330 mg/kg bw per day) gives a margin of exposure of about 30.
Because of the limited biochemical and toxicological database and the 
low margin of exposure, the Committee was unable to complete the 
evaluation for Jagua (Genipin–Glycine) Blue.
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Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological and dietary 
exposure conclusions 
Metatartaric acid T As metatartaric acid undergoes enzymatic hydrolysis to tartaric acid prior to 
systemic absorption, the biochemical and toxicological data on tartaric acid 
considered at previous meetings are relevant to the safety assessment of 
metatartaric acid. Previously evaluated and new studies suggest no change 
to the group ADI previously established for L(+)-tartaric acid and its sodium, 
potassium and potassium–sodium salts, expressed as L(+)-tartaric acid.
The Committee concluded that metatartaric acid (when used in 
winemaking) should be included in the group ADI of 0–30 mg/kg bw 
for L(+)-tartaric acid and its sodium, potassium, potassium–sodium 
salts, expressed as L(+)-tartaric acid.
The Committee noted that the dietary exposure estimate for metatartaric 
acid for adult consumers of wine was 4% of the upper bound of the ADI and 
concluded that dietary exposure to metatartaric acid in wine at the 
maximum use level of 100 mg/L does not present a health concern.
Tamarind seed polysaccharide N The Committee noted the absence of toxicity in long-term rodent studies 
and lack of concern regarding genotoxicity, reproductive toxicity and 
developmental toxicity, and established an ADI “not specified”c for 
tamarind seed polysaccharide.
The Committee concluded that the estimated dietary exposure of 75 
mg/kg bw per day based on proposed uses and use levels does not 
present a health concern.
Tannins (oenological tannins) – The Committee noted that the available data do not provide clear information 
on which tannin sources and individual tannin compounds are present in 
commercially used oenological tannins and, thus, how the oenological tannins 
would compare to the tannins used in the submitted studies. Therefore, it is 
not possible to establish which studies are relevant and, consequently, the 
extent of the data gaps.
The information on biochemical aspects is incomplete, with the implications 
of repeated dosing on absorption, tissue distribution and interindividual 
variation needing consideration. In general, there are also few data available 
on reproductive and developmental toxicity and/or long-term toxicity for some 
or all of the tannins.
In the absence of specifications and identification of the products 
in commerce, the Committee concluded that it was not possible to 
evaluate tannins used in winemaking. 
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Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological and dietary 
exposure conclusions 
Yeast extracts containing 
mannoproteins
N,T In addition to the natural presence of yeast mannoproteins in wine and 
the long history of consumption of yeast products in common foods, the 
Committee considered that the tentative product specifications for yeast 
extracts containing mannoproteins indicate that these do not contain 
chemical residues or microbiological contaminants of concern. In addition, 
the Committee estimated that dietary exposure to yeast mannoproteins due 
to the addition of yeast extracts containing mannoproteins to wine at the 
maximum level of 400 mg/L would result, on average, in a 20% increase in 
dietary exposure compared to the background exposure through the regular 
diet of 0.4–21 mg/kg bw per day, primarily driven by bread and pastries. These 
conservative dietary exposure estimates are based on the assumption that 
100% of the yeast extracts containing mannoproteins is mannoproteins.
In considering the data and information regarding yeast and yeast-derived 
products, the Committee concluded that it is unlikely that there 
would be a health concern for the use of yeast extracts containing 
mannoproteins as a food additive for oenological uses at maximum 
use levels up to 400 mg/L for the stabilization of wine.
The Committee noted that any change in the uses and/or use levels of yeast 
extracts containing mannoproteins as a food additive will require a new 
evaluation.
–: no specifications prepared; N: new specifications; R: existing specifications revised; T: tentative specifications
a A maximum limit for manganese was added. High-performance liquid chromatography (HPLC) methods were added for determining subsidiary colouring matters 
and organic compounds other than colouring matters. The method of assay was changed to visible spectrophotometry, and spectrophotometric data were provided 
for the colour dissolved in water or aqueous ammonium acetate.
b An HPLC method for the identification of the gum constituents was added to replace the thin-layer chromatography (TLC) method. One identity method, using a 
mercury-containing reagent, was removed. L-Rhamnose was added as one of the constituents of gum ghatti, based on current literature reports.
c ADI “not specified” is used to refer to a food substance of very low toxicity that, on the basis of the available data (chemical, biochemical, toxicological and other) and 
the total dietary exposure to the substance arising from its use at the levels necessary to achieve the desired effects and from its acceptable background levels in food, 
does not, in the opinion of the Committee, represent a hazard to health. For that reason, and for the reasons stated in the individual evaluations, the establishment 
of an ADI expressed in numerical form is not deemed necessary. An additive meeting this criterion must be used within the bounds of good manufacturing practice 
– i.e. it should be technologically efficacious and should be used at the lowest level necessary to achieve this effect; it should not conceal food of inferior quality or 
adulterated food; and it should not create a nutritional imbalance.
d “Blue polymer” refers to the blue-coloured genipin–glycine polymer and dimer content of Jagua (Genipin–Glycine) Blue.
R: existing specifications revised
a The Committee assessed the information submitted on the solubility of microcrystalline cellulose and redesignated its solubility as “Insoluble in water and ethanol. 
Practically insoluble or insoluble in sodium hydroxide solution (50 g/L)”.
b Silicon dioxide, amorphous was on the agenda at the present meeting for revisions related to pH, assay, loss on drying, loss on ignition and impurities. The Committee 
at its present meeting received the requested information. The tentative status was removed.
Food additive Specifications
Microcrystalline cellulose Ra
Silicon dioxide, amorphous Rb
Sodium aluminium silicate Rc
Steviol glycosides Rd
Sucrose esters of fatty acids Re
Food additives considered for specifications only
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c At the current meeting, the Committee evaluated the data submitted for loss on ignition, impurities soluble in 0.5 mol/L hydrochloric acid and the suitability of the 
proposed assay method for the determination of aluminium, silicon and sodium. Information received on functional uses confirmed that the substance is used only 
as an anticaking agent. The tentative status was removed.
d The Committee received a validated HPLC–ultraviolet (UV) method for the assay of steviol glycosides, for which reference standards are commercially available. 
The presence of steviol glycosides that exist in small quantities is confirmed using an HPLC–mass spectrometric method and quantified using HPLC–UV data. The 
Committee also received assay data for three batches of a commercial product using the proposed methods. The Committee, at its present meeting, assessed the 
information received and replaced the existing assay. Two additional saccharides (galactose and arabinose) have been identified in the extracts of Stevia rebaudiana 
Bertoni since the last evaluation of steviol glycosides. The Committee included the two saccharides in the definition of the specifications for steviol glycosides from S. 
rebaudiana Bertoni. The tentative status was removed.
e The Committee assessed the information submitted on the solubility of sucrose esters of fatty acids and revised the solubility criterion. In addition, the Committee 
reviewed the information submitted on the chromatographic conditions for the separation of the compounds and revised the UV integration instructions.
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